<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001478.pub6" GROUP_ID="ARI" ID="166399081614124003" MERGED_FROM="" MODIFIED="2014-09-21 09:29:40 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A001" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="16.0">
<COVER_SHEET MODIFIED="2014-09-21 09:29:40 +0100" MODIFIED_BY="Liz Dooley">
<TITLE>Acellular vaccines for preventing whooping cough in children</TITLE>
<CONTACT MODIFIED="2014-09-21 09:29:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="BCFE36B982E26AA2007834EBE1DEA3AC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linjie</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>zhanglinjie63@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 53 32258394</PHONE_1><FAX_1>+55 53 32258394</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-09-21 09:29:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="BCFE36B982E26AA2007834EBE1DEA3AC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linjie</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>zhanglinjie63@yahoo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 53 32258394</PHONE_1><FAX_1>+55 53 32258394</FAX_1></ADDRESS></PERSON><PERSON ID="82D917D782E26AA201B8424EFCA3F3E1" ROLE="AUTHOR"><FIRST_NAME>Sílvio</FIRST_NAME><MIDDLE_INITIALS>OM</MIDDLE_INITIALS><LAST_NAME>Prietsch</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor, Pediatric Pulmonologist</POSITION><EMAIL_1>silvio@brturbo.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 53 3233 0311</PHONE_1></ADDRESS></PERSON><PERSON ID="18794" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Inge</FIRST_NAME><LAST_NAME>Axelsson</LAST_NAME><POSITION>Consultant Paediatrician</POSITION><EMAIL_1>inge.axelsson@miun.se</EMAIL_1><ADDRESS><ORGANISATION>Östersund County Hospital</ORGANISATION><CITY>Östersund</CITY><COUNTRY CODE="SE">Sweden</COUNTRY><PHONE_1>+46 70 342 7981</PHONE_1><FAX_1>+46 63 165 626</FAX_1></ADDRESS></PERSON><PERSON ID="7D4D12F082E26AA201B8424EE1D2B0FF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Scott</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Halperin</LAST_NAME><POSITION>Pediatric Infectious Diseases Director</POSITION><EMAIL_1>scott.halperin@dal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Canadian Center for Vaccinology</DEPARTMENT><ORGANISATION>Halifax Dalhousie University, IWK Health Centre</ORGANISATION><ADDRESS_1>5850/5980 University Avenue</ADDRESS_1><CITY>Halifax</CITY><ZIP>B3K 6R8</ZIP><REGION>NS</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 902 470 8141</PHONE_1><FAX_1>+1 902 470 7232</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-05-25 18:55:34 -0300" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-09-19 17:24:33 -0300" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-09-19 17:24:33 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>Abstract and Plain language summary corrected in reporting the efficacy of one- and two-component vaccines against typical whooping cough and against mild pertussis disease.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-09-19 17:19:33 -0300" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-09-19 17:19:33 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Searches updated. We did not identify any new trials for inclusion or exclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-09-19 17:19:30 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-23 22:46:19 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Searches conducted. No new included or excluded trials found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-23 22:46:30 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged in this update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-03-23 22:59:32 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback comment added to review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-23 22:59:29 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>Searches conducted. Three trials were excluded and seven additional trials were included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-23 22:59:30 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>New team of review authors updated this previously withdrawn review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-23 22:59:27 -0300" MODIFIED_BY="Liz Dooley">
<DATE DAY="13" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="3" YEAR="2006"/>
<DESCRIPTION>
<P>Review withdrawn from <I>The Cochrane Library</I>, Issue 3, 2006</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-23 22:59:22 -0300" MODIFIED_BY="Liz Dooley">
<DATE DAY="22" MONTH="1" YEAR="1998"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-09-08 05:44:00 -0300" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-09-08 05:44:00 -0300" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-09-08 05:44:00 -0300" MODIFIED_BY="[Empty name]">
<NAME>UK Department of Health Cochrane Incentive Scheme 2008</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This updated review received an award from the UK Department of Health Cochrane Incentive Scheme 2008</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-19 17:20:31 -0300" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-09-19 17:20:31 -0300" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-05-18 11:06:29 -0300" MODIFIED_BY="[Empty name]">Acellular vaccines for preventing whooping cough (pertussis) in children</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-19 17:20:31 -0300" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
<BR/>We aimed to answer the question of whether acellular pertussis vaccines are as effective as the whole-cell vaccines at protecting children against whooping cough (pertussis), but with fewer side effects.</P>
<P>
<B>Background</B>
<BR/>Whooping cough can be a serious respiratory infection in children and is caused by the bacterium <I>Bordetella pertussis </I>(<I>B. pertussis</I>). Vaccines made from killed whole <I>B. pertussis</I>, known as whole-cell pertussis vaccines, can cause severe neurologic disorders and minor side effects, such as anorexia, drowsiness, fever, irritability, prolonged crying, vomiting and pain/redness/swelling/hardening at the injection site. This led to a fall in immunisation rates, which resulted in an increase in the number of cases of whooping cough. Acellular pertussis vaccines (containing more purified antigens of <I>B. pertussis</I>) were developed in the hope that they would be as effective but safer than the whole-cell pertussis vaccines.</P>
<P>
<B>Search date</B>
<BR/>We searched for trials published up to January 2014.</P>
<P>
<B>Study characteristics</B>
<BR/>We included trials comparing the efficacy and safety of whole-cell and acellular pertussis vaccines in children up to six years old.</P>
<P>
<B>Key results</B>
<BR/>This updated review included six trials with 46,283 participants evaluating the efficacy and 52 trials with 136,541 participants assessing the safety of pertussis vaccines. Duration varied from 12 months to 27 months and from 3 days to 12 months for efficacy trials and safety trials, respectively. The efficacy of acellular vaccines with three or more components varied from 84% to 85% in preventing typical whooping cough (characterised by 21 or more consecutive days of severe coughing attacks with laboratory evidence of <I>B. pertussis</I> infection or contact with a household member who has culture-confirmed pertussis) and from 71% to 78% in preventing mild pertussis disease (characterised by seven or more consecutive days of cough with laboratory evidence of <I>B. pertussis</I> infection). In contrast, the efficacy vaccines with one and two components varied from 59% to 78% in protecting against typical whooping cough and from 41% to 58% against mild pertussis disease. Most systemic and local side effects were significantly less common with acellular vaccines than with whole-cell vaccines for the first doses and booster dose. We found that acellular pertussis vaccines with three or more components are more effective than low-efficacy whole-cell vaccines, but may be less effective than the highest-efficacy whole-cell vaccines. Acellular vaccines have fewer side effects than whole-cell vaccines.</P>
<P>
<B>Implications for practice</B>
<BR/>The implications of the findings of this review for clinical practice may be different in high-income and low-income countries. In high-income countries, death from whooping cough is rare and parental acceptance is a major determinant of immunisation uptake. In these circumstances, the improved side effect profile of acellular vaccines argues in favour of their use, even though they might sacrifice some degree of effectiveness compared to the best whole-cell vaccines. In low-income countries, where the risk of pertussis is higher and cases are more likely to be fatal, greater weight needs to be given to vaccine efficacy. If an acellular vaccine has been shown to be less effective than a high-efficacy whole-cell vaccine it is intended to replace, the safety advantage of the acellular vaccine may be offset by increased mortality and morbidity due to a significantly higher rate of pertussis. However, most of the whole-cell vaccines used in low-income countries have not been adequately studied for efficacy and, therefore, it is not known where on the wide spectrum of whole-cell vaccine efficacy an individual product lies.</P>
<P>
<B>Quality of evidence</B>
<BR/>All included trials were randomised and double-blind, that is, the participants had an equal chance of receiving either acellular or whole-cell vaccines and both researchers and participants were unaware of the treatment assignment. However, most of trials did not report details of these methodological techniques. This may cast some uncertainty on the quality of evidence in this review.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-19 17:20:15 -0300" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Routine use of whole-cell pertussis (wP) vaccines was suspended in some countries in the 1970s and 1980s because of concerns about adverse effects. Following this action, there was a resurgence of whooping cough. Acellular pertussis (aP) vaccines, containing purified or recombinant <I>Bordetella pertussis </I>(<I>B. pertussis</I>) antigens, were developed in the hope that they would be as effective, but less reactogenic than the whole-cell vaccines. This is an update of a Cochrane review first published in 1999, and previously updated in 2012. In this update, we included no new studies.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of acellular pertussis vaccines in children and to compare them with the whole-cell vaccines.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2013, Issue 12), MEDLINE (1950 to January week 2, 2014), EMBASE (1974 to January 2014), Biosis Previews (2009 to January 2014) and CINAHL (2009 to January 2014).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-01-27 21:18:28 -0200" MODIFIED_BY="[Empty name]">
<P>We selected double-blind randomised efficacy and safety trials of aP vaccines in children up to six years old, with active follow-up of participants and laboratory verification of pertussis cases.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-27 02:44:57 -0200" MODIFIED_BY="Liz Dooley">
<P>Two review authors independently extracted data and assessed the risk of bias in the studies. Differences in trial design precluded a meta-analysis of the efficacy data. We pooled the safety data from individual trials using a random-effects meta-analysis model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-19 17:20:15 -0300" MODIFIED_BY="[Empty name]">
<P>We included six efficacy trials with a total of 46,283 participants and 52 safety trials with a total of 136,541 participants. Most of the safety trials did not report the methods for random sequence generation, allocation concealment and blinding, which made it difficult to assess the risk of bias in the studies. The efficacy of multi-component (&#8805; three) vaccines varied from 84% to 85% in preventing typical whooping cough (characterised by 21 or more consecutive days of paroxysmal cough with confirmation of <I>B. pertussis</I> infection by culture, appropriate serology or contact with a household member who has culture-confirmed pertussis), and from 71% to 78% in preventing mild pertussis disease (characterised by seven or more consecutive days of cough with confirmation of <I>B. pertussis</I> infection by culture or appropriate serology). In contrast, the efficacy of one- and two-component vaccines varied from 59% to 78% against typical whooping cough and from 41% to 58% against mild pertussis disease. Multi-component acellular vaccines are more effective than low-efficacy whole-cell vaccines, but may be less effective than the highest-efficacy whole-cell vaccines. Most systemic and local adverse events were significantly less common with aP vaccines than with wP vaccines for the primary series as well as for the booster dose.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Multi-component (&#8805; three) aP vaccines are effective in preventing whooping cough in children. Multi-component aP vaccines have higher efficacy than low-efficacy wP vaccines, but they may be less efficacious than the highest-efficacy wP vaccines. Acellular vaccines have fewer adverse effects than whole-cell vaccines for the primary series as well as for booster doses.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-19 08:25:34 -0300" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-09-08 06:45:24 -0300" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Whooping cough, or pertussis, is a highly contagious disease caused predominantly by the fastidious Gram-negative coccobacillus, <I>Bordetella pertussis</I> (<I>B.</I> <I>pertussis</I>). The disease can occur at any age but is more severe in infants, with most deaths occurring in this age group (<LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>). The disease in this age group is also more easily diagnosed because they present with whooping cough, which is characterised by paroxysmal coughing followed by an audible inspiratory whoop and occasionally vomiting. Infants often have a cough and apnoeic episodes, which can be severe and may require admission to hospital. Although habitually a persistent, relatively benign respiratory illness, pertussis can result in serious consequences, such as pneumonia, seizures, encephalopathy and death, especially among infants (<LINK REF="REF-Galanis-2006" TYPE="REFERENCE">Galanis 2006</LINK>). Immunised children, adolescents and adults may not exhibit whooping cough. They may be asymptomatic or present with a cough lasting several weeks.</P>
<P>The reported incidence of pertussis should be interpreted cautiously, because the case definitions and surveillance system performance vary markedly between countries. In low-income countries, case definition is mostly based on clinical confirmation due to limited access to laboratory facilities (<LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>). According to the World Health Organization (WHO) there are about 16 million pertussis cases annually worldwide among children, teenagers and adults, 95% of which are in low-income countries, and about 195,000 children die of the disease (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). Before the introduction of the pertussis vaccine in the 1940s, there were approximately 200,000 cases reported annually in the United States. Immunisations reduced disease rates and there were only 1010 reported cases in 1976 (<LINK REF="REF-Bamberger-2008" TYPE="REFERENCE">Bamberger 2008</LINK>). The incidence decreased from 157 per 100,000 population in the early 1940s to less than 1 per 100,000 in 1973 (<LINK REF="REF-Cherry-2012" TYPE="REFERENCE">Cherry 2012</LINK>). It has been generally believed that pertussis particularly affected children under six years of age, but recent trends show that in countries that have achieved good control of pertussis, there is a change in the epidemiology of pertussis in the older age group. Several factors have been proposed as possible causes for the increasing incidence of pertussis disease, including waning immunity with subsequent atypical disease manifestations (<LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>). There is a frequent misconception that protection provided by childhood immunisation is lifelong. However, the protection provided by vaccination tends to reduce over time. Evidence shows that the proportion of susceptible children with infections in countries with good vaccination coverage (70%) can be estimated at 10% by one year, 60% by five years and 100% by 15 years (<LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>).</P>
<P>Since the 1980s, there has been a substantial increase in the number of cases reported, especially in high-income countries. This has occurred in children and adolescents aged 6 to 10 years, after childhood immunisations were completed (<LINK REF="REF-Bamberger-2008" TYPE="REFERENCE">Bamberger 2008</LINK>; <LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>). In the USA, for example, there were 25,827 cases reported in 2004 and there has been a 19-fold increase of pertussis cases in adolescents (<LINK REF="REF-Bamberger-2008" TYPE="REFERENCE">Bamberger 2008</LINK>; <LINK REF="REF-CDC-2011" TYPE="REFERENCE">CDC 2011</LINK>). Affected adolescents and adults act as reservoirs of the disease to the vulnerable population of infants, for whom the disease can be life-threatening (<LINK REF="REF-Harnden-2009" TYPE="REFERENCE">Harnden 2009</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-09-08 06:45:24 -0300" MODIFIED_BY="[Empty name]">
<P>After the isolation of <I>B. pertussis</I> in 1906, the possibility of vaccine development was considered. In 1933, Madsen reported some degree of protection in individuals who received a vaccine composed of suspended organisms in saline (<LINK REF="REF-Cherry-1996" TYPE="REFERENCE">Cherry 1996</LINK>). Vaccines made from killed whole <I>B. pertussis</I> bacteria (whole-cell pertussis vaccines - wP) have been available since the 1940s. Today, wP vaccines are manufactured in many countries. Although their basic preparation procedures are similar, the vaccines frequently elicit markedly different immune responses to various <I>B. pertussis</I> antigens (<LINK REF="REF-Cherry-1996" TYPE="REFERENCE">Cherry 1996</LINK>). The wP vaccines are based on regular cultures of selected <I>B. pertussis</I> strains that are killed, usually by being heating and treated with formalin. The methods used for the production vary between laboratories, therefore wP vaccines are relatively heterogeneous. Most wP vaccines are combined with diphtheria toxoid and tetanus toxoid. This combination has shown an efficacy of 80% and has been effective in reducing the incidence rates markedly in countries with good immunisation coverage (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). The immune response to wP vaccines is directed against an array of antigens of whole bacterial cells. Significant differences in the immune responses to various antigens have been observed among the different wP vaccines. Unwanted components such as endotoxin cannot be eliminated during whole-cell vaccine production, therefore an acceptable level of potency is inevitably associated with a greater incidence of adverse effects.</P>
<P>Concerns about possible relations of wP vaccines with neurological disorders led to the development of acellular pertussis (aP) vaccines in the 1970s and they were widely tested and used in Japan during the 1980s (<LINK REF="REF-Sato-1984" TYPE="REFERENCE">Sato 1984</LINK>). aP vaccines consist of recombinant or isolated, purified antigens of <I>B. pertussis</I>. They include antigens extracted by various methods, as well as those produced by genetic recombinant technology. Five antigens have been identified as appropriate vaccine components: pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin and fimbriae type 2 and 3 (FIM 2 and 3) (<LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK>; <LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>). One or more of these components may be included in various combinations to produce the vaccine. Vaccines differ from each other, with regard to the bacterial clone used for primary antigen production, methods of cleansing and detoxification, included adjuvants and the use of preservatives (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). The exact contribution of the different aP antigens to protection is not well established.</P>
<P>Vaccination strategies vary by health policies in each country. Over the last several years, many potential immunisation strategies have been proposed to improve pertussis control. Immunogenicity data indicate that a primary series should consist of three doses and that booster doses are necessary at ages two and four to six years (<LINK REF="REF-Cherry-1996" TYPE="REFERENCE">Cherry 1996</LINK>). Most immunisation schedules consist of five to six intramuscular injections given from the age two months to 16 years (<LINK REF="REF-CDC-2009" TYPE="REFERENCE">CDC 2009</LINK>; <LINK REF="REF-Rodr_x00ed_guez_x002d_Cobo-2008" TYPE="REFERENCE">Rodríguez-Cobo 2008</LINK>), but booster doses every 10 years throughout life have been suggested because protection provided by childhood immunisation is only partial and not lifelong (<LINK REF="REF-Forsyth-2004" TYPE="REFERENCE">Forsyth 2004</LINK>; <LINK REF="REF-Rodr_x00ed_guez_x002d_Cobo-2008" TYPE="REFERENCE">Rodríguez-Cobo 2008</LINK>).</P>
<P>In the 1990s, safety concerns prompted a switch from wP to aP vaccines in most high-income countries. However, wP vaccines remain the choice for the national childhood immunisation programmes in many low-income countries, as they are considerably less expensive and highly effective against pertussis (<LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). In children older than six years of age, only aP vaccines should be used for vaccination (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The mechanism of vaccine-induced protection against <I>B. pertussis </I>is still not well understood. Induction of antibodies to the components of <I>B. pertussis</I> appears to be associated with protection by vaccines (<LINK REF="REF-Cherry-1998" TYPE="REFERENCE">Cherry 1998</LINK>; <LINK REF="REF-Kerr-2000" TYPE="REFERENCE">Kerr 2000</LINK>; <LINK REF="REF-Storsaeter-1998" TYPE="REFERENCE">Storsaeter 1998</LINK>; <LINK REF="REF-Taranger-2000" TYPE="REFERENCE">Taranger 2000</LINK>), and it is believed that anti-<I>B. pertussis </I>IgG antibodies may play a key role in preventing bacterial adherence (<LINK REF="REF-Mills-1999" TYPE="REFERENCE">Mills 1999</LINK>). However, no consensus has been reached regarding the protective antigens. A household study nested in the Swedish vaccine efficacy trial (<LINK REF="REF-Storsaeter-1998" TYPE="REFERENCE">Storsaeter 1998</LINK>) (SmithKline Beecham DTaP 2 vaccine, Connaught DTaP 5 vaccine, Connaught DTwP vaccine, SBT DT vaccine) found a correlation between clinical protection and levels of anti-pertactin, anti-FIM2/3 and anti-PT antibodies in serum, listed in order of a decreasing degree of correlation. There was no correlation between anti-FHA antibodies and clinical protection. Similar results were found in the German vaccine efficacy trial (<LINK REF="REF-Cherry-1998" TYPE="REFERENCE">Cherry 1998</LINK>) (Lederle/Takeda DTaP vaccine, Lederle wP vaccine).</P>
<P>Cell-mediated immunity has also been proposed as a possible protective mechanism of vaccines (<LINK REF="REF-Mills-1999" TYPE="REFERENCE">Mills 1999</LINK>; <LINK REF="REF-Plotkin-2008" TYPE="REFERENCE">Plotkin 2008</LINK>; <LINK REF="REF-Tran-Minh-1998" TYPE="REFERENCE">Tran Minh 1998</LINK>). Both human and animal studies demonstrate that aP and wP vaccines induce distinct T cell populations (<LINK REF="REF-Feunou-2010" TYPE="REFERENCE">Feunou 2010</LINK>; <LINK REF="REF-Millis-1998" TYPE="REFERENCE">Millis 1998</LINK>; <LINK REF="REF-Mills-1999" TYPE="REFERENCE">Mills 1999</LINK>). Th1 responses are important for bacterial clearance following primary infection and in immunity induced with a wP vaccine, whereas Th2 cells play a more critical role in the protective mechanism of the aP vaccine (<LINK REF="REF-Mills-1999" TYPE="REFERENCE">Mills 1999</LINK>). It is believed that  <I>B. pertussis</I>-specific T cells (probably IL-4 and IL-5 secreting Th0/Th2 cells) are required for the induction of humoral response, whereas Th1 cells function in limiting the course of infection through enhanced bacterial uptake and killing by phagocytic cells (<LINK REF="REF-Mills-1999" TYPE="REFERENCE">Mills 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>This systematic review was initially conducted by <LINK REF="REF-Tinnion-1999" TYPE="REFERENCE">Tinnion 1999</LINK> to assess the efficacy and safety of aP vaccines in children and to compare them with wP vaccines. The review has been regularly updated (<LINK REF="REF-Zhang-2009" TYPE="REFERENCE">Zhang 2009</LINK>; <LINK REF="REF-Zhang-2012" TYPE="REFERENCE">Zhang 2012</LINK>). This review can provide high-level evidence regarding the benefits and risks of vaccines against pertussis for health policy makers, as well as for paediatricians and parents.                            </P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy and safety of acellular pertussis vaccines in children and to compare them with the whole-cell vaccines. </P>
<P>The following four questions were answered by the review.</P>
<OL>
<LI>Do acellular vaccines protect against pertussis?</LI>
<LI>If so, do different vaccines confer different levels of protection?</LI>
<LI>Do acellular vaccines protect against pertussis to the same degree as the whole-cell vaccines, which they are intended to replace?</LI>
<LI>Do acellular vaccines cause fewer side effects than wP vaccines?</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-08 07:42:12 -0300" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Double-blind randomised controlled trials (RCTs) of the efficacy of aP vaccines, with active follow-up of participants and laboratory verification of pertussis cases.</LI>
<LI>Double-blind RCTs of the safety of aP vaccines.</LI>
</OL>
<P>Active follow-up was required to minimise the potential for bias in the recording of pertussis cases. Passive follow-up (such as relying on parents to report cases spontaneously, or monitoring laboratory records of pertussis isolates) has been shown to lead to bias in case ascertainment. This occurs because disease in vaccinated individuals tends to be less severe than in unvaccinated ones and therefore less likely to come to the attention of a physician (<LINK REF="REF-Taranger-1997" TYPE="REFERENCE">Taranger 1997</LINK>). Laboratory verification was required because case definitions of pertussis based on clinical criteria alone have been shown to lack specificity (<LINK REF="REF-Blackwelder-1991" TYPE="REFERENCE">Blackwelder 1991</LINK>). There was no requirement for laboratory verification to be performed according to any particular method, because the most appropriate method will vary according to the composition of the vaccine under study.</P>
<P>We did not consider trials which only examined antibody response after immunisation in this review, as no particular antibody level has been found to correlate with the clinical efficacy of pertussis vaccines (<LINK REF="REF-Granoff-1997" TYPE="REFERENCE">Granoff 1997</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-21 23:38:14 -0200" MODIFIED_BY="[Empty name]">
<P>Children up to six years of age at time of study entry.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We considered two types of interventions in the experimental (acellular vaccine) group.</P>
<OL>
<LI>aP vaccine: a vaccine containing purified, detoxified pertussis antigens. This includes antigens extracted from <I>B. pertussis </I>organisms by various purification methods, as well as those produced by genetic recombinant technology.</LI>
<LI>Diphtheria-tetanus-aP (DTaP) vaccine. An aP vaccine which also contains diphtheria and tetanus toxoids.</LI>
</OL>
<P>We included four types of control intervention.</P>
<OL>
<LI>wP vaccine: a vaccine containing killed, whole <I>B. pertussis</I> organisms. (An appropriate control where the acellular vaccine used in the experimental group contains only pertussis antigens).</LI>
<LI>Diphtheria-tetanus-wP vaccine (DTwP): a whole-cell pertussis vaccine, which also contains diphtheria and tetanus toxoids. (An appropriate control if these antigens are present in the acellular vaccine used in the experimental group).</LI>
<LI>Placebo: a preparation containing no antigens or organisms. (An appropriate control where the acellular vaccine used in the experimental group contains only pertussis antigens).</LI>
<LI>DT: diphtheria-tetanus (DT) toxoid vaccine. (An appropriate control if these antigens are present in the acellular vaccine used in the experimental group).</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure was vaccine efficacy. Trials comparing acellular vaccines with a randomised placebo/DT group permitted the determination of absolute vaccine efficacy. This is the conventional parameter used to express effectiveness in vaccine trials and represents the percentage of potential disease cases prevented by the vaccine. Absolute vaccine efficacy is calculated as (1 - RR) x 100%, where risk ratio (RR) equals the risk of disease in the vaccine group divided by the risk of disease in the placebo/DT group. Trials with no placebo/DT control do not permit the estimation of absolute efficacy but do allow an assessment of the comparative efficacy of the various vaccines within each trial (expressed as the RR of disease in the acellular compared to the whole-cell group).</P>
<P>Estimates of pertussis vaccine efficacy may vary greatly according to the case definition used (<LINK REF="REF-Blackwelder-1991" TYPE="REFERENCE">Blackwelder 1991</LINK>), and most studies report efficacy results for a range of case definitions. In this review, we examined two case definitions. The first, 'whooping cough', corresponds to the well-recognised clinical syndrome of pertussis, characterised by protracted, paroxysmal cough. The second, 'pertussis disease', includes milder cases that do not fit the classical picture but may be important in the spread of infection. The criteria for these two case definitions were as follows.</P>
<OL>
<LI>Whooping cough: 21 or more consecutive days of paroxysmal cough with confirmation of <I>B. pertussis</I> infection by culture, appropriate serology or contact with a household member who has culture-confirmed pertussis. This case definition is recommended by the WHO for use in pertussis vaccine trials (<LINK REF="REF-WHO-1991" TYPE="REFERENCE">WHO 1991</LINK>).</LI>
<LI>Pertussis disease: seven or more consecutive days of cough with confirmation of <I>B. pertussis</I> infection by culture or appropriate serology.</LI>
</OL>
<P>When studies did not report vaccine efficacy using these exact criteria, we reviewed efficacy for the case definitions that corresponded most closely to those above.</P>
<P>Where possible, we reviewed efficacy endpoints for the population who received all scheduled doses of the randomised vaccine ('per protocol' population) and for the population who received at least one dose of the randomised vaccine.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The safety outcome measures were as follows.</P>
<OL>
<LI>Failure to complete all scheduled doses of the primary immunisation series because of adverse events.</LI>
<LI>Mortality due to any cause.</LI>
<LI>Mortality due to infection.</LI>
<LI>Encephalopathy.</LI>
<LI>Convulsions.</LI>
<LI>Hypotonic-hyporesponsive episodes.</LI>
<LI>Selected minor adverse events generally considered to be associated with wP vaccines: anorexia, drowsiness, fever, irritability/fretfulness, prolonged crying, vomiting, injection site pain/tenderness, injection site redness and injection site swelling/induration.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The initial search was carried out in March 1997 and updated in March 1998 (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search terms). The search was updated again in April 2009. See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for details of search terms.</P>
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 12), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (April 2009 to January week 2, 2014) and EMBASE (April 2009 to January 2014). We also searched Biosis Previews (2009 to January 2014) and CINAHL (2009 to January 2014) as we aimed to include a broader range of databases in order to identify potential studies.</P>
<P>We used the search strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision- maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We modified the search strategy to search EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), Biosis Previews (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), and CINAHL (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-01-27 05:52:51 -0200" MODIFIED_BY="Liz Dooley">
<P>We did not manually search the reference lists of retrieved papers for either initial or updated searches, and we made no systematic attempt to obtain unpublished articles. We did not limit the searches to English language reports because such limitation has been shown to be a potential source of bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-08 07:42:12 -0300" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-09-08 07:42:09 -0300" MODIFIED_BY="[Empty name]">
<P>One of the original review authors identified and assessed trials in the first publication of this review (<LINK REF="REF-Tinnion-1999" TYPE="REFERENCE">Tinnion 1999</LINK>), to determine whether they satisfied the predefined inclusion criteria. The review author was not blinded to the trial authors or sources of the trial reports during study selection and data extraction.</P>
<P>Two review authors (LZ, SP) independently assessed the titles and abstracts of all studies identified by the searches to select new trials when updating this review. We obtained the full articles when they appeared to meet the inclusion criteria or there were insufficient data in the title and abstract to make a clear decision for their inclusion. We resolved any disagreement between the review authors about study inclusion by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-09-08 07:42:10 -0300" MODIFIED_BY="[Empty name]">
<P>We gave each study a unique identifier for use in <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>. When a single study was reported in several publications, we used the lead author of the publication containing the main efficacy or adverse event data in the identifier (for example, <LINK REF="STD-Decker-1995" TYPE="STUDY">Decker 1995</LINK>).</P>
<P>We extracted data into a database (MS Access 7.0) using pre-prepared electronic forms, which had been refined after testing on a sample of trials. We then sorted the data for entry into <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>. Two review authors (LZ, SP) independently extracted data from the new trials included for update using a standardised data extraction form. We resolved any disagreement by discussion.</P>
<P>A number of studies reported the percentage of vaccine recipients with each adverse event, but not the actual number. To permit entry into <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>, we calculated the number of participants experiencing each event from the reported percentage and the number vaccinated. This practice was required only for the common, minor adverse events. It may have introduced a small rounding error in some instances but would not have materially affected the odds ratio (OR) and overall conclusions for these common events.</P>
<P>We excluded the data from the review if adverse event data for a particular dose were available for less than 80% of those who had received the dose. This was done because excessive loss to follow-up could lead to a spurious reduction in the reported frequency of adverse events.</P>
<P>Study reports often graded adverse events according to severity. For the purposes of this review, we defined two (overlapping) severity categories. The primary category was the number of patients with any occurrence of the event under consideration. A secondary category was the number of patients with 'moderate to severe' grades of the event.</P>
<P>We applied the following rules during data extraction.</P>
<OL>
<LI>We defined primary series immunisation as the first series of up to three doses administered to children who had not previously been immunised against pertussis. We defined booster immunisation as doses administered at or after the age of 12 months to children who had completed a primary series.</LI>
<LI>When results for both pain and tenderness were reported, we used the result for pain. When results for both swelling and induration were reported, we used that for swelling.</LI>
<LI>We defined fever as a temperature of 38 ºC or greater. When a study did not report a result using this cut-point, we entered the result for the cut-point closest to 38 ºC but below 39 ºC. We defined moderate to severe fever as a temperature at or above 39 ºC. If a study did not report a result using this cut-point, we recorded the result for the next highest cut-point.</LI>
<LI>We defined moderate to severe redness and swelling/induration as reactions with a diameter of 2 cm or greater. When a study did not report a result using this cut-point, we recorded the result for the next highest cut-point.</LI>
<LI>We recorded data for deaths if the study report explicitly stated the number of deaths (or that there were no deaths), or if the absence of deaths could be confirmed by one or more of the following: (1) the number of withdrawals was stated and all were accounted for by causes other than death; (2) the report stated that there were no withdrawals, or that all participants completed the study; and (3) the report stated that there were no serious reactions and also defined death as a serious reaction. While the last requirement may seem superfluous, this was not the case, as one study stated that "there were no serious reactions to the vaccines" and then went on to report that there had been two convulsions and one death (<LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>).</LI>
<LI>We recorded data for encephalopathy, convulsions or hypotonic-hyporesponsive episodes if: (1) the report explicitly stated the number of these reactions (or that there were none); or (2) the report stated that there were no serious reactions and defined the event under consideration (encephalopathy, convulsions or hypotonic-hyporesponsive episodes) as a serious reaction.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-09-08 07:42:12 -0300" MODIFIED_BY="[Empty name]">
<P>Two review authors (LZ, SP) independently assessed the risk of bias of each eligible RCT by using The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The tool contains seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. We rated each domain as having 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We used risk ratio (RR) and 95% confidence interval (CI), rather than odds ratio (OR) and 95% CI, to estimate the risk of adverse events because the interpretation of the OR is more difficult, and it may produce inflated estimates of risk when the outcomes are frequent, as are minor adverse events.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2011-11-21 23:58:04 -0200" MODIFIED_BY="[Empty name]">
<P>Selective reporting of outcomes in some included studies may result in missing data. We based the analysis on available data but the potential impact of missing data on the findings of the review is addressed in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-01-27 06:54:12 -0200" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity across studies using the Chi<SUP>2</SUP> test. We took a conservative approach, as the test for heterogeneity has low statistical power (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>), whereby heterogeneity was assumed if the P value for the test was less than 0.10. We addressed the possible causes of heterogeneity across studies in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-25 10:05:06 -0200" MODIFIED_BY="[Empty name]">
<P>Reporting biases, especially publication bias, may be expected to occur in the majority of systematic reviews. Unfortunately there is no reliable method to detect publication bias. We examined the possibility of selective reporting of outcomes and its potential impact on the findings of the review is addressed in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Due to the small number of efficacy studies and differences between them in dose schedule, vaccine characteristics, case definitions and background pertussis incidence, we considered a meta-analysis of the efficacy data inappropriate. In any event, the adjusted absolute and relative vaccine efficacies in these studies were reported as percentages and RR, respectively. Data in this form cannot be entered into <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>.</P>
<P>We synthesised safety data using meta-analysis routines available in <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>. In the original review, the fixed-effect model was used for meta-analysis when the endpoints were homogeneous and the random-effects model was applied when there was significant heterogeneity across studies. However, this strategy is currently not recommended by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In this updated review, we used only the Mantel-Haenszel (random-effects model) method for meta-analysis because it is more appropriate than a fixed-effect model and gives more conservative estimates with wider CIs when there is significant heterogeneity across studies. Otherwise, the two models generate similar results.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We analysed adverse events for the 'any' severity category. A few studies only contributed data in the 'moderate to severe' category for some reactions. We did not include these data in the analysis because we considered it inappropriate to combine them with the 'any' severity data.</P>
<P>We performed an analysis within the following Review Manager-defined hierarchy of comparisons, outcomes and subcategories.</P>
<OL>
<LI>Comparisons: the two comparisons were (1) safety - acellular versus whole-cell vaccines; and (2) safety - acellular vaccines versus placebo/DT.</LI>
<LI>Outcomes: each safety endpoint (as described in the Outcomes section of this review) constituted a separate outcome. We considered it inappropriate to combine data across event types (for example, 'children with any adverse event') because different studies examined different event subsets. Furthermore, data for different events were obtained from the same cohort of participants within the one study. Such data cannot be legitimately combined within Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), because the observations are not independent. Finally, the use of combined endpoints could lead to an increase in one type of adverse event (for example, convulsions) being offset and therefore hidden by a decrease in another type (for example, fever).</LI>
<LI>Subcategories: some events occurred only once in any individual, either by virtue of their nature (failure to complete the primary series and death), or because they consistently led to withdrawal from further vaccine doses (encephalopathy, convulsions and hypotonic-hyporesponsive episodes). We analysed these events in terms of the number of participants experiencing the event out of the total receiving at least one dose of the vaccine. We analysed deaths and encephalopathy only for the primary series because follow-up after single booster doses was generally too short to provide useful data for these potentially delayed events. We analysed convulsions and hypotonic-hyporesponsive episodes separately for the primary series and boosters to determine if risk varied across these subcategories.</LI>
</OL>
<P>Minor adverse events often occurred more than once in any individual (after successive doses of vaccine). Data for these events were almost always reported as the number of children experiencing the event after each dose of the vaccine. Events occurring in the same individual are not independent, therefore they could not then be combined across doses. We analysed such data, therefore, using separate subcategories for each dose of the primary series and two subcategories of booster dose (acellular boosters in children who had previously been vaccinated with whole-cell vaccines, and acellular boosters in children who had previously been vaccinated with acellular vaccines). We selected the booster subcategories on the basis of a preliminary reading of the literature, which suggested that when acellular vaccines are given after acellular priming, adverse events may be more common than when they are given after whole-cell priming.</P>
<P>We could not incorporate data in the meta-analysis for minor adverse events from studies that did not report results separately for each dose (for example, <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>). We calculated a summary estimate of effect and 95% CI for each subcategory. We did not calculate an overall summary estimate for each type of adverse event for reasons given above.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We planned three sensitivity analyses, and conducted two. The first compared random- and fixed-effect analyses to determine whether the conclusions were sensitive to model selection.</P>
<P>The second pre-planned sensitivity analysis dropped any study which contributed more than 50% of the total weight to an endpoint. This was done in order to assess whether the summary estimate of effect was sensitive to the inclusion of individual, heavily weighted studies. The third pre-planned sensitivity analysis would have dropped any study with inadequate allocation concealment, but we did not identify such studies from those included in the meta-analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-08 07:49:48 -0300" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>During the initial search, the MEDLINE database yielded 13,509 citations; of these, 156 were reports of possibly eligible trials. The CENTRAL database yielded 129 citations and we identified 61 as potentially eligible trials. The updated search (March 1998) yielded 172 citations; of these, 57 were reports of possibly eligible trials. From an examination of the retrieved publications, we identified 52 eligible studies, of which we included 45 in the primary review and excluded the remaining seven studies for various reasons (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables).</P>
<P>The new comprehensive search in May 2008 yielded a total of 1197 citations (451 for MEDLINE, 403 for EMBASE and 343 for CENTRAL), plus an additional 31 search results when the searches were updated in April 2009. We identified 10 additional studies, of which we included seven and excluded three studies in the updated review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables).</P>
<P>For the 2012 update, we identified 75 search results when the search was run in May 2011 and a further 29 search results when the search was updated in January 2012; although we did not identify any new eligible studies. For this new 2014 update, we identified 54 citations when the search was run in January 2014; again we did not identify any new eligible trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Studies included in the review of efficacy</HEADING>
<P>We included six eligible RCTs of acellular vaccine efficacy in the review (<LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>; <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>; <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>; <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK>; <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>), all of which were identified by the initial search. The trial of <LINK REF="STD-Afari-1996" TYPE="STUDY">Afari 1996</LINK> compared two formulations of an acellular vaccine with a whole-cell vaccine but was ineligible because pertussis cases were not confirmed by any laboratory procedure. In any event, vaccine efficacy in this trial could not be calculated because no pertussis cases were reported in either the vaccine or control groups. <LINK REF="STD-Blennow-1988" TYPE="STUDY">Blennow 1988</LINK> reported the comparative efficacy of two acellular vaccines after randomised administration but did not employ active follow-up. In addition, it inappropriately combined case data from three different vaccination schedules across two separate studies (<LINK REF="STD-Blennow-1988" TYPE="STUDY">Blennow 1988</LINK>; <LINK REF="REF-Hedenskog-1987" TYPE="REFERENCE">Hedenskog 1987</LINK>).</P>
<P>
<LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK> did not meet the active follow-up criterion specified in this review but was a very large and well publicised study which merits some consideration. It was conducted in Sweden and involved the randomised immunisation of 82,892 infants using a British whole-cell vaccine (Evans Medical, ex Wellcome), or one of three acellular vaccines: a two-component (SKB), a three-component (Chiron-Biocine) or a four-component (Connaught). Vaccines were given at three, five and 12 months to 72,698 infants and at two, four and six months to the remaining 10,194. Efficacy data were reported only for the three, five and 12-month schedule. Follow-up for the whole-cell, three- and four-component vaccines lasted for a mean of 22 months after the third dose. Part way through the trial, the two-component acellular vaccine was shown (in <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>) to have an unacceptably low efficacy, so the blind was broken for infants who had received this vaccine; they were offered boosting with a three-component vaccine, and efficacy data were only available for this group up to the time of the third dose.</P>
<P>Cases of whooping cough in <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK> were detected by surveillance of Swedish laboratories for reports of positive <I>B. pertussis </I>culture. Computer matching was performed on each report to determine if it originated from a study participant, and a nurse then contacted the family for clinical follow-up. Based on the incidence of whooping cough with the two- and five-component vaccines in <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>, this passive follow-up method appeared to miss about 90% of cases amongst the study participants. Despite this, the RR for culture-confirmed whooping cough (21 or more days of paroxysmal cough) in the five-component versus the two-component group was the same in both trials (0.25). This suggests that although the passive follow-up in <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK> had a low sensitivity, it was not associated with differential case ascertainment, at least for this case definition.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies included in the review of safety</HEADING>
<P>Fifty-two included studies contributed safety data for one or more endpoints; of these we identified 45 in the initial search and seven in the updated search. The salient features of these trials, including details of the specific endpoints to which each trial contributed data, are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>We excluded 10 randomised trials from the review. The reasons for exclusion and study characteristics are summarised in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The overall risk of bias is presented graphically in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. </P>
<ALLOCATION MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Most of the safety trials did not describe the methods for random sequence generation and allocation concealment, which made it difficult to assess the risk of selection bias. However, selection bias may nevertheless have affected the assessment of adverse events at other than the first vaccine dose. This is because children were more likely to be withdrawn due to adverse events after whole-cell than after acellular vaccines. The incidence of adverse events in the whole-cell group after subsequent vaccine doses would be lower than if these children had remained in the study and this bias would tend to reduce the apparent difference in reactogenicity between the whole-cell and acellular vaccines. Selection bias may also have occurred in <LINK REF="STD-Pichichero-1996" TYPE="STUDY">Pichichero 1996</LINK>, a booster dose study performed as a follow-on to <LINK REF="STD-Pichichero-1993" TYPE="STUDY">Pichichero 1993</LINK> and <LINK REF="STD-Pichichero-1994" TYPE="STUDY">Pichichero 1994</LINK>, in which parents of only 83% of the participants who had enrolled in the primary series studies elected to have their child continue into the booster study.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>To be eligible for inclusion, a claim of double-blinding had to be made in the study report. However, most of the safety trials did not provide details about the methods of blinding.</P>
<P>Bias in case ascertainment may have occurred in <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> and possibly <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>, due to partial unblinding of the whole-cell vaccine. It is uncertain in which direction such a bias may have operated. On the one hand, whole-cell vaccines are generally perceived to be effective, so one might expect any bias to favour of the whole-cell preparations. On the other hand, Europe has a history of withdrawal of wP vaccines due to inadequate efficacy, so observers in these European studies might have been biased against the whole-cell vaccines. In any event, the codified, active case ascertainment procedures used in the included studies would have minimised the potential for observer bias from any source. Moreover, observer bias alone would seem an unlikely explanation for the very low efficacy of the whole-cell vaccines in these two studies. Finally, unblinding of the whole-cell vaccine groups would not have affected the acellular versus placebo/DT comparisons.</P>
<P>Pertussis in immunised children tends to have a milder clinical course than in those who are not immunised. Such milder cases may be selectively excluded, leading to over-estimation of absolute vaccine efficacy (<LINK REF="REF-Fine-1997" TYPE="REFERENCE">Fine 1997</LINK>). Laboratory confirmation of cases did not eliminate this bias, because participants had to exhibit clinical symptoms (generally at least seven days of cough) before laboratory samples were collected. This problem should not occur in direct comparisons of acellular and whole-cell vaccines.</P>
<P>The partial unblinding in <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>, <LINK REF="STD-Halperin-2003" TYPE="STUDY">Halperin 2003</LINK> and possibly <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK> might have biased the assessment of adverse events in favour of the acellular preparations. However, the only summary odds ratios (ORs) that were materially altered in the sensitivity analysis, which excluded these studies, were those for drowsiness and vomiting - endpoints which should be interpreted with caution due to other problems.</P>
<P>In all studies, detection bias could have arisen in the assessment of minor adverse event incidence because reactions to whole-cell vaccines tended to be more severe than those to acellular vaccines (more severe reactions would be more likely to be noticed by the parents). However, the requirement for parents to look for specific events and complete diaries or forms at regular intervals would have reduced the potential for such differential reporting.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Follow-up in all but one study was balanced across the vaccine groups and covered over 90% of available participants at each vaccine dose; the exception was <LINK REF="STD-Simondon-1996" TYPE="STUDY">Simondon 1996</LINK>. The rates of withdrawal and loss to follow-up were high in this study, which was included for safety only. Eighty-one per cent of the acellular group and 87% of the whole-cell group contributed data after the first dose. Data for minor adverse events were available for less than 80% of vaccinated individuals after the second and third doses, and so we excluded these doses from the review, in accordance with the pre-defined data extraction rules. In addition, we conducted a sensitivity analysis in which this study was excluded entirely.</P>
<P>Active case ascertainment was a requirement for inclusion in the efficacy review. All but one of the studies included in the review of safety actively questioned parents at regular intervals regarding prospectively defined adverse events, using standardised forms or diaries; the exception was <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>. This large study, which enrolled over 80,000 infants, did not examine minor adverse events. Data for serious adverse events were collected from participating physicians and child health nurses, by weekly surveillance of admissions to hospitals within the study area (which covered much of Sweden) and by questioning parents at the time of each vaccine dose, and when the child was aged 18 months. It is possible that this type of follow-up may have led to under-reporting of serious adverse events. However, while reducing the power of the study to detect a significant difference, there is no reason to suspect that any such under-reporting would have been differential, or introduced a systematic bias. Nevertheless, we conducted sensitivity analyses, eliminating this study from the endpoints to which it contributed, to determine if the summary ORs were materially affected.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-01-28 08:08:57 -0200" MODIFIED_BY="Liz Dooley">
<P>Some studies reported results for only a subset of the adverse events for which data had been collected. Vomiting was the endpoint most affected, with up to 11 studies collecting data but failing to report it (<LINK REF="STD-Bernstein-1992" TYPE="STUDY">Bernstein 1992</LINK>; <LINK REF="STD-Bernstein-1994" TYPE="STUDY">Bernstein 1994</LINK>; <LINK REF="STD-Blennow-1988" TYPE="STUDY">Blennow 1988</LINK>; <LINK REF="STD-Edwards-1986a" TYPE="STUDY">Edwards 1986a</LINK>; <LINK REF="STD-Edwards-1986b" TYPE="STUDY">Edwards 1986b</LINK>; <LINK REF="STD-Feldman-1992" TYPE="STUDY">Feldman 1992</LINK>; <LINK REF="STD-Feldman-1993" TYPE="STUDY">Feldman 1993</LINK>; <LINK REF="STD-Halperin-1996" TYPE="STUDY">Halperin 1996</LINK>; <LINK REF="STD-Marcinak-1993" TYPE="STUDY">Marcinak 1993</LINK>; <LINK REF="STD-Pichichero-1993" TYPE="STUDY">Pichichero 1993</LINK>; <LINK REF="STD-Pichichero-1997" TYPE="STUDY">Pichichero 1997</LINK>). Six studies collected data on drowsiness and did not report it (<LINK REF="STD-Edwards-1986a" TYPE="STUDY">Edwards 1986a</LINK>; <LINK REF="STD-Edwards-1986b" TYPE="STUDY">Edwards 1986b</LINK>; <LINK REF="STD-Kanra-1993a" TYPE="STUDY">Kanra 1993a</LINK>; <LINK REF="STD-Kanra-1993b" TYPE="STUDY">Kanra 1993b</LINK>; <LINK REF="STD-Pichichero-1993" TYPE="STUDY">Pichichero 1993</LINK>; <LINK REF="STD-Pichichero-1997" TYPE="STUDY">Pichichero 1997</LINK>), while data for anorexia were collected but not reported in three studies (<LINK REF="STD-Blennow-1988" TYPE="STUDY">Blennow 1988</LINK>; <LINK REF="STD-Pichichero-1993" TYPE="STUDY">Pichichero 1993</LINK>; <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>). Qualitative statements within some reports indicated that data for these events had been omitted because they had occurred with similar frequency in each vaccine group. In contrast, those studies which did include extractable data generally reported a significant difference. Accordingly, there is a possibility that inclusion of the missing data could significantly alter the pooled ORs for these endpoints.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Bias introduced by the methods of the review</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Study selection and data extraction</HEADING>
<P>The review author was not blinded to study authorship or journal of publication, allowing the potential for bias during study selection and data extraction. The use of predefined criteria for study inclusion and rules for data extraction helped to minimise this potential. While desirable, the need for review author blinding during study selection and data extraction is unproven. Berlin and co-workers have shown that rigorous blinding had neither a clinically nor statistically significant effect on the summary OR in a random sample of five meta-analyses (<LINK REF="REF-Berlin-1997" TYPE="REFERENCE">Berlin 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Publication bias</HEADING>
<P>It is well recognised that studies reporting statistically significant results are more likely to be published than those that do not (<LINK REF="REF-Mahid-2008" TYPE="REFERENCE">Mahid 2008</LINK>). The review is potentially subject to bias arising from this source because the databases we searched for eligible trials only included published studies. While it would be desirable to identify unpublished studies and include these in the review, this was precluded by resource limitations. Although we may have missed small unpublished studies of vaccine safety in this manner, it seems unlikely that an efficacy or safety trial large enough to materially affect the conclusions of the review would have been suppressed from publication.</P>
<P>Publication bias also occurred within studies and took two forms. The first involved the selective reporting of events as previously mentioned. The second type of within-study publication bias was the tendency to collect adverse event data at several time points and then report the time point which showed the maximum difference between vaccines. This is not a problem as long as one remains aware that the summary results reflect the maximum observable difference between vaccines and not the difference at a specific time point.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Confounding in the included studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Confounding due to the use of erythromycin for post-exposure prophylaxis of pertussis contacts</HEADING>
<P>Erythromycin prophylaxis would not confound the assessment of vaccine safety. By reducing the number of pertussis cases observed in a study it could widen the CI for vaccine efficacy but as long as its use was not associated with one or other vaccine type, then it should not act as a confounder. Equivalent use would be expected in double-blind studies but there is some doubt that all the efficacy studies in this review were truly blinded in respect to the whole-cell vaccines. <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> and possibly <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK> used identifiable whole-cell vaccines and in all studies the rate of adverse reactions following whole-cell vaccines was appreciably higher than after the acellular vaccines or placebo/DT. These factors may have led to partial unblinding of the whole-cell vaccines during the efficacy follow-up period, which in turn may have allowed differential use of erythromycin prophylaxis.</P>
<P>
<LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK> made no statement regarding erythromycin prophylaxis during the study. In <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>, prophylaxis was assumed to occur in accordance with Swedish guidelines, which recommend it only in infants under six months of age. Actual prophylaxis use was not documented in the trial, but if the assumption is valid then it should not have affected the main efficacy follow-up period (which started after the third vaccine dose, at the age of six months). In another Swedish study, <LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>, the first vaccination was scheduled at a minimum age of five months in order to avoid potential problems due to use of prophylaxis during the efficacy follow-up period (which began at a minimum age of seven months). In any case, this study did not use a whole-cell vaccine, and blinding of the two acellular vaccines and placebo was confirmed by a questionnaire. In a third Swedish study, <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>, prophylaxis use was low (six per cent) and equivalent in the two study groups. <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK> and <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK> included no information on this topic. The study vaccines were adequately blinded at administration, but partial unblinding may have occurred during the efficacy assessment due to a higher incidence of adverse events in the whole-cell arms. In theory this might have provided the opportunity for differential use of prophylaxis but the probability of such bias seems low.</P>
<P>Overall, erythromycin prophylaxis appears unlikely to have significantly confounded the estimation of vaccine efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Confounding due to the use of antipyretic/analgesic medication</HEADING>
<P>The use of antipyretic/analgesic medication would be a potential confounding factor in the assessment of reactogenicity. Truly prophylactic use (i.e. use before a fever or pain appeared) should be non-differential in a blinded study, but by lowering the incidence of fever and pain in each treatment group, it would reduce the ability to detect a difference between vaccines. Antipyretic/analgesic medication might also be used in a 'reactive' fashion after a low fever or mild pain had occurred, in order to prevent a higher fever or more severe pain. One would expect this type of use to be differential (more common with the more reactogenic vaccines). The result would be to reduce the apparent difference between vaccines in the incidence of severe fever or pain. It would also reduce the apparent difference in the incidence of systemic events that may be associated with a high fever, such as convulsions, irritability, anorexia, vomiting, drowsiness and withdrawal from the study.</P>
<P>No study report specifically stated that prophylactic use of antipyretic/analgesic medications was permitted. A few stated that it was not permitted, or that it was discouraged, while most made no statement. Similarly, only a few studies documented 'reactive' use of antipyretic/analgesic medication. It is worth noting that where such use was recorded, parents were asked to give the drug only when the child's temperature had reached a point higher than that used for defining fever in the analysis of reactogenicity, or if the child was in obvious pain or distress. This would have served to minimise the effect on the assessment of fever and other minor adverse events.</P>
<P>Allowance for undocumented antipyretic/analgesic use would strengthen the conclusion that acellular vaccines are less reactogenic that the whole-cell vaccines, but weaken the finding of no significant difference between the acellular vaccines and placebo.</P>
</SUBSECTION>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-08 07:49:48 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Absolute vaccine efficacy - whooping cough</HEADING>
<P>Four of the eligible efficacy trials included a randomised placebo/diphtheria-tetanus (DT) group and were able to determine the absolute efficacy of acellular vaccines against a case definition identical to, or closely approximating 'whooping cough', as specified in this review. These results are summarised below. 'All': efficacy (with 95% confidence interval (CI), where reported) in participants receiving all scheduled vaccine doses; "&#8805; 1 immunisation (immunis) dose": efficacy (with 95% CI, where reported) in participants receiving at least one dose of the randomised vaccine. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for information on the composition of each vaccine.</P>
<P>Study: <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>
<BR/>Dose schedule: 3, 5 and 12 months.<BR/>Vaccine: Amvax [1] - All: 71% (63 to 78); &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>
<BR/>Dose schedule: 5 to 11, and 7 to 13 months.<BR/>Vaccine: JNIH7 [1] - All: 78% (57 to 88); &#8805; 1 immunisation dose: not reported.<BR/>Vaccine: JNIH6 [2] - All: 78% (58 to 89), &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Vaccine: SKB [3] - All: 84% (76 to 89); &#8805; 1 immunisation dose: 82% (73 to 87).<BR/>Vaccine: Chiron-Biocine [3] - All: 84% (76 to 90); &#8805; 1 immunisation dose: 84% (76 to 89).<BR/>Vaccine: Connaught [W] - All: 36% (14 to 52); &#8805; 1 immunisation dose: 34% (13 to 50).</P>
<P>Study: <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Vaccine: SKB [2] - All: 59% (51 to 66); &#8805; immunisation dose: 59% (51 to 66).<BR/>Vaccine: Connaught [5] - All: 85% (81 to 89); &#8805; immunisation dose: 84% (80 to 88).<BR/>Vaccine: Connaught [W] - All: 48% (37 to 58); &#8805; immunisation dose: 48% (37 to 57).</P>
<P>In the trial of <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>, comparison with a non-randomised controlled trial (RCT) DT control group gave an estimated absolute efficacy against whooping cough of 84% (95% CI 77% to 89%) for the whole-cell vaccine and 79% (95% CI 72% to 85%) for the acellular vaccine. In <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK>, a substudy examined the incidence of whooping cough in vaccine recipients who came into household contact with confirmed pertussis cases. In this substudy, comparison with an unvaccinated control group gave an estimated absolute efficacy of 96% for the whole-cell vaccine and 85% for the acellular vaccine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Relative vaccine efficacy - whooping cough</HEADING>
<P>Four eligible studies determined the relative risk of whooping cough after administration of acellular vaccines compared to that after whole-cell vaccines. Results are summarised below. Risk ratios (RRs) are expressed in relation to the incidence in the whole-cell vaccine group. A RR &lt; 1.0 favours the acellular vaccine.</P>
<P>Study: <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Whole-cell comparator: Connaught [W].<BR/>Vaccine: SKB [3] - All: 0.25 (0.17 to 0.36); &#8805; 1 immunisation dose: 0.28 (0.20 to 0.39).<BR/>Vaccine: Chiron-Biocine [3P] - All: 0.25 (0.17 to 0.36); &#8805; 1 immunisation dose: 0.25 (0.17 to 0.36).</P>
<P>Study: <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Whole-cell comparator: Connaught [W].<BR/>Vaccine: SKB [2] - All: 0.83 (0.65 to 1.05); &#8805; 1 immunisation dose: 0.83 (0.66 to 1.05).<BR/>Vaccine: Connaught [5] - All: 0.29 (0.21 to 0.40); &#8805; 1 immunisation dose: 0.30 (0.22 to 0.42).</P>
<P>Study: <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>
<BR/>Dose schedule: 2, 4 to 10, 6 to 12, and 15 to 18 months.<BR/>Whole-cell comparator: Lederle [W].<BR/>Vaccine: Lederle/Takeda [4] - All: 2.1 (upper 1-sided 95% CI = 3.3); &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK>
<BR/>Whole-cell comparator: Pasteur-Merieux [W].<BR/>Dose schedule: two, four and six months.<BR/>Pasteur-Merieux [2] - All: 2.42 (1.35 to 4.34); &#8805; 1 immunisation dose: 2.06 (1.25 to 3.39).</P>
<P>As previously noted, <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK> did not meet the active follow-up criterion specified in this review, but the passive follow-up method used in that trial (although low in sensitivity) did not appear to be associated with differential case ascertainment for the 'whooping cough' case definition. Results from this study are summarised below:</P>
<P>Study: <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>
<BR/>Dose schedule: 3, 5 and 12 months.<BR/>Whole-cell comparator: Evans Medical [W].<BR/>Vaccine: Chiron-Biocine [3] - All: 2.55 (1.50 to 4.33); &#8805; 1 immunisation dose: 1.84 (1.36 to 2.51).<BR/>Vaccine: Connaught [5] - All: 1.40 (0.78 to 2.52); &#8805; 1 immunisation dose: 1.25 (0.90 to 1.75).</P>
<P>Thus, the efficacy of the five-component vaccine against this case definition was not significantly different to that of the whole-cell vaccine, whereas that of the three-component vaccine was. While this suggests that the five-component vaccine may have an advantage over the three-component, it should be noted that the two acellular vaccines were not actually significantly different from each other (the 95% CIs overlapped). Furthermore, any conclusions from this study must be tempered by its reliance on passive follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Absolute vaccine efficacy - pertussis disease</HEADING>
<P>Four trials determined absolute vaccine efficacy against pertussis disease, as defined in this review. These results are summarised below:</P>
<P>Study: <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>
<BR/>Dose schedule: 3, 5 and 12 months.<BR/>Vaccine: Amvax [1] - All: 54% (43 to 63); &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>
<BR/>Dose schedule: 5 to 11, and 7 to 13 months.<BR/>Vaccine: JNIH7 [1] - All: 41% (12 to 60); &#8805; 1 immunisation dose: not reported.<BR/>Vaccine: JNIH6 [2] - All: 58% (35 to 73); &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Vaccine: SKB [3] - All: 71% (61 to 78); &#8805; 1 immunisation dose: not reported.<BR/>Vaccine: Chiron-Biocine [3] - All: 71% (61 to 79); &#8805; 1 immunisation dose: not reported.<BR/>Vaccine: Connaught [W] - All: 23% (1 to 40); &#8805; 1 immunisation dose: not reported.</P>
<P>Study: <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>
<BR/>Dose schedule: two, four and six months.<BR/>Vaccine: SKB [2] - All: 44% (35 to 52); &#8805; 1 immunisation dose: 44% (35 to 52).<BR/>Vaccine: Connaught [5] - All: 78% (73 to 83); &#8805; 1 immunisation dose: 78% (73 to 83).<BR/>Vaccine: Connaught [W] - All: 42% (30 to 51); &#8805; 1 immunisation dose: 41% (30 to 50).</P>
<P>In <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>, comparison with a non-RCT DT control group gave an estimated absolute efficacy against pertussis disease of 83% (95% CI 76% to 88%) for the whole-cell vaccine and 72% (95% CI 62% to 79%) for the acellular vaccine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Relative vaccine efficacy - pertussis disease</HEADING>
<P>One trial determined relative vaccine efficacy against pertussis disease, as defined in this review. The results of this trial are summarised below.</P>
<P>Study: <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK>
<BR/>Whole-cell comparator: Pasteur-Merieux (W).<BR/>Dose schedule: two, four and six months.<BR/>Pasteur-Merieux [2] - All: 1.54 (1.23 to 1.94); &#8805; 1 immunisation dose: 1.43 (1.16 to 1.74).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of acellular and whole-cell vaccines</HEADING>
<P>Seven additional trials identified by the updated search (2009) provided available data only for minor adverse events. Updated meta-analysis including the data from these seven trials did not significantly alter the results of any endpoint (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">1. Failure to complete all scheduled doses of the primary immunisation series because of adverse events</HEADING>
<P>The risk of failure to complete the primary series because of adverse events was significantly lower in acellular vaccine recipients compared to those immunised with whole-cell vaccines (11 trials with a total of 108,909 participants, RR 0.23, 95% CI 0.12 to 0.43, P value &lt; 0.00001) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Mortality due to any cause</HEADING>
<P>The risk of death due to any cause did not differ significantly between acellular and whole-cell recipients (nine trials with a total of 122,451 participants, RR 0.87, 95% CI 0.62 to 1.22, P value = 0.41) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mortality due to infection</HEADING>
<P>The risk of death due to infection did not differ significantly between acellular and whole-cell recipients (two trials with a total of 34,498 participants, RR 0.97, 95% CI 0.23 to 4.16, P value = 0.97) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Encephalopathy</HEADING>
<P>No cases of encephalopathy after primary series immunisation were observed in 81,601 acellular and 32,161 whole-cell vaccine recipients (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Convulsions</HEADING>
<P>The risk of convulsion after primary series immunisation was significantly lower in acellular vaccine recipients compared to those immunised with whole-cell vaccines (nine trials with a total of 124,387 participants, RR 0.47, 95% CI 0.31 to 0.73, P value = 0.0007) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Hypotonic-hyporesponsive episodes</HEADING>
<P>The risk of hypotonic-hyporesponsive episodes after primary series immunisation was significantly lower in acellular vaccine recipients compared to those immunised with whole-cell vaccines (six trials with a total of 121,573 participants, RR 0.26, 95% CI 0.08 to 0.81, P value = 0.02) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). No hypotonic-hyporesponsive episodes were recorded after any booster dose in the 2171 acellular and 316 whole-cell vaccine recipients for whom data were available (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Minor adverse events</HEADING>
<P>Minor adverse events (anorexia, drowsiness, fever, irritability/fretfulness, prolonged crying, vomiting, injection site pain/tenderness/redness/swelling) after most vaccine doses were significantly less common in acellular vaccine recipients than in those immunised with whole-cell vaccines (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> to <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
<P>We conducted two pre-planned sensitivity analyses. The first compared random-effects and fixed-effect analyses to determine whether the conclusions were sensitive to model selection. This led to changes from a non-significant difference (a random-effects model) to a significant difference in favour of acellular vaccines for two endpoints: vomiting (the third primary dose and booster after acellular priming), and drowsiness (the first primary dose). The second repeated the random-effects analysis after removing, from each endpoint, any study allocated more than 50% of the total weight in the original analysis. This led to changes from a significant difference in favour of acellular vaccines to a non-significant difference for vomiting after the first and second primary series doses.</P>
<P>We performed an unplanned sensitivity analysis excluding <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>. This was the largest study in the review and differed from the others in that follow-up was not fully active. Removal of this study did not change the significance or otherwise of any endpoints.</P>
<P>We performed a second unplanned sensitivity analysis excluding three studies with possible inadequate blinding (<LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>; <LINK REF="STD-Halperin-2003" TYPE="STUDY">Halperin 2003</LINK>). This resulted in the summary OR for drowsiness changing from non-significant to significant (in favour of acellular vaccines), while that for vomiting after the first and second primary series doses changed from significant to non-significant.</P>
<P>No analysis of any endpoint resulted in a RR that significantly favoured whole-cell vaccines.</P>
<P>We also examined the incidence of minor adverse events in cohorts of children after successive doses of acellular and whole-cell vaccines. The incidence of anorexia and vomiting fell with successive doses of the primary series for both acellular and whole-cell vaccines. The incidence of irritability and injection site pain/tenderness remained relatively constant, whereas the incidence of fever, local redness and swelling/induration increased markedly over the primary series of acellular vaccines (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>).</P>
<P>The incidence of minor adverse reactions in children boosted with acellular vaccines after whole-cell priming was lower than if whole-cell vaccines were used for every dose. However, an unexpected rise in the incidence of fever, irritability, local pain, redness and swelling was seen among children primed and boosted with acellular vaccines compared with those boosted with acellular vaccines after whole-cell priming (<LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison of acellular vaccines and placebo/DT</HEADING>
<P>The number of studies and participants in this comparison was considerably less than in the comparison of acellular with whole-cell vaccines, with a maximum of four studies contributing data to any endpoint. No booster data were available (<LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>; <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">1. Failure to complete all scheduled doses of the primary immunisation series because of adverse events</HEADING>
<P>There was no statistically significant difference between acellular and placebo/DT recipients in terms of the risk of failure to complete the primary series because of adverse events (four trials with a total of 25,901 participants, RR 0.70, 95% CI 0.38 to 1.29, P value = 0.25) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Mortality due to any cause</HEADING>
<P>The risk of death due to any cause did not differ significantly between acellular and placebo/DT recipients (four trials with a total of 25,901 participants, RR 1.08, 95% CI 0.26 to 4.42, P value = 0.91) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mortality due to infection</HEADING>
<P>The risk of death due to infection did not differ significantly between acellular and placebo/DT recipients (four trials with a total of 25,901 participants, RR 1.21, 95% CI 0.19 to 7.80, P value = 0.84) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Encephalopathy</HEADING>
<P>No cases of encephalopathy after primary series immunisation were observed in 14,521 acellular and 4129 placebo/DT recipients (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Convulsions</HEADING>
<P>There was no statistically significant difference between acellular and placebo/DT recipients in terms of the risk of convulsion after primary series immunisation (four trials with a total of 25,901 participants, RR 0.44, 95% CI 0.12 to 1.69, P value = 0.23) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Hypotonic-hyporesponsive episodes</HEADING>
<P>The risk of hypotonic-hyporesponsive episodes after primary series immunisation did not differ significantly between acellular and placebo/DT recipients (four trials with a total of 25,901 participants, RR 0.29, 95% CI 0.02 to 5.13, P value = 0.40) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Minor adverse events</HEADING>
<P>There was no statistically significant difference between acellular and placebo/DT in terms of the risk of minor adverse events (anorexia, drowsiness, fever, irritability/fretfulness, prolonged crying, vomiting, injection site pain/tenderness, injection site redness and injection site swelling/induration) after most vaccine doses (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> to <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
<P>Most endpoints in this comparison were homogeneous. For these, the fixed-effect analysis differed from the random-effects analysis in only three cases: the RRs for convulsions in the primary series and swelling/induration after the first two primary doses were significantly in favour of placebo/DT in the fixed-effect analysis but non-significant in the random-effects analysis.</P>
<P>We conducted a second planned sensitivity analysis in which the random-effects analysis was repeated after removing from each endpoint any study which had been assigned more than 50% of the total weight. A number of endpoints contained data from only a single study and were thus not evaluable after that study had been excluded. In addition, the RR for swelling/induration after the second dose became significant and after the third dose became non-significant.</P>
<P>No analysis of any endpoint resulted in a RR which significantly favoured acellular vaccines over placebo/DT.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-19 08:25:34 -0300" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-09-19 08:25:34 -0300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>Due to a small number of efficacy trials and significant heterogeneity across studies regarding immunisation schedules, case definitions, follow-up duration and background pertussis rates, it was not applicable to conduct a meta-analysis in this review to estimate the pooled efficacy of acellular pertussis vaccines against whooping cough. However, some considerations could be made on the basis of the data from six included trials.</P>
<P>Firstly, comparisons across studies suggest that multi-component (&#8805; three) acellular vaccines have a higher efficacy than one- and two-component vaccines against both typical whooping cough (characterised by 21 or more consecutive days of paroxysmal cough with confirmation of <I>B. pertussis</I> infection by culture, appropriate serology or contact with a household member who has culture-confirmed pertussis) and mild pertussis disease (characterised by seven or more consecutive days of cough with confirmation of <I>B. pertussis</I> infection by culture or appropriate serology) (<LINK REF="REF-WHO-1991" TYPE="REFERENCE">WHO 1991</LINK>). The efficacy of multi-component vaccines varied from 84% to 85% in preventing typical whooping cough and from 71% to 78% in preventing mild pertussis disease (<LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>). In contrast, the efficacy of one- and two-component vaccines varied from 59% to 78% against typical whooping cough and from 41% to 58% against mild pertussis disease (<LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>; <LINK REF="STD-Trollfors-1995" TYPE="STUDY">Trollfors 1995</LINK>). The superiority of five-component vaccines over two-component vaccines in preventing typical whooping cough has been confirmed by direct comparison of such vaccines in the trials of <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> and <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>. However, the data are insufficient to determine whether there is a clinically significant difference between three- and five-component vaccines. Comparisons across trials do not confirm such a difference. A small and statistically non-significant difference was observed in the trial of <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>, but incomplete case ascertainment would have reduced the statistical power of the study.  </P>
<P>Secondly, not all whole-cell vaccines are efficacious, as has traditionally been thought, as evidenced by the low efficacy of the Connaught whole-cell vaccine used in the trials of <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK> (efficacy: 36%; 95% confidence interval (CI) 14% to 52%) and <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> (efficacy: 48%; 95% CI 37% 58%). This makes it more difficult to interpret the results of direct efficacy comparisons between acellular vaccines and whole-cell vaccines across studies. The multi-component (&#8805; 3) acellular vaccines are more effective than low-efficacy whole-cell vaccines, but may be less effective than the highest-efficacy whole-cell vaccines in preventing whooping cough (<LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>; <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>; <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>; <LINK REF="STD-Simondon-1997" TYPE="STUDY">Simondon 1997</LINK>).</P>
<P>Thirdly, randomised controlled trials (RCTs) generally measure vaccine efficacy but not the effectiveness of a large-scale vaccination programme. Compliance with immunisation is likely to be higher in these studies than would be expected in actual practice and 'real world' effectiveness would probably be correspondingly lower. Having said this, it is encouraging that where data were available for the population who did not complete all scheduled doses, efficacy was only marginally lower than in those who had received all vaccine doses. Moreover, the effectiveness of national vaccination programmes with acellular pertussis (aP) vaccines in preventing whooping cough in children has been shown in Japan, the United States and Canada, where such vaccines have been routinely used among infants and young children (<LINK REF="REF-Bettinger-2007" TYPE="REFERENCE">Bettinger 2007</LINK>; <LINK REF="REF-Bisgard-2005" TYPE="REFERENCE">Bisgard 2005</LINK>; <LINK REF="REF-Kuno_x002d_Sakai-2004" TYPE="REFERENCE">Kuno-Sakai 2004</LINK>; <LINK REF="REF-Watanabe-2005" TYPE="REFERENCE">Watanabe 2005</LINK>). In contrast, recent research from Queensland, Australia (<LINK REF="REF-Sheridan-2012" TYPE="REFERENCE">Sheridan 2012</LINK>) and Oregon, United States (<LINK REF="REF-Liko-2013" TYPE="REFERENCE">Liko 2013</LINK>) suggests that children primed with acellular rather than whole-cell pertussis vaccine are at a higher risk of subsequent pertussis. The authors raised the hypothesis that the recent pertussis epidemic in many high-income countries might be related to the shift from whole-cell pertussis (wP) to aP vaccines. However, further nationwide studies are needed to test this hypothesis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>The comparison of acellular vaccines with whole-cell vaccines displays that the former have a better safety profile. The superiority of acellular vaccines over whole-cell vaccines is evident for all selected minor reactions during the primary and booster doses. The incidence of primary series non-completion due to adverse events is significantly lower for acellular vaccines than for whole-cell vaccines. Acellular vaccines are also less likely to cause febrile convulsions and hypotonic-hyporesponsive episodes during the primary series. A benefit has not been seen in respect to febrile convulsions after booster doses, hypotonic-hyporesponsive episodes after booster doses or encephalopathy during the primary series, but the former was very uncommon, while the latter two were non-existent with either type of vaccine. The risk of death due to any cause, and death due to infection, were similar between acellular and whole-cell vaccine recipients.</P>
<P>The comparison of acellular vaccines with placebo/DT also reveals a good safety profile of such vaccines. There is no significant difference between acellular vaccines and placebo/DT in the incidence of severe or minor adverse events, with the exception of injection site swelling, which was significantly more common among recipients of acellular vaccines than placebo/DT after the third dose during the primary series. However, given the uncommon occurrence of severe adverse reactions, the statistical power of this meta-analysis may be not enough to detect small but clinically relevant differences between acellular vaccines and placebo/DT. In this sense, continuing surveillance for rare severe adverse reactions of aP vaccines may be warranted.</P>
<P>Two points about minor adverse events of acellular vaccines deserve special comment. Firstly, a significant increase in incidence (number of events per 1000 recipients) from the first dose to the third dose during the primary series has been observed for some minor adverse reactions, such as fever (from 60 to 162), local redness (from 96 to 162) and swelling (from 117 to 275). In spite of this increase, the incidence of these minor adverse events among recipients of acellular vaccines is still lower than that among recipients of whole-cell vaccines. Secondly, the incidence of adverse reactions in children boosted with acellular vaccines after whole-cell priming is lower than if whole-cell vaccines are used for every dose. Comparison across studies displays a rise in the incidence of some minor adverse reactions (fever, irritability, local pain, redness and swelling) among children primed and boosted with acellular vaccines compared with those boosted with acellular vaccines after whole-cell priming. The rate of reported injection site reactions continues to increase after the fifth consecutive dose of aP vaccine at four to six years of age. Although redness and swelling increase to rates similar to those associated with five consecutive doses of whole-cell vaccine, injection site tenderness after five does of acellular vaccine is significantly lower than after five doses of whole-cell vaccine, and the vaccine is preferred by parents of these preschool-aged children. These increases in injection site reactions may have limited clinical implications as the current evidence suggests an acceptable safety profile of acellular vaccines for booster doses among preschool children and adolescents who had been primed with acellular vaccines (<LINK REF="REF-Jacquet-2006" TYPE="REFERENCE">Jacquet 2006</LINK>; <LINK REF="REF-Pichichero-2005" TYPE="REFERENCE">Pichichero 2005</LINK>; <LINK REF="REF-Pichichero-2006" TYPE="REFERENCE">Pichichero 2006</LINK>).</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>This review provides evidence to answer the questions posed in the <LINK TAG="OBJECTIVES" TYPE="SECTION">Objectives</LINK> section.</P>
<P>1. Do acellular vaccines protect against pertussis?</P>
<P>All aP vaccines reported in the efficacy trials protect against pertussis. Acellular vaccines with three or more components (multi-component vaccines) are effective against both classical whooping cough and mild pertussis disease.</P>
<P>2. Do different types of acellular vaccine confer different levels of protection?</P>
<P>Currently available evidence suggests that multi-component vaccines confer better protection against both classical whooping cough and mild pertussis infection than vaccines containing only one or two components. However, the clinical implication of any possible superiority of multi-component vaccines over mono- and bivalent vaccines in the efficacy demonstrated by RCTs should be considered with caution. The effectiveness of vaccination programmes on a national scale for controlling infectious disease depends not only on the efficacy of the vaccine, but also other factors such as the vaccination schedule and adherence, and transportation and storage of the vaccine. Moreover, indirect effects in producing herd immunity in the population may also contribute to the effectiveness of large-scale vaccination in controlling infectious diseases (<LINK REF="REF-Carlsson-2009" TYPE="REFERENCE">Carlsson 2009</LINK>; <LINK REF="REF-Stephens--2008" TYPE="REFERENCE">Stephens 2008</LINK>). Therefore, successful control of pertussis infections by two-component vaccines in Japan and in other countries (<LINK REF="REF-Carlsson-2009" TYPE="REFERENCE">Carlsson 2009</LINK>; <LINK REF="REF-Hviid-2004" TYPE="REFERENCE">Hviid 2004</LINK>; <LINK REF="REF-Kuno_x002d_Sakai-2004" TYPE="REFERENCE">Kuno-Sakai 2004</LINK>) does not necessarily exclude the potential additional benefits of large-scale vaccination with multi-component vaccines.</P>
<P>3. Do acellular vaccines protect against pertussis to the same degree as the whole-cell vaccines which they are intended to replace?</P>
<P>The answer here remains unclear because the effectiveness of whole-cell vaccines varies and there are limited efficacy and effectiveness data with different whole-cell vaccines. Studies to date indicate that multi-component acellular vaccines are more effective than low-efficacy whole-cell vaccines but may be less effective than the highest-efficacy whole-cell vaccines.</P>
<P>4. Do acellular vaccines cause fewer side effects than whole-cell vaccines?</P>
<P>Acellular vaccines cause fewer side effects than whole-cell vaccines during the primary immunisation series, when used as a booster in toddlers and four-to-six-year-olds who have previously received whole-cell vaccines, and when used in toddlers after acellular priming.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-09-08 07:34:08 -0300" MODIFIED_BY="[Empty name]">
<P>As previously mentioned, meta-analysis was not applicable in this review to estimate the pooled efficacy. However, three large, double-blind RCTs from Italy, Sweden and Germany (<LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK>; <LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>) provide high-level evidence about effectiveness of multi-component aP vaccines against whooping cough.</P>
<P>Regarding the safety profile, meta-analysis of 52 studies provides robust evidence about the superiority of aP vaccines over whole-cell vaccines. However, the heterogeneity of results across studies deserves special consideration.</P>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity in the meta-analysis of safety endpoints</HEADING>
<P>Many of the safety endpoints in the comparison of acellular with whole-cell vaccines displayed significant heterogeneity. This heterogeneity did not invalidate the finding of significant differences for various endpoints because the point estimates for the individual studies were almost always in favour of the acellular vaccines. In other words, the individual study results were quantitatively but not qualitatively different.</P>
<P>Possible explanations for the heterogeneity, which was sometimes substantial, include the following.</P>
<OL>
<LI>Differences between studies in the definition or recording of adverse events. For example, the threshold for fever differed slightly amongst studies, albeit within the confines of the definition specified in the review. Prolonged crying was defined as longer then one hour in some studies and longer than three hours in others. In some studies the mildest recorded category of redness or swelling was 'any', whereas in others it was a diameter of one centimetre. Some studies reported the incidence of events within a certain time period of each dose, whereas others reported the incidence at a specific time point.</LI>
<LI>The use of different immunisation schedules. Most studies used a two-, four- and six-month schedule for the primary series but others used a three-, five- and 12-month schedule. <LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK> used a 5 to 11-month, and 7 to 14-month schedule. The difference in reactogenicity between acellular and whole-cell vaccines has been shown to be less with the earlier dose schedule, primarily because the reactogenicity of whole-cell vaccines increases with the age of administration (for example, in <LINK REF="STD-Miller-1997" TYPE="STUDY">Miller 1997</LINK>).</LI>
<LI>Differences in the reactogenicity of separate acellular vaccines. This is a possibility, although a number of head-to-head studies of acellular vaccines have not shown any consistent differences (for example, <LINK REF="STD-AHGSPV-1988" TYPE="STUDY">AHGSPV 1988</LINK>; <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK>; <LINK REF="STD-Decker-1995" TYPE="STUDY">Decker 1995</LINK>; <LINK REF="STD-Englund-1994a" TYPE="STUDY">Englund 1994a</LINK>; <LINK REF="STD-Greco-1996" TYPE="STUDY">Greco 1996</LINK>; <LINK REF="STD-Pichichero-1997" TYPE="STUDY">Pichichero 1997</LINK>).</LI>
<LI>Differences in the reactogenicity of the whole-cell vaccines used as controls.</LI>
<LI>Differences in the duration over which adverse events were recorded.</LI>
<LI>Differences in the susceptibility of different patient populations (for example, different racial groups) to adverse events after pertussis immunisation.</LI>
<LI>Given the large number of endpoints examined in the review and the conservative critical value for determining heterogeneity, approximately 10% of the endpoints would be expected to fail the test of homogeneity by chance alone.</LI>
</OL>
<P>A special comment is warranted about drowsiness after the first and second doses of the primary series. The statistical test displays an extreme heterogeneity for this endpoint and it strongly suggests inconsistent findings across studies. By visual inspection of the forest plot, we identified that <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> was responsible for this extreme heterogeneity. In contrast with other studies, <LINK REF="STD-Gustafsson-1996" TYPE="STUDY">Gustafsson 1996</LINK> demonstrated the results in favour of whole-cell vaccines. This is only one safety endpoint where the superiority of whole-cell vaccines over acellular vaccines was reported. Partial unblinding of the whole-cell vaccine arm occurred in this trial but the expected effect of unblinding would be to bias the assessment of adverse events in favour of the acellular preparations. We have no plausible explanations for this finding.</P>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The potential sources and impact of bias and confounding have been addressed in the <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> section. In addition to the potential bias and confounding, the following limitations of the review should also be noted.</P>
<OL>
<LI>The review examines the safety of acellular vaccines as a group and does not attempt to determine whether different vaccines have different safety profiles.</LI>
<LI>The absence of statistically significant differences between acellular vaccines and placebo/DT in respect to severe adverse events may be due to a lack of statistical power in the meta-analysis, rather than a true lack of difference.</LI>
<LI>The review is based entirely on public domain information and did not use any confidential vaccine manufacturer data that might contribute to the decisions of regulatory agencies.</LI>
</OL>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-09-08 07:37:54 -0300" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL, MEDLINE and EMBASE for systematic reviews of pertussis vaccines and identified 11 papers. Two could be compared to our review (<LINK REF="REF-Casey-2005" TYPE="REFERENCE">Casey 2005</LINK>; <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK>). Like us, <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> searched the literature without any publication year restriction, whereas <LINK REF="REF-Casey-2005" TYPE="REFERENCE">Casey 2005</LINK> limited their search to efficacy studies from 1990 onwards. Unlike us, both reviews included observational studies. <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> and our review both included 52 studies; most but not all studies were common to <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> and our review.                           </P>
<SUBSECTION>
<HEADING LEVEL="3">Efficacy</HEADING>
<P>All efficacy studies of acceptable quality were published between 1988 and 1997.</P>
<P>
<LINK REF="REF-Casey-2005" TYPE="REFERENCE">Casey 2005</LINK> retrieved eight efficacy trials; six of them were also included in our efficacy review. Of the remaining two, one was a case-controlled study (<LINK REF="REF-Liese-1997" TYPE="REFERENCE">Liese 1997</LINK>) and the other a cohort study (<LINK REF="REF-Schmitt-1996" TYPE="REFERENCE">Schmitt 1996</LINK>).</P>
<P>
<LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> included <LINK REF="STD-Afari-1996" TYPE="STUDY">Afari 1996</LINK> and <LINK REF="STD-Decker-1995" TYPE="STUDY">Decker 1995</LINK>, which we excluded due to the absence of laboratory-confirmed pertussis cases. (<LINK REF="STD-Decker-1995" TYPE="STUDY">Decker 1995</LINK> also lacked efficacy data). However, we included these studies in the safety review.</P>
<P>In contrast to <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK>, we did not study the absolute efficacy of whole-cell vaccines and we did not perform meta-analyses of efficacy studies due to significant heterogeneity.</P>
<P>Several studies of acellular vaccines with three to five components showed that the efficacy of the acellular vaccines was superior or equal to the whole-cell comparator. <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> claims that <LINK REF="STD-AHGSPV-1997" TYPE="STUDY">AHGSPV 1997</LINK> "is the source of the widely-held view that acellular vaccines are less effective than high-efficacy whole-cell vaccines". However, both <LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> and our review included several studies with acellular vaccines inferior to whole-cell vaccines, including a study of a four-component acellular vaccine (<LINK REF="STD-PVSG-1998" TYPE="STUDY">PVSG 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>
<LINK REF="REF-Jefferson-2003" TYPE="REFERENCE">Jefferson 2003</LINK> included a systematic review of studies assessing the safety of DTP vaccines. We excluded some of these studies because of lack of sufficient data. However, the results of the reviews were largely similar.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Booster doses</HEADING>
<P>
<LINK REF="REF-Casey-2005" TYPE="REFERENCE">Casey 2005</LINK> found that booster doses of all DTaP vaccines in 1% to 2% of individuals caused large, local injection reactions, in most cases probably IgE-mediated. These reactions cause no permanent harm, and the authors of <LINK REF="REF-Casey-2005" TYPE="REFERENCE">Casey 2005</LINK> argue that everybody should have access to a booster dose every 10 years throughout life. </P>
<P>Despite different designs, there are no significant disagreements between our review and the above mentioned two systematic reviews regarding efficacy and safety of aP vaccines.</P>
<P>Observational studies have also demonstrated the effectiveness of aP vaccines. <LINK REF="REF-Gustafsson-2006" TYPE="REFERENCE">Gustafsson 2006</LINK> (Swedish birth cohorts) showed that immunisation with aP vaccines at three, five and 12 months of age resulted in a reduction in the incidence of laboratory-confirmed pertussis from 113 to 150 per 100,000 during 1992/1995, to 11 to 16 per 100,000 during 2001/2004. <LINK REF="REF-Bisgard-2005" TYPE="REFERENCE">Bisgard 2005</LINK> (case-control study of 1072 children in the United States) found that any combination of &#8805; three DTwP/DTaP vaccine doses was highly protective against pertussis. As compared with 0 doses, the unadjusted vaccine effectiveness was 83.6%, 95.6% and 97.7% for one or two, three and &#8805; four vaccine doses, respectively. In contrast with the findings of our review, this study showed that four-component DTaP vaccine was less effective than two-component DTaP vaccine, however, the potential biases related to study design might cast serious doubt on the validity of comparison between different vaccines.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Multi-component acellular vaccines are effective against both typical whooping cough and mild pertussis disease, with a good safety profile. However, the implications of this finding for clinical practice may be different in high-income and low-income countries. In high-income countries, death from whooping cough is rare and parental acceptance is a major determinant of immunisation uptake. In these circumstances, the improved side effect profile of acellular vaccines argues in favour of their use, even though they might sacrifice some degree of effectiveness compared to the best whole-cell vaccines. The available efficacy data favours the multi-component acellular vaccines over the one- and two-component vaccines in this regard.</P>
<P>In low-income countries, where the risk of pertussis is higher and cases are more likely to be fatal, greater weight needs to be given to vaccine efficacy. If an acellular vaccine has been shown to be less effective than a high-efficacy whole-cell vaccine it is intended to replace, the reactogenicity advantage of the acellular vaccine may be offset by increased mortality and morbidity due to a higher breakthrough rate of pertussis. However, most of the whole-cell vaccines used in low-income countries have not been studied for efficacy or effectiveness and, therefore, it is not known where on the wide spectrum of whole-cell vaccine efficacy an individual product lies. The more consistent manufacturing of the acellular vaccines may lead to more consistent efficacy of these products. However, the higher cost of acellular vaccines at this time would seem likely to affect their usefulness in low-income countries.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>There are several gaps in our current knowledge of acellular pertussis vaccines. One of the more notable is that the optimal composition of these vaccines has yet to be defined. All vaccines in this review included some form of inactivated pertussis toxin, while those with more than one component all included filamentous haemagglutinin. Although the available multi-component vaccines are more effective than those with one or two components, it has not yet been determined what the optimal composition is for the acellular vaccines.</P>
<P>More data are needed on the optimal timing of booster doses, school-entry acellular boosting in children who have received acellular vaccines for all previous doses, the effectiveness of acellular vaccines in adults and what is the proper interval for subsequent doses of acellular pertussis vaccine in adulthood.</P>
<P>Ethical barriers to the inclusion of a placebo group, combined with the evidence that whole-cell vaccines are not uniformly effective, will create problems for future efficacy studies. Such studies will need to include a self selected, non-immunised and potentially biased control group, in order to provide an estimate of absolute vaccine efficacy. Further analyses of the data from existing placebo-controlled studies, with the aim of determining characteristics of participants and their environment which affect vaccine efficacy, will permit future studies to improve these estimates of absolute efficacy by adjusting for such factors.</P>
<P>Finally, the lack of a laboratory correlate of efficacy means that the testing of new acellular pertussis vaccines currently requires prolonged and expensive clinical trials. Research into determining such a laboratory correlate should be a priority.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-28 19:06:18 -0200" MODIFIED_BY="[Empty name]">
<P>Thanks to Sarah Thorning, Trials Search Co-ordinator of the Cochrane Acute Respiratory Infections (ARI) Group, for performing the updated search and to Elizabeth Dooley, Managing Editor of the Cochrane ARI Group, for continuous support. Owen Tinnion and Mark Hanlon were responsible for the first published version of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-14 22:09:19 -0300" MODIFIED_BY="Liz  Dooley">
<P>Inge Axelsson was in part paid by the Research and Development Unit, Jämtland County Council, Östersund, Sweden. "In the last 10 years, I have been a Clinical Investigator in a trial of an infant combination vaccine containing acellular pertussis (aP) vaccine from Sanofi Pasteur MSD but I have not received any fee from any pharmaceutical company".</P>
<P>Scott A Halperin has undertaken clinical trials of acellular pertussis vaccines for most manufacturers of these products including GlaxoSmithKline, Sanofi Pasteur, Novartis and Wyeth. He has given Continuing Medical Education talks (not as part of a manufacturers' speakers bureau) for which an honorarium has been paid. He has served on occasional ad hoc advisory boards of vaccine manufacturers but does not have any ongoing consultancies.</P>
<P>Linjie Zhang: none known.<BR/>
<BR/>Sílvio OM Prietsch: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Inge Axelsson (IA) contributed to updating the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section and the section "Agreements and disagreements with other studies or reviews" in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.<BR/>Silvio Prietsch (SP) was responsible for updating the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section. He participated in study selection, quality assessment and data collection for the updated review. He also provided input to updating the section <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>.<BR/>Linjie Zhang (LZ) was responsible for study selection, quality assessment, data collection and data analysis for the updated review. He was also responsible for updating the Abstract, <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>, <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK>, <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> and References. He contributed to updating the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section.<BR/>Scott Halperin (SH) performed a critical review of the manuscript and provided input to updating the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section.<BR/>The final version of the updated review was approved by all review authors.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-01-28 19:12:13 -0200" MODIFIED_BY="[Empty name]">
<P>This review was previously withdrawn from <I>The Cochrane Library</I> in Issue 3, 2006. The electronic searches had been conducted in 1998 and the lead author was unable to update the review. In May 2008 this review was taken over and updated by a new team of review authors.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-09-08 07:49:17 -0300" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-09-08 07:49:17 -0300" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-09-08 07:49:17 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Afari-1996" MODIFIED="2012-01-30 01:03:12 -0200" MODIFIED_BY="Liz Dooley" NAME="Afari 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-30 01:03:12 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Afari EA, Kamiya Y, Nkrumah FK, Dunyo SK, Akpedonu P, Kamiya H, et al</AU>
<TI>Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>1</NO>
<PG>39-48</PG>
<IDENTIFIERS MODIFIED="2012-01-30 01:03:12 -0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="1996260449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AHGSPV-1988" MODIFIED="2012-01-30 01:03:30 -0200" MODIFIED_BY="Liz Dooley" NAME="AHGSPV 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-01-30 01:03:30 -0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events [published erratum appears in Lancet 1988 May 28;1(8596):1238]. Lancet 1988; 1:955-60.&lt;/p&gt;" NOTES_MODIFIED="2012-01-30 01:03:30 -0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ad Hoc Group for the Study of Pertussis Vaccines</AU>
<TI>Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>8592</NO>
<PG>955-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-14 23:50:48 -0300" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child 1991; 145:1285-9.&lt;/p&gt;" NOTES_MODIFIED="2009-06-14 23:50:48 -0300" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackwelder WC, Storsaeter J, Olin P, Hallander HO</AU>
<TI>Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1991</YR>
<VL>145</VL>
<PG>1285-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992058882"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-08 21:56:44 -0300" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Kallings LO, Olin P, Storsaeter J. [Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial] Skyddseffekten av tva acellulara kikhostevacciner i en dubbelblind placebokontrollerad klinisk provning. Lakartidningen 1988; 85:1994-6.&lt;/p&gt;" NOTES_MODIFIED="2009-06-08 21:56:44 -0300" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kallings LO, Olin P, Storsaeter J</AU>
<TI>Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial</TI>
<TO>Skyddseffekten av tva acellulara kikhostevacciner i en dubbelblind placebokontrollerad klinisk provning</TO>
<SO>Lakartidningen</SO>
<YR>1988</YR>
<VL>85</VL>
<PG>1994-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988231964"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-21 22:31:41 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olin P, Romanus V, Storsaeter J</AU>
<TI>Invasive bacterial infections during an efficacy trial of acellular pertussis vaccines - implications for future surveillance in pertussis vaccine programmes</TI>
<SO>Tokai Journal of Experimental and Clinical Medicine</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>143-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990232563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 22:47:32 -0200" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Olin P, Storsaeter J, Linder T, Winter C, S&amp;#246;nstenby C. A Clinical Trial of Acellular Pertussis Vaccines in Sweden. Technical Report 1988. Stockholm: National Bacteriological Laboratory, 1988.&lt;/p&gt;" NOTES_MODIFIED="2012-01-29 22:47:32 -0200" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="OTHER">
<AU>Olin P, Storsaeter J, Linder T, Winter C, Sönstenby C</AU>
<TI>A clinical trial of acellular pertussis vaccines in Sweden</TI>
<SO>Technical Report</SO>
<YR>1988</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988215677"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990; 8:457-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E</AU>
<TI>Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial</TI>
<SO>Vaccine</SO>
<YR>1990</YR>
<VL>8</VL>
<PG>457-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991068476"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 22:50:04 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storsaeter J, Olin P, Renemar B, Lagergård T, Norberg R, Romanus V, et al</AU>
<TI>Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>9</NO>
<PG>637-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989016311"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AHGSPV-1997" MODIFIED="2012-01-29 22:54:18 -0200" MODIFIED_BY="Liz Dooley" NAME="AHGSPV 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-01-29 22:51:35 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-14 23:52:22 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Rasmussen F, Olin P</AU>
<TI>Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>99-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Olin P, Gustafsson L, Rasmussen H, Hallander H, Heijbel H, Gottfarb P. Efficacy trial of acellular pertussis vaccines. Technical report trial II with preplanned analysis of efficacy, immunogenicity and safety. Stockholm: Swedish Institute for Infectious Disease Control, 1997.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Olin P, Gustafsson L, Rasmussen H, Hallander H, Heijbel H, Gottfarb P</AU>
<TI>Efficacy trial of acellular pertussis vaccines. Technical report trial II with preplanned analysis of efficacy, immunogenicity and safety</TI>
<SO>Swedish Institute for Infectious Disease Control</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 22:54:18 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H; Ad Hoc Group for the Study of Pertussis Vaccines</AU>
<TI>Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>1569-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1988" MODIFIED="2011-11-21 22:30:48 -0200" MODIFIED_BY="Liz Dooley" NAME="Anderson 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-11-21 22:30:48 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson EL, Belshe RB, Bartram J</AU>
<TI>Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>157</VL>
<NO>4</NO>
<PG>731-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988154610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1992" MODIFIED="2012-01-29 22:57:17 -0200" MODIFIED_BY="Liz Dooley" NAME="Bernstein 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-01-29 22:57:17 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein HH, Rothstein EP, Pichichero ME, Francis AB, Kovel AJ, Disney FA, et al</AU>
<TI>Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1992</YR>
<VL>146</VL>
<NO>5</NO>
<PG>556-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992321088"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1994" MODIFIED="2012-01-29 22:58:08 -0200" MODIFIED_BY="[Empty name]" NAME="Bernstein 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-29 22:58:08 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein HH, Rothstein EP, Reisinger KS, Blatter MM, Arbeter AM, Fontana ME, et al</AU>
<TI>Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>4</NO>
<PG>656-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994181388"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-1997" MODIFIED="2012-01-29 22:58:50 -0200" MODIFIED_BY="Liz Dooley" NAME="Black 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-01-29 22:58:50 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black SB, Shinefield HR, Bergen R, Hart C, Kremers R, Lavetter A, et al</AU>
<TI>Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>1</NO>
<PG>53-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997155401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blennow-1988" MODIFIED="2012-01-29 23:00:48 -0200" MODIFIED_BY="Liz Dooley" NAME="Blennow 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-06-07 17:15:55 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blennow M, Granstrom M, Jaatmaa E, Olin P</AU>
<TI>Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial</TI>
<SO>Pediatrics</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>3</NO>
<PG>293-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988303187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:00:25 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blennow M, Granstrom M, Olin P, Tiru M, Jäätmaa E, Askelöf P, et al</AU>
<TI>Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1986</YR>
<VL>65</VL>
<PG>185-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987162902"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:00:48 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blennow M, Hedenskog S, Granstrom M</AU>
<TI>Protective effect of acellular pertussis vaccines</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>381-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988312660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumberg-1990" MODIFIED="2012-01-29 23:02:52 -0200" MODIFIED_BY="Liz Dooley" NAME="Blumberg 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-01-29 23:01:30 -0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg DA, Mink CM, Cherry JD, Reisinger KS, Blatter MM, Congeni BL, et al</AU>
<TI>Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<NO>1 Pt 1</NO>
<PG>46-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990317732"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:02:52 -0200" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Cherry JD, Mortimer EA, Hackell JG, Scott JV. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Dev Biol Stand 1991;73:51-8 .&lt;/p&gt;" NOTES_MODIFIED="2012-01-29 23:02:52 -0200" NOTES_MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD, Mortimer EA, Hackell JG, Scott JV; Multicenter APDT Vaccine Study Groups</AU>
<TI>Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1991</YR>
<VL>73</VL>
<PG>51-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992137524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumberg-1991" MODIFIED="2012-01-29 23:03:28 -0200" MODIFIED_BY="[Empty name]" NAME="Blumberg 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-01-29 23:03:28 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg DA, Mink CM, Cherry JD, Johnson C, Garber R, Plotkin SA, et al</AU>
<TI>Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>119</VL>
<NO>2</NO>
<PG>194-204</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991318373"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Decker-1995" MODIFIED="2012-01-29 23:05:17 -0200" MODIFIED_BY="Liz Dooley" NAME="Decker 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-01-29 23:04:19 -0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al</AU>
<TI>Comparison of 13 acellular pertussis vaccines: adverse reactions</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<NO>3 Pt 2</NO>
<PG>557-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995388466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-21 22:30:14 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Decker MD, Edwards KM</AU>
<TI>The multicenter acellular pertussis trial: an overview</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>Suppl 3</NO>
<PG>270-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997051893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-08 22:01:49 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deloria MA, Blackwelder WC, Decker MD, Englund JA, Steinhoff MC, Pichichero ME, et al</AU>
<TI>Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<NO>3 pt 2</NO>
<PG>592-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:05:17 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al</AU>
<TI>Comparison of 13 acellular pertussis vaccines: overview and serologic response</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<NO>3 Pt 2</NO>
<PG>548-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995388465"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1986a" MODIFIED="2009-06-14 23:54:46 -0300" MODIFIED_BY="Liz Dooley" NAME="Edwards 1986a" YEAR="1986">
<REFERENCE MODIFIED="2009-06-14 23:54:46 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Lawrence E, Wright PF</AU>
<TI>Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1986</YR>
<VL>140</VL>
<NO>9</NO>
<PG>867-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986292846"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1986b" MODIFIED="2009-06-14 23:56:54 -0300" MODIFIED_BY="Liz Dooley" NAME="Edwards 1986b" YEAR="1986">
<REFERENCE MODIFIED="2009-06-14 23:56:54 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Lawrence E, Wright PF</AU>
<TI>Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1986</YR>
<VL>140</VL>
<NO>9</NO>
<PG>867-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986292846"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1989a" MODIFIED="2012-01-29 23:06:28 -0200" MODIFIED_BY="Liz Dooley" NAME="Edwards 1989a" YEAR="1989">
<REFERENCE MODIFIED="2012-01-29 23:06:28 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, et al</AU>
<TI>Evaluation of a new highly purified pertussis vaccine in infants and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<NO>5</NO>
<PG>832-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990038637"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1989b" MODIFIED="2012-01-29 23:07:14 -0200" MODIFIED_BY="Liz Dooley" NAME="Edwards 1989b" YEAR="1989">
<REFERENCE MODIFIED="2012-01-29 23:07:14 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, et al</AU>
<TI>Evaluation of a new highly purified pertussis vaccine in infants and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<NO>5</NO>
<PG>832-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990038637"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1989c" MODIFIED="2012-01-29 23:08:05 -0200" MODIFIED_BY="Liz Dooley" NAME="Edwards 1989c" YEAR="1989">
<REFERENCE MODIFIED="2012-01-29 23:08:05 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, et al</AU>
<TI>Evaluation of a new highly purified pertussis vaccine in infants and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<NO>5</NO>
<PG>832-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990038637"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englund-1992" MODIFIED="2012-01-29 23:08:23 -0200" MODIFIED_BY="Liz Dooley" NAME="Englund 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-21 22:29:22 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englund JA, Glezen WP, Barreto L</AU>
<TI>Controlled study of a new five-component acellular pertussis vaccine in adults and young children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>166</VL>
<NO>6</NO>
<PG>1436-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-01-29 23:08:23 -0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englund-1994a" MODIFIED="2009-06-07 18:37:17 -0300" MODIFIED_BY="[Empty name]" NAME="Englund 1994a" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL</AU>
<TI>Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994089352"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Englund-1994b" MODIFIED="2009-06-07 18:37:38 -0300" MODIFIED_BY="[Empty name]" NAME="Englund 1994b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL</AU>
<TI>Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994089352"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-1992" MODIFIED="2012-01-29 23:30:55 -0200" MODIFIED_BY="Liz Dooley" NAME="Feldman 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-01-29 23:30:55 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman S, Perry S, Andrew M, Jones L, Moffitt JE</AU>
<TI>Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>121</VL>
<NO>6</NO>
<PG>857-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993078106"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldman-1993" MODIFIED="2012-01-29 23:32:06 -0200" MODIFIED_BY="Liz Dooley" NAME="Feldman 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-29 23:32:06 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman S, Perry CS, Andrew M, Jones L, Moffitt JE, Lamb D, et al</AU>
<TI>Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids</TI>
<SO>Southern Medical Journal</SO>
<YR>1993</YR>
<VL>86</VL>
<NO>3</NO>
<PG>269-75, 284</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993197923"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glode-1992" MODIFIED="2012-01-29 23:33:03 -0200" MODIFIED_BY="Liz Dooley" NAME="Glode 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-01-29 23:33:03 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glode M, Joffe L, Reisinger K, Blatter M, Plotkin S, Watson B, et al</AU>
<TI>Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>7</NO>
<PG>530-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992409269"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greco-1996" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Greco 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-06-14 23:59:48 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciofi degli Atti ML, Olin P</AU>
<TI>Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>77-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-8.&lt;/p&gt;" NOTES_MODIFIED="2014-09-08 06:34:42 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al; Progetto Pertosse Working Group</AU>
<TI>A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>6</NO>
<PG>341-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996140456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:00:04 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greco D</AU>
<TI>Italian trial on acellular pertussis vaccines</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>55-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997472093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:35:34 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:00:22 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tozzi AE, Olin P</AU>
<TI>Common side effects in the Italian and Stockholm I trials</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>105-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gustafsson-1996" MODIFIED="2014-09-08 07:49:17 -0300" MODIFIED_BY="[Empty name]" NAME="Gustafsson 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-06-15 00:00:37 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciofi degli Atti ML, Olin P</AU>
<TI>Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>77-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418329"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-08 07:49:17 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gustaffson L, Hallander H ,Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Stockholm: Swedish Institute for Infectious Disease Control, 1995.&lt;/p&gt;" NOTES_MODIFIED="2014-09-08 07:49:17 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gustaffson L, Hallander H, Olin P, Reizenstein E, Storsaeter J</AU>
<TI>Efficacy trial of acellular pertussis vaccines. Technical report Trial I with results of preplanned analysis of safety, efficacy and immunogenicity</TI>
<SO>Swedish Institute for Infectious Disease Control</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:37:45 -0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J</AU>
<TI>A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>6</NO>
<PG>349-55</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996140457"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-29 23:38:37 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:01:03 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olin P</AU>
<TI>Efficacy trial of acellular pertussis vaccines; trial I</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>52-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997472092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:01:12 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tozzi AE, Olin P</AU>
<TI>Common side effects in the Italian and Stockholm I trials</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>105-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-1994a" MODIFIED="2012-01-30 00:15:50 -0200" MODIFIED_BY="Liz Dooley" NAME="Halperin 1994a" YEAR="1994">
<REFERENCE MODIFIED="2012-01-30 00:15:50 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Barreto L, Eastwood BJ, Law B, Roberts EA</AU>
<TI>Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1994</YR>
<VL>148</VL>
<NO>11</NO>
<PG>1220-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995005321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-1994b" MODIFIED="2009-06-15 00:03:45 -0300" MODIFIED_BY="Liz Dooley" NAME="Halperin 1994b" YEAR="1994">
<REFERENCE MODIFIED="2009-06-15 00:03:45 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Barreto L, Eastwood BJ, Law B, Roberts EA</AU>
<TI>Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1994</YR>
<VL>148</VL>
<NO>11</NO>
<PG>1220-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995005321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-1995" MODIFIED="2011-11-21 22:27:26 -0200" MODIFIED_BY="Liz Dooley" NAME="Halperin 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-11-21 22:27:26 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Mills E, Barreto L, Pim C, Eastwood BJ</AU>
<TI>Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole-cell or acellular pertussis vaccine at two, four and six months of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>9</NO>
<PG>792-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996079357"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-1996" MODIFIED="2012-01-30 00:17:05 -0200" MODIFIED_BY="Liz Dooley" NAME="Halperin 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-30 00:17:05 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Eastwood BJ, Barreto L, Friesen B, Medd L, Meekison W, et al</AU>
<TI>Adverse reactions and antibody response to four doses of acellular or whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life</TI>
<SO>Vaccine</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>8</NO>
<PG>767-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996414822"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-1999" MODIFIED="2011-11-21 22:27:11 -0200" MODIFIED_BY="Liz Dooley" NAME="Halperin 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-11-21 22:27:11 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, et al</AU>
<TI>Comparison of a fifth dose of a five-component acellular or a whole-cell pertussis vaccine in children four to six years of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>9</NO>
<PG>772-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halperin-2003" MODIFIED="2009-06-08 22:08:24 -0300" MODIFIED_BY="Liz Dooley" NAME="Halperin 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-06-08 22:08:24 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, et al</AU>
<TI>Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>19-20</NO>
<PG>2298-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heininger-1994" MODIFIED="2012-01-30 00:18:10 -0200" MODIFIED_BY="[Empty name]" NAME="Heininger 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-30 00:18:10 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heininger U, Cherry JD, Christenson PD, Eckhardt T, Göering U, Jakob P, et al</AU>
<TI>Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany</TI>
<SO>Vaccine</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>1</NO>
<PG>81-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994136019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanra-1993a" MODIFIED="2009-06-09 22:01:05 -0300" MODIFIED_BY="[Empty name]" NAME="Kanra 1993a" YEAR="1992">
<REFERENCE MODIFIED="2009-06-09 22:01:05 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H</AU>
<TI>Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>152</VL>
<NO>6</NO>
<PG>478-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993327795"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanra-1993b" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Kanra 1993b" YEAR="1993">
<REFERENCE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanra G, Ceyhan M, Vandevoorde D, Bogaerts H</AU>
<TI>Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>152</VL>
<NO>6</NO>
<PG>478-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993327795"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosuwon-2003" MODIFIED="2012-01-30 00:19:42 -0200" MODIFIED_BY="[Empty name]" NAME="Kosuwon 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-30 00:19:42 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosuwon P, Warachit B, Hutagalung Y, Borkird T, Kosalaraksa P, Bock HL, et al</AU>
<TI>Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>27-30</NO>
<PG>4194-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1986" MODIFIED="2009-06-15 00:08:21 -0300" MODIFIED_BY="Liz Dooley" NAME="Lewis 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-06-15 00:08:21 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis K, Cherry JD, Holroyd HJ, Baker LR, Dudenhoeffer FE, Robinson RG</AU>
<TI>A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1986</YR>
<VL>140</VL>
<NO>9</NO>
<PG>872 -6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986292847"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcinak-1993" MODIFIED="2012-01-30 00:20:43 -0200" MODIFIED_BY="Liz Dooley" NAME="Marcinak 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-30 00:20:43 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcinak JF, Ward M, Frank AL, Boyer KM, Froeschle JE, Hosbach PH IV</AU>
<TI>Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>3</NO>
<PG>290-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993175417"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1991" MODIFIED="2009-06-09 01:20:18 -0300" MODIFIED_BY="Liz Dooley" NAME="Miller 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-06-09 01:20:18 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller E, Ashworth LA, Robinson A, Waight PA, Irons LI</AU>
<TI>Phase II trial of whole-cell pertussis vaccine versus an acellular vaccine containing agglutinogens</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8733</NO>
<PG>70-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991087673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1990" MODIFIED="2012-01-30 00:25:30 -0200" MODIFIED_BY="Liz Dooley" NAME="Morgan 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-01-30 00:21:23 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD, Mortimer EA, Hackell JG, Scott JV; Multicenter APDT Vaccine Study Groups</AU>
<TI>Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1991</YR>
<VL>73</VL>
<PG>51-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992137524"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 00:22:46 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mink CM, Uhari M, Blumberg DA, Knip M, Lewis K, Christenson PD, et al</AU>
<TI>Metabolic and hematologic effects and immune complex formation related to pertussis immunization</TI>
<SO>Pediatric Research</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>4 Pt 1</NO>
<PG>353-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990259589"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 00:25:30 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan CM, Blumberg DA, Cherry JD, Reisinger KS, Blatter MM, Blumer JL, et al</AU>
<TI>Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1990</YR>
<VL>144</VL>
<NO>1</NO>
<PG>41-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990102386"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1992" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Pichichero 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Francis AB, Blatter MM, Reisinger KS, Green JL, Marsocci SM, et al</AU>
<TI>Acellular pertussis vaccination of 2-month-old infants in the United States</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>89</VL>
<NO>5 Pt 1</NO>
<PG>882-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1993" MODIFIED="2012-01-30 00:27:15 -0200" MODIFIED_BY="Liz Dooley" NAME="Pichichero 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-30 00:27:15 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Francis AB, Marsocci SM, Green JL, Disney FA</AU>
<TI>Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>3</NO>
<PG>295-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993175418"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1994" MODIFIED="2011-11-21 22:26:29 -0200" MODIFIED_BY="Liz Dooley" NAME="Pichichero 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-11-21 22:26:29 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Green JL, Francis AB, Marsocci SM, Lynd AM, Litteer TTI</AU>
<TI>Comparison of a three-component acellular pertussis vaccine with whole-cell pertussis vaccine in two-month-old children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>3</NO>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1996" MODIFIED="2009-06-15 02:46:59 -0300" MODIFIED_BY="Liz Dooley" NAME="Pichichero 1996" YEAR="">
<REFERENCE MODIFIED="2009-06-15 02:46:59 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C</AU>
<TI>Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole-cell pertussis vaccine</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>2</NO>
<PG>159-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996384595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1997" MODIFIED="2012-01-30 00:28:07 -0200" MODIFIED_BY="[Empty name]" NAME="Pichichero 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-01-30 00:28:07 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, et al</AU>
<TI>A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>5</NO>
<PG>772-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998010670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-2000" MODIFIED="2012-01-30 00:28:54 -0200" MODIFIED_BY="[Empty name]" NAME="Pichichero 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-30 00:28:54 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, et al</AU>
<TI>Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children</TI>
<SO>Pediatrics</SO>
<YR>2000</YR>
<VL>105</VL>
<NO>1</NO>
<PG>e11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Podda-1994" MODIFIED="2012-01-30 00:29:28 -0200" MODIFIED_BY="[Empty name]" NAME="Podda 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-30 00:29:28 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Podda A, De Luca EC, Contu B, Furlan R, Maida A, Moiraghi A, et al</AU>
<TI>Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<NO>6</NO>
<PG>921-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994260369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PVSG-1998" MODIFIED="2012-01-30 00:54:53 -0200" MODIFIED_BY="Liz Dooley" NAME="PVSG 1998" YEAR="1997">
<REFERENCE MODIFIED="2012-01-30 00:33:23 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 00:35:47 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt-Grohe S, Stehr K, Cherry JD, Heininger U, Uberall MA, Laussucq S, et al; Pertussis Vaccine Study Group</AU>
<TI>Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>113-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418336"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-10 21:32:02 -0300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Überall M, Laussucq S, et al</AU>
<TI>A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:10:26 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stehr K, Cherry JD</AU>
<TI>A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>58-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997472094"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 00:54:53 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uberall MA, Stehr K, Cherry JD, Heininger U, Uberall MA, Laussucq S, et al; Pertussis Vaccine Study Group</AU>
<TI>Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>83-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418330"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothstein-1993" MODIFIED="2012-01-30 00:56:33 -0200" MODIFIED_BY="Liz Dooley" NAME="Rothstein 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-30 00:56:33 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothstein EP, Bernstein HH, Glode MP, Laussucq S, Nonenmacher J, Long SS, et al</AU>
<TI>Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1993</YR>
<VL>147</VL>
<NO>8</NO>
<PG>854-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993356098"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simondon-1996" MODIFIED="2012-01-30 00:56:52 -0200" MODIFIED_BY="Liz Dooley" NAME="Simondon 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-30 00:56:52 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simondon F, Yam A, Gagnepain JY, Wassilak S, Danve B, Cadoz M</AU>
<TI>Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>12</NO>
<PG>927-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997183915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simondon-1997" MODIFIED="2012-01-30 01:00:00 -0200" MODIFIED_BY="Liz Dooley" NAME="Simondon 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-01-30 01:00:00 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:11:21 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preziosi M-P, Ndiaye M, Coll-Seck A, Simondon F</AU>
<TI>The Senegal pertussis trial: safety and surveillance of adverse reactions</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>91-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 00:58:32 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al</AU>
<TI>A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal</TI>
<SO>Vaccine</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>15</NO>
<PG>1606-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:11:29 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simondon F</AU>
<TI>Senegal pertussis trial</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>63-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997472095"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-1993" MODIFIED="2009-06-08 22:11:50 -0300" MODIFIED_BY="Liz Dooley" NAME="Tian 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-08 22:11:50 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian X</AU>
<TI>An observation on immunization reaction and serological effect of adsorbed purified pertussis vaccine</TI>
<SO>Chung Hua Liu Hsing Ping Hsueh Tsa Chih</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>3</NO>
<PG>155-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994037040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trollfors-1995" MODIFIED="2012-01-30 01:01:42 -0200" MODIFIED_BY="Liz Dooley" NAME="Trollfors 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-01-30 00:59:54 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heijbel H, Ciofi degli Atti MC, Harzer E, Liese J, Preziosi MP, Rasmussen F, et al</AU>
<TI>Hypotonic hyporesponsive episodes in eight pertussis vaccine studies</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>101-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418333"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:11:48 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taranger J, Trollfors B, Knutsson N</AU>
<TI>Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>109-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997418335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-30 01:01:42 -0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333:1045-50.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-01-30 01:01:42 -0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trollfors B, Taranger J, Lagergard T, Lind L, Sundh V, Zackrisson G, et al</AU>
<TI>A placebo-controlled trial of a pertussis-toxoid vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>16</NO>
<PG>1045-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995405432"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-15 00:11:59 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trollfors B, Taranger J</AU>
<TI>The Gothenburg pertussis vaccine study</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>49-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997472091"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanura-1994" MODIFIED="2012-01-30 01:02:31 -0200" MODIFIED_BY="[Empty name]" NAME="Vanura 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-30 01:02:31 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanura H, Just M, Ambrosch F, Berger RM, Bogaerts H, Wynen J, et al</AU>
<TI>Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine</TI>
<SO>Vaccine</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>3</NO>
<PG>210-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994219162"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Annunziato-1994" MODIFIED="2009-06-15 00:12:35 -0300" MODIFIED_BY="Liz Dooley" NAME="Annunziato 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-06-15 00:12:35 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME</AU>
<TI>Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1994</YR>
<VL>148</VL>
<NO>5</NO>
<PG>503-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994236176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1993" MODIFIED="2011-11-21 22:25:09 -0200" MODIFIED_BY="[Empty name]" NAME="Bernstein 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-11-21 22:25:09 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein DI, Smith VE, Schift GM, Rathfon HM, Boscia JA</AU>
<TI>Comparison of acellular pertussis vaccine with whole-cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>131-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1995" MODIFIED="2012-01-30 01:09:17 -0200" MODIFIED_BY="[Empty name]" NAME="Bernstein 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-01-30 01:09:17 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein HH, Rothstein EP, Pichichero ME, Green JL, Reisinger KS, Blatter MM, et al</AU>
<TI>Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>17</NO>
<PG>1631-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996363700"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hori-1994" MODIFIED="2012-01-30 01:10:00 -0200" MODIFIED_BY="Liz Dooley" NAME="Hori 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-30 01:10:00 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hori H, Afari EA, Akanmori BD, Kamiya Y, Sakatoku H, Nkrumah FK, at al</AU>
<TI>A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccine in primary immunization in Ghana: antibody responses and adverse reactions</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2</NO>
<PG>91-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hori-1995" MODIFIED="2012-01-30 01:10:39 -0200" MODIFIED_BY="Liz Dooley" NAME="Hori 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-01-30 01:10:39 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hori H, Afari A, Akanmori BD, Kamiya Y, Sakatoku H, Nkrumah FK, et al</AU>
<TI>Pertussis immunization with acellular vaccines in Ghanaian children</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>141-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995407918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Just-1991" MODIFIED="2009-06-15 00:13:18 -0300" MODIFIED_BY="Liz Dooley" NAME="Just 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-06-15 00:13:18 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Just M, Kanra G, Bogaerts H, Berger R, Ceyhan M, Petre J</AU>
<TI>Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1991</YR>
<VL>73</VL>
<PG>275-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992137508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1997" MODIFIED="2009-05-12 15:15:39 -0300" MODIFIED_BY="[Empty name]" NAME="Miller 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller E, Ashworth LA, Redhead K, Thornton C, Waight PA, Coleman T</AU>
<TI>Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance</TI>
<SO>Vaccine</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>1</NO>
<PG>51-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997194088"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1983" MODIFIED="2009-05-12 15:16:02 -0300" MODIFIED_BY="[Empty name]" NAME="Murphy 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy MD, Rasnack J, Dickson HD, Dietch M, Brunell PA</AU>
<TI>Evaluation of the pertussis components of diphtheria-tetanus-pertussis vaccine</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>2</NO>
<PG>200-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1983116628"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichichero-1987" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Pichichero 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pichichero ME, Badgett JT, Rodgers GC, Jr., McLinn S, Trevino Scatterday B, Nelson JD. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis versus. a whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 1987;6(4):352-63.&lt;/p&gt;" NOTES_MODIFIED="2014-09-08 06:34:42 -0300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Badgett JT, Rodgers GC Jr, McLinn S, Trevino Scatterday B, Nelson JD</AU>
<TI>Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis versus a whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>4</NO>
<PG>352-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987230696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shek-2003" MODIFIED="2014-09-07 13:06:42 -0300" MODIFIED_BY="[Empty name]" NAME="Shek 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-09-07 13:06:42 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shek LP, Khor ES, Tan GH, Low KT, Ong D, Roy J, et al</AU>
<TI>Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>4</NO>
<PG>863-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bamberger-2008" MODIFIED="2012-01-30 01:13:39 -0200" MODIFIED_BY="[Empty name]" NAME="Bamberger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bamberger ES, Srugo I</AU>
<TI>What is new in pertussis?</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>167</VL>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1997" MODIFIED="2012-01-30 01:14:01 -0200" MODIFIED_BY="[Empty name]" NAME="Berlin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA; University of Pennsylvania Meta-analysis Blinding Study Group</AU>
<TI>Does blinding of readers affect the results of meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>185-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bettinger-2007" MODIFIED="2009-06-15 00:14:17 -0300" MODIFIED_BY="Liz Dooley" NAME="Bettinger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T</AU>
<TI>The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bisgard-2005" MODIFIED="2009-06-10 06:52:39 -0300" MODIFIED_BY="[Empty name]" NAME="Bisgard 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, et al</AU>
<TI>Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>2</NO>
<PG>e285-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blackwelder-1991" MODIFIED="2009-06-15 00:14:39 -0300" MODIFIED_BY="Liz Dooley" NAME="Blackwelder 1991" TYPE="JOURNAL_ARTICLE">
<AU>Blackwelder WC, Storsaeter J, Olin P, Hallander HO</AU>
<TI>Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1991</YR>
<VL>145</VL>
<NO>11</NO>
<PG>1285-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsson-2009" MODIFIED="2011-11-21 22:24:09 -0200" MODIFIED_BY="[Empty name]" NAME="Carlsson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson RM, Trollfors B</AU>
<TI>Control of pertussis - lessons learnt from a 10-year surveillance programme in Sweden</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>42</NO>
<PG>5709-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-2005" MODIFIED="2014-09-07 13:08:06 -0300" MODIFIED_BY="[Empty name]" NAME="Casey 2005" TYPE="JOURNAL_ARTICLE">
<AU>Casey JR, Pichichero ME</AU>
<TI>Acellular pertussis vaccine safety and efficacy in children, adolescents and adults</TI>
<SO>Drug</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1367-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2009" MODIFIED="2012-01-30 01:17:05 -0200" MODIFIED_BY="Liz Dooley" NAME="CDC 2009" TYPE="OTHER">
<AU>Centers for Disease Control</AU>
<TI>Recommendations and Guidelines: 2009 Child and Adolescent Immunization Schedules</TI>
<SO>www.cdc.gov/vaccines/recs/schedules/child-schedule.htm</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDC-2011" MODIFIED="2012-01-30 01:19:34 -0200" MODIFIED_BY="[Empty name]" NAME="CDC 2011" TYPE="JOURNAL_ARTICLE">
<AU>Centers for Disease Control</AU>
<TI>Local health department costs associated with response to a school-based pertussis outbreak - Omaha, Nebraska, September&#8211;November 2008</TI>
<SO>Morbidity and Mortality Weekly Report</SO>
<YR>2011</YR>
<VL>60</VL>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cherry-1996" MODIFIED="2011-11-21 22:23:08 -0200" MODIFIED_BY="[Empty name]" NAME="Cherry 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD</AU>
<TI>Historical review of pertussis and the classical vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>Suppl 3</NO>
<PG>8259-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cherry-1998" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Cherry 1998" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD, Gornbein J, Heininger U, Stehr K</AU>
<TI>A search for serologic correlates of immunity to Bordetella pertussis cough illnesses</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1901&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cherry-2012" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Cherry 2012" TYPE="JOURNAL_ARTICLE">
<AU>Cherry JD</AU>
<TI>Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>367</VL>
<NO>9</NO>
<PG>785-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-06-08 22:15:34 -0300" MODIFIED_BY="Liz Dooley" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G</AU>
<TI>Language bias in randomised controlled trials published in English and German</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>326-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feunou-2010" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Feunou 2010" TYPE="JOURNAL_ARTICLE">
<AU>Feunou PF, Bertout J, Locht C</AU>
<TI>T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>4</NO>
<PG>e10178</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fine-1997" MODIFIED="2009-06-15 00:15:08 -0300" MODIFIED_BY="Liz Dooley" NAME="Fine 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fine PE</AU>
<TI>Implications of different study designs for the evaluation of acellular pertussis vaccines</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>123-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forsyth-2004" MODIFIED="2014-05-22 14:30:29 -0300" MODIFIED_BY="[Empty name]" NAME="Forsyth 2004" TYPE="JOURNAL_ARTICLE">
<AU>Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, et al</AU>
<TI>New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>12</NO>
<PG>1802-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galanis-2006" MODIFIED="2009-06-15 00:15:14 -0300" MODIFIED_BY="Liz Dooley" NAME="Galanis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Galanis E, King AS, Varughese P, Halperin SA</AU>
<TI>Changing epidemiology and emerging risk groups for pertussis</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>4</NO>
<PG>451-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Granoff-1997" MODIFIED="2009-06-15 00:15:23 -0300" MODIFIED_BY="Liz Dooley" NAME="Granoff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Granoff DM, Rappuoli R</AU>
<TI>Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?</TI>
<SO>Developments in Biological Standardization</SO>
<YR>1997</YR>
<VL>89</VL>
<PG>379-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gustafsson-2006" MODIFIED="2011-09-20 16:48:11 -0300" MODIFIED_BY="[Empty name]" NAME="Gustafsson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gustafsson L, Hessel L, Storsaeter J, Olin P</AU>
<TI>Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>3</NO>
<PG>978-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harnden-2009" MODIFIED="2012-01-30 01:20:54 -0200" MODIFIED_BY="[Empty name]" NAME="Harnden 2009" TYPE="JOURNAL_ARTICLE">
<AU>Harnden A</AU>
<TI>Practice: Easily missed? Whooping cough</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b1772</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedenskog-1987" MODIFIED="2009-06-15 00:15:55 -0300" MODIFIED_BY="Liz Dooley" NAME="Hedenskog 1987" TYPE="JOURNAL_ARTICLE">
<AU>Hedenskog S, Granström M, Olin P, Tiru M, Sato Y</AU>
<TI>A clinical trial of a monocomponent pertussis toxoid vaccine</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1987</YR>
<VL>141</VL>
<NO>8</NO>
<PG>844-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-01-30 01:31:55 -0200" MODIFIED_BY="Liz Dooley" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hviid-2004" MODIFIED="2011-11-21 22:22:22 -0200" MODIFIED_BY="[Empty name]" NAME="Hviid 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M</AU>
<TI>Impact of routine vaccination with a pertussis toxoid vaccine in Denmark</TI>
<SO>Vaccine</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>27-8</NO>
<PG>3530-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacquet-2006" MODIFIED="2012-01-30 01:24:01 -0200" MODIFIED_BY="[Empty name]" NAME="Jacquet 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jacquet JM, Bégué P, Grimprel E, Reinert P, Sandbu S, Silfverdal SA, et al</AU>
<TI>Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2003" MODIFIED="2012-01-30 01:25:13 -0200" MODIFIED_BY="Liz Dooley" NAME="Jefferson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T, Rudin M, DiPietrantonj C</AU>
<TI>Systematic review of the effects of pertussis vaccines in children</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>17-18</NO>
<PG>2003-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerr-2000" MODIFIED="2012-01-30 01:25:25 -0200" MODIFIED_BY="[Empty name]" NAME="Kerr 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kerr JR, Matthews RC</AU>
<TI>Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>77-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuno_x002d_Sakai-2004" MODIFIED="2009-06-15 00:16:17 -0300" MODIFIED_BY="Liz Dooley" NAME="Kuno-Sakai 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kuno-Sakai H, Kimura M</AU>
<TI>Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<NO>6</NO>
<PG>650-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2012-01-30 02:38:25 -0200" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liese-1997" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Liese 1997" TYPE="JOURNAL_ARTICLE">
<AU>Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, et al</AU>
<TI>Efficacy of a two-component acellular pertussis vaccine in infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1038-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liko-2013" MODIFIED="2014-05-25 20:25:43 -0300" MODIFIED_BY="Liz Dooley" NAME="Liko 2013" TYPE="JOURNAL_ARTICLE">
<AU>Liko J, Robison SG, Cieslak PR</AU>
<TI>Priming with whole-cell versus acellular pertussis vaccine</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>6</NO>
<PG>581-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahid-2008" MODIFIED="2009-06-15 00:17:05 -0300" MODIFIED_BY="Liz Dooley" NAME="Mahid 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mahid SS, Qadan M, Hornung CA, Galandiuk S</AU>
<TI>Assessment of publication bias for the surgeon scientist</TI>
<SO>British Journal of Surgery</SO>
<YR>2008</YR>
<VL>95</VL>
<NO>8</NO>
<PG>943-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Millis-1998" MODIFIED="2011-12-01 22:19:35 -0200" MODIFIED_BY="[Empty name]" NAME="Millis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mills KHG, Ryan M, Ryan E, Mahon BP</AU>
<TI>A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis</TI>
<SO>Infection and Immunity</SO>
<YR>1998</YR>
<VL>66</VL>
<PG>594-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mills-1999" MODIFIED="2014-09-07 13:11:24 -0300" MODIFIED_BY="[Empty name]" NAME="Mills 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mills KHG, Ryan M, McGuirk P, Griffin F, Murphy G, Mahon B</AU>
<TI>The immunology of Bordetella pertussis infection</TI>
<SO>Biologicals</SO>
<YR>1999</YR>
<VL>27</VL>
<NO>2</NO>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Petitti 1994" TYPE="BOOK">
<AU>Petitti DB</AU>
<SO>Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine</SO>
<YR>1989</YR>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pichichero-2005" MODIFIED="2014-05-25 20:26:04 -0300" MODIFIED_BY="Liz Dooley" NAME="Pichichero 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Casey JR</AU>
<TI>Acellular pertussis vaccines for adolescents</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>Suppl 6</NO>
<PG>117-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pichichero-2006" MODIFIED="2009-06-15 00:17:39 -0300" MODIFIED_BY="Liz Dooley" NAME="Pichichero 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME, Casey JR, Francis AB, Murphy M, Hoeger W, Cleary C</AU>
<TI>Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules</TI>
<SO>Clinical Pediatrics</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>7</NO>
<PG>613-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plotkin-2008" MODIFIED="2011-12-01 21:54:31 -0200" MODIFIED_BY="[Empty name]" NAME="Plotkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Plotkin SA</AU>
<TI>Correlates of vaccine-induced immunity</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>401&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-09-07 13:12:03 -0300" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodr_x00ed_guez_x002d_Cobo-2008" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Rodríguez-Cobo 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rodríguez-Cobo I, Chen YF, Olowokure B, Litchfield I</AU>
<TI>Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<PG>6768-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-1984" NAME="Sato 1984" TYPE="JOURNAL_ARTICLE">
<AU>Sato Y, Kimura M, Fukumi H</AU>
<TI>Development of a pertussis component vaccine in Japan</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>1</VL>
<NO>8369</NO>
<PG>122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitt-1996" MODIFIED="2012-01-30 01:46:44 -0200" MODIFIED_BY="Liz Dooley" NAME="Schmitt 1996" TYPE="JOURNAL_ARTICLE">
<AU>Schmitt HJ, Von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, et al</AU>
<TI>Efficacy of acellular pertussis vaccine in early childhood after household exposure</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>1</NO>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheridan-2012" MODIFIED="2014-05-25 20:27:07 -0300" MODIFIED_BY="Liz Dooley" NAME="Sheridan 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sheridan SL, Ware RS, Grimwood K, Lambert SB</AU>
<TI>Number and order of whole cell pertussis vaccines in infancy and disease protection</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>308</VL>
<NO>5</NO>
<PG>454-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-2006" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="Singh 2006" TYPE="JOURNAL_ARTICLE">
<AU>Singh M, Lingappan K</AU>
<TI>Whooping cough</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>130</VL>
<PG>1547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stephens--2008" MODIFIED="2011-11-21 22:21:22 -0200" MODIFIED_BY="[Empty name]" NAME="Stephens  2008" TYPE="JOURNAL_ARTICLE">
<AU>Stephens DS</AU>
<TI>Vaccines for the unvaccinated: protecting the herd</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>197</VL>
<PG>643-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Storsaeter-1998" MODIFIED="2014-09-07 13:12:55 -0300" MODIFIED_BY="[Empty name]" NAME="Storsaeter 1998" TYPE="JOURNAL_ARTICLE">
<AU>Storsaeter J, Hallander HO, Gustafsson L, Olin P</AU>
<TI>Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1907&#8211;16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taranger-1997" MODIFIED="2011-12-13 20:50:41 -0200" MODIFIED_BY="Liz Dooley" NAME="Taranger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Taranger J, Trollfors B, Lagergård, Lind L, Sund VH, Zackrisson G, et al</AU>
<TI>Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>180-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taranger-2000" MODIFIED="2012-01-30 02:36:24 -0200" MODIFIED_BY="[Empty name]" NAME="Taranger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, et al</AU>
<TI>Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2000</YR>
<VL>181</VL>
<PG>1010-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tran-Minh-1998" MODIFIED="2011-12-01 22:07:27 -0200" MODIFIED_BY="[Empty name]" NAME="Tran Minh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J</AU>
<TI>Antibody and cell-mediated immune responses to booster immunisation with a new acellular pertussis vaccine in school children</TI>
<SO>Vaccine</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>1604-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-2005" MODIFIED="2009-06-15 00:19:19 -0300" MODIFIED_BY="Liz Dooley" NAME="Watanabe 2005" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe M, Nagai M</AU>
<TI>Acellular pertussis vaccines in Japan: past, present and future</TI>
<SO>Expert Review of Vaccines</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>2</NO>
<PG>173-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1991" MODIFIED="2014-05-25 20:27:49 -0300" MODIFIED_BY="Liz Dooley" NAME="WHO 1991" NOTES="&lt;p&gt;WHO meeting on case definitions of pertussis. Geneva 10-11 Jan 1991. Geneva: WHO, MIN/EPI/PERT/91. 1:4-5.&lt;/p&gt;" NOTES_MODIFIED="2014-05-25 20:27:49 -0300" NOTES_MODIFIED_BY="Liz Dooley" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO meeting on case definitions of pertussis</TI>
<SO>MIN/EPI/PERT/91</SO>
<YR>1991</YR>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NAME="WHO 2010" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Pertussis vaccines: WHO position paper</TI>
<SO>Weekly Epidemiological Record, WHO</SO>
<YR>2010</YR>
<VL>No. 40, 85</VL>
<PG>385&#8211;400</PG>
<IDENTIFIERS MODIFIED="2011-10-26 10:28:53 -0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-25 19:54:24 -0300" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Tinnion-1999" MODIFIED="2009-08-03 18:49:26 -0300" MODIFIED_BY="[Empty name]" NAME="Tinnion 1999" TYPE="COCHRANE_REVIEW">
<AU>Tinnion ON</AU>
<TI>Acellular vaccines for preventing whooping cough in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-08-03 18:49:26 -0300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-03 18:49:26 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001478.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tinnion-2001" MODIFIED="2009-08-03 18:52:58 -0300" MODIFIED_BY="[Empty name]" NAME="Tinnion 2001" TYPE="COCHRANE_REVIEW">
<AU>Tinnion ON, Hanlon M</AU>
<TI>Acellular vaccines for preventing whooping cough in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-08-03 18:52:58 -0300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-03 18:52:58 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001478.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2009" MODIFIED="2011-11-21 22:20:31 -0200" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Prietsch SOM, Axelsson I, Halperin SA</AU>
<TI>Acellular vaccines for preventing whooping cough in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-21 22:20:31 -0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-21 22:20:31 -0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001478.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2012" MODIFIED="2014-05-25 19:54:24 -0300" MODIFIED_BY="Liz Dooley" NAME="Zhang 2012" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Prietsch SOM, Axelsson I, Halperin SA</AU>
<TI>Acellular vaccines for preventing whooping cough in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-05-25 19:54:24 -0300" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2014-05-25 19:54:24 -0300" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD001478.pub5"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-08 07:49:27 -0300" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-08 07:49:27 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Afari-1996">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Ghana<BR/>Design: parallel-group RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 19:44:44 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 6 weeks<BR/>Excluded: neurological disorder; serious disease; birth weight &lt; 2 kg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:31:41 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series</P>
<P>(aP versus wP)</P>
<OL>
<LI>DTaP: Biken[2] liquid</LI>
<LI>DTaP: Biken[2] freeze dried</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 266 aP, 137 wP<BR/>Dose schedule: 3 doses (6, 10, 14 weeks)<BR/>Concurrent vaccine: not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:32:36 -0200" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Efficacy: excluded (no laboratory confirmation of pertussis cases)</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: until 12 months after 3rd dose (16 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 7 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: drowsiness, fever, prolonged crying, vomiting within 7 days of each dose</LI>
</OL>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-21 22:57:01 -0200" MODIFIED_BY="[Empty name]">
<P>Local adverse events excluded (results only for all local adverse event types combined). No statement on antipyretic/analgesic use. In this review, results are combined for the 2 aP vaccine formulations</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 07:49:09 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AHGSPV-1988">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Sweden<BR/>Design: DB parallel-group RCT</P>
<P>Active case ascertainment (monthly telephone). Case incidence adjusted for follow-up duration by actuarial method. Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-29 00:30:09 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 5 to 11 months</P>
<P>Excluded: suspected progressive neurological disease; failure to thrive; renal failure; cardiac failure; prior pertussis or pertussis immunisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-12 19:52:23 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus placebo)</P>
<OL>
<LI>aP: JNIH7[1]</LI>
<LI>aP: JNIH6[2]</LI>
<LI>Placebo</LI>
</OL>
<P>Number randomised: 2837 aP, 954 placebo<BR/>Dose schedule: 2 doses (entry + 8 to 12 weeks later)<BR/>Concurrent vaccines: DT and IPV (not within 1 week before or 2 weeks after aP or wP)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 07:49:09 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: 3801 infants randomised in a 3:3:2 ratio - 1428 to JNIH7, 1419 to JNIH6, 954 to placebo. Of these, 1403, 1385 and 923 were assessed for efficacy in the 3 groups, respectively. Assessment commenced 30 days after the second dose and lasted for 17 to 19 months. Efficacy data were not available for the intention-to-treat population. Several case definitions, those closest to the definitions selected for review were: whooping cough = 21 days paroxysmal cough with whoops "after adjustment for non-pertussis disease" (i.e. exclusion of cases that could not be verified by culture, serology or contact with culture-proven case). Pertussis disease = cough for 7 days or more or household exposure to pertussis, with confirmation by appropriate serology</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 15 to 17 months after 2nd dose (17 to 19 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 14 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 14 days of any dose</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, vomiting, pain/tenderness, redness, swelling/induration within 1 day of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-22 00:47:12 -0200" MODIFIED_BY="Liz Dooley">
<P>Macrolide prophylaxis not used (not recommended in Sweden for age &gt; 6 months and efficacy follow-up in this study started at minimum age of 7 months). Reactive antipyretic/analgesic use allowed. Blinding of study nurses confirmed by questionnaire</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AHGSPV-1997">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:09 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Sweden<BR/>Design: DB parallel-group RCT</P>
<P>Passive case ascertainment (based on laboratory reports of pertussis and questionnaire of parents at 18-month visit). Case incidence adjusted for follow-up duration by Cox proportional hazard regression. Follow-up of serious adverse events by active weekly surveillance in study area hospitals, reports from participating physicians and child health nurses, plus questioning of parents at each trial dose and when the child was 18 months old</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 23:01:05 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months<BR/>Excluded: progressive neurological disease; uncontrolled epilepsy; infantile spasm; failure to thrive; renal failure; cardiac failure; immunosuppression; prior pertussis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:27:07 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: Chiron-Biocine[3]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 62172 aP, 2072 wP<BR/>Dose schedules: 3 doses (3, 5, 10 months - 88% of vaccinees; 2, 4, 6 months - 12% of vaccinees)<BR/>Concurrent vaccines: HiB and IPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:36:12 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: excluded (case ascertainment not active)</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until mean of 22 months after 3rd dose</LI>
<LI>Encephalopathy: within 2 days of any dose</LI>
<LI>Convulsions: within 2 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 3 days of any dose</LI>
<LI>Minor adverse events: not studied</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>There was good evidence that the passive case ascertainment led to significant under-reporting of cases. It is possible (not discussed in study report) that under-reporting of serious adverse events may have occurred but there are no grounds to suspect that under-reporting would affect the acellular and whole-cell groups differently<BR/>Deaths recorded for this study are due to any cause and include at least 1 due to injury (vaccine group not specified)<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:09 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1988">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:09 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA</P>
<P>Design: DB parallel-group RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 23:02:30 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months; healthy<BR/>Excluded: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:45:31 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)<BR/>1. DTaP: Wyeth/Takeda[4]<BR/>2. DTwP: Wyeth[W]<BR/>Number randomised: 19 aP, 20 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:37:12 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied.</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: within 14 days of any dose</LI>
<LI>Convulsions: within 14 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-28 19:50:56 -0200" MODIFIED_BY="[Empty name]">
<P>Reactive analgesic/antipyretic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:10 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernstein-1992">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:10 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:24:43 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 4 to 6 years; healthy; completed DTwP primary series and 15- to 24-month booster<BR/>Excluded: personal or family history of developmental delay or neurological disorder; previous aP or DTaP; previous contraindicating reaction to DTwP<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:37:50 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 240 aP, 76 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:39:04 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 14 days of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 14 days of dose</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 10:31:04 -0200" MODIFIED_BY="[Empty name]">
<P>Prophylactic antipyretic/analgesic use not allowed. Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:10 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernstein-1994">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:10 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 23:04:03 -0200" MODIFIED_BY="Liz Dooley">
<P>Age: 15 to 20 months; healthy; completed DTwP primary series<BR/>Excluded: personal or family history of developmental delay or neurological disorder; previous DTaP; previous contraindicating reaction to DTwP</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:39:28 -0200" MODIFIED_BY="Liz Dooley">
<P>BOOSTER (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: SKB[3]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 110 aP, 22 wP<BR/>Dose schedule: 1 dose (15 to 20 months)<BR/>Concurrent vaccine: not stated<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:40:20 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied.</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 10:33:37 -0200" MODIFIED_BY="[Empty name]">
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black-1997">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:10 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:04:55 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months<BR/>Excluded: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:36:58 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Chiron/Biocine[3]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 2000 aP, 498 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccines: HiB (separate injection site) and OPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:41:51 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: data incomplete (SIDS only)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 2 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Booster dose of Chiron/Biocine[3] or Lederle/Takeda[4] at age 15 to 18 months. Data for this dose are not included as there was no DTwP or placebo control<BR/>SIDS was recorded in 4/2000 (0.2%) DTaP and 1/498 (0.2%) DTwP recipients in the first year of life. Death due to other causes was not studied<BR/>Late onset fever (&gt; 3 days after dose) occurred in both groups, with peak percentage slightly higher in DTaP group (approximately 5% versus 4.5% in DTwP group) but the overall percentage with fever over the 14-day follow-up was lower in the DTaP group<BR/>No statement on antipyretic/analgesic use<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blennow-1988">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:11 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Sweden<BR/>Design: parallel-group RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-13 20:30:43 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 6 months<BR/>Excluded: contraindication to DTP vaccine as per ref Anon 1977<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:43:20 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP - see notes)</P>
<OL>
<LI>aP: JNIH6[2]</LI>
<LI>wP: Wellcome[W]</LI>
<LI>Placebo - see notes</LI>
</OL>
<P>Number randomised: 121 aP, 119 P, 79 wP<BR/>Dose schedule: 3 doses (6, 7, 8 months)<BR/>Concurrent vaccine: DT and polio vaccines not given within 2 weeks of dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: excluded (no data on number of cases in DTwP group)</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 1 month after 3rd dose (5 months after 1st dose)</LI>
<LI>Encephalopathy: until at least 1 week after 3rd dose (4 months after 1st dose)</LI>
<LI>Convulsions: until at least 1 week after 3rd dose (4 months after 1st dose)</LI>
<LI>Hypotonic-hyporesponsive episodes: until at least 1 week after 3rd dose (4 months after 1st dose)</LI>
<LI>Minor adverse events: drowsiness, fever, irritability, redness, swelling/induration within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The whole-cell series was given as 3 doses of whole-cell vaccine.<BR/>The acellular series was given as 3 doses of acellular vaccine, or 2 doses of acellular vaccine plus 1 dose of placebo (replacing the 1st, 2nd or 3rd dose of acellular vaccine). In this review, data for series non-completion, deaths and serious adverse events relate to all acellular-containing vaccine regimens. The acellular primary series non-completion (due to adverse events) data include 1 infant who withdrew after receiving placebo at the 1st dose. Data for minor adverse events at each dose are recorded only for those patients who actually received the acellular vaccine at that dose<BR/>Data for anorexia and vomiting collected but not reported<BR/>No statement on antipyretic/analgesic use<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:11 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blumberg-1990">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:11 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 23:05:42 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 17 to 24 months; healthy; completed DTwP primary series<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:47:58 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 38 aP, 37 wP<BR/>Dose schedule: 1 dose (17 to 24 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:48:53 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-21 23:05:54 -0200" MODIFIED_BY="[Empty name]">
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blumberg-1991">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:11 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 23:05:58 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months; healthy<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:46:05 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle/Takeda[W]</LI>
</OL>
<P>Number randomised: 245 aP, 252 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:50:23 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 12 months after 3rd dose (16 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 3 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 3 days of any dose</LI>
<LI>Minor adverse events: drowsiness, fever, irritability, prolonged crying, vomiting, pain/tenderness, redness, swelling/induration within 3 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>1 death in DTwP arm due to accident (strangulation by pacifier cord)<BR/>4th dose of DTaP given at 18 months to all children. 4th dose not included in review because no DTwP control group for that dose.<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Decker-1995">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:12 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Phased parallel-group RCT (2 to 3 vaccines per phase)</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:20:34 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 6 to 12 weeks; healthy<BR/>Excluded: born &lt; 36 weeks gestation; immune system disease; major congenital malformation; serious chronic disease; developmental delay; neurological disease; convulsions; other contraindications to DTP vaccine as per ref CID 1991a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:23:12 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Biocine[1]</LI>
<LI>DTaP: SSVI[1]</LI>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTaP: Michigan[2]</LI>
<LI>DTaP: Pasteur-Merieux[2]</LI>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: Biocine[3]</LI>
<LI>DTaP: Lederle[3]</LI>
<LI>DTaP: SKB[3P]</LI>
<LI>DTaP: Connaught[4]</LI>
<LI>DTaP: Porton[4]</LI>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 1827 aP, 373 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: HiB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:53:23 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 1 month after 3rd dose (5 months after 1st dose)</LI>
<LI>Encephalopathy: until 1 month after 3rd dose</LI>
<LI>Convulsions: until 1 month after 3rd dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, pain/tenderness, redness, swelling/induration within 3 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>In this review, safety results are combined for all acellular vaccines. Irritability and pain were reported only for the moderate/severe category<BR/>At an additional retrospective medical record review 1 year after dose 3 (not all subjects studied), convulsions were documented in 1.1% DTaP recipients compared to 0.7% DTwP<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:12 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1986a">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:12 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA</P>
<P>Design: parallel-group RCT<BR/>
</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-27 16:19:24 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 18 to 24 months; completed DTwP primary series<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:54:02 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Wyeth/Takeda[4]</LI>
<LI>DTwP: Wyeth[W]</LI>
</OL>
<P>Number randomised: 20 aP, 20 wP<BR/>Dose schedule: 1 dose (18 to 24 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:54:56 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 1 month of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 11:22:10 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1986b">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:12 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:14:43 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; completed DTwP primary series and 15- to 24-month booster<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Booster (wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: Wyeth/Takeda[4]</LI>
<LI>DTwP: Wyeth[W]</LI>
</OL>
<P>Number randomised: 20 aP, 20 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:56:17 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: within 1 month of dose</LI>
<LI>Convulsions: within 1 month of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 11:23:20 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1989a">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-13 20:31:42 -0200" MODIFIED_BY="[Empty name]">
<P>Included: infants<BR/>Excluded: previous DTP vaccination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:56:44 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Merieux[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 23 aP, 27 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:57:42 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until at least 2 weeks after 3rd dose (4 months after 1st dose)</LI>
<LI>Encephalopathy: until at least 2 weeks after 3rd dose (4 months after 1st dose)</LI>
<LI>Convulsions: until at least 2 weeks after 3rd dose (4 months after 1st dose)</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, fever, irritability, pain/tenderness within 3 days of dose; redness, swelling/induration within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:28:41 -0200" MODIFIED_BY="[Empty name]">
<P>Follow-up for deaths probably longer than until 2 weeks after dose 3 but not clearly stated to be so<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1989b">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:17:04 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 18 to 24 months; completed DTwP primary series<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 20:58:08 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Merieux[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 19 aP, 21 wP<BR/>Dose schedule: 1 dose (18 to 24 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 20:59:00 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: until at least 2 weeks after dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, fever, irritability, pain/tenderness within 3 days of dose; redness, swelling/induration within 1 day of dose</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:29:09 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1989c">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:13 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:17:52 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; completed DTwP primary series and 18- to 24-month booster<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:46:30 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster</P>
<P>(wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: Merieux[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 20 aP, 20 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:00:18 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: until at least 2 weeks after dose</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, fever, irritability, pain/tenderness within 3 days of dose; redness, swelling/induration within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:29:30 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:14 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englund-1992">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:14 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Houston, USA<BR/>Design: parallel-group RCT</P>
<P>Parents were interviewed by telephone. Parents recorded adverse events in diary for 14 days after immunisations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:18:59 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: ages 16 to 20 months, who had received primary immunisation with DTwP<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:00:45 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (aP versus wP)</P>
<OL>
<LI>DTaP: local laboratory [5]</LI>
<LI>DTwP: Connaught [W]</LI>
</OL>
<P>Number randomised: 28 aP, 13 wP<BR/>Dose schedule: 1 dose (16 to 20 months)<BR/>Concurrent vaccines: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:01:33 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability/fretfulness, prolong crying, vomiting, pain/tenderness, redness, swelling/induration</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:29:51 -0200" MODIFIED_BY="[Empty name]">
<P>Prolonged crying was studied as increased crying. Use of analgesic/antipyretic was allowed during the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englund-1994a">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:14 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:19:38 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 16 to 21 months; healthy; completed DTwP primary series<BR/>Excluded: known immune deficiency; receipt of blood products in past month; contraindication to DTwP as specified in ref CID 1991a; physician did not recommend DTwP</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:03:06 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Massachusetts[1]</LI>
<LI>DTaP: Biocine[1]</LI>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTaP: Lederle[3]</LI>
<LI>DTaP: Biocine[3]</LI>
<LI>DTaP: SKB[3]</LI>
<LI>DTaP: Porton[4]</LI>
<LI>DTaP: Wyeth/Takeda[4]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
<LI>DTwP: Massachusetts[W]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number studied: 102 aP, 29 wP<BR/>Dose schedule: 1 dose (16 to 21 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:04:07 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: until post-vaccination phlebotomy (timing not specified)</LI>
<LI>Hypotonic-hyporesponsive episodes: until post-vaccination phlebotomy (timing not specified)</LI>
<LI>Minor adverse events: fever, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The number of 16- to 24-month old children randomised to aP or wP was not stated. A total of 258 children aged 16 to 24 months or 4 to 6 years were randomised in Englund 1994a and Englund 1994b combined: 192 to aP and 66 to wP. 240 of these contributed safety data<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Englund-1994b">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:14 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:21:06 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; healthy; completed DTwP primary series and 15- to 24-month booster<BR/>Excluded: known immune deficiency; receipt of blood products in past month; contraindication to DTwP as specified in ref CID 1991a; physician did not recommend DTwP</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:06:08 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: Massachusetts[1]</LI>
<LI>DTaP: Biocine[1]</LI>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTaP: Lederle[3]</LI>
<LI>DTaP: Biocine[3]</LI>
<LI>DTaP: SKB[3]</LI>
<LI>DTaP: Porton[4]</LI>
<LI>DTaP: Wyeth/Takeda[4]</LI>
<LI>DTwP: Connaught[W]</LI>
<LI>DwTP: Massachusetts[W]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number studied: 80 aP, 29 wP<BR/>Dose schedule: 1 dose (16 to 21 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:07:06 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: until post-vaccination phlebotomy (timing not specified)</LI>
<LI>Hypotonic-hyporesponsive episodes: until post-vaccination phlebotomy (timing not specified)</LI>
<LI>Minor adverse events: fever, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Number of 4 to 6-year old children randomised to aP or wP not stated. A total of 258 children aged 16 to 24 months or 4 to 6 years were randomised in Englund 1994a and Englund 1994b combined: 192 to aP and 66 to wP. 240 of these contributed safety data.<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldman-1992">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:23:17 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 15 to 24 months; healthy; completed DTwP primary series<BR/>Excluded: immune dysfunction; major congenital malformation; serious chronic disorder; developmental delay; receipt of immunoglobulin within past 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:37:04 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 84 aP, 78 wP<BR/>Dose schedule: 1 dose (15 to 24 months)<BR/>Concurrent vaccine: OPV; HiB 4 weeks after study vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:09:11 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 3 days of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 3 days of dose</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, pain/tenderness, redness, swelling/induration within 1 day of dose; prolonged crying within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 11:29:31 -0200" MODIFIED_BY="[Empty name]">
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feldman-1993">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months; healthy<BR/>Excluded: born &lt; 36 weeks gestation; immune disorder; major congenital malformation; serious chronic disease; ongoing immunoglobulin therapy; pertussis infection; personal or family history of neurological disorder or developmental delay</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:37:11 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 109 aP, 36 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: OPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:10:45 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded - see notes</LI>
<LI>Deaths: until at least 14 days after 3rd dose (4 months after 1st dose)</LI>
<LI>Encephalopathy: until age 12 months (10 months after 1st dose)</LI>
<LI>Convulsions: within 14 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 14 days of any dose</LI>
<LI>Minor adverse events: excluded (separate data for each dose not available)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>1 infant did not complete the primary series due to an adverse event (high pitched cry) but the report does not state whether this infant received aP or wP. Deaths were not specifically reported but all infants either completed the study up to the final dose or withdrew due to reasons other than death<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glode-1992">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 20:25:42 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 17 to 24 months; healthy; full-term; completed DTwP primary series<BR/>Excluded: acute or chronic illness; history of diphtheria, tetanus or pertussis; known contraindication to DTP</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:11:39 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4] (lot 1)</LI>
<LI>DTaP: Lederle/Takeda[4] (lot 2)</LI>
<LI>DTaP: Lederle/Takeda[4] (lot 3)</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 345 aP, 52 wP<BR/>Dose schedule: 1 dose (17 to 24 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:12:40 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 10 days of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 10 days of dose</LI>
<LI>Minor adverse events: drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-28 23:23:56 -0200" MODIFIED_BY="[Empty name]">
<P>Results for DTaP lots combined<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greco-1996">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:15 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Italy</P>
<P>Design: DB parallel-group RCT<BR/>Passive and active case ascertainment (parent report and monthly telephone). Case incidence adjusted for follow-up duration by use of incidence density. Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-13 20:33:01 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 6 to 12 weeks; weight &gt; 3rd percentile<BR/>Excluded: history of seizures or central nervous system disease; known/suspected immunological deficit; major congenital abnormality; failure to thrive; renal failure; prior pertussis or pertussis vaccination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:37:18 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP versus DT)</P>
<OL>
<LI>DTaP: SKB[3]</LI>
<LI>DTaP: Biocine[3]</LI>
<LI>DTwP: Connaught[W]</LI>
<LI>DT</LI>
</OL>
<P>Number randomised: 9368 aP, 4678 wP, 1555 DT<BR/>Dose schedule: 3 doses (6 to 12, 13 to 20, and 21 to 28 weeks)<BR/>Concurrent vaccine: OPV and hepatitis B vaccine with doses 1 and 2. Booster dose of DT to all subjects at 12 months of age</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: 15,601 infants randomised and received at least 1 dose of vaccine: 4696 SKB, 4672 Biocine, 4678 DTwP and 1555 DT (randomisation ratio 3:3:3:1). Main efficacy assessment was in children who had received all 3 doses of study vaccine, commenced 30 days after 3rd dose and lasted 17 months. It included 4481 SKB, 4452 Biocine, 4358 DTwP and 1470 DT subjects. Efficacy data were also available for the intent-to-treat population. Several case definitions used. Those closest to the definitions selected for review were: whooping cough = 21 days or more of paroxysmal cough with confirmation by culture or appropriate serology. Pertussis disease = 7 days or more of paroxysmal cough with confirmation by culture or appropriate serology</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Encephalopathy: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Convulsions: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Hypotonic-hyporesponsive episodes: within 2 days of each dose</LI>
<LI>Minor adverse events: excluded (separate data for each dose not available)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>No statement on macrolide prophylaxis. Possible partial unblinding of DTwP (not discussed in article but study used same DTwP as Gustafsson96)<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gustafsson-1996">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:16 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Sweden<BR/>Design: DB parallel-group RCT</P>
<P>Passive and active case ascertainment (parent report and telephone every 6 to 8 weeks). Case incidence adjusted for follow-up duration by use of Cox proportional hazards regression. Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:14:14 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 2 to 3 months<BR/>Excluded: progressive neurological disease; failure to thrive; renal failure; cardiac failure; uncontrolled epilepsy; infantile spasms; immunosuppression; prior pertussis or pertussis vaccination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:23:38 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP versus DT)</P>
<OL>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
<LI>DT</LI>
</OL>
<P>Number randomised: 5153 aP, 2102 wP, 2574 DT<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: inactivated polio vaccine and HiB at least 2 weeks after study vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: 9829 infants randomised and received at least 1 dose of vaccine: 2566 SKB, 2587 Connaught DTaP, 2102 DTwP and 2574 DT. Due to delayed availability of the DTwP, children were randomised only to DTaP and DT vaccines during the first 2 months of the trial. Main efficacy assessment was in children who had received all 3 doses of study vaccine, commenced 30 days after the 3rd dose and lasted for 21 months. It included 2538 SKB, 2551 Connaught DTaP, 2001 DTwP and 2538 DT subjects. Efficacy data were also available for the intention-to-treat population. Comparisons between DTaP and DT vaccines utilised data from all children randomised to those vaccines over the whole trial period. Comparisons involving the whole-cell vaccine utilised data only from children who were enrolled after the date the whole-cell vaccine became available. Several case definitions used. Those closest to the definitions selected for review were: whooping cough = 21 days or more of paroxysmal cough with confirmation by culture, appropriate serology or documented household contact with a culture-confirmed case. Pertussis disease = more than 7 days of cough with confirmation as above</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 2 years after 3rd dose (28 months after 1st dose)</LI>
<LI>Encephalopathy: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Convulsions: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Hypotonic-hyporesponsive episodes: within 60 days of any dose (6 months after 1st dose)</LI>
<LI>Minor adverse events: fever, prolonged crying, redness, swelling/induration, pain/tenderness within 1 day of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Macrolide prophylaxis not used (not recommended in Sweden for age &gt; 6 months and main efficacy follow-up in this study started at age 6 months)<BR/>DTwP unavailable for first 2 months of study. Only DTaP and DT randomised during that period. Questionnaire of study nurses showed partial post-allocation unblinding of DTwP (harder to re-suspend and more likely to be followed by adverse events). Pre-allocation concealment was determined to be adequate (see text for reasons)<BR/>Redness reported only for moderate/severe category<BR/>Reactive antipyretic/analgesic use allowed<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-1994a">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:16 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: DB parallel-group RCT</P>
<P>Adverse events recorded by structured telephone interview of parents</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-13 20:43:39 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months; healthy<BR/>Excluded: children with contraindications to pertussis vaccine as specified in ref NACI 1989</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Connaught[5]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTaP: Connaught[W]</LI>
</OL>
<P>Number randomised: 67 aP, 33 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: HiB</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:31:56 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 1 month after 3rd dose (5 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The 2 acellular vaccines had differing amounts of PT and FH. In this review, results for the 2 acellular vaccine formulations are combined</P>
<P>Antipyretic/analgesic prophylaxis was discouraged but not prohibited<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:16 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-1994b">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:16 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: DB parallel-group RCT</P>
<P>Adverse events recorded by structured telephone interview of parents<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-29 23:27:34 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 17 to 19 months; healthy<BR/>Excluded: children with contraindications to pertussis vaccine as specified in ref NACI 1989</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:33:21 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Connaught[5]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 61 aP, 30 wP<BR/>Dose schedule: 1 dose (17 to 19 months)<BR/>Concurrent vaccine: Hib</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:34:16 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-25 20:19:10 -0300" MODIFIED_BY="Liz Dooley">
<P>The 2 acellular vaccines had differing amounts of PT, FH, Prn and Fim2,3. In this review, results for the 2 acellular vaccine formulations are combined<BR/>Antipyretic/analgesic prophylaxis was discouraged but not prohibited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-1995">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: DB parallel-group RCT. Subjects had been randomised and received primary series in Halperin 1994a</P>
<P>Adverse events recorded by structured telephone interview of parents<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:35:22 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 17 to 19 months; healthy; primary series DTaP or DTwP given in Halperin 1994a<BR/>Excluded: children with contraindications to pertussis vaccine as specified in ref NACI 1989<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:36:05 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (aP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Connaught[5]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number studied: 56 aP, 30 wP<BR/>Dose schedule: 1 dose (17 to 19 months)<BR/>Concurrent vaccine: Hib</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:37:01 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 2 days of dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 2 days of dose</LI>
<LI>Minor adverse events: anorexia, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The 2 acellular vaccines had differing amounts of PT and FH. In this review, results for the 2 acellular vaccine formulations are combined. DTaP or DTwP primary series was given in Halperin 1994a. Randomisation took place in that study, parents and investigators remained blinded and children received the same vaccine in Halperin 1995 as they had received in Halperin 1994a<BR/>Antipyretic/analgesic prophylaxis was discouraged but not prohibited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-1996">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:17 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: DB parallel-group RCT</P>
<P>Adverse events recorded by structured telephone interview of parents</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:39:10 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 2 to 3 months; healthy<BR/>Excluded: children with contraindications to pertussis vaccine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series + booster (aP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 324 aP, 108 wP<BR/>4 doses (2, 4, 6, 17 to 19 months)<BR/>Concurrent vaccine: Hib</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: included up to 3rd dose (4 months after 1st dose). Excessive loss to follow-up after that dose</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: until 1 to 2 months after 3rd dose</LI>
<LI>Hypotonic-hyporesponsive episodes: until 1 to 2 months after 3rd dose</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:35:26 -0200" MODIFIED_BY="[Empty name]">
<P>Antipyretic/analgesic prophylaxis was discouraged but not prohibited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-1999">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:17 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: DB parallel-group RCT</P>
<P>Adverse events recorded by structured telephone interview of parents</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:41:30 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; healthy; primary series DTaP or DTwP given in Halperin 1994 or Halperin 1996<BR/>Excluded: children with contraindications to pertussis vaccine as specified in ref NACI 1989</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Booster (aP versus wP)</P>
<OL>
<LI>5 doses DTaP-IPV: Connaught[5]</LI>
<LI>4 doses DTwP-IPV + 1 dose DTaP-IPV: Connaught[5]</LI>
<LI>4 doses DTaP-IPV+ 1 dose DTwP: Connaught[W]</LI>
<LI>5 doses DTwP-IPV: Connaught[W]</LI>
</OL>
<P>Number studied: 178 aP, 178 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: IPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:43:26 -0200" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: excluded (booster)</LI>
<LI>Hypotonic-hyporesponsive episodes: excluded (booster)</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:35:53 -0200" MODIFIED_BY="[Empty name]">
<P>Antipyretic/analgesic prophylaxis was discouraged but not prohibited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halperin-2003">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:18 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Canada<BR/>Design: parallel-group RCT</P>
<P>Computer-generated randomisation list kept in a locked file. Study personnel collecting telephone reactogenicity data were blinded as to which vaccine the subject had received</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:44:06 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; healthy<BR/>Excluded: children with contraindications to pertussis vaccine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Booster (aP versus wP) </P>
<OL>
<LI>4 doses DTaP-Hib+DTaP-IPV: Pasteur [5]  </LI>
<LI>4 doses DTwP-Hib+DTaP-IPV: Pasteur [5] </LI>
<LI>4 doses DTwP+DTwP-IPV: Pasteur [W]                                           </LI>
</OL>
<P>Number randomised: 408 aP, 97 wP<BR/>1 dose (4 to 6 years)<BR/>
</P>
<P>Concurrent vaccines: Hib; IPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:46:15 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-25 20:21:05 -0300" MODIFIED_BY="Liz Dooley">
<P>Only participants who had received 4 previous doses of DTwP were blinded to which vaccine they received for the fifth dose, because of different vaccine container formats. Antipyretic/analgesic prophylaxis was discouraged but not prohibited</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heininger-1994">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:18 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Germany<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:47:13 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 to 4 months; healthy<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 75 aP, 74 wP<BR/>Dose schedule: 3 doses (2 to 4 months, then 2 doses at 6-week intervals)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:48:43 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Excluded for adverse events after 2nd and 3rd doses (number vaccinated/studied at these doses was uncertain due to inconsistencies in tabulated data). Redness and induration were reported only for the moderate/severe category<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanra-1993a">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:18 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Turkey<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 21:49:18 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 15 to 20 months; completed DTwP primary series<BR/>Excluded: history of pertussis or progressive neurological disease; chronic drug therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:49:46 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: SKB[3]</LI>
<LI>DTwP: Behringwerke[W]</LI>
</OL>
<P>Number randomised: 55 aP, 55 wP<BR/>Dose schedule: 1 dose (15 to 20 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:50:44 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Data for drowsiness, irritability (restlessness), "unusual" crying and "gastrointestinal symptoms" collected but not reported. Report states "no serious events" but serious events not defined<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanra-1993b">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:18 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Turkey<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Included: age 4 to 6 years; completed DTwP primary series and 15- to 24-month booster<BR/>Excluded: history of pertussis or progressive neurological disease; chronic drug therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:59:05 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: SKB[3]</LI>
<LI>DTwP: Behringwerke[W]</LI>
</OL>
<P>Number studied: 53 aP, 52 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:52:57 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-28 21:53:02 -0200" MODIFIED_BY="[Empty name]">
<P>Total 108 randomised, data for 105<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kosuwon-2003">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:19 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Thailand<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Included: age 4 to 6 years old; healthy, who had received 4 doses of DTwP at 2, 4, 6 and 18 months<BR/>Excluded: history of diphtheria or tetanus at any time, confirmed pertussis in the previous 5 years, if received vaccines not foreseen in the protocol within 30 days prior to study start or after receiving a study vaccine, history of allergic disease or reactions by any component of the vaccine or previously recorded following previous DTP, history of any serious adverse reactions following previous DTP vaccination, history of administration of immunosuppressive agents, immunoglobulin or blood products within the previous 3 months or during the trial, major congenital defects, neurological including seizure disorders and acute febrile illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 21:55:18 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (aP versus wP)</P>
<OL>
<LI>DTaP: GSK [3]</LI>
<LI>DTwP: GSK [W]</LI>
</OL>
<P>Number studied: 165 aP, 165 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 21:56:22 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, pain/tenderness, redness, swelling/induration</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-28 21:58:19 -0200" MODIFIED_BY="Liz Dooley">
<P>All symptoms (solicited or unsolicited) were classified by the investigators as not related, unlikely, suspected or probably related. But not a clear temporal definition of this criterion (before or after data collection)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:19 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lewis-1986">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:19 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:23:17 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 18 to 24 months; healthy; completed DTwP primary series<BR/>Excluded: contraindication to DTwP as specified in ref CID 1982 or in the Wyeth [W] pack insert</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 22:00:19 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Wyeth/Takeda[4]</LI>
<LI>DTwP: Wyeth[W]</LI>
</OL>
<P>Number randomised: 40 aP, 20 wP<BR/>Dose schedule: 1 dose (18 to 24 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 22:01:10 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, vomiting, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:38:04 -0200" MODIFIED_BY="[Empty name]">
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcinak-1993">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:19 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 22:01:29 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 15 to 20 months; completed DTwP primary series<BR/>Excluded: routine contraindications to DTP vaccine; immunodeficiency; immunosuppressive therapy; major congenital malformation; serious chronic disease; personal or immediate family history of developmental delay or neurological disorder; antibiotic therapy within 7 days before enrolment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 23:28:52 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTwP: Connaught[W]</LI>
</OL>
<P>Number randomised: 164 aP, 82 wP<BR/>Dose schedule: 1 dose (15 to 20 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 22:02:55 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, pain/tenderness, redness, swelling/induration at 1 day after dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Study report states that only adverse events for which there was a significant difference between vaccines were reported. Not clear whether adverse event types were omitted or just certain time points for individual adverse events<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1991">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:20 -0300" MODIFIED_BY="[Empty name]">
<P>Site: UK</P>
<P>Design: parallel-group RCT<BR/>
</P>
<P>Parents and study nurses recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:20:41 -0200" MODIFIED_BY="[Empty name]">
<P>Included: infants attending clinics for 1st dose DTP (due at age 3 months)<BR/>Excluded: history of neurological disorder, serious chronic disease or confirmed pertussis; immediate family history of idiopathic epilepsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 22:04:19 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: CAMR[4]</LI>
<LI>DTwP: Wellcome[W]</LI>
</OL>
<P>Number randomised: 94 aP, 94 wP<BR/>Dose schedule: 3 doses (3, 5, 8 to 10 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 22:05:21 -0200" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 3rd dose (5 to 7 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever within 1 day of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Minor adverse event data for fever only. Anorexia, drowsiness, irritability, prolonged crying and vomiting combined as "any systemic symptom"<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:20 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morgan-1990">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:20 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 22:05:53 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years; healthy; completed DTwP primary series and 15- to 24-month booster<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 22:06:29 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.wP.aP versus wP.wP.wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 41 aP, 42 wP<BR/>Dose schedule: 1 dose (4 to 6 years)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 22:07:18 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:39:06 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1992">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on questionnaires and measured their child's rectal temperature</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:21:13 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: infants due to receive 1st dose DTP (mean age = 2 months), 2nd dose (mean age = 4 months) and 3rd dose (mean age = 6 months)<BR/>Excluded: contraindication to DTP vaccine as specified in ref CID 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-07 12:31:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Biken/Connaught [2]</LI>
<LI>DTwP: Connaught [W]</LI>
</OL>
<P>Number randomised:                                                                                              </P>
<UL>
<LI>1 dose: 218 aP versus 72 wP</LI>
<LI>2 dose: 207 aP versus 62 wP </LI>
<LI>3 dose: 204 aP versus 57 wP                                                 </LI>
</UL>
<P>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 22:10:32 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolong crying, vomiting, pain/tenderness, redness, swelling/induration, within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The pattern of crying is not clear, considered unusual, or high-pitched cries. 7 children left the study for severe reactions not described and 2 experienced hypotonic/hyporesponsive episodes following the second vaccination. Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:21 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1993">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:21 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:16:50 -0200" MODIFIED_BY="[Empty name]">
<P>Included: infants due to receive 1st dose DTP (mean age = 2 months)<BR/>Excluded: contraindication to DTP vaccine as specified in ref CID 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 23:12:55 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: SKB[2]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 88 aP, 22 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:13:58 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 3rd dose (4 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-28 23:14:25 -0200" MODIFIED_BY="Liz Dooley">
<P>The choice of reported adverse event types was not limited to those showing a significant difference between vaccines but was based on the preliminary results of Decker 1995 (reported in Pichichero 1995), which identified the chosen adverse events as sufficient to differentiate between DTP vaccines in regard to reactogenicity. Irritability and pain were reported only for the moderate/severe category.</P>
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:21 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1994">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:21 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:21:28 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months (6 to 12 weeks); healthy<BR/>Excluded: contraindication to DTP vaccine as specified in ref CID 1988</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 23:30:09 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: SKB[3]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 62 aP, 18 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:31:27 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration, within 2 days of each dose</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:40:47 -0200" MODIFIED_BY="[Empty name]">
<P>Redness and pain were reported only for the moderate/severe category<BR/>Antipyretic/analgesic use discouraged but allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1996">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT. Subjects had been randomised and received primary series in Pichichero 1993 and Pichichero 1994 (latter excluded due to discrepancies in reported data). 158 out of 190 (83%) parents elected to remain blinded and allow child to participate in booster study</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-27 16:40:53 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 15 to 20 months; primary series DTaP or DTwP given in Pichichero 1993 or Pichichero 1994<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 23:32:43 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (aP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: SKB[3P]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number studied: 124 aP, 34 wP<BR/>Dose schedule: 1 dose (15 to 20 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:33:41 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Possible bias due to parental self selection of 83% subset who continued in the study. Number of subjects studied for redness and pain in the DTwP group is unclear due to discrepancies in the data table. Irritability and pain were reported only for the moderate/severe category<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1997">
<CHAR_METHODS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT. Subjects had been randomised and received primary series in Decker 1995. 1374 of 2264 (61%) parents elected to remain blinded and allow child to participate in booster study</P>
<P>Parents recorded adverse events on forms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:34:38 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: completed DTaP or DTwP primary series in Decker 1995<BR/>Excluded: see Decker 1995; contraindications to DTP vaccine as per ref CID 1994</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-25 20:20:04 -0300" MODIFIED_BY="Liz Dooley">
<P>Booster (aP.aP versus wP.aP versus wP.wP)</P>
<P>Children who had received DTaP primary series received the same DTaP as a booster, except for those who had received Lederle[3P] (no longer available) who were boosted with Lederle/Takeda[4F2]. Children who had received DTwP primary series were re-randomised to receive 1 of the 12 DTaP vaccines or DTwP</P>
<OL>
<LI>DTaP: Biocine[1]</LI>
<LI>DTaP: SSVI[1]</LI>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTaP: Michigan[2]</LI>
<LI>DTaP: Pasteur-Merieux[2]</LI>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: Biocine[3P]</LI>
<LI>DTaP: SKB[3P]</LI>
<LI>DTaP: Connaught[4]</LI>
<LI>DTaP: Porton[4]</LI>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTaP: Connaught[5]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number studied: 1079 aP.aP, 187 wP.aP, 16 wP.wP<BR/>Dose schedule: 1 dose (15 to 20 months)<BR/>Concurrent vaccine: OPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:46:20 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: within 3 days of dose (possibly 2 weeks)</LI>
<LI>Hypotonic-hyporesponsive episodes: within 3 days of dose (possibly 2 weeks)</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Most failures to proceed from primary series to booster study were due to prior receipt of booster dose or reluctance regarding venipuncture. Possible selection bias exists due to loss of 39% of subjects after primary series, although authors state that DTwP primary series recipients with severe reactions were not less likely to proceed to the booster study. Safety results are combined for all acellular vaccines. Data for drowsiness and vomiting were collected but not reported (stated to be not significantly different between groups)<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-2000">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:22 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT. Subjects had been randomised and received primary series in Decker 1995 and Pichichero 1997. Details of allocation concealment in Decker 1995 and Pichichero 1997. Parents recorded adverse events on forms. Parents elected to remain blinded and allow child to participate in booster study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-10 17:03:19 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 4 to 6 years of age who had completed earlier National Institute of Allergy and Infectious Diseases (NIAID) multicentre acellular pertussis vaccine trials in Decker 1995, Pichichero 1997</P>
<P>Excluded: subjects with contraindications or precautions to immunisations as specified in the Report of the Committee on Infectious Diseases of the American Academy of Pediatrics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:37:38 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (same aPaPaP, mixed aPaPaP, wPaPaP  versus wPwPwP)</P>
<OL>
<LI>DTaP: Connaught/Biken[2]</LI>
<LI>DTaP: Connaught[2]</LI>
<LI>DTaP: Chiron [3]</LI>
<LI>DTaP: SKB[3]</LI>
<LI>DTaP: Connaught[4]</LI>
<LI>DTaP: Lederle [4]</LI>
<LI>DTwP: Lederle [W]</LI>
</OL>
<P>Number of studies: 316 aP, 10 wP</P>
<P>Dose schedule: 1 dose (4 to 6 years)</P>
<P>Concurrent vaccine: OPV</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:51:05 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, irritability, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Possible bias due to parental self selection of 83% subset who continued in the study</P>
<P>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-07 12:04:22 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Podda-1994">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:22 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Italy</P>
<P>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-27 16:42:04 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months; healthy<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-28 23:51:51 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Biocine[3]</LI>
<LI>DTwP: Biocine[W]</LI>
</OL>
<P>Number randomised: 240 aP, 240 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-28 23:53:05 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until 3rd dose (4 months after 1st dose)</LI>
<LI>Encephalopathy: until 7 days after 3rd dose</LI>
<LI>Convulsions: until 7 days after 3rd dose</LI>
<LI>Hypotonic-hyporesponsive episodes: until 7 days after 3rd dose</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, vomiting, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-27 16:42:16 -0200" MODIFIED_BY="[Empty name]">
<P>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PVSG-1998">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:23 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Germany<BR/>Design: parallel-group RCT</P>
<P>Active case ascertainment (bi-weekly telephone). Case incidence adjusted for follow-up duration by use of incidence density. Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-28 23:53:43 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 2 to 4 months; healthy<BR/>Excluded: known or suspected neurological disorder, immunological dysfunction or immunosuppressive therapy; birth weight &lt; 2 kg; significant congenital abnormality or chronic illness; history of convulsions; hereditary disease in the family with an increased risk of neurological manifestations after vaccination (for example, tuberous sclerosis); immunoglobulins in previous 4 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series + booster (aP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>A third non-randomised group received DT (n = 1739)<BR/>Number randomised: 4273 aP, 4259 wP<BR/>Dose schedule: 4 doses (dose 1: 2 to 4 months; dose 2: at least 6 weeks after dose 1; dose 3: at least 6 weeks after dose 2 but before 1st birthday; dose 4: at least 6 months after dose 3, at 15 to 18 months of age). DT vaccinees received doses at times corresponding to doses 1, 2 and 4 of the randomised schedule<BR/>Concurrent vaccines: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: the main efficacy assessment was conducted in children who had received all 3 doses of study vaccine and commenced 2 weeks after the third dose (or at age 7 months in DT recipients). Follow-up duration not reported but must have been at least 12 months, based on reported study dates. The number of participants in the efficacy analysis was not stated and data were not available for the intention-to-treat population at the time of this review. Several case definitions; that closest to a definition selected for review was: whooping cough = 21 days or more of cough with paroxysms, whoops or post-tussive vomiting, confirmed by culture, serology or contact with a culture-proven case). Results for other case definitions were not reported at the time of this review</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: until at least 6 months after 3rd dose (12 months after 1st dose)</LI>
<LI>Encephalopathy: until at least 6 months after 3rd dose (12 months after 1st dose)</LI>
<LI>Convulsions: within 3 days of each dose</LI>
<LI>Hypotonic-hyporesponsive episodes: until at least 6 months after 3rd dose (12 months after 1st dose)</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, prolonged crying, redness, swelling/induration within 3 days of each dose</LI>
</OL>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Macrolide prophylaxis was not documented<BR/>During the total period of the study (until at least 6 months after 3rd dose) convulsions occurred in 46 (1.1%) DTaP, 56 (1.3%) DTwP and 19 (1.1%) DT recipients<BR/>Redness and induration were reported only for the moderate/severe category<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothstein-1993">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:24 -0300" MODIFIED_BY="[Empty name]">
<P>Site: USA<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events on forms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-29 01:39:12 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 15 to 16 months; healthy; completed DTwP primary series<BR/>Excluded: past pertussis, mumps, measles or rubella; previous DTaP; contraindication to DTP, OPV or MMR vaccine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 01:38:03 -0200" MODIFIED_BY="Liz Dooley">
<P>Booster (wP.aP versus wP.wP)</P>
<OL>
<LI>DTaP: Lederle/Takeda[4]</LI>
<LI>DTwP: Lederle[W]</LI>
</OL>
<P>Number randomised: 48 aP, 49 wP<BR/>Dose schedule: 1 dose (age 15 to 16 months)<BR/>Concurrent vaccine: OPV and MMR vaccine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-29 00:01:49 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): excluded (booster)</LI>
<LI>Deaths: excluded (booster)</LI>
<LI>Encephalopathy: excluded (booster)</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, fever, irritability, pain/tenderness, redness, swelling/induration within 3 days of dose</LI>
</OL>
<P> </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>No "severe" or contraindicating adverse events but these not defined in the study report. DTaP or DTwP administered at same time as OPV and MMR (but MMR at a different injection site)<BR/>Reactive antipyretic/analgesic use allowed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simondon-1996">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:24 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Senegal<BR/>Design: parallel-group RCT</P>
<P>Study physicians visited homes, recorded adverse events and measured temperature at 2 to 3 days after each dose. Parents interviewed regarding deaths</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-10 16:58:51 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Pasteur-Merieux[2]</LI>
<LI>DTwP: Pasteur-Merieux[W]</LI>
</OL>
<P>Number randomised: 141 aP, 145 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: Bacille Calmette-Guérin (BCG) (2 months); IPV (2, 4, 6 months), measles and yellow fever (6 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-29 00:04:49 -0200" MODIFIED_BY="Liz Dooley">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: within 2 months of any dose (until 5 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, drowsiness, irritability, vomiting within 2 to 3 days of first dose; fever, pain/tenderness, redness, swelling/induration at 2 to 3 days after first dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Study conducted in Senegal in an area with high background infant mortality. High loss to follow-up (see text). Data included for 1st dose only. Second and third doses excluded because follow-up for those doses was less than 80% in both vaccine groups. Irritability and pain were reported only for the moderate/severe category<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simondon-1997">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:24 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Senegal<BR/>Design: parallel-group RCT</P>
<P>Active case ascertainment (weekly visit by field workers). Case incidence adjusted for follow-up duration by use of incidence density. Field workers recorded adverse events during 2 weekly visits after each dose<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 22:50:18 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 2 months<BR/>Excluded: serious congenital defect; serious chronic illness manifested as failure to thrive or cardiac failure; history of seizure or neurological disorder; history of pertussis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 00:06:24 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: Pasteur-Merieux[2]</LI>
<LI>DTaP: Pasteur-Merieux[W]</LI>
</OL>
<P>Number studied (efficacy): 1847 aP, 1772 wP<BR/>Number studied (safety): 2396 aP, 2379 wP<BR/>Dose schedule: 3 doses (2, 4, 6 months)<BR/>Concurrent vaccine: BCG (2 months); IPV (2, 4, 6 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: children randomised in a 1:1 ratio but the number of children receiving each vaccine was not stated. A total of 3619 were studied for efficacy (1847 DTaP and 1772 DTwP). The main efficacy assessment was conducted in children who had received all 3 doses of study vaccine, commenced 28 days after the third dose and lasted for a mean of 22 months. Efficacy data were not available for the intention-to-treat population. Several case definitions used. That closest to 1 of the definitions selected for review was: whooping cough = 21 days or more of paroxysmal cough with confirmation by culture or appropriate serology. Results were not reported for other case definitions at the time of review</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: within 2 months of any trial dose (until 5 months after 1st dose)</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 2 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 2 days of any dose</LI>
<LI>Minor adverse events: not recorded systematically due to trial conditions. Available results were reported combined across 3 doses</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Number randomised not stated. A total of 4821 were studied for safety.<BR/>No statement on macrolide prophylaxis<BR/>Study conducted in Senegal in an area with high background infant mortality. Deaths recorded are due to any cause and may include some due to injury. No breakdown by vaccine group of the number of deaths due to infection<BR/>A household contact substudy compared pertussis attack rates with non-randomised unvaccinated controls<BR/>No statement on antipyretic/analgesic use<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tian-1993">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:25 -0300" MODIFIED_BY="[Empty name]">
<P>Site: China<BR/>Design: parallel-group RCT</P>
<P>Adverse event recording method not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-29 00:08:43 -0200" MODIFIED_BY="[Empty name]">
<P>Included: age 3 to 6 months<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series (aP versus wP versus P)</P>
<OL>
<LI>aP: Canton[2]</LI>
<LI>wP: Wuhan[W]</LI>
<LI>Placebo</LI>
</OL>
<P>Number studied: 105 aP, 101 wP, 100 P<BR/>Dose schedule: 3 doses at 4-week intervals<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-29 00:10:38 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): no data</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: fever, swelling/induration at 2 days after each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Number randomised not stated<BR/>Data for redness and tenderness excluded (combined as 1 outcome in study report)<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trollfors-1995">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:25 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Sweden<BR/>Design: DB parallel-group RCT</P>
<P>Passive and active case ascertainment (parent report and monthly telephone). Case incidence adjusted for follow-up duration by use of incidence density. Parents recorded adverse events in diary</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 22:47:38 -0200" MODIFIED_BY="[Empty name]">
<P>Included: full-term, healthy infants<BR/>Excluded: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 00:11:50 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus DT)</P>
<OL>
<LI>DTaP: Amvax[1]</LI>
<LI>DT</LI>
</OL>
<P>Number randomised: 1724 aP, 1726 DT<BR/>Dose schedule: 3 doses (3, 5, 12 months)<BR/>Concurrent vaccine: nil</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy (median 17.5 months follow-up after 3rd dose). Several case definitions used. Those closest to the definitions selected for review were: whooping cough = 21 days or more of paroxysmal cough with confirmation by culture, appropriate serology or household contact with a culture-confirmed case; pertussis disease = cough for 7 days or more with confirmation as above</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: until (median) 17.5 months after 3rd dose</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: within 7 days of any dose</LI>
<LI>Hypotonic-hyporesponsive episodes: within 7 days of any dose</LI>
<LI>Minor adverse events: excluded. Data were reported only as percentages, rounded to nearest percent (e.g. 6%). With approximately 1700 participants in each group, numeric values could not be calculated with sufficient confidence for inclusion in the review</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Macrolide prophylaxis not used (not recommended in Sweden for age &gt; 6 months and main efficacy follow-up in this study started at age 10 months)<BR/>Target adverse events assessed in the trial included anorexia, irritability, fever, redness and induration. Data for anorexia and irritability were collected but not reported (stated to be equally frequent with both vaccines). Data for other events are not included in the review because the number of children experiencing the event could not be determined with sufficient confidence (fever) and because data were reported only for the moderate/severe category (redness and induration)<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanura-1994">
<CHAR_METHODS MODIFIED="2014-09-07 12:04:26 -0300" MODIFIED_BY="[Empty name]">
<P>Site: Austria and Switzerland<BR/>Design: parallel-group RCT</P>
<P>Parents recorded adverse events in diary<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-21 22:45:14 -0200" MODIFIED_BY="Liz Dooley">
<P>Included: age 10 to 16 weeks; healthy<BR/>Excluded: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-29 00:14:55 -0200" MODIFIED_BY="Liz Dooley">
<P>Primary series (aP versus wP)</P>
<OL>
<LI>DTaP: SKB[2]</LI>
<LI>DTaP: SKB[2]</LI>
<LI>DTwP: Behringwerke[W]</LI>
</OL>
<P>Number studied: 200 aP, 101 wP<BR/>Dose schedule: 3 doses (3, 4, 5 months)<BR/>Concurrent vaccine: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-29 00:15:54 -0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Efficacy: not studied</LI>
<LI>Primary series non-completion (due to adverse events): included</LI>
<LI>Deaths: no data</LI>
<LI>Encephalopathy: no data</LI>
<LI>Convulsions: no data</LI>
<LI>Hypotonic-hyporesponsive episodes: no data</LI>
<LI>Minor adverse events: anorexia, fever, irritability, pain/tenderness, redness, swelling/induration within 2 days of each dose</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>The 2 acellular vaccine formulations contained differing amounts of PT. In this review, data for the 2 acellular vaccine formulations are combined<BR/>Total 308 enrolled but cannot determine number randomised to each vaccine. Denominator for primary series non-completion is the number with adverse event data at the first dose (200 DTaP, 101 DTwP)<BR/>No statement on antipyretic/analgesic use</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Interventions</B>
<BR/>Primary series: primary series pertussis immunisation performed in the study.<BR/>Booster: pertussis booster immunisation performed in the study.</P>
<P>The pertussis immunisation history of study participants (including doses received in the study under consideration) is indicated in the form (X.Y.Z). The first element (X) indicates the type of pertussis vaccine received in the primary series (aP = acellular, wP = whole-cell, P = placebo, DT = diphtheria-tetanus toxoids). The second element (Y) indicates the vaccine type received at the 15- to 24-month booster and the third element (Z) indicates the vaccine type received at the 4- to 6-year booster. For example: aP = acellular primary series; wP.wP.aP = acellular 4- to 6-year booster after whole-cell primary series and whole-cell 18- to 24-month booster.</P>
<P>The vaccines used in each study are further identified by type, manufacturer and number, and type of pertussis components, as follows:</P>
<P>Vaccine types:<BR/>aP: acellular pertussis vaccine<BR/>DTaP: diphtheria-tetanus-acellular pertussis vaccine<BR/>wP: whole-cell pertussis vaccine<BR/>DTwP: diphtheria-tetanus-whole-cell pertussis vaccine<BR/>DT: diptheria-tetanus (toxoids) vaccine<BR/>DTP: diptheria-tetanus (toxoids) pertussis vaccine<BR/>P: placebo</P>
<P>Manufacturer abbreviations:<BR/>CAMR: Centre for Applied Microbiology and Research<BR/>Canton: Canton Department of Health<BR/>JNIH: Japanese National Institute of Health<BR/>Massachusetts: Massachusetts Public Health Laboratory<BR/>Michigan: Michigan Department of Health<BR/>Porton: Porton Products (later Speywood Pharmaceuticals)<BR/>SKB: SmithKline Beecham<BR/>SSVI: Swedish Serum and Vaccine Institute<BR/>Wuhan: Wuhan Department of Health</P>
<P>Pertussis components (in square brackets after manufacturer: [1] = PT (inactivated pertussis toxin); [2] = PT+FH (filamentous haemagglutinin); [3] = PT+FH+Prn (pertactin); [4] = PT+FH+Fim2&amp;3 (fimbrial antigen serotypes 2 and 3) or PT+FH+Prn+Fim2 or PT+FH+Prn+Fim (serotype unspecified); [5] = PT+FH+Prn+Fim2&amp;3; [W] = killed whole <I>Bordetella pertussis</I> organisms.</P>
<P>
<B>Outcomes</B>
<BR/>Non-completion of the primary series due to adverse events, defined as withdrawal from the study due to an adverse event or events before completion of all scheduled doses of the primary series.<BR/>Deaths, encephalopathy, convulsions, hypotonic-hyporesponsive episodes (HT-HR): these events generally led to withdrawal from the study and were reported and analysed across all doses in a study.<BR/>Minor adverse events: fever, irritability, drowsiness, anorexia, vomiting, redness, pain/tenderness and swelling/induration. These events usually did not lead to withdrawal and data were reported and analysed separately for each dose within a study. Data for these events were not combined across doses (see 'Methods' section of the review for reasons).</P>
<P>
<B>Other abbreviations</B>
<BR/>BCG: Bacille Calmette-Guérin<BR/>DB: double-blind (claim made in study report)<BR/>Hib: <I>Haemophilus influenzae</I> type B vaccine<BR/>IPV: inactivated polio vaccine<BR/>MMR: measles-mumps-rubella vaccine<BR/>OPV: oral polio vaccine<BR/>RCT: randomised controlled trial<BR/>SIDS: sudden infant death syndrome<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:49:50 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Annunziato-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:49:50 -0200" MODIFIED_BY="[Empty name]">
<P>Booster<BR/>Efficacy: not studied<BR/>Primary series non-completion: booster<BR/>Deaths: booster, no data<BR/>Encephalopathy: booster, no data<BR/>Convulsions: no data<BR/>Hypotonic-hyporesponsive episodes: no data<BR/>Minor AEs: data expressed as percentages in graph form only. Could not be converted to numeric values with sufficient accuracy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:51:27 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernstein-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:51:27 -0200" MODIFIED_BY="[Empty name]">
<P>Booster<BR/>Efficacy: not studied<BR/>Primary series non-completion: booster<BR/>Deaths: booster, no data<BR/>Encephalopathy: booster, no data<BR/>Convulsions: no data<BR/>Hypotonic-hyporesponsive episodes: no data<BR/>Minor AEs: data expressed as percentages in graph form only. Could not be converted to numeric values with sufficient accuracy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-25 20:20:41 -0300" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Bernstein-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-25 20:20:41 -0300" MODIFIED_BY="Liz Dooley">
<P>Primary series<BR/>Efficacy: not studied<BR/>Primary series non-completion: cannot determine number studied for each vaccine<BR/>Deaths: cannot determine number studied for each vaccine<BR/>Encephalopathy: cannot determine number studied for each vaccine<BR/>Convulsions: cannot determine number studied for each vaccine<BR/>Hypotonic-hyporesponsive episodes: cannot determine number studied for each vaccine<BR/>Minor AEs: data combined across 3 doses. Cannot determine number receiving each vaccine or experiencing AEs at each dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:52:27 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hori-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:52:27 -0200" MODIFIED_BY="[Empty name]">
<P>Primary series<BR/>Efficacy: not studied<BR/>Primary series non-completion: no data<BR/>Deaths: no data<BR/>Encephalopathy: no data<BR/>Convulsions: no data<BR/>Hypotonic-hyporesponsive episodes: no data<BR/>Minor AEs: unable to extract data separately for each event</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:53:35 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hori-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:53:35 -0200" MODIFIED_BY="[Empty name]">
<P>Booster<BR/>Efficacy: not studied<BR/>Safety: not reported (immunogenicity only)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Just-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>Primary series<BR/>Report of 2 studies comparing acellular versus whole-cell primary series immunisation (1 study in Turkey, 1 in Switzerland); Swiss study possibly reported in <LINK REF="STD-Vanura-1994" TYPE="STUDY">Vanura 1994</LINK>
<BR/>Efficacy: not studied<BR/>Primary series non-completion: no data<BR/>Deaths: 1 death (pneumonia) in acellular arm in Turkey but cannot determine number receiving each vaccine<BR/>Encephalopathy: cannot determine number studied for each vaccine<BR/>Convulsions: cannot determine number studied for each vaccine<BR/>Hypotonic-hyporesponsive episodes: cannot determine number studied for each vaccine<BR/>Minor AEs: unable to determine number studied for each vaccine (Turkey). Swiss results were combined across doses or across different reaction types</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:52:39 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:52:39 -0200" MODIFIED_BY="[Empty name]">
<P>Primary series<BR/>Efficacy: not studied<BR/>Primary series non-completion: no data<BR/>Deaths: no data<BR/>Encephalopathy: no data<BR/>Convulsions: no data<BR/>Hypotonic-hyporesponsive episodes: no data<BR/>Minor AEs: data combined across 3 doses. Unable to extract data separately for each dose<BR/>This report examines 2-4-6 and 3-5-10 month immunisation schedules. It includes some data previously reported in <LINK REF="STD-Miller-1991" TYPE="STUDY">Miller 1991</LINK>
<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:52:47 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:52:47 -0200" MODIFIED_BY="[Empty name]">
<P>Primary series<BR/>Efficacy: not studied<BR/>Primary series non-completion: no data<BR/>Deaths: cannot determine number studied for each vaccine<BR/>Encephalopathy: cannot determine number studied for each vaccine<BR/>Convulsions: cannot determine number studied for each vaccine<BR/>Hypotonic-hyporesponsive episodes: cannot determine number studied for each vaccine<BR/>Minor AEs: cannot determine number studied for each vaccine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-29 01:50:16 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichichero-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-29 01:50:16 -0200" MODIFIED_BY="[Empty name]">
<P>Booster<BR/>Efficacy: not studied<BR/>Primary series non-completion: booster<BR/>Deaths: follow-up of only 65% of participants<BR/>Encephalopathy: follow-up of only 65% of participants<BR/>Convulsions: follow-up of only 65% of participants<BR/>Hypotonic-hyporesponsive episodes: follow-up of only 65% of participants<BR/>Minor AEs: follow-up of only 65% of participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-25 20:20:43 -0300" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Shek-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-25 20:20:43 -0300" MODIFIED_BY="Liz Dooley">
<P>Primary series<BR/>Efficacy: not studied<BR/>Primary series non-completion: no data<BR/>Deaths: no data<BR/>Encephalopathy: no data<BR/>Convulsions: no data<BR/>Hypotonic-hyporesponsive episodes: no data<BR/>Minor AEs: data combined across 3 doses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AEs: adverse events<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION>
<P>Centrally generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION>
<P>Centrally generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 09:01:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Afari-1996">
<DESCRIPTION>
<P>Using a computer program (EPI Info) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 20:00:58 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 20:03:10 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION>
<P>Randomisation at study site, but details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:32:49 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:42:54 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:02:39 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION>
<P>Computer-generated random sequence key concealed from study personnel and parents</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:07:56 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION>
<P>Details not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 20:26:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glode-1992">
<DESCRIPTION>
<P>On-site randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:34:50 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-1996">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION>
<P>Centrally generated randomisation in blocks of 12 or 16</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:32:22 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:34:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:37:37 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:41:07 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:43:41 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:46:39 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION>
<P>Computer-generated randomisation list kept in a locked file</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 21:59:29 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-28 22:03:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION>
<P>Computer-generated randomisation but no statement regarding file locking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:40:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1991">
<DESCRIPTION>
<P>Computer-generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:28:50 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:36:50 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION>
<P>Computer-generated random sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:09:50 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:21:52 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-12 19:51:58 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION>
<P>On-site computer assignment but file locking not reported. Vaccines visually distinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:24:58 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION>
<P>Vaccines in coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:28:19 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION>
<P>Allocation concealment details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:33:03 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:42:42 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:02:36 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION>
<P>Vaccines indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:08:08 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:13:30 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:14:25 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:21:45 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:23:38 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:24:49 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:25:20 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:25:44 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:26:34 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:27:19 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:28:22 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:29:39 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:30:51 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:31:38 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:25:54 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greco-1996">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:39:16 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION>
<P>Vaccines in identical vials. At each study site, vaccines administered in numbered order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:25:56 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION>
<P>Vaccines in identical, coded vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:53:42 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION>
<P>Different vaccine container formats</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:57:12 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:58:01 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:58:51 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:59:48 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 12:01:07 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 12:01:59 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:16:33 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:19:27 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:33:00 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:20:26 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:21:07 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:23:28 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:25:24 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:28:04 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION>
<P>Vaccine vials labelled with letter codes instead of type/manufacturer details but unable to ascertain from study report whether vaccinators remained unaware of what each code represented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:31:24 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:32:23 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:33:52 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:34:25 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:35:02 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:35:38 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:36:09 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION>
<P>Vaccines indistinguishable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:39:09 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION>
<P>Details not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-05-25 20:21:09 -0300" MODIFIED_BY="Liz Dooley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 10:20:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 10:23:50 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-02-12 19:52:04 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION>
<P>Parents and nurses collecting efficacy and adverse event data were blinded but blinding details not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 10:27:26 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:04:48 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:19:49 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION>
<P>Vaccine vials labelled with letter codes instead of type/manufacturer details but unable to ascertain from study report whether vaccinators remained unaware of what each code represented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:35:07 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greco-1996">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:40:25 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:42:19 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:44:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:46:30 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:48:06 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 11:50:20 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-05-25 20:21:09 -0300" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION>
<P>Study personnel collecting telephone reactogenicity data were blinded as to which vaccine the subject had received. Only participants who had received 4 previous doses of DTwP were blinded to which vaccine they received for the fifth dose</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 13:23:49 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION>
<P>Parents and investigators are unaware of the type of vaccination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-28 19:40:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION>
<P>Vaccinators took no further part in the study and did not participate in follow-up data collection, so outcome assessment was double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-29 13:37:35 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-09-07 10:29:08 -0300" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 10:10:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 10:23:31 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-02-12 19:52:10 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION>
<P>Parents and nurses collecting efficacy and adverse event data were blinded but blinding details not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 10:27:31 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:05:45 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:35:10 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greco-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:40:28 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:42:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:44:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:46:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:48:12 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 11:50:22 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-25 20:21:12 -0300" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION>
<P>Only participants who had received 4 previous doses of DTwP were blinded to which vaccine they received for the fifth dose</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 13:23:54 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 13:28:39 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-11-29 13:38:01 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-09-07 10:29:08 -0300" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 10:10:12 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 10:23:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-12 19:52:13 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION>
<P>Parents and nurses collecting efficacy and adverse event data were blinded but blinding details not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 10:27:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:05:47 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-28 19:40:06 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Decker-1995">
<DESCRIPTION>
<P>Vaccinators took no further part in the study and did not participate in follow-up data collection, so outcome assessment was double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:35:12 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greco-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:40:30 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:42:24 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:44:19 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:46:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:48:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 11:50:25 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-25 20:21:14 -0300" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION>
<P>Only participants who had received 4 previous doses of DTwP were blinded to which vaccine they received for the fifth dose</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 13:23:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 13:28:41 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-11-29 13:38:03 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-09-07 10:29:08 -0300" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Greco-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:30:52 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION>
<P>Data for vomiting collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 10:33:49 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION>
<P>Data for vomiting collected but not reported (stated to be "infrequent" and "not significantly different")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:05:40 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION>
<P>Data for anorexia and vomiting collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:22:19 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION>
<P>Data for drowsiness and vomiting collected but not reported (stated to be "rare"). Data for irritability, pain, redness and induration only reported for moderate/severe category</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:23:28 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION>
<P>Data for drowsiness and vomiting collected but not reported (stated to be "rare&#8217;'). Data for irritability, pain, redness and induration only reported for moderate/severe category</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:27:41 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION>
<P>Data for irritability collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:28:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION>
<P>Data for irritability collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:29:46 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION>
<P>Data for vomiting collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:30:43 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION>
<P>Data for vomiting collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 11:32:41 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glode-1992">
<DESCRIPTION>
<P>Data for prolonged crying collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greco-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION>
<P>Data for drowsiness, irritability (restlessness), "unusual" crying and "gastrointestinal symptoms" collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 12:02:34 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION>
<P>Vomiting is the only target adverse event without data. Redness reported only for moderate/severe category</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:18:43 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miller-1991">
<DESCRIPTION>
<P>Data for redness, swelling collected but not reported (stated not to differ in frequency)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:21:32 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION>
<P>Data on anorexia, drowsiness and vomiting were collected but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-29 13:30:43 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION>
<P>Data for drowsiness and vomiting were collected but not reported (stated to be not significantly different between groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-13 20:47:54 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION>
<P>Data for anorexia and irritability were collected but not reported (stated to be equally frequent with both vaccines)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-09-07 10:29:08 -0300" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-AHGSPV-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Afari-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bernstein-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Black-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blennow-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blumberg-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Decker-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1986b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Edwards-1989c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Englund-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Feldman-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Glode-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greco-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gustafsson-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1994b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halperin-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heininger-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kanra-1993b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kosuwon-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lewis-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marcinak-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miller-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-PVSG-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pichichero-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Podda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simondon-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tian-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Trollfors-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vanura-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-04-19 10:48:23 -0300" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-04-19 11:00:35 -0300" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-09-14 22:06:55 -0300" MODIFIED_BY="Liz  Dooley">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-14 22:06:55 -0300" MODIFIED_BY="Liz  Dooley" NO="1">
<NAME>Safety: acellular versus whole-cell pertussis vaccines</NAME>
<DICH_OUTCOME CHI2="56.23467823737619" CI_END="0.42551351779588975" CI_START="0.12077759795876734" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22669914110638525" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="338" I2="82.21737846922802" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.37108663860898067" LOG_CI_START="-0.9180136119493127" LOG_EFFECT_SIZE="-0.6445501252791467" METHOD="MH" MODIFIED="2011-09-18 14:35:56 -0300" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="1.855238096482026E-8" P_Q="1.0" P_Z="3.844594778588793E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5904603703964502" TOTALS="YES" TOTAL_1="80060" TOTAL_2="28849" WEIGHT="100.00000000000001" Z="4.619611368085906">
<NAME>Primary series non-completion due to adverse events</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7016684392949184" CI_START="0.42941390443010846" EFFECT_SIZE="0.5489136399589752" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="102" LOG_CI_END="-0.15386805738641365" LOG_CI_START="-0.3671238972087972" LOG_EFFECT_SIZE="-0.2604959772976054" MODIFIED="2009-05-03 12:37:13 -0300" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.12526753594510026" STUDY_ID="STD-AHGSPV-1997" TOTAL_1="62172" TOTAL_2="20720" VAR="0.015691955561756985" WEIGHT="17.02754798770303"/>
<DICH_DATA CI_END="1.6405353048853233" CI_START="0.027016382706245595" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2149855809896046" LOG_CI_START="-1.5683728002393378" LOG_EFFECT_SIZE="-0.6766936096248666" ORDER="23" O_E="0.0" SE="1.0475535409002403" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="1.0973684210526315" WEIGHT="6.115127239445811"/>
<DICH_DATA CI_END="0.6653213067308383" CI_START="0.026056750228389408" EFFECT_SIZE="0.13166666666666665" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.17696856817057455" LOG_CI_START="-1.58407975001583" LOG_EFFECT_SIZE="-0.8805241590932023" ORDER="24" O_E="0.0" SE="0.8265440735285882" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="0.6831751054852321" WEIGHT="8.103800509298946"/>
<DICH_DATA CI_END="1.047224194408082" CI_START="0.04988893327537551" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.020039667324730222" LOG_CI_START="-1.3019957820413943" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="25" O_E="0.0" SE="0.7765701671386791" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.6030612244897959" WEIGHT="8.647759590051573"/>
<DICH_DATA CI_END="0.7282803313767022" CI_START="0.13848828599617224" EFFECT_SIZE="0.3175819497658578" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="-0.13770141885241655" LOG_CI_START="-0.8585869597574576" LOG_EFFECT_SIZE="-0.49814418930493704" ORDER="26" O_E="0.0" SE="0.42345173516859963" STUDY_ID="STD-Decker-1995" TOTAL_1="1827" TOTAL_2="373" VAR="0.17931137201729785" WEIGHT="13.408244612548465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="27" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.1691538494894076" CI_START="0.0777321420923657" EFFECT_SIZE="0.11466774203751147" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="135" LOG_CI_END="-0.7717181143821505" LOG_CI_START="-1.1093993641216613" LOG_EFFECT_SIZE="-0.9405587392519059" ORDER="28" O_E="0.0" SE="0.19835563764613323" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="0.039344958986004104" WEIGHT="16.388060463431707"/>
<DICH_DATA CI_END="0.2721532250718915" CI_START="0.11454550300605569" EFFECT_SIZE="0.1765614002566249" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="67" LOG_CI_END="-0.5651865148371616" LOG_CI_START="-0.9410219563042816" LOG_EFFECT_SIZE="-0.7531042355707217" ORDER="29" O_E="0.0" SE="0.22076759873322588" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.04873833265043463" WEIGHT="16.14722897420229"/>
<DICH_DATA CI_END="2.0253466294734395" CI_START="0.004937426440727266" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3064993615678561" LOG_CI_START="-2.3064993615678557" LOG_EFFECT_SIZE="-1.0" ORDER="30" O_E="0.0" SE="1.5348883845222026" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="2.3558823529411765" WEIGHT="3.5030845992075195"/>
<DICH_DATA CI_END="2.7241531101523417" CI_START="0.004587882124926856" EFFECT_SIZE="0.1117948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.4352315133088783" LOG_CI_START="-2.3383877488247045" LOG_EFFECT_SIZE="-0.9515781177579131" ORDER="31" O_E="0.0" SE="1.629237684214043" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="2.654415431663138" WEIGHT="3.180795952670994"/>
<DICH_DATA CI_END="15.752901478575575" CI_START="0.06348036908375453" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19736055686092" LOG_CI_START="-1.1973605568609202" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="1.4066710362609016" STUDY_ID="STD-Miller-1991" TOTAL_1="94" TOTAL_2="94" VAR="1.978723404255319" WEIGHT="4.017341196041978"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Pichichero-1993" TOTAL_1="88" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.144039760745191" CI_START="0.009652417039745561" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6174239136747713" LOG_CI_START="-2.015363922346809" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="34" O_E="0.0" SE="1.54651260738905" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="2.391701244813278" WEIGHT="3.461008875397691"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.139999966713581" CI_END="1.2182282023446662" CI_START="0.6160306889497008" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8662943834449928" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.08572864932801151" LOG_CI_START="-0.21039765194349366" LOG_EFFECT_SIZE="-0.062334501307741104" METHOD="MH" MODIFIED="2014-05-18 14:11:11 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9764162417296115" P_Q="1.0" P_Z="0.4092900139889627" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86863" TOTAL_2="35588" WEIGHT="100.00000000000001" Z="0.8251437108615494">
<NAME>Death (all causes)</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell-vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.139999966713581" CI_END="1.2182282023446662" CI_START="0.6160306889497008" DF="8" EFFECT_SIZE="0.8662943834449928" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="61" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.08572864932801151" LOG_CI_START="-0.21039765194349366" LOG_EFFECT_SIZE="-0.062334501307741104" MODIFIED="2009-05-03 12:27:32 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9764162417296115" P_Z="0.4092900139889627" STUDIES="16" TAU2="0.0" TOTAL_1="86863" TOTAL_2="35588" WEIGHT="100.00000000000001" Z="0.8251437108615494">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.374893379201476" CI_START="0.014032951750120943" EFFECT_SIZE="0.3428184281842818" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9229792867394252" LOG_CI_START="-1.8528509680338725" LOG_EFFECT_SIZE="-0.46493584064722365" ORDER="40" O_E="0.0" SE="1.6305364322352014" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="2.6586490568462997" WEIGHT="1.1380678486764848"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1993" TOTAL_1="109" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.0" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.03776436640813" CI_START="0.02505244144101718" EFFECT_SIZE="0.6137855579868708" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.1771832753845117" LOG_CI_START="-1.6011499443398516" LOG_EFFECT_SIZE="-0.21198333447767004" ORDER="41" O_E="0.0" SE="1.6320066862373337" STUDY_ID="STD-Decker-1995" TOTAL_1="1827" TOTAL_2="373" VAR="2.6634458239233627" WEIGHT="1.1360182307195656"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="47" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.66489354402371" CI_START="0.18061436543976617" EFFECT_SIZE="3.4958907033834987" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8303634028861275" LOG_CI_START="-0.7432477103729754" LOG_EFFECT_SIZE="0.543557846256576" ORDER="44" O_E="0.0" SE="1.511751907508869" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="2.285393829856704" WEIGHT="1.3239394335376102"/>
<DICH_DATA CI_END="6.550846352531039" CI_START="0.2530815380016979" EFFECT_SIZE="1.287593984962406" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8162974133488282" LOG_CI_START="-0.5967395349540735" LOG_EFFECT_SIZE="0.10977893919737741" ORDER="36" O_E="0.0" SE="0.8300248980788267" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="0.6889413314307666" WEIGHT="4.391844231826141"/>
<DICH_DATA CI_END="6.5185611845615465" CI_START="0.025526624635695952" EFFECT_SIZE="0.4079177178342713" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8141517462591005" LOG_CI_START="-1.5930066077968033" LOG_EFFECT_SIZE="-0.38942743076885133" ORDER="45" O_E="0.0" SE="1.4139767327984631" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="1.9993302008954166" WEIGHT="1.513368332632468"/>
<DICH_DATA CI_END="2.7629564786309495" CI_START="0.09568938068000453" EFFECT_SIZE="0.5141843971631206" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.441374044077103" LOG_CI_START="-1.0191362562458754" LOG_EFFECT_SIZE="-0.28888110608438616" ORDER="50" O_E="0.0" SE="0.8579109800523023" STUDY_ID="STD-Simondon-1996" TOTAL_1="141" TOTAL_2="145" VAR="0.7360112496943018" WEIGHT="4.110973865912446"/>
<DICH_DATA CI_END="7.072561539368519" CI_START="0.14046649943617218" EFFECT_SIZE="0.9967236133863796" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.84957673500381" LOG_CI_START="-0.8524272404907054" LOG_EFFECT_SIZE="-0.0014252527434476612" ORDER="49" O_E="0.0" SE="0.9997655602610346" STUDY_ID="STD-PVSG-1998" TOTAL_1="4273" TOTAL_2="4259" VAR="0.9995311754840605" WEIGHT="3.0271422109925825"/>
<DICH_DATA CI_END="1.4061362469819865" CI_START="0.5612786127922755" EFFECT_SIZE="0.8883885423073543" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.14802740350433882" LOG_CI_START="-0.250821506013464" LOG_EFFECT_SIZE="-0.051397051254562585" MODIFIED="2009-05-03 12:27:32 -0300" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.23428582378470117" STUDY_ID="STD-Simondon-1997" TOTAL_1="2396" TOTAL_2="2379" VAR="0.054889847226476045" WEIGHT="55.12354589049358"/>
<DICH_DATA CI_END="1.6069826395913487" CI_START="0.44536882665652056" EFFECT_SIZE="0.8459905275191899" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="13" LOG_CI_END="0.20601118505805152" LOG_CI_START="-0.3512801844390514" LOG_EFFECT_SIZE="-0.07263449969049994" ORDER="37" O_E="0.0" SE="0.327355709079368" STUDY_ID="STD-AHGSPV-1997" TOTAL_1="62172" TOTAL_2="20720" VAR="0.10716176026685581" WEIGHT="28.235099955209147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5492371222663854" CI_END="4.157094246758699" CI_START="0.22864183225110016" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.97492853349331" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.61878987064123" LOG_CI_START="-0.6408443082637686" LOG_EFFECT_SIZE="-0.01102721881126921" METHOD="MH" MODIFIED="2014-05-18 14:11:11 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4586296679037647" P_Q="1.0" P_Z="0.9726249782377248" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22154" TOTAL_2="12344" WEIGHT="100.0" Z="0.03431623574793507">
<NAME>Death (infection)</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell-vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5492371222663854" CI_END="4.157094246758699" CI_START="0.22864183225110016" DF="1" EFFECT_SIZE="0.97492853349331" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.61878987064123" LOG_CI_START="-0.6408443082637686" LOG_EFFECT_SIZE="-0.01102721881126921" MODIFIED="2009-05-03 12:38:11 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4586296679037647" P_Z="0.9726249782377248" STUDIES="13" TAU2="0.0" TOTAL_1="22154" TOTAL_2="12344" WEIGHT="100.0" Z="0.03431623574793507">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.0" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="55" O_E="0.0" SE="0.0" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="58" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1993" TOTAL_1="109" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="61" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="63" O_E="0.0" SE="0.0" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="56" O_E="0.0" SE="0.0" STUDY_ID="STD-Decker-1995" TOTAL_1="1827" TOTAL_2="373" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="59" O_E="0.0" SE="0.0" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.550846352531039" CI_START="0.2530815380016979" EFFECT_SIZE="1.287593984962406" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8162974133488282" LOG_CI_START="-0.5967395349540735" LOG_EFFECT_SIZE="0.10977893919737741" MODIFIED="2009-04-20 17:13:34 -0300" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.8300248980788267" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="0.6889413314307666" WEIGHT="79.46608849211546"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="60" O_E="0.0" SE="0.0" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.153385211532303" CI_START="0.01353847326881881" EFFECT_SIZE="0.3322414599906411" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9113379613097782" LOG_CI_START="-1.8684303081997669" LOG_EFFECT_SIZE="-0.4785461734449941" MODIFIED="2009-05-03 12:38:11 -0300" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.6328496415847604" STUDY_ID="STD-PVSG-1998" TOTAL_1="4273" TOTAL_2="4259" VAR="2.6661979520234804" WEIGHT="20.533911507884543"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-09-18 14:47:20 -0300" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="81601" TOTAL_2="32161" WEIGHT="0.0" Z="0.0">
<NAME>Encephalopathy</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="9" TAU2="0.0" TOTAL_1="81601" TOTAL_2="32161" WEIGHT="0.0" Z="0.0">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="66" O_E="0.0" SE="0.0" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989a" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1993" TOTAL_1="109" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="70" O_E="0.0" SE="0.0" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.0" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-PVSG-1998" TOTAL_1="4273" TOTAL_2="4259" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-AHGSPV-1997" TOTAL_1="62172" TOTAL_2="20720" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.1614124510804285" CI_END="0.724308129705167" CI_START="0.3070937692868408" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4716253954954734" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.1400766402082597" LOG_CI_START="-0.5127289949922753" LOG_EFFECT_SIZE="-0.32640281760026757" METHOD="MH" MODIFIED="2014-05-25 20:29:03 -0300" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.7236611441183448" P_Q="0.9900151796835465" P_Z="5.959974945907604E-4" Q="1.5661128671537442E-4" RANDOM="YES" SCALE="542.801969178122" SORT_BY="YEAR" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="90763" TOTAL_2="36271" WEIGHT="200.0" Z="3.4334293543895855">
<NAME>Convulsions</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.161247805362391" CI_END="0.7274380896561031" CI_START="0.30600007282272706" DF="8" EFFECT_SIZE="0.471800920313635" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.138203962431195" LOG_CI_START="-0.5142784701638293" LOG_EFFECT_SIZE="-0.3262412162975122" NO="1" P_CHI2="0.629175374530795" P_Z="6.726227477511708E-4" STUDIES="15" TAU2="0.0" TOTAL_1="88513" TOTAL_2="35874" WEIGHT="100.00000000000001" Z="3.4005018743267463">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="2.6891308260333915" CI_START="0.00455293498024125" EFFECT_SIZE="0.11065006915629322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.4296119311345313" LOG_CI_START="-2.3417085517397056" LOG_EFFECT_SIZE="-0.9560483103025873" ORDER="78" O_E="0.0" SE="1.6278873698979623" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="2.6500172890733054" WEIGHT="1.8415108757623493"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.0" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989a" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="22.54073458267392" CI_START="0.1877417401448267" EFFECT_SIZE="2.057142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3529680652151168" LOG_CI_START="-0.7264391610531312" LOG_EFFECT_SIZE="0.3132644520809928" ORDER="79" O_E="0.0" SE="1.221454097941746" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="1.4919501133786848" WEIGHT="3.270910746295245"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1993" TOTAL_1="109" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="21.264542103751996" CI_START="0.04921242828595644" EFFECT_SIZE="1.0229759299781183" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.327656035347486" LOG_CI_START="-1.3079252050701131" LOG_EFFECT_SIZE="0.009865415138686398" ORDER="80" O_E="0.0" SE="1.5481534669588464" STUDY_ID="STD-Decker-1995" TOTAL_1="1827" TOTAL_2="373" VAR="2.396779157256696" WEIGHT="2.036080647652301"/>
<DICH_DATA CI_END="2.7241531101523417" CI_START="0.004587882124926856" EFFECT_SIZE="0.1117948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.4352315133088783" LOG_CI_START="-2.3383877488247045" LOG_EFFECT_SIZE="-0.9515781177579131" ORDER="85" O_E="0.0" SE="1.629237684214043" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="2.654415431663138" WEIGHT="1.8384596474897439"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="74" O_E="0.0" SE="0.0" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1878117477007042" CI_START="0.17729748175140825" EFFECT_SIZE="0.4589074325635552" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.07474761622334082" LOG_CI_START="-0.751297432866281" LOG_EFFECT_SIZE="-0.33827490832147006" ORDER="84" O_E="0.0" SE="0.4852229508241832" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.23544131200652774" WEIGHT="20.727185119710203"/>
<DICH_DATA CI_END="1.4813560933230507" CI_START="0.3130144237673524" EFFECT_SIZE="0.6809448024221721" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.1706594682282906" LOG_CI_START="-0.5044356496157233" LOG_EFFECT_SIZE="-0.1668880906937163" ORDER="83" O_E="0.0" SE="0.3965542139963025" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="0.15725524463822524" WEIGHT="31.032578086750316"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-Black-1997" TOTAL_1="1854" TOTAL_2="464" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6740897418544999" CI_START="0.1403937888927474" EFFECT_SIZE="0.30763291909788726" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="-0.1712822818062956" LOG_CI_START="-0.8526521052352295" LOG_EFFECT_SIZE="-0.5119671935207626" ORDER="75" O_E="0.0" SE="0.40024000711717816" STUDY_ID="STD-AHGSPV-1997" TOTAL_1="62172" TOTAL_2="20720" VAR="0.16019206329715882" WEIGHT="30.463654430458302"/>
<DICH_DATA CI_END="7.042916964345003" CI_START="0.13997893615261253" EFFECT_SIZE="0.9929048414023373" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8477525681112934" LOG_CI_START="-0.8539373114713082" LOG_EFFECT_SIZE="-0.0030923716800075173" ORDER="88" O_E="0.0" SE="0.9995810587675766" STUDY_ID="STD-Simondon-1997" TOTAL_1="2396" TOTAL_2="2379" VAR="0.9991622930469095" WEIGHT="4.88412712604001"/>
<DICH_DATA CI_END="2.2284789127000177" CI_START="0.027862557836544954" EFFECT_SIZE="0.2491809033465949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3480085288680779" LOG_CI_START="-1.5549790170108981" LOG_EFFECT_SIZE="-0.60348524407141" ORDER="87" O_E="0.0" SE="1.1178243043895855" STUDY_ID="STD-PVSG-1998" TOTAL_1="4273" TOTAL_2="4259" VAR="1.2495311754840606" WEIGHT="3.9054933198415425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.198458351005321" CI_START="0.01907739730416749" DF="0" EFFECT_SIZE="0.4622093023255814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="1.0491582391224048" LOG_CI_START="-1.7194808756245616" LOG_EFFECT_SIZE="-0.33516131825107864" MODIFIED="2008-04-28 22:19:42 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6351204907953094" STUDIES="11" TAU2="0.0" TOTAL_1="2250" TOTAL_2="397" WEIGHT="99.99999999999999" Z="0.4745321333388137">
<NAME>Booster</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1986a" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="96" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.198458351005321" CI_START="0.01907739730416749" EFFECT_SIZE="0.4622093023255814" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.0491582391224048" LOG_CI_START="-1.7194808756245616" LOG_EFFECT_SIZE="-0.33516131825107864" ORDER="97" O_E="0.0" SE="1.6263123209870172" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="2.6448917653941786" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="98" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="99" O_E="0.0" SE="0.0" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1266" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.071086949868153" CI_END="0.8086802417209329" CI_START="0.08137205259082782" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2565228472446053" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="51" I2="50.35292590671697" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.09222316776659109" LOG_CI_START="-1.0895247288903764" LOG_EFFECT_SIZE="-0.5908739483284838" METHOD="MH" MODIFIED="2014-05-25 20:29:09 -0300" MODIFIED_BY="Liz Dooley" NO="6" P_CHI2="0.073245948197602" P_Q="1.0" P_Z="0.020208701251443056" Q="0.0" RANDOM="YES" SCALE="173.04209849635757" SORT_BY="YEAR" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.914218652976874" TOTALS="SUB" TOTAL_1="88518" TOTAL_2="35542" WEIGHT="100.0" Z="2.322450306448616">
<NAME>Hypotonic hyporesponsive episodes</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.071086949868153" CI_END="0.8086802417209329" CI_START="0.08137205259082782" DF="5" EFFECT_SIZE="0.2565228472446053" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="51" I2="50.35292590671697" ID="CMP-001.06.01" LOG_CI_END="-0.09222316776659109" LOG_CI_START="-1.0895247288903764" LOG_EFFECT_SIZE="-0.5908739483284838" MODIFIED="2009-02-14 22:34:39 -0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.073245948197602" P_Z="0.020208701251443056" STUDIES="11" TAU2="0.914218652976874" TOTAL_1="86347" TOTAL_2="35226" WEIGHT="100.0" Z="2.322450306448616">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="101" O_E="0.0" SE="0.0" STUDY_ID="STD-Blennow-1988" TOTAL_1="240" TOTAL_2="79" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.352727729647416" CI_START="0.064696190211459" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2135902058725294" LOG_CI_START="-1.189121293038506" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="102" O_E="0.0" SE="1.4113646280740795" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="1.9919501133786848" WEIGHT="11.808843602818323"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="104" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1993" TOTAL_1="109" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="108" O_E="0.0" SE="0.0" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="103" O_E="0.0" SE="0.0" STUDY_ID="STD-Decker-1995" TOTAL_1="1827" TOTAL_2="373" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7241531101523417" CI_START="0.004587882124926856" EFFECT_SIZE="0.1117948717948718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.4352315133088783" LOG_CI_START="-2.3383877488247045" LOG_EFFECT_SIZE="-0.9515781177579131" ORDER="107" O_E="0.0" SE="1.629237684214043" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="2.654415431663138" WEIGHT="9.616702534171461"/>
<DICH_DATA CI_END="0.69788983316446" CI_START="0.009537142203010614" EFFECT_SIZE="0.08158354356685427" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.15621312841536128" LOG_CI_START="-2.0205817417943788" LOG_EFFECT_SIZE="-1.0883974351048702" MODIFIED="2009-02-14 22:34:39 -0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="1.0951393522723107" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="1.1993302008954165" WEIGHT="16.237378370702153"/>
<DICH_DATA CI_END="0.437810944899206" CI_START="0.007031614249800285" EFFECT_SIZE="0.05548439130847329" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.3587133856417387" LOG_CI_START="-2.1529449624192565" LOG_EFFECT_SIZE="-1.2558291740304974" ORDER="105" O_E="0.0" SE="1.0539405097886592" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="4678" VAR="1.1107905981735788" WEIGHT="16.947326253344848"/>
<DICH_DATA CI_END="0.9919572827433888" CI_START="0.4347990900519547" EFFECT_SIZE="0.656735962093774" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="34" LOG_CI_END="-0.0035070297291658354" LOG_CI_START="-0.3617113734767928" LOG_EFFECT_SIZE="-0.1826092016029793" ORDER="100" O_E="0.0" SE="0.2104110046574544" STUDY_ID="STD-AHGSPV-1997" TOTAL_1="62172" TOTAL_2="20720" VAR="0.0442727908809593" WEIGHT="35.80469357885942"/>
<DICH_DATA CI_END="8.153385211532303" CI_START="0.01353847326881881" EFFECT_SIZE="0.3322414599906411" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9113379613097782" LOG_CI_START="-1.8684303081997669" LOG_EFFECT_SIZE="-0.4785461734449941" ORDER="109" O_E="0.0" SE="1.6328496415847604" STUDY_ID="STD-PVSG-1998" TOTAL_1="4273" TOTAL_2="4259" VAR="2.6661979520234804" WEIGHT="9.585055660103794"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="110" O_E="0.0" SE="0.0" STUDY_ID="STD-Simondon-1997" TOTAL_1="2396" TOTAL_2="2379" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-04-28 22:19:45 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="7" TAU2="0.0" TOTAL_1="2171" TOTAL_2="316" WEIGHT="0.0" Z="0.0">
<NAME>Booster</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="111" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="113" O_E="0.0" SE="0.0" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="112" O_E="0.0" SE="0.0" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="116" O_E="0.0" SE="0.0" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="117" O_E="0.0" SE="0.0" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1266" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="235.47309688207875" CI_END="0.5113373171310778" CI_START="0.40880614151953903" CI_STUDY="95" CI_TOTAL="95" DF="45" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4572065568551142" ESTIMABLE="YES" EVENTS_1="3849" EVENTS_2="5049" I2="80.88953659851202" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.29129251153178953" LOG_CI_START="-0.3884825883919072" LOG_EFFECT_SIZE="-0.3398875499618484" METHOD="MH" MODIFIED="2012-02-10 15:49:44 -0200" MODIFIED_BY="Liz Dooley" NO="7" P_CHI2="-8.881784197001252E-16" P_Q="0.6510171447051656" P_Z="9.024731024403384E-43" Q="2.4644256213408955" RANDOM="YES" SCALE="10.06" SORT_BY="YEAR" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08641680919702463" TOTALS="SUB" TOTAL_1="41426" TOTAL_2="25739" WEIGHT="500.0" Z="13.708546761982156">
<NAME>Anorexia</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="89.5943406257342" CI_END="0.5731128509543075" CI_START="0.3206529428658642" DF="10" EFFECT_SIZE="0.4286844086886577" ESTIMABLE="YES" EVENTS_1="1275" EVENTS_2="1896" I2="88.83858072936395" ID="CMP-001.07.01" LOG_CI_END="-0.24175985321391374" LOG_CI_START="-0.4939647698913206" LOG_EFFECT_SIZE="-0.36786231155261717" MODIFIED="2009-05-03 12:41:58 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.995204332975845E-15" P_Z="1.0807203476287386E-8" STUDIES="11" TAU2="0.14343829283844192" TOTAL_1="12310" TOTAL_2="7322" WEIGHT="100.0" Z="5.717548185906333">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.2643608866661067" CI_START="0.022243581930609952" EFFECT_SIZE="0.16770186335403728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.1018710523622431" LOG_CI_START="-1.6527952761079678" LOG_EFFECT_SIZE="-0.7754621118728624" ORDER="119" O_E="0.0" SE="1.0306996870818097" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="1.0623418449505406" WEIGHT="1.820179320527237"/>
<DICH_DATA CI_END="0.29348224172010234" CI_START="0.07807878828503761" EFFECT_SIZE="0.15137614678899083" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="24" LOG_CI_END="-0.5324181722913068" LOG_CI_START="-1.1074669351621278" LOG_EFFECT_SIZE="-0.8199425537267173" MODIFIED="2009-03-22 07:30:16 -0300" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="0.3377864898476047" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.11409971272356592" WEIGHT="8.521989083190125"/>
<DICH_DATA CI_END="1.0073347525376428" CI_START="0.4102561785755583" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="42" LOG_CI_END="0.0031738171484991134" LOG_CI_START="-0.3869448696263254" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="124" O_E="0.0" SE="0.22915764773017616" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.05251322751322751" WEIGHT="11.200403385322804"/>
<DICH_DATA CI_END="1.1234274136272937" CI_START="0.21594007960012068" EFFECT_SIZE="0.4925373134328358" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.05054501722732541" LOG_CI_START="-0.6656667428732034" LOG_EFFECT_SIZE="-0.307560862822939" ORDER="121" O_E="0.0" SE="0.42070633318844103" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.17699381878486356" WEIGHT="6.849301278787198"/>
<DICH_DATA CI_END="1.3618056977663406" CI_START="0.14120846417303723" EFFECT_SIZE="0.43851851851851853" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.13411514692508544" LOG_CI_START="-0.8501392704692581" LOG_EFFECT_SIZE="-0.35801206177208633" ORDER="123" O_E="0.0" SE="0.5781559169153804" STUDY_ID="STD-Heininger-1994" TOTAL_1="75" TOTAL_2="74" VAR="0.33426426426426425" WEIGHT="4.594356968104149"/>
<DICH_DATA CI_END="1.1243482076615003" CI_START="0.4032360924208215" EFFECT_SIZE="0.6733333333333333" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.05090083191506101" LOG_CI_START="-0.3944406024611384" LOG_EFFECT_SIZE="-0.17176988527303866" ORDER="127" O_E="0.0" SE="0.261595763028233" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.06843234323432343" WEIGHT="10.35884968576874"/>
<DICH_DATA CI_END="0.6125886010847097" CI_START="0.36975456284838004" EFFECT_SIZE="0.4759279676589489" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="72" LOG_CI_END="-0.2128310887114062" LOG_CI_START="-0.43208645801356793" LOG_EFFECT_SIZE="-0.32245877336248707" ORDER="118" O_E="0.0" SE="0.1287916892596718" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.01658729922235986" WEIGHT="13.71490674486677"/>
<DICH_DATA CI_END="1.3081640698831343" CI_START="0.019542902906816158" EFFECT_SIZE="0.15989159891598917" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11666221660011973" LOG_CI_START="-1.7090109256339518" LOG_EFFECT_SIZE="-0.7961743545169162" ORDER="126" O_E="0.0" SE="1.0724094409760982" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="1.1500620090946674" WEIGHT="1.6967418319315435"/>
<DICH_DATA CI_END="0.3063042183176935" CI_START="0.25360308188891234" EFFECT_SIZE="0.278710770801814" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="824" LOG_CI_END="-0.5138470221960967" LOG_CI_START="-0.5958454730331451" LOG_EFFECT_SIZE="-0.5548462476146209" MODIFIED="2009-05-03 12:41:58 -0300" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.048166295920560105" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.002319992062706965" WEIGHT="15.057367568467384"/>
<DICH_DATA CI_END="1.066878023159181" CI_START="0.4348933484220667" EFFECT_SIZE="0.6811594202898551" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="23" LOG_CI_END="0.028114769099221264" LOG_CI_START="-0.36161723470229695" LOG_EFFECT_SIZE="-0.16675123280153784" ORDER="122" O_E="0.0" SE="0.2289305082375444" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.05240917760190039" WEIGHT="11.206353939478293"/>
<DICH_DATA CI_END="0.5404365392217386" CI_START="0.4348187188353385" EFFECT_SIZE="0.48475965549558736" ESTIMABLE="YES" EVENTS_1="416" EVENTS_2="859" LOG_CI_END="-0.2672552957604561" LOG_CI_START="-0.3616917679162249" LOG_EFFECT_SIZE="-0.31447353183834054" ORDER="125" O_E="0.0" SE="0.055472451212375054" STUDY_ID="STD-PVSG-1998" TOTAL_1="4073" TOTAL_2="4077" VAR="0.003077192843509331" WEIGHT="14.979550193555756"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="48.63219446883424" CI_END="0.6045528397635636" CI_START="0.3296359535544402" DF="7" EFFECT_SIZE="0.4464105193759517" ESTIMABLE="YES" EVENTS_1="1047" EVENTS_2="1208" I2="85.60624278535091" ID="CMP-001.07.02" LOG_CI_END="-0.21856573448087993" LOG_CI_START="-0.4819654256802299" LOG_EFFECT_SIZE="-0.3502655800805549" MODIFIED="2009-03-22 07:32:06 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.6782844386730176E-8" P_Z="1.8614118376897865E-7" STUDIES="8" TAU2="0.10884663584886028" TOTAL_1="11653" TOTAL_2="6848" WEIGHT="100.0" Z="5.212670666818247">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="3.0674223345991773" CI_START="0.009055739558409236" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4867735754472843" LOG_CI_START="-2.0430760762145717" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="129" O_E="0.0" SE="1.4860462083439174" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="2.2083333333333335" WEIGHT="1.0331085633404717"/>
<DICH_DATA CI_END="0.31086825029827286" CI_START="0.06390700289378072" EFFECT_SIZE="0.140949133276499" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-0.5074236312034319" LOG_CI_START="-1.1944515494865566" LOG_EFFECT_SIZE="-0.8509375903449943" MODIFIED="2009-03-22 07:32:06 -0300" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.403563600042551" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.16286357927930406" WEIGHT="8.810483874645438"/>
<DICH_DATA CI_END="1.705894016938249" CI_START="0.18622842173009563" EFFECT_SIZE="0.5636363636363636" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.23195204600579278" LOG_CI_START="-0.7299540373257352" LOG_EFFECT_SIZE="-0.2490009956599712" ORDER="131" O_E="0.0" SE="0.5650283948608447" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.31925708699902255" WEIGHT="5.5918655718248775"/>
<DICH_DATA CI_END="0.8585332654613801" CI_START="0.23381107644605864" EFFECT_SIZE="0.4480341359341664" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="-0.06624287263303125" LOG_CI_START="-0.631134918642712" LOG_EFFECT_SIZE="-0.3486888956378716" ORDER="134" O_E="0.0" SE="0.3318203840868117" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.11010476729551924" WEIGHT="10.93346941186107"/>
<DICH_DATA CI_END="0.9756620764071218" CI_START="0.31611625378217667" EFFECT_SIZE="0.5553581191908147" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="31" LOG_CI_END="-0.010700575533988397" LOG_CI_START="-0.5001531734219468" LOG_EFFECT_SIZE="-0.25542687447796764" ORDER="132" O_E="0.0" SE="0.2875068788288212" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.08266020537389047" WEIGHT="12.500328728093205"/>
<DICH_DATA CI_END="0.7126485452647076" CI_START="0.4098203972655504" EFFECT_SIZE="0.5404238243555691" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="59" LOG_CI_END="-0.1471245970530793" LOG_CI_START="-0.3874064300260303" LOG_EFFECT_SIZE="-0.2672655135395548" ORDER="128" O_E="0.0" SE="0.14114273810256728" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.019921272519089896" WEIGHT="18.59080029569671"/>
<DICH_DATA CI_END="0.4174604120842378" CI_START="0.3336165723250811" EFFECT_SIZE="0.373191253596543" ESTIMABLE="YES" EVENTS_1="489" EVENTS_2="523" LOG_CI_END="-0.3793847025241876" LOG_CI_START="-0.4767523840217967" LOG_EFFECT_SIZE="-0.42806854327299215" ORDER="130" O_E="0.0" SE="0.05719425808949228" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="0.0032711831584074534" WEIGHT="21.351632507299815"/>
<DICH_DATA CI_END="0.7171532424795575" CI_START="0.5573595319512208" EFFECT_SIZE="0.6322279617082011" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="553" LOG_CI_END="-0.14438803365960648" LOG_CI_START="-0.2538645671768878" LOG_EFFECT_SIZE="-0.19912630041824714" ORDER="133" O_E="0.0" SE="0.06430705770563193" STUDY_ID="STD-PVSG-1998" TOTAL_1="4043" TOTAL_2="3993" VAR="0.004135397670755475" WEIGHT="21.18831104723841"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.108541266220495" CI_END="0.596862899585162" CI_START="0.4251917245909476" DF="8" EFFECT_SIZE="0.5037669755144422" ESTIMABLE="YES" EVENTS_1="941" EVENTS_2="966" I2="47.04981864869834" ID="CMP-001.07.03" LOG_CI_END="-0.22412541559014654" LOG_CI_START="-0.3714151966404176" LOG_EFFECT_SIZE="-0.29777030611528216" MODIFIED="2009-03-22 07:33:22 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.057069022268316116" P_Z="2.285625888238517E-15" STUDIES="9" TAU2="0.021666093268206905" TOTAL_1="11840" TOTAL_2="6806" WEIGHT="100.0" Z="7.924773483806406">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="2.2872439384318466" CI_START="0.0073467637603341135" EFFECT_SIZE="0.12962962962962962" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.35931248531740645" LOG_CI_START="-2.1339039249348297" LOG_EFFECT_SIZE="-0.8872957198087117" ORDER="136" O_E="0.0" SE="1.4645276610024374" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="2.14484126984127" WEIGHT="0.34550971858273216"/>
<DICH_DATA CI_END="0.5400408450602061" CI_START="0.09252151643882617" EFFECT_SIZE="0.2235294117647059" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="-0.2675733918188419" LOG_CI_START="-1.0337572577040857" LOG_EFFECT_SIZE="-0.6506653247614638" MODIFIED="2009-03-22 07:33:22 -0300" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="0.45006019549229576" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.20255417956656346" WEIGHT="3.3384552604080735"/>
<DICH_DATA CI_END="0.8483535151287653" CI_START="0.2161091937045696" EFFECT_SIZE="0.4281786941580756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.0714231363319908" LOG_CI_START="-0.6653267569935221" LOG_EFFECT_SIZE="-0.3683749466627565" ORDER="142" O_E="0.0" SE="0.3488619266469194" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.12170464386380059" WEIGHT="5.221074846299714"/>
<DICH_DATA CI_END="0.8961807025097441" CI_START="0.12968256060300423" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="-0.04760441200048506" LOG_CI_START="-0.8871184228605273" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="138" O_E="0.0" SE="0.4931346856405643" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.24318181818181817" WEIGHT="2.826336614236879"/>
<DICH_DATA CI_END="0.8098100917035214" CI_START="0.23187878207687845" EFFECT_SIZE="0.43333333333333335" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="30" LOG_CI_END="-0.0916168154364081" LOG_CI_START="-0.6347389893892432" LOG_EFFECT_SIZE="-0.36317790241282566" ORDER="140" O_E="0.0" SE="0.31903265347801596" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.10178183398522381" WEIGHT="6.06368503700065"/>
<DICH_DATA CI_END="0.8395853901812316" CI_START="0.46072040856308394" EFFECT_SIZE="0.6219438270357648" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="49" LOG_CI_END="-0.07593512728220209" LOG_CI_START="-0.33656254934919067" LOG_EFFECT_SIZE="-0.20624883831569635" ORDER="135" O_E="0.0" SE="0.15309383784869524" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.023437723187242587" WEIGHT="16.596142148519498"/>
<DICH_DATA CI_END="0.7462550072061249" CI_START="0.28103101922502877" EFFECT_SIZE="0.4579528417609377" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" LOG_CI_END="-0.12711274183283347" LOG_CI_START="-0.5512457415370264" LOG_EFFECT_SIZE="-0.33917924168492997" ORDER="139" O_E="0.0" SE="0.24913782351845168" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.062069655107511175" WEIGHT="8.93942388830956"/>
<DICH_DATA CI_END="0.5348229648346468" CI_START="0.4106204231016113" EFFECT_SIZE="0.4686248308667188" ESTIMABLE="YES" EVENTS_1="418" EVENTS_2="351" LOG_CI_END="-0.2717899527809674" LOG_CI_START="-0.3865594538457142" LOG_EFFECT_SIZE="-0.32917470331334087" ORDER="137" O_E="0.0" SE="0.06741617304362506" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="0.004544940387847998" WEIGHT="28.558558932011188"/>
<DICH_DATA CI_END="0.7025249294498616" CI_START="0.5330117967337151" EFFECT_SIZE="0.6119265273677038" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="476" LOG_CI_END="-0.1533382599916887" LOG_CI_START="-0.27326317896655716" LOG_EFFECT_SIZE="-0.21330071947912294" ORDER="141" O_E="0.0" SE="0.07044449104376077" STUDY_ID="STD-PVSG-1998" TOTAL_1="3996" TOTAL_2="3919" VAR="0.004962426318414491" WEIGHT="28.110813554631708"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.698364989537488" CI_END="0.5378199564446537" CI_START="0.30150978012834734" DF="13" EFFECT_SIZE="0.40268843640743507" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="244" I2="42.727152347791666" ID="CMP-001.07.04" LOG_CI_END="-0.2693630868040701" LOG_CI_START="-0.5206985960051398" LOG_EFFECT_SIZE="-0.395030841404605" MODIFIED="2012-02-10 15:49:03 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.04544171982498335" P_Z="7.226089037034352E-10" STUDIES="14" TAU2="0.11118595712744227" TOTAL_1="1149" TOTAL_2="790" WEIGHT="100.0" Z="6.161057181269032">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.5413517934974666" CI_START="0.009424630854853544" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.2665204200656321" LOG_CI_START="-2.025735651290844" LOG_EFFECT_SIZE="-1.146128035678238" ORDER="150" O_E="0.0" SE="1.033371735077529" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="1.0678571428571428" WEIGHT="1.8486437417169626"/>
<DICH_DATA CI_END="1.408238943505249" CI_START="0.005084196362151506" EFFECT_SIZE="0.08461538461538462" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.14867635014810587" LOG_CI_START="-2.2937776844453293" LOG_EFFECT_SIZE="-1.0725506671486118" ORDER="146" O_E="0.0" SE="1.4347095902626457" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="2.0583916083916085" WEIGHT="1.0046336589397826"/>
<DICH_DATA CI_END="1.0571879058568519" CI_START="0.01930419668276973" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.024152186194750208" LOG_CI_START="-1.714348266223264" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="147" O_E="0.0" SE="1.0212037714663722" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="1.0428571428571427" WEIGHT="1.8886908539466025"/>
<DICH_DATA CI_END="1.335388290542258" CI_START="0.187211466335745" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12560756376867918" LOG_CI_START="-0.7276675550966415" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="152" O_E="0.0" SE="0.501218028601448" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.25121951219512195" WEIGHT="6.014342587255653"/>
<DICH_DATA CI_END="1.764402352688941" CI_START="0.4515038988603058" EFFECT_SIZE="0.8925438596491229" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.24659762820359457" LOG_CI_START="-0.34533849508202435" LOG_EFFECT_SIZE="-0.04937043343921492" ORDER="145" O_E="0.0" SE="0.34770620894903936" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.12089960774171302" WEIGHT="9.391495973607398"/>
<DICH_DATA CI_END="2.7750286684946506" CI_START="0.39324952256135426" EFFECT_SIZE="1.0446428571428572" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.443267474127062" LOG_CI_START="-0.4053317959751019" LOG_EFFECT_SIZE="0.01896783907598006" MODIFIED="2009-05-07 01:32:24 -0300" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.498471411892145" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.24847374847374848" WEIGHT="6.060258110809769"/>
<DICH_DATA CI_END="0.4177833145266413" CI_START="0.1123655321123431" EFFECT_SIZE="0.21666666666666667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="-0.37904890890743265" LOG_CI_START="-0.949366887246181" LOG_EFFECT_SIZE="-0.6642078980768068" ORDER="143" O_E="0.0" SE="0.3350076035957043" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.11223009446693656" WEIGHT="9.755926812090838"/>
<DICH_DATA CI_END="0.885428203857505" CI_START="0.04517588193569373" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.052846648401220594" LOG_CI_START="-1.345093360270817" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="148" O_E="0.0" SE="0.7590721152765897" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.5761904761904763" WEIGHT="3.17094177564416"/>
<DICH_DATA CI_END="1.1643656852894018" CI_START="0.2545761669477101" EFFECT_SIZE="0.5444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.06608939797850852" LOG_CI_START="-0.5941822568001311" LOG_EFFECT_SIZE="-0.26404642941081125" ORDER="153" O_E="0.0" SE="0.3878468384143761" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.1504251700680272" WEIGHT="8.331567052851323"/>
<DICH_DATA CI_END="0.5741947222689663" CI_START="0.13438036058962022" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="-0.24094080365420942" LOG_CI_START="-0.871664197880365" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="151" O_E="0.0" SE="0.3704900438995983" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.13726287262872627" WEIGHT="8.772955985102415"/>
<DICH_DATA CI_END="1.0043967463723238" CI_START="0.20570712817835454" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.0019052971961669564" LOG_CI_START="-0.6867506588405795" LOG_EFFECT_SIZE="-0.3424226808222062" ORDER="144" O_E="0.0" SE="0.40451991747794525" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.16363636363636364" WEIGHT="7.931053933113163"/>
<DICH_DATA CI_END="0.6458230948874225" CI_START="0.15477407438982418" EFFECT_SIZE="0.3161592505854801" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="-0.1898864284999851" LOG_CI_START="-0.8103017845600503" LOG_EFFECT_SIZE="-0.5000941065300177" ORDER="149" O_E="0.0" SE="0.3644350512552249" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.1328129065833984" WEIGHT="8.932954091885104"/>
<DICH_DATA CI_END="0.6212443718056513" CI_START="0.20321497456187293" EFFECT_SIZE="0.3553113553113553" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="39" LOG_CI_END="-0.20673753275329282" LOG_CI_START="-0.6920442927957297" LOG_EFFECT_SIZE="-0.44939091277451115" MODIFIED="2009-03-22 07:38:12 -0300" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.2850715931561335" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.0812658132245761" WEIGHT="11.325594168420755"/>
<DICH_DATA CI_END="0.7166541775195379" CI_START="0.36849264039384905" EFFECT_SIZE="0.5138888888888888" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="72" LOG_CI_END="-0.14469036319700115" LOG_CI_START="-0.4335711815315459" LOG_EFFECT_SIZE="-0.2891307723642735" MODIFIED="2009-05-07 02:00:38 -0300" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.16969002267282482" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.028794703794703797" WEIGHT="15.570941254616088"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.521556009392015" CI_END="0.5754133176098318" CI_START="0.30962923675529774" DF="3" EFFECT_SIZE="0.4220957075715956" ESTIMABLE="YES" EVENTS_1="457" EVENTS_2="735" I2="68.49254473700711" ID="CMP-001.07.05" LOG_CI_END="-0.24002009083371736" LOG_CI_START="-0.5091580377759628" LOG_EFFECT_SIZE="-0.3745890643048401" MODIFIED="2012-02-10 15:49:44 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.023103220120981427" P_Z="4.8753517151457355E-8" STUDIES="4" TAU2="0.05919163077140543" TOTAL_1="4474" TOTAL_2="3973" WEIGHT="100.00000000000001" Z="5.455797544577345">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.4836804060508724" CI_START="0.04413316766545407" EFFECT_SIZE="0.1461038961038961" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.3154415055748356" LOG_CI_START="-1.3552348998753658" LOG_EFFECT_SIZE="-0.8353382027251006" ORDER="154" O_E="0.0" SE="0.6107797868724439" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.373051948051948" WEIGHT="5.782245462869429"/>
<DICH_DATA CI_END="0.5418305806344861" CI_START="0.2644762783807508" EFFECT_SIZE="0.37855162855162855" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="39" LOG_CI_END="-0.26613648725778416" LOG_CI_START="-0.5776132749722477" LOG_EFFECT_SIZE="-0.421874881115016" ORDER="155" O_E="0.0" SE="0.18296300693844147" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.03347546190795619" WEIGHT="26.971154486887453"/>
<DICH_DATA CI_END="0.6132978820294134" CI_START="0.4812251329380671" EFFECT_SIZE="0.5432626941086968" ESTIMABLE="YES" EVENTS_1="356" EVENTS_2="646" LOG_CI_END="-0.21232853510792013" LOG_CI_START="-0.3176516988482354" LOG_EFFECT_SIZE="-0.2649901169780778" ORDER="156" O_E="0.0" SE="0.061867347739130066" STUDY_ID="STD-PVSG-1998" TOTAL_1="3805" TOTAL_2="3751" VAR="0.003827568716274442" WEIGHT="39.659952725905306"/>
<DICH_DATA CI_END="0.5774356343178996" CI_START="0.28826959374282746" EFFECT_SIZE="0.40799158780231337" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="39" LOG_CI_END="-0.23849641874053443" LOG_CI_START="-0.5402011639458789" LOG_EFFECT_SIZE="-0.38934879134320666" MODIFIED="2009-03-22 07:41:04 -0300" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="0.1772228607961944" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.031407942388787295" WEIGHT="27.586647324337825"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="277.06102639034236" CI_END="0.5313877915445189" CI_START="0.4596657557410576" CI_STUDY="95" CI_TOTAL="95" DF="44" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49422744844037436" ESTIMABLE="YES" EVENTS_1="5312" EVENTS_2="5982" I2="84.11902223374796" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.27458842758052887" LOG_CI_START="-0.3375578491899855" LOG_EFFECT_SIZE="-0.3060731383852571" METHOD="MH" MODIFIED="2014-09-14 22:06:55 -0300" MODIFIED_BY="Liz  Dooley" NO="8" NOTES="&lt;p&gt;13/09/14&lt;/p&gt;&lt;p&gt;Attached please find the main report of Gustaffson 1996 trial. In the table 2, limpness rather than &amp;quot;drowsness&amp;quot; was reported, but the numbers are very different compared with numbers of drowsness presented in the analyses 1.8.1 and 1.8.2. As such data were initially imported by the original review authors, we need confirm data accurary. It seems less possible that outcome &amp;quot;drowsness&amp;quot; was not reported by the main trial reporting but by the secondary articels, but we should confirm the data through checking other related articles. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;15/09/14 &lt;/p&gt;&lt;p&gt;Dear Liz,&lt;/p&gt;&lt;p&gt;As the outcome &amp;quot;drowsiness&amp;quot; was not reported by the main article of Gustafsson 1996 trial and we failed to get the secondary articles of this trial, so we can not confirm the data. However, in the section &amp;quot;Heterogeneity in the meta-analysis of safety endpoints&amp;quot;, the authors of the first published version of this review made the following comments on this outcome of Gustafsson 1996 trial &amp;quot; A special comment is warranted about drowsiness after the first and second doses of the primary series. The statistical test displays an extreme heterogeneity for this endpoint and it strongly suggests inconsistent findings across studies. By visual inspection of the forest plot, we identified that Gustafsson 1996 was responsible for this extreme heterogeneity. In contrast with other studies, Gustafsson 1996 demonstrated the results in favour of whole-cell vaccines. This is only one safety endpoint where the superiority of whole-cell vaccines over acellular vaccines was reported. Partial unblinding of the whole-cell vaccine arm occurred in this trial but the expected effect of unblinding would be to bias the assessment of adverse events in favour of the acellular preparations. We have no plausible explanations for this finding.&amp;quot; These comments indicate that the data have been confirmed by the authors of the first version of the review. We have responded other comments from the copy editor. The updated review is ready for publication.&lt;/p&gt;" NOTES_MODIFIED="2014-09-14 22:06:55 -0300" NOTES_MODIFIED_BY="Liz  Dooley" P_CHI2="1.7763568394002505E-15" P_Q="0.7149872053646882" P_Z="0.0" Q="2.1129859706880416" RANDOM="YES" SCALE="16.575700908405878" SORT_BY="YEAR" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07945947060359054" TOTALS="SUB" TOTAL_1="43120" TOTAL_2="26729" WEIGHT="500.0" Z="19.053448881612653">
<NAME>Drowsiness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="89.38890089323866" CI_END="0.6816701296660062" CI_START="0.445354205181716" DF="11" EFFECT_SIZE="0.5509851711194426" ESTIMABLE="YES" EVENTS_1="1922" EVENTS_2="2237" I2="87.69422166501654" ID="CMP-001.08.01" LOG_CI_END="-0.1664257360814112" LOG_CI_START="-0.3512944425767631" LOG_EFFECT_SIZE="-0.2588600893290872" MODIFIED="2014-09-09 22:44:59 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.2426505097428162E-14" P_Z="4.046047669409403E-8" STUDIES="12" TAU2="0.09840742389452535" TOTAL_1="12813" TOTAL_2="7677" WEIGHT="100.00000000000003" Z="5.488830010638802">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="0.7906878751347834" CI_START="0.32895407679757627" EFFECT_SIZE="0.51" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="26" LOG_CI_END="-0.10199492087422124" LOG_CI_START="-0.4828647269299061" LOG_EFFECT_SIZE="-0.2924298239020636" ORDER="158" O_E="0.0" SE="0.2237248094130555" STUDY_ID="STD-Blennow-1988" TOTAL_1="200" TOTAL_2="78" VAR="0.050052790346908" WEIGHT="7.943134676971444"/>
<DICH_DATA CI_END="0.7872429930200477" CI_START="0.40842076532019633" EFFECT_SIZE="0.567032967032967" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="78" LOG_CI_END="-0.10389119618048905" LOG_CI_START="-0.3888921852072754" LOG_EFFECT_SIZE="-0.24639169069388225" ORDER="159" O_E="0.0" SE="0.16741099173198273" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.028026440152685995" WEIGHT="9.326927439719807"/>
<DICH_DATA CI_END="0.702216352973833" CI_START="0.45204244966740587" EFFECT_SIZE="0.5634106853750674" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="51" LOG_CI_END="-0.15352906105180802" LOG_CI_START="-0.34482078025350044" LOG_EFFECT_SIZE="-0.24917492065265423" MODIFIED="2009-03-22 07:47:46 -0300" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.11236570276835578" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.01262605115862648" WEIGHT="10.620576140008552"/>
<DICH_DATA CI_END="1.2837674619632735" CI_START="0.6051214426599002" EFFECT_SIZE="0.8813825608798115" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="19" LOG_CI_END="0.10848636397259138" LOG_CI_START="-0.21815745743961695" LOG_EFFECT_SIZE="-0.054835546733512784" ORDER="162" O_E="0.0" SE="0.19187219761052438" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.036814940215892114" WEIGHT="8.720742930724215"/>
<DICH_DATA CI_END="0.9426771685816433" CI_START="0.4469827345286366" EFFECT_SIZE="0.6491228070175439" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="57" LOG_CI_END="-0.025637011300969518" LOG_CI_START="-0.3497092519100233" LOG_EFFECT_SIZE="-0.1876731316054964" ORDER="165" O_E="0.0" SE="0.1903616383172211" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.0362375533428165" WEIGHT="8.75813936834098"/>
<DICH_DATA CI_END="0.8330374221233938" CI_START="0.24893857397234265" EFFECT_SIZE="0.4553846153846154" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.07933548856123118" LOG_CI_START="-0.6039078026066028" LOG_EFFECT_SIZE="-0.341621645583917" ORDER="164" O_E="0.0" SE="0.3081363739450845" STUDY_ID="STD-Heininger-1994" TOTAL_1="75" TOTAL_2="74" VAR="0.09494802494802494" WEIGHT="6.0988168833659095"/>
<DICH_DATA CI_END="0.7879600167406742" CI_START="0.6005824109938397" EFFECT_SIZE="0.6879207269888445" ESTIMABLE="YES" EVENTS_1="543" EVENTS_2="161" LOG_CI_END="-0.10349581924832253" LOG_CI_START="-0.2214273909518459" LOG_EFFECT_SIZE="-0.1624616051000842" ORDER="160" O_E="0.0" SE="0.06927358898934453" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.004798830131464636" WEIGHT="11.426046677314499"/>
<DICH_DATA CI_END="1.018014859670423" CI_START="0.6532335072681068" EFFECT_SIZE="0.8154761904761905" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="56" LOG_CI_END="0.007754117318782825" LOG_CI_START="-0.18493154645769505" LOG_EFFECT_SIZE="-0.08858871456945609" ORDER="163" O_E="0.0" SE="0.11318451271172164" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.012810733917789877" WEIGHT="10.602940195087113"/>
<DICH_DATA CI_END="14.714942270060682" CI_START="0.1622414458137406" EFFECT_SIZE="1.5451127819548873" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1677585626066616" LOG_CI_START="-0.7898381921166571" LOG_EFFECT_SIZE="0.18896018524500224" MODIFIED="2009-06-09 23:06:38 -0300" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="1.1499020239846958" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="1.3222746647641" WEIGHT="0.8300516247129922"/>
<DICH_DATA CI_END="0.15169387267878665" CI_START="0.06476736673915817" EFFECT_SIZE="0.09912019311860798" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="107" LOG_CI_END="-0.8190319611746063" LOG_CI_START="-1.1886437597918798" LOG_EFFECT_SIZE="-1.003837860483243" MODIFIED="2014-09-09 22:44:59 -0300" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.2171118001156972" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.04713753374947845" WEIGHT="8.102235178604428"/>
<DICH_DATA CI_END="1.3439361645737964" CI_START="0.37181252927728425" EFFECT_SIZE="0.7068891741548995" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="19" LOG_CI_END="0.1283786407179895" LOG_CI_START="-0.42967597953371645" LOG_EFFECT_SIZE="-0.15064866940786345" ORDER="167" O_E="0.0" SE="0.327804046350774" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="0.10745549280394039" WEIGHT="5.728275372776391"/>
<DICH_DATA CI_END="0.623065948109552" CI_START="0.5447973624690556" EFFECT_SIZE="0.582618816357973" ESTIMABLE="YES" EVENTS_1="952" EVENTS_2="1636" LOG_CI_END="-0.20546598322160747" LOG_CI_START="-0.2637650036428259" LOG_EFFECT_SIZE="-0.23461549343221663" ORDER="166" O_E="0.0" SE="0.03424513318022905" STUDY_ID="STD-PVSG-1998" TOTAL_1="4088" TOTAL_2="4093" VAR="0.0011727291465316245" WEIGHT="11.842113512373674"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="42.234347440678576" CI_END="0.5989776329237109" CI_START="0.34936543001182196" DF="7" EFFECT_SIZE="0.4574517223640714" ESTIMABLE="YES" EVENTS_1="1107" EVENTS_2="1309" I2="83.42581234424885" ID="CMP-001.08.02" LOG_CI_END="-0.22258939477124795" LOG_CI_START="-0.4567200710127396" LOG_EFFECT_SIZE="-0.3396547328919938" MODIFIED="2014-09-09 22:52:22 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.6866631353559285E-7" P_Z="1.2954627573432403E-8" STUDIES="9" TAU2="0.10505377088466675" TOTAL_1="12134" TOTAL_2="7174" WEIGHT="100.0" Z="5.686662289056384">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="0.6146933879742866" CI_START="0.2073060040228431" EFFECT_SIZE="0.3569728700618753" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" LOG_CI_END="-0.2113414583965098" LOG_CI_START="-0.6833881196319952" LOG_EFFECT_SIZE="-0.44736478901425253" ORDER="169" O_E="0.0" SE="0.27728254547838255" STUDY_ID="STD-Blennow-1988" TOTAL_1="191" TOTAL_2="75" VAR="0.07688561002697128" WEIGHT="10.395972701865013"/>
<DICH_DATA CI_END="0.9674447486534222" CI_START="0.4142530957065397" EFFECT_SIZE="0.6330615942028985" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="48" LOG_CI_END="-0.014373828417700006" LOG_CI_START="-0.3827342374210113" LOG_EFFECT_SIZE="-0.19855403291935564" ORDER="170" O_E="0.0" SE="0.21637672766197724" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.046818888273705464" WEIGHT="12.454097056266237"/>
<DICH_DATA CI_END="0.5057140752501627" CI_START="0.23715983433742352" EFFECT_SIZE="0.34631642512077293" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="32" LOG_CI_END="-0.2960949587297075" LOG_CI_START="-0.6249588616934424" LOG_EFFECT_SIZE="-0.4605269102115749" MODIFIED="2009-03-22 07:48:01 -0300" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="0.19317628450347205" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.03731707689456638" WEIGHT="13.285281831604737"/>
<DICH_DATA CI_END="1.1070041652568219" CI_START="0.37160986406356833" EFFECT_SIZE="0.6413841807909605" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="0.044149254975064486" LOG_CI_START="-0.42991276655266913" LOG_EFFECT_SIZE="-0.19288175578880234" ORDER="174" O_E="0.0" SE="0.27846637809024355" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.07754352372669848" WEIGHT="10.358515121361949"/>
<DICH_DATA CI_END="0.9952866481252736" CI_START="0.29510947403569043" EFFECT_SIZE="0.541958041958042" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="-0.0020518219975228734" LOG_CI_START="-0.5300168479199802" LOG_EFFECT_SIZE="-0.2660343349587515" ORDER="173" O_E="0.0" SE="0.31012926969587923" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.09618016392209941" WEIGHT="9.399194222226246"/>
<DICH_DATA CI_END="0.6842472584324806" CI_START="0.4732476584382836" EFFECT_SIZE="0.5690504484191068" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="111" LOG_CI_END="-0.16478693399826363" LOG_CI_START="-0.32491152618582075" LOG_EFFECT_SIZE="-0.24484923009204218" ORDER="171" O_E="0.0" SE="0.09405797808048572" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.008846903240589132" WEIGHT="16.606019691082846"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Afari-1996" TOTAL_1="261" TOTAL_2="129" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.22727790652332294" CI_START="0.07139670261294943" EFFECT_SIZE="0.12738482288930425" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="47" LOG_CI_END="-0.6434427795911577" LOG_CI_START="-1.1463218452275912" LOG_EFFECT_SIZE="-0.8948823124093744" MODIFIED="2014-09-09 22:52:22 -0300" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.2953936524463627" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="0.08725740990560252" WEIGHT="9.835293140934809"/>
<DICH_DATA CI_END="0.7049140108036629" CI_START="0.5911768892944544" EFFECT_SIZE="0.6455454067120197" ESTIMABLE="YES" EVENTS_1="659" EVENTS_2="1006" LOG_CI_END="-0.15186385735062874" LOG_CI_START="-0.22828255202877978" LOG_EFFECT_SIZE="-0.19007320468970426" ORDER="175" O_E="0.0" SE="0.04488871953258533" STUDY_ID="STD-PVSG-1998" TOTAL_1="4058" TOTAL_2="3999" VAR="0.0020149971412751076" WEIGHT="17.66562623465818"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="92.85584976032354" CI_END="0.7653598133946818" CI_START="0.4045336388494204" DF="8" EFFECT_SIZE="0.5564295016816273" ESTIMABLE="YES" EVENTS_1="1548" EVENTS_2="1231" I2="91.38449540804449" ID="CMP-001.08.03" LOG_CI_END="-0.11613434493242894" LOG_CI_START="-0.39304535894848514" LOG_EFFECT_SIZE="-0.25458985194045697" MODIFIED="2009-05-03 12:45:59 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.2212453270876722E-15" P_Z="3.1341549154240676E-4" STUDIES="10" TAU2="0.18210371794951846" TOTAL_1="12301" TOTAL_2="7129" WEIGHT="100.00000000000001" Z="3.6039515611592665">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="0.6993670901578906" CI_START="0.19552804051051226" EFFECT_SIZE="0.3697916666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="-0.1552948079705872" LOG_CI_START="-0.7087909519983615" LOG_EFFECT_SIZE="-0.4320428799844743" ORDER="177" O_E="0.0" SE="0.3251263748520153" STUDY_ID="STD-Blennow-1988" TOTAL_1="192" TOTAL_2="71" VAR="0.10570715962441316" WEIGHT="9.192813729232048"/>
<DICH_DATA CI_END="0.6965097092885331" CI_START="0.27575648413683157" EFFECT_SIZE="0.4382545705415661" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="52" LOG_CI_END="-0.15707282516816873" LOG_CI_START="-0.5594742667690498" LOG_EFFECT_SIZE="-0.3582735459686093" ORDER="178" O_E="0.0" SE="0.23637259871561875" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.055872005423574934" WEIGHT="11.11790626910269"/>
<DICH_DATA CI_END="0.8277313034233093" CI_START="0.32005814475429606" EFFECT_SIZE="0.5147058823529411" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="-0.08211062019448748" LOG_CI_START="-0.494771116517434" LOG_EFFECT_SIZE="-0.2884408683559607" MODIFIED="2009-03-22 07:48:16 -0300" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.24239881824249981" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.05875718708536046" WEIGHT="10.984729075898919"/>
<DICH_DATA CI_END="0.9677565336960778" CI_START="0.20924684354918005" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.014233887910247987" LOG_CI_START="-0.6793410845390647" LOG_EFFECT_SIZE="-0.3467874862246563" ORDER="183" O_E="0.0" SE="0.39068725963348827" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.15263653483992468" WEIGHT="7.904014425322811"/>
<DICH_DATA CI_END="1.4209336851261092" CI_START="0.24036419073103818" EFFECT_SIZE="0.5844155844155844" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.1525738099078781" LOG_CI_START="-0.6191302327021545" LOG_EFFECT_SIZE="-0.23327821139713822" ORDER="181" O_E="0.0" SE="0.4533027746257522" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.2054834054834055" WEIGHT="6.82631498009981"/>
<DICH_DATA CI_END="0.6576853930011485" CI_START="0.42134786935877744" EFFECT_SIZE="0.5264165071969382" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="84" LOG_CI_END="-0.18198180358615074" LOG_CI_START="-0.3753591978458982" LOG_EFFECT_SIZE="-0.27867050071602445" ORDER="179" O_E="0.0" SE="0.11359083862171532" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.012902878618784572" WEIGHT="13.567704033320984"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="176" O_E="0.0" SE="0.0" STUDY_ID="STD-Afari-1996" TOTAL_1="257" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6414724128620637" CI_START="0.2958601285615555" EFFECT_SIZE="0.4356444772266273" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="34" LOG_CI_END="-0.1928220161392468" LOG_CI_START="-0.5289135583690623" LOG_EFFECT_SIZE="-0.3608677872541545" ORDER="182" O_E="0.0" SE="0.19742183558575918" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.03897538116605053" WEIGHT="11.967625150312722"/>
<DICH_DATA CI_END="1.405432688951656" CI_START="1.0644545945743324" EFFECT_SIZE="1.2231186709062816" ESTIMABLE="YES" EVENTS_1="718" EVENTS_2="231" LOG_CI_END="0.1478100505717866" LOG_CI_START="0.027127140883421545" LOG_EFFECT_SIZE="0.08746859572760406" MODIFIED="2009-05-03 12:45:59 -0300" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.07088973854098317" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="0.005025355030408954" WEIGHT="14.138860117517742"/>
<DICH_DATA CI_END="0.670567009993783" CI_START="0.5426354509603888" EFFECT_SIZE="0.6032192237214726" ESTIMABLE="YES" EVENTS_1="472" EVENTS_2="768" LOG_CI_END="-0.17355781644565013" LOG_CI_START="-0.2654918367197594" LOG_EFFECT_SIZE="-0.21952482658270475" ORDER="184" O_E="0.0" SE="0.05400249858975163" STUDY_ID="STD-PVSG-1998" TOTAL_1="4002" TOTAL_2="3928" VAR="0.002916269853936127" WEIGHT="14.300032219192278"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.079639282495041" CI_END="0.5562722113883569" CI_START="0.40661658737780715" DF="12" EFFECT_SIZE="0.4755938479920023" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="292" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-0.25471263472415706" LOG_CI_START="-0.3908149088762535" LOG_EFFECT_SIZE="-0.32276377180020527" MODIFIED="2012-02-10 15:50:31 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.5221063117363011" P_Z="1.4578859420887543E-20" STUDIES="13" TAU2="0.0" TOTAL_1="1453" TOTAL_2="801" WEIGHT="99.99999999999999" Z="9.296029360034952">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="1.2008537868107867" CI_START="0.14457306378005058" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.07949013192673515" LOG_CI_START="-0.8399126153499471" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="191" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.2916666666666667" WEIGHT="2.1913874474811026"/>
<DICH_DATA CI_END="1.1924065668494095" CI_START="0.17327275443798115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.07642435912393504" LOG_CI_START="-0.7612697207683475" LOG_EFFECT_SIZE="-0.3424226808222062" ORDER="193" O_E="0.0" SE="0.4920656491812986" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.24212860310421283" WEIGHT="2.639732208370666"/>
<DICH_DATA CI_END="1.2556598822002678" CI_START="0.33556891046960424" EFFECT_SIZE="0.6491228070175439" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.09887201894980135" LOG_CI_START="-0.4742182821607942" LOG_EFFECT_SIZE="-0.1876731316054964" ORDER="187" O_E="0.0" SE="0.33663607971510634" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.11332385016595545" WEIGHT="5.640071981723067"/>
<DICH_DATA CI_END="0.6699455545122983" CI_START="0.08263853894755811" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.17396049033747166" LOG_CI_START="-1.0828173697631511" LOG_EFFECT_SIZE="-0.6283889300503115" ORDER="188" O_E="0.0" SE="0.533867029888755" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.2850140056022409" WEIGHT="2.2425377687368044"/>
<DICH_DATA CI_END="1.049316660097805" CI_START="0.2054300981647464" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.02090656825099137" LOG_CI_START="-0.6873359263217563" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2009-03-28 17:20:15 -0300" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.41602514716892186" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.17307692307692307" WEIGHT="3.6928936614959325"/>
<DICH_DATA CI_END="0.7082066083824021" CI_START="0.2936092342811396" EFFECT_SIZE="0.456" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="25" LOG_CI_END="-0.14984002509185665" LOG_CI_START="-0.5322302895792734" LOG_EFFECT_SIZE="-0.341035157335565" ORDER="185" O_E="0.0" SE="0.2246179342222455" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.050453216374269" WEIGHT="12.668264148724429"/>
<DICH_DATA CI_END="0.9581244786100895" CI_START="0.2158932284376951" EFFECT_SIZE="0.45481049562682213" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="-0.018578064134828303" LOG_CI_START="-0.6657609792417896" LOG_EFFECT_SIZE="-0.34216952168830894" ORDER="189" O_E="0.0" SE="0.38015844794092596" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.1445204455408537" WEIGHT="4.422589964970106"/>
<DICH_DATA CI_END="0.6864301270717388" CI_START="0.2174683971709349" EFFECT_SIZE="0.38636363636363635" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="-0.1634036637754898" LOG_CI_START="-0.6626038464403373" LOG_EFFECT_SIZE="-0.41300375510791354" ORDER="192" O_E="0.0" SE="0.2932326583780887" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.08598539193948089" WEIGHT="7.433293699839673"/>
<DICH_DATA CI_END="0.9880178001950543" CI_START="0.20188359562614022" EFFECT_SIZE="0.4466145833333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.005235231063331795" LOG_CI_START="-0.6948989689141513" LOG_EFFECT_SIZE="-0.3500670999887415" ORDER="194" O_E="0.0" SE="0.40511189350413224" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.1641156462585034" WEIGHT="3.8945383133990585"/>
<DICH_DATA CI_END="0.8209394733991469" CI_START="0.18019476328788497" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="-0.08568886156236406" LOG_CI_START="-0.744257834379272" LOG_EFFECT_SIZE="-0.4149733479708179" ORDER="186" O_E="0.0" SE="0.38684667460164324" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.14965034965034965" WEIGHT="4.270986828131978"/>
<DICH_DATA CI_END="0.7057484214959928" CI_START="0.16425978052933213" EFFECT_SIZE="0.34047919293820933" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="-0.15135008453966384" LOG_CI_START="-0.7844687617775692" LOG_EFFECT_SIZE="-0.4679094231586165" ORDER="190" O_E="0.0" SE="0.37189704499754217" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.1383074120779039" WEIGHT="4.621261164383396"/>
<DICH_DATA CI_END="0.7900642222421943" CI_START="0.47269168709296855" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="90" LOG_CI_END="-0.10233760461872077" LOG_CI_START="-0.3254220352714412" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2009-03-22 07:49:26 -0300" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.13104089885114942" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.01717171717171717" WEIGHT="37.221360321186374"/>
<DICH_DATA CI_END="0.5125468302452508" CI_START="0.18096352326261034" EFFECT_SIZE="0.304552590266876" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="49" LOG_CI_END="-0.2902664479542639" LOG_CI_START="-0.742408956855985" LOG_EFFECT_SIZE="-0.5163377024051244" MODIFIED="2009-05-29 20:51:35 -0300" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.2655907478703863" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.07053844535435108" WEIGHT="9.061082491557391"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6729726696417906" CI_END="0.5402864535245936" CI_START="0.4440135504104296" DF="2" EFFECT_SIZE="0.4897902678372799" ESTIMABLE="YES" EVENTS_1="532" EVENTS_2="913" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="-0.26737592128788396" LOG_CI_START="-0.3526037758793465" LOG_EFFECT_SIZE="-0.3099898485836152" MODIFIED="2012-02-10 15:51:08 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.43323033874014816" P_Z="4.025035624299865E-46" STUDIES="3" TAU2="0.0" TOTAL_1="4419" TOTAL_2="3948" WEIGHT="99.99999999999999" Z="14.257520424731474">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.6540074417937544" CI_START="0.27502266354817906" EFFECT_SIZE="0.42410714285714285" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="28" LOG_CI_END="-0.18441730991491434" LOG_CI_START="-0.5606315161757157" LOG_EFFECT_SIZE="-0.37252441304531503" ORDER="195" O_E="0.0" SE="0.22099008704795037" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.04883661857346068" WEIGHT="5.132071881047706"/>
<DICH_DATA CI_END="0.5612693823340545" CI_START="0.45267388723743573" EFFECT_SIZE="0.5040555456380884" ESTIMABLE="YES" EVENTS_1="427" EVENTS_2="836" LOG_CI_END="-0.25082864822402123" LOG_CI_START="-0.3442145573178206" LOG_EFFECT_SIZE="-0.2975216027709209" ORDER="196" O_E="0.0" SE="0.05485534526940316" STUDY_ID="STD-PVSG-1998" TOTAL_1="3806" TOTAL_2="3756" VAR="0.0030091089046254318" WEIGHT="83.2914476977057"/>
<DICH_DATA CI_END="0.5665929142069943" CI_START="0.3182581035131048" EFFECT_SIZE="0.4246443056717955" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="49" LOG_CI_END="-0.24672886105462968" LOG_CI_START="-0.4972205294929383" LOG_EFFECT_SIZE="-0.371974695273784" MODIFIED="2009-05-29 20:52:18 -0300" MODIFIED_BY="[Empty name]" ORDER="592" O_E="0.0" SE="0.14714004599441893" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.02165019313523972" WEIGHT="11.576480421246577"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1210.6435280203787" CI_END="0.3192727258421747" CI_START="0.2685177117845759" CI_STUDY="95" CI_TOTAL="95" DF="84" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2927975098568377" ESTIMABLE="YES" EVENTS_1="6488" EVENTS_2="13129" I2="93.06154139878358" I2_Q="88.57751750242262" ID="CMP-001.09" LOG_CI_END="-0.49583817987008605" LOG_CI_START="-0.5710270623792902" LOG_EFFECT_SIZE="-0.5334326211246881" METHOD="MH" MODIFIED="2014-05-25 20:29:28 -0300" MODIFIED_BY="Liz Dooley" NO="9" P_CHI2="0.0" P_Q="4.6045573776076765E-7" P_Z="0.0" Q="35.01865729142826" RANDOM="YES" SCALE="70.83824325151889" SORT_BY="YEAR" STUDIES="46" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.22756889184886883" TOTALS="SUB" TOTAL_1="51123" TOTAL_2="29136" WEIGHT="500.0" Z="27.810194557824516">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="64.41022007984279" CI_END="0.20401868397358108" CI_START="0.13412863396819225" DF="18" EFFECT_SIZE="0.1654229348831798" ESTIMABLE="YES" EVENTS_1="898" EVENTS_2="3900" I2="72.05412436460047" ID="CMP-001.09.01" LOG_CI_END="-0.6903300581865515" LOG_CI_START="-0.8724784984578379" LOG_EFFECT_SIZE="-0.7814042783221947" MODIFIED="2009-03-22 08:21:28 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.890902948722186E-7" P_Z="1.8562719898251058E-63" STUDIES="19" TAU2="0.08180484061571767" TOTAL_1="14910" TOTAL_2="8357" WEIGHT="100.0" Z="16.816221325815455">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="0.720384210347249" CI_START="0.08191141135914312" EFFECT_SIZE="0.242914979757085" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.14243581477839473" LOG_CI_START="-1.0866555909736497" LOG_EFFECT_SIZE="-0.6145457028760222" ORDER="198" O_E="0.0" SE="0.5546393705003656" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.30762483130904184" WEIGHT="2.939659836117586"/>
<DICH_DATA CI_END="0.37618084357138" CI_START="0.12078979090942664" EFFECT_SIZE="0.2131637995512341" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" LOG_CI_END="-0.4246033239984754" LOG_CI_START="-0.917969770508473" LOG_EFFECT_SIZE="-0.6712865472534741" ORDER="200" O_E="0.0" SE="0.28980589288327013" STUDY_ID="STD-Blennow-1988" TOTAL_1="191" TOTAL_2="76" VAR="0.08398745554986943" WEIGHT="6.904969603691899"/>
<DICH_DATA CI_END="3.0674223345991773" CI_START="0.009055739558409236" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4867735754472843" LOG_CI_START="-2.0430760762145717" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="203" O_E="0.0" SE="1.4860462083439174" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="2.2083333333333335" WEIGHT="0.4998784695927837"/>
<DICH_DATA CI_END="0.21678168850271923" CI_START="0.06543113862533134" EFFECT_SIZE="0.11909774436090226" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="95" LOG_CI_END="-0.6639774053351789" LOG_CI_START="-1.1842155220920434" LOG_EFFECT_SIZE="-0.9240964637136111" ORDER="201" O_E="0.0" SE="0.3055904450031928" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.09338552007724941" WEIGHT="6.534553391073764"/>
<DICH_DATA CI_END="2.0949441135807563" CI_START="0.02724077499949407" EFFECT_SIZE="0.2388888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32117244186688376" LOG_CI_START="-1.5647805409143227" LOG_EFFECT_SIZE="-0.6218040495237195" ORDER="208" O_E="0.0" SE="1.1078181177035085" STUDY_ID="STD-Miller-1991" TOTAL_1="90" TOTAL_2="86" VAR="1.2272609819121447" WEIGHT="0.8745097044387147"/>
<DICH_DATA CI_END="1.372641503003855" CI_START="0.0032378770674778034" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.13755712602271344" LOG_CI_START="-2.4897396441340756" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2009-03-22 08:21:28 -0300" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="1.5432871281188576" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="2.3817351598173513" WEIGHT="0.4646933946063062"/>
<DICH_DATA CI_END="2.649824398548133" CI_START="0.007255324995963805" EFFECT_SIZE="0.13865546218487396" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.42321709459022844" LOG_CI_START="-2.139343128947477" LOG_EFFECT_SIZE="-0.8580630171786244" ORDER="213" O_E="0.0" SE="1.5052605601837339" STUDY_ID="STD-Tian-1993" TOTAL_1="101" TOTAL_2="98" VAR="2.2658093540446482" WEIGHT="0.4876400765310942"/>
<DICH_DATA CI_END="3.841478594914314" CI_START="0.016269776976694076" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.584498417600514" LOG_CI_START="-1.7886184002564387" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="209" O_E="0.0" SE="1.3939805659268776" STUDY_ID="STD-Pichichero-1993" TOTAL_1="88" TOTAL_2="22" VAR="1.9431818181818181" WEIGHT="0.5653324976617159"/>
<DICH_DATA CI_END="0.3285492027802894" CI_START="0.052695362655192445" EFFECT_SIZE="0.13157894736842105" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="38" LOG_CI_END="-0.48339958228123103" LOG_CI_START="-1.2782276022803518" LOG_EFFECT_SIZE="-0.8808135922807914" ORDER="210" O_E="0.0" SE="0.4668859134096368" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.21798245614035086" WEIGHT="3.818676701572046"/>
<DICH_DATA CI_END="0.4977903964723371" CI_START="0.17272605935855345" EFFECT_SIZE="0.2932258064516129" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="31" LOG_CI_END="-0.3029534861912712" LOG_CI_START="-0.7626421350333392" LOG_EFFECT_SIZE="-0.5327978106123052" ORDER="214" O_E="0.0" SE="0.2700233878253413" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.07291262997267468" WEIGHT="7.399233979175145"/>
<DICH_DATA CI_END="0.8705911523604767" CI_START="0.25763753673794254" EFFECT_SIZE="0.4736" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="25" LOG_CI_END="-0.06018575080203877" LOG_CI_START="-0.5889908617682345" LOG_EFFECT_SIZE="-0.32458830628513663" ORDER="207" O_E="0.0" SE="0.3106227398090592" STUDY_ID="STD-Heininger-1994" TOTAL_1="75" TOTAL_2="74" VAR="0.09648648648648647" WEIGHT="6.420899906664677"/>
<DICH_DATA CI_END="0.9622192426862916" CI_START="0.04033891560037774" EFFECT_SIZE="0.19701492537313434" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.01672596222361229" LOG_CI_START="-1.3942757807663408" LOG_EFFECT_SIZE="-0.7055008714949765" ORDER="205" O_E="0.0" SE="0.8091795823935756" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.6547715965626413" WEIGHT="1.5542049782844976"/>
<DICH_DATA CI_END="0.20223028621644493" CI_START="0.11648422731043513" EFFECT_SIZE="0.15348172082919428" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="101" LOG_CI_END="-0.694153803484301" LOG_CI_START="-0.9337328768335643" LOG_EFFECT_SIZE="-0.8139433401589327" ORDER="202" O_E="0.0" SE="0.14072993362089684" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.019804914216942027" WEIGHT="11.266543920266422"/>
<DICH_DATA CI_END="0.2620688047387514" CI_START="0.030149466189910466" EFFECT_SIZE="0.08888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.5815846720565516" LOG_CI_START="-1.520720372838211" LOG_EFFECT_SIZE="-1.0511525224473812" ORDER="206" O_E="0.0" SE="0.5516529594358404" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.304320987654321" WEIGHT="2.964812715789242"/>
<DICH_DATA CI_END="0.11786265265377023" CI_START="0.09676417732576081" EFFECT_SIZE="0.10679364504254911" ESTIMABLE="YES" EVENTS_1="393" EVENTS_2="1509" LOG_CI_END="-0.9286237887632631" LOG_CI_START="-1.0142853913398495" LOG_EFFECT_SIZE="-0.9714545900515563" ORDER="204" O_E="0.0" SE="0.05031804938525847" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5092" TOTAL_2="2088" VAR="0.0025319060939373098" WEIGHT="13.574044650913795"/>
<DICH_DATA CI_END="3.956390239850046" CI_START="0.009311323639848728" EFFECT_SIZE="0.19193548387096773" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5972991218166761" LOG_CI_START="-2.0309885780281225" LOG_EFFECT_SIZE="-0.7168447281057231" ORDER="212" O_E="0.0" SE="1.5438692051227751" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="2.3835321225264297" WEIGHT="0.4643546836253139"/>
<DICH_DATA CI_END="0.3513427199976276" CI_START="0.15047032715453848" EFFECT_SIZE="0.22992749731471537" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="56" LOG_CI_END="-0.45426904083919734" LOG_CI_START="-0.8225491347784487" LOG_EFFECT_SIZE="-0.638409087808823" ORDER="197" O_E="0.0" SE="0.21632955019578246" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="0.04679847428790956" WEIGHT="8.901720507030067"/>
<DICH_DATA CI_END="0.1472780491206509" CI_START="0.08176011345746069" EFFECT_SIZE="0.10973363206372914" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="130" LOG_CI_END="-0.831861977231823" LOG_CI_START="-1.0874585145440625" LOG_EFFECT_SIZE="-0.9596602458879429" ORDER="199" O_E="0.0" SE="0.15013867124047456" STUDY_ID="STD-Black-1997" TOTAL_1="1854" TOTAL_2="464" VAR="0.022541620601855304" WEIGHT="10.971055004564638"/>
<DICH_DATA CI_END="0.17234132795755117" CI_START="0.13590918779281233" EFFECT_SIZE="0.15304499307669453" ESTIMABLE="YES" EVENTS_1="275" EVENTS_2="1839" LOG_CI_END="-0.7636105649681716" LOG_CI_START="-0.8667511829081066" LOG_EFFECT_SIZE="-0.8151808739381391" ORDER="211" O_E="0.0" SE="0.06058530953221075" STUDY_ID="STD-PVSG-1998" TOTAL_1="3880" TOTAL_2="3971" VAR="0.0036705797311137873" WEIGHT="13.393215978400285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="77.14335074561791" CI_END="0.3710396496584083" CI_START="0.25604840622317737" DF="16" EFFECT_SIZE="0.3082273689026358" ESTIMABLE="YES" EVENTS_1="1809" EVENTS_2="3427" I2="79.25939196916609" ID="CMP-001.09.02" LOG_CI_END="-0.4305796787737137" LOG_CI_START="-0.5916779230931417" LOG_EFFECT_SIZE="-0.5111288009334277" MODIFIED="2009-03-22 08:22:51 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.421573190389495E-10" P_Z="1.6445168236689795E-35" STUDIES="17" TAU2="0.0627436441356929" TOTAL_1="14167" TOTAL_2="7834" WEIGHT="100.0" Z="12.4370572196217">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="0.44251414330867533" CI_START="0.1117949806834164" EFFECT_SIZE="0.2224204579244722" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="-0.35407284414637336" LOG_CI_START="-0.951577694753975" LOG_EFFECT_SIZE="-0.6528252694501742" ORDER="218" O_E="0.0" SE="0.3509773069436169" STUDY_ID="STD-Blennow-1988" TOTAL_1="177" TOTAL_2="68" VAR="0.12318506998939385" WEIGHT="4.816264761708935"/>
<DICH_DATA CI_END="1.0809908397092582" CI_START="0.3927520160876249" EFFECT_SIZE="0.6515837104072398" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.033822013767762164" LOG_CI_START="-0.4058815769474843" LOG_EFFECT_SIZE="-0.18602978158986103" ORDER="216" O_E="0.0" SE="0.258284065754013" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="0.06671065862242331" WEIGHT="6.917359214422612"/>
<DICH_DATA CI_END="2.6337566158684744" CI_START="0.18836435269848653" EFFECT_SIZE="0.7043478260869566" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42057563954413485" LOG_CI_START="-0.7250012824940587" LOG_EFFECT_SIZE="-0.1522128214749619" ORDER="221" O_E="0.0" SE="0.6729175547024547" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.4528180354267311" WEIGHT="1.7369054945870646"/>
<DICH_DATA CI_END="0.4183304214398892" CI_START="0.17213526391262854" EFFECT_SIZE="0.2683457051961824" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="82" LOG_CI_END="-0.3784805519073609" LOG_CI_START="-0.7641301502776828" LOG_EFFECT_SIZE="-0.5713053510925219" ORDER="219" O_E="0.0" SE="0.2265324830790269" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.051316965889949606" WEIGHT="7.850930429262058"/>
<DICH_DATA CI_END="1.4027277583728697" CI_START="0.17822417679250463" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.1469733912642771" LOG_CI_START="-0.7490333825922394" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="224" O_E="0.0" SE="0.5263188142683801" STUDY_ID="STD-Miller-1991" TOTAL_1="87" TOTAL_2="87" VAR="0.27701149425287364" WEIGHT="2.6356684943095026"/>
<DICH_DATA CI_END="2.082836003701086" CI_START="0.04307126348200283" EFFECT_SIZE="0.2995169082125604" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.3186550762408191" LOG_CI_START="-1.365812388158147" LOG_EFFECT_SIZE="-0.5235786559586639" MODIFIED="2009-03-22 08:22:30 -0300" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="0.989464526836379" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.9790400498675393" WEIGHT="0.8595660684508002"/>
<DICH_DATA CI_END="7.929557538663495" CI_START="0.013473388538445315" EFFECT_SIZE="0.3268608414239482" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8992489547983193" LOG_CI_START="-1.8705231660827037" LOG_EFFECT_SIZE="-0.4856371056421921" ORDER="228" O_E="0.0" SE="1.6269778543986329" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="100" VAR="2.647056938703579" WEIGHT="0.3304604477914175"/>
<DICH_DATA CI_END="19.501414123215696" CI_START="0.03459979331221553" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.290066104882606" LOG_CI_START="-1.4609264955318586" LOG_EFFECT_SIZE="-0.08543019532462635" ORDER="225" O_E="0.0" SE="1.615946671116451" STUDY_ID="STD-Pichichero-1993" TOTAL_1="83" TOTAL_2="22" VAR="2.6112836438923392" WEIGHT="0.33488136715720845"/>
<DICH_DATA CI_END="2.409000297497477" CI_START="0.07872402592480277" EFFECT_SIZE="0.43548387096774194" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.38183685363118053" LOG_CI_START="-1.1038927043097135" LOG_EFFECT_SIZE="-0.3610279253392666" MODIFIED="2009-03-22 08:22:51 -0300" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.8727248968144046" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.7616487455197132" WEIGHT="1.0862326305617873"/>
<DICH_DATA CI_END="0.6355988143759861" CI_START="0.222580399698562" EFFECT_SIZE="0.37612742275954714" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="-0.1968169215817869" LOG_CI_START="-0.6525130820387831" LOG_EFFECT_SIZE="-0.424665001810285" ORDER="229" O_E="0.0" SE="0.2676781803848138" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.07165160825412491" WEIGHT="6.663047229028115"/>
<DICH_DATA CI_END="0.608949815295305" CI_START="0.029574534990315607" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.21541849692111711" LOG_CI_START="-1.5290820751946264" LOG_EFFECT_SIZE="-0.8722502860578716" ORDER="223" O_E="0.0" SE="0.7716524886174466" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.5954475631894987" WEIGHT="1.3605194114786776"/>
<DICH_DATA CI_END="0.9602089335246896" CI_START="0.358000985492689" EFFECT_SIZE="0.5863068688670829" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="38" LOG_CI_END="-0.017634257789443795" LOG_CI_START="-0.4461157778437019" LOG_EFFECT_SIZE="-0.23187501781657283" ORDER="226" O_E="0.0" SE="0.2516921658976028" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.0633489463742264" WEIGHT="7.1017806074819685"/>
<DICH_DATA CI_END="0.40564259947270925" CI_START="0.2752316303487522" EFFECT_SIZE="0.33413421553588263" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="122" LOG_CI_END="-0.3918564428649364" LOG_CI_START="-0.5603016572949789" LOG_EFFECT_SIZE="-0.47607905007995766" ORDER="220" O_E="0.0" SE="0.09894555277346599" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.009790222413646745" WEIGHT="12.345707689819307"/>
<DICH_DATA CI_END="0.2641807604513559" CI_START="0.2326279027713492" EFFECT_SIZE="0.247902836321691" ESTIMABLE="YES" EVENTS_1="925" EVENTS_2="1505" LOG_CI_END="-0.578098814026797" LOG_CI_START="-0.6333381946254375" LOG_EFFECT_SIZE="-0.6057185043261172" ORDER="222" O_E="0.0" SE="0.032447885602985456" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5023" TOTAL_2="2026" VAR="0.001052865280104431" WEIGHT="14.036534635369408"/>
<DICH_DATA CI_END="0.3185711879886951" CI_START="0.1201480254916368" EFFECT_SIZE="0.1956417624521073" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="48" LOG_CI_END="-0.4967935049421281" LOG_CI_START="-0.9202833619814526" LOG_EFFECT_SIZE="-0.7085384334617902" ORDER="215" O_E="0.0" SE="0.24876003833350033" STUDY_ID="STD-Afari-1996" TOTAL_1="261" TOTAL_2="129" VAR="0.061881556671684546" WEIGHT="7.185399969100791"/>
<DICH_DATA CI_END="0.21881330033528848" CI_START="0.12751312255455283" EFFECT_SIZE="0.1670376220562895" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="112" LOG_CI_END="-0.659926283405025" LOG_CI_START="-0.894445119074952" LOG_EFFECT_SIZE="-0.7771857012399885" ORDER="217" O_E="0.0" SE="0.13775752495947424" STUDY_ID="STD-Black-1997" TOTAL_1="1741" TOTAL_2="423" VAR="0.018977135682960167" WEIGHT="10.957823897638734"/>
<DICH_DATA CI_END="0.3729741866130303" CI_START="0.30986654105620703" EFFECT_SIZE="0.3399591462352969" ESTIMABLE="YES" EVENTS_1="487" EVENTS_2="1434" LOG_CI_END="-0.42832122449011156" LOG_CI_START="-0.508825315723129" LOG_EFFECT_SIZE="-0.46857327010662025" ORDER="227" O_E="0.0" SE="0.04728850169195296" STUDY_ID="STD-PVSG-1998" TOTAL_1="3885" TOTAL_2="3889" VAR="0.0022362023922698373" WEIGHT="13.780917651831597"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="38.72402683150464" CI_END="0.38270965463555173" CI_START="0.29702005497692796" DF="16" EFFECT_SIZE="0.3371534408248753" ESTIMABLE="YES" EVENTS_1="2270" EVENTS_2="3439" I2="58.68198297243481" ID="CMP-001.09.03" LOG_CI_END="-0.41713058166874206" LOG_CI_START="-0.527214225862035" LOG_EFFECT_SIZE="-0.47217240376538855" MODIFIED="2009-03-22 08:23:54 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0011919047788566672" P_Z="1.9463421286582623E-63" STUDIES="17" TAU2="0.019358853609295727" TOTAL_1="14024" TOTAL_2="7707" WEIGHT="100.0" Z="16.813413339567663">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.3850752530477317" CI_START="0.38688314877779073" EFFECT_SIZE="0.7320261437908496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.14147336985933495" LOG_CI_START="-0.4124201861541693" LOG_EFFECT_SIZE="-0.1354734081474172" ORDER="231" O_E="0.0" SE="0.32535981661965413" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="0.10585901027077496" WEIGHT="3.339292862134903"/>
<DICH_DATA CI_END="1.000773802449808" CI_START="0.003767475607649673" EFFECT_SIZE="0.06140350877192982" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="3.3592817976613214E-4" LOG_CI_START="-2.4239495508241973" LOG_EFFECT_SIZE="-1.2118068113222158" ORDER="235" O_E="0.0" SE="1.4240372907735894" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="2.0278822055137846" WEIGHT="0.20424518021615226"/>
<DICH_DATA CI_END="0.3890726830342092" CI_START="0.022773595940701424" EFFECT_SIZE="0.09413067552602436" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="21" LOG_CI_END="-0.40996926013424284" LOG_CI_START="-1.6425683890641833" LOG_EFFECT_SIZE="-1.026268824599213" ORDER="239" O_E="0.0" SE="0.7240348297975385" STUDY_ID="STD-Miller-1991" TOTAL_1="86" TOTAL_2="85" VAR="0.5242264347599506" WEIGHT="0.7692244952414288"/>
<DICH_DATA CI_END="0.528631710714001" CI_START="0.26116396136582803" EFFECT_SIZE="0.37156365763306687" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="92" LOG_CI_END="-0.2768467886597766" LOG_CI_START="-0.5830867525875918" LOG_EFFECT_SIZE="-0.42996677062368416" ORDER="233" O_E="0.0" SE="0.17988687072346846" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.032359286258681855" WEIGHT="8.08496052127737"/>
<DICH_DATA CI_END="0.8333963257080956" CI_START="0.09367803990463044" EFFECT_SIZE="0.27941176470588236" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="-0.07914841859942305" LOG_CI_START="-1.0283622049073915" LOG_EFFECT_SIZE="-0.5537553117534073" MODIFIED="2009-03-22 08:23:44 -0300" MODIFIED_BY="[Empty name]" ORDER="599" O_E="0.0" SE="0.5575728767613224" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.3108875128998968" WEIGHT="1.2661429813334855"/>
<DICH_DATA CI_END="15.600449676933184" CI_START="0.06279921286277008" EFFECT_SIZE="0.9897959183673469" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1931371169054925" LOG_CI_START="-1.2020457997579925" LOG_EFFECT_SIZE="-0.00445434142625001" ORDER="243" O_E="0.0" SE="1.4069423015947853" STUDY_ID="STD-Tian-1993" TOTAL_1="98" TOTAL_2="97" VAR="1.9794866400168316" WEIGHT="0.20919031530943857"/>
<DICH_DATA CI_END="0.8027691056045823" CI_START="0.047097779064173326" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="-0.09540934959216121" LOG_CI_START="-1.3269995719138996" LOG_EFFECT_SIZE="-0.7112044607530305" ORDER="240" O_E="0.0" SE="0.7234421930617123" STUDY_ID="STD-Pichichero-1993" TOTAL_1="81" TOTAL_2="21" VAR="0.5233686067019399" WEIGHT="0.7704403216058232"/>
<DICH_DATA CI_END="0.9017443312725706" CI_START="0.18559071135456898" EFFECT_SIZE="0.4090909090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="-0.0449165791507473" LOG_CI_START="-0.7314437636150154" LOG_EFFECT_SIZE="-0.38818017138288136" ORDER="237" O_E="0.0" SE="0.4032694665186823" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.16262626262626262" WEIGHT="2.297655586983652"/>
<DICH_DATA CI_END="0.39517995006151535" CI_START="0.11323580739127435" EFFECT_SIZE="0.21153846153846154" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="52" LOG_CI_END="-0.4032050979875913" LOG_CI_START="-0.946016218965557" LOG_EFFECT_SIZE="-0.6746106584765741" ORDER="241" O_E="0.0" SE="0.31884993942084056" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.1016652838686737" WEIGHT="3.455005982939691"/>
<DICH_DATA CI_END="0.35968134948494596" CI_START="0.09712174491401997" EFFECT_SIZE="0.18690339824360444" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="27" LOG_CI_END="-0.4440820810187655" LOG_CI_START="-1.0126835235533858" LOG_EFFECT_SIZE="-0.7283828022860755" ORDER="244" O_E="0.0" SE="0.33399930196737004" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.11155553371469044" WEIGHT="3.1939890459227502"/>
<DICH_DATA CI_END="2.9171556508535597" CI_START="0.11557449916366819" EFFECT_SIZE="0.5806451612903226" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.4649596024173614" LOG_CI_START="-0.9371379798792947" LOG_EFFECT_SIZE="-0.23608918873096657" MODIFIED="2009-03-22 08:23:54 -0300" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="0.8235990603360229" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.6783154121863799" WEIGHT="0.5993328685982497"/>
<DICH_DATA CI_END="0.5000308773478896" CI_START="0.35275500634078893" EFFECT_SIZE="0.4199861846649781" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="129" LOG_CI_END="-0.3010031767684605" LOG_CI_START="-0.4525268139712031" LOG_EFFECT_SIZE="-0.3767649953698317" ORDER="234" O_E="0.0" SE="0.08900573454699189" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.007922020782249585" WEIGHT="15.327189043327971"/>
<DICH_DATA CI_END="0.3151919555832523" CI_START="0.06960607334537457" EFFECT_SIZE="0.1481191222570533" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.5014248752255857" LOG_CI_START="-1.157352865198213" LOG_EFFECT_SIZE="-0.8293888702118994" ORDER="238" O_E="0.0" SE="0.3852953482058369" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.14845250534905707" WEIGHT="2.4917211901625396"/>
<DICH_DATA CI_END="0.44457836652459254" CI_START="0.17558739082828573" EFFECT_SIZE="0.2793964126411692" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="41" LOG_CI_END="-0.3520516741776959" LOG_CI_START="-0.7555066745934418" LOG_EFFECT_SIZE="-0.5537791743855688" ORDER="230" O_E="0.0" SE="0.2369914643786705" STUDY_ID="STD-Afari-1996" TOTAL_1="257" TOTAL_2="128" VAR="0.05616495418834665" WEIGHT="5.536520618595625"/>
<DICH_DATA CI_END="0.3723013511529146" CI_START="0.3298839606478384" EFFECT_SIZE="0.35045148633279494" ESTIMABLE="YES" EVENTS_1="1134" EVENTS_2="1286" LOG_CI_END="-0.42910538764088735" LOG_CI_START="-0.4816387998577393" LOG_EFFECT_SIZE="-0.4553720937493133" ORDER="236" O_E="0.0" SE="0.030858386380763242" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="4972" TOTAL_2="1976" VAR="9.522400100244743E-4" WEIGHT="20.586735845122593"/>
<DICH_DATA CI_END="0.3376565275488871" CI_START="0.20716811259703452" EFFECT_SIZE="0.2644837717486113" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="106" LOG_CI_END="-0.4715248501165812" LOG_CI_START="-0.6836770905719818" LOG_EFFECT_SIZE="-0.5776009703442815" ORDER="232" O_E="0.0" SE="0.12461927621402949" STUDY_ID="STD-Black-1997" TOTAL_1="1644" TOTAL_2="419" VAR="0.015529964004108575" WEIGHT="11.98490369320658"/>
<DICH_DATA CI_END="0.42372977039022297" CI_START="0.36099867681462483" EFFECT_SIZE="0.39110853536817025" ESTIMABLE="YES" EVENTS_1="634" EVENTS_2="1624" LOG_CI_END="-0.3729110222817561" LOG_CI_START="-0.4424943899313507" LOG_EFFECT_SIZE="-0.4077027061065534" ORDER="242" O_E="0.0" SE="0.04087361460059688" STUDY_ID="STD-PVSG-1998" TOTAL_1="3825" TOTAL_2="3832" VAR="0.0016706523705181265" WEIGHT="19.883449448021757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.278478534140795" CI_END="0.43275835852015826" CI_START="0.25554727369091634" DF="23" EFFECT_SIZE="0.3325510768089356" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="305" I2="41.44376040429256" ID="CMP-001.09.04" LOG_CI_END="-0.3637545351819158" LOG_CI_START="-0.5925287479597983" LOG_EFFECT_SIZE="-0.47814164157085703" MODIFIED="2012-02-10 15:54:21 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.0184887038765027" P_Z="2.5540893373245967E-16" STUDIES="24" TAU2="0.15345170368883107" TOTAL_1="2184" TOTAL_2="1197" WEIGHT="99.99999999999999" Z="8.192710057733754">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.22994551796219462" CI_START="0.015047945457348035" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="17" LOG_CI_END="-0.6383750511617288" LOG_CI_START="-1.822522791594819" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="259" O_E="0.0" SE="0.6955742443562475" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.4838235294117647" WEIGHT="2.8337550215698983"/>
<DICH_DATA CI_END="0.7178453027446178" CI_START="0.04605149760439423" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.143969137098962" LOG_CI_START="-1.3367562418895258" LOG_EFFECT_SIZE="-0.7403626894942439" ORDER="249" O_E="0.0" SE="0.7006490497453707" STUDY_ID="STD-Edwards-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.4909090909090909" WEIGHT="2.8025943028514053"/>
<DICH_DATA CI_END="0.8889865388127346" CI_START="0.3152767835869751" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="-0.05110481514183409" LOG_CI_START="-0.501308008736064" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="248" O_E="0.0" SE="0.2644515844590004" STUDY_ID="STD-Edwards-1986a" TOTAL_1="20" TOTAL_2="20" VAR="0.06993464052287582" WEIGHT="8.084119458123533"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="251" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="1.44072714298153"/>
<DICH_DATA CI_END="140.03244580468458" CI_START="0.42340187418205144" EFFECT_SIZE="7.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1462286742592993" LOG_CI_START="-0.3732472239143358" LOG_EFFECT_SIZE="0.8864907251724818" ORDER="250" O_E="0.0" SE="1.479952614194029" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="2.1902597402597404" WEIGHT="0.7705222827595527"/>
<DICH_DATA CI_END="3.1948772303590096" CI_START="0.31300107262263394" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5044541741682707" LOG_CI_START="-0.5044541741682707" LOG_EFFECT_SIZE="0.0" ORDER="261" O_E="0.0" SE="0.5926377579897537" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.35121951219512193" WEIGHT="3.5783334477633364"/>
<DICH_DATA CI_END="1.071358257091711" CI_START="0.05530718456878765" EFFECT_SIZE="0.24342105263157895" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.02993472112224764" LOG_CI_START="-1.2572184488778029" LOG_EFFECT_SIZE="-0.6136418638777775" ORDER="247" O_E="0.0" SE="0.7560801435689796" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.5716571834992887" WEIGHT="2.490497529169614"/>
<DICH_DATA CI_END="0.6349903015849747" CI_START="0.09842670013068885" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="20" LOG_CI_END="-0.19723290777935332" LOG_CI_START="-1.0068870748765715" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="254" O_E="0.0" SE="0.4755948656056709" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.22619047619047616" WEIGHT="4.756799922745812"/>
<DICH_DATA CI_END="1.1595195524377848" CI_START="0.11897960960073743" EFFECT_SIZE="0.37142857142857144" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.0642780763411843" LOG_CI_START="-0.9245274604280619" LOG_EFFECT_SIZE="-0.43012469204343884" MODIFIED="2009-03-28 17:21:15 -0300" MODIFIED_BY="[Empty name]" ORDER="601" O_E="0.0" SE="0.5808292669646025" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.3373626373626374" WEIGHT="3.679358447538862"/>
<DICH_DATA CI_END="0.4882280243666001" CI_START="0.10479146826044916" EFFECT_SIZE="0.2261904761904762" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.3113772956307047" LOG_CI_START="-0.9796740745874006" LOG_EFFECT_SIZE="-0.6455256851090527" ORDER="245" O_E="0.0" SE="0.3925608360815717" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.15410401002506263" WEIGHT="5.8717227851630085"/>
<DICH_DATA CI_END="1.0649990920840682" CI_START="0.2458197450890843" EFFECT_SIZE="0.5116618075801749" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" LOG_CI_END="0.027349237537153435" LOG_CI_START="-0.6093832360190088" LOG_EFFECT_SIZE="-0.29101699924092767" ORDER="255" O_E="0.0" SE="0.37401980684346664" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.1398908159112241" WEIGHT="6.156222747329948"/>
<DICH_DATA CI_END="1.367804296008849" CI_START="0.18277468547911524" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.13602396343415643" LOG_CI_START="-0.7380839547621187" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="257" O_E="0.0" SE="0.5134553180524706" STUDY_ID="STD-Kanra-1993a" TOTAL_1="55" TOTAL_2="55" VAR="0.26363636363636367" WEIGHT="4.3297376103376575"/>
<DICH_DATA CI_END="0.836228291101425" CI_START="0.19939066028428346" EFFECT_SIZE="0.4083333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.07767514357657096" LOG_CI_START="-0.7002951884616513" LOG_EFFECT_SIZE="-0.38898516601911115" ORDER="263" O_E="0.0" SE="0.3657300963844246" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.13375850340136053" WEIGHT="6.287666132122685"/>
<DICH_DATA CI_END="0.5106235116523151" CI_START="0.09371202345375404" EFFECT_SIZE="0.21875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.29189919198814324" LOG_CI_START="-1.028204684623155" LOG_EFFECT_SIZE="-0.6600519383056491" ORDER="260" O_E="0.0" SE="0.43250949114477655" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.18706445993031356" WEIGHT="5.303366139002895"/>
<DICH_DATA CI_END="1.9761357476875958" CI_START="0.006018141935535829" EFFECT_SIZE="0.10905349794238683" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2958167744857758" LOG_CI_START="-2.2205375738087842" LOG_EFFECT_SIZE="-0.9623603996615043" ORDER="258" O_E="0.0" SE="1.4781190003431393" STUDY_ID="STD-Kanra-1993b" TOTAL_1="53" TOTAL_2="52" VAR="2.1848357791754016" WEIGHT="0.7723096091285003"/>
<DICH_DATA CI_END="0.4420012613850484" CI_START="0.06979804652952667" EFFECT_SIZE="0.1756440281030445" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.3545764912577307" LOG_CI_START="-1.1561567320089168" LOG_EFFECT_SIZE="-0.7553666116333239" ORDER="256" O_E="0.0" SE="0.47085220130343164" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.2217017954722873" WEIGHT="4.813714642030735"/>
<DICH_DATA CI_END="1.3175396356736149" CI_START="0.14361996776154323" EFFECT_SIZE="0.435" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.11976368900444483" LOG_CI_START="-0.8427851750951701" LOG_EFFECT_SIZE="-0.3615107430453627" ORDER="253" O_E="0.0" SE="0.5654059674658352" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.319683908045977" WEIGHT="3.8168378095647024"/>
<DICH_DATA CI_END="0.5761989813551257" CI_START="0.16270186563776023" EFFECT_SIZE="0.30618401206636503" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="-0.23942751383109867" LOG_CI_START="-0.7886074671520217" LOG_EFFECT_SIZE="-0.5140174904915602" ORDER="252" O_E="0.0" SE="0.3225910230653222" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.10406496816233125" WEIGHT="7.012679524550129"/>
<DICH_DATA CI_END="0.3959615325995817" CI_START="0.020871883073234888" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.4023470034462192" LOG_CI_START="-1.680438366870231" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="246" O_E="0.0" SE="0.7507571935295484" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.5636363636363637" WEIGHT="2.5183544033260072"/>
<DICH_DATA CI_END="1.4886943260908274" CI_START="0.31472496439966585" EFFECT_SIZE="0.6844919786096256" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="5" LOG_CI_END="0.17280553313153757" LOG_CI_START="-0.5020688069087988" LOG_EFFECT_SIZE="-0.16463163688863064" ORDER="262" O_E="0.0" SE="0.3964245280215546" STUDY_ID="STD-Pichichero-1997" TOTAL_1="187" TOTAL_2="16" VAR="0.1571524064171123" WEIGHT="5.814095284524651"/>
<DICH_DATA CI_END="0.3430720397099396" CI_START="0.00640145012289749" EFFECT_SIZE="0.04686318972033258" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="21" LOG_CI_END="-0.4646146753990817" LOG_CI_START="-2.1937216339794126" LOG_EFFECT_SIZE="-1.329168154689247" MODIFIED="2009-03-22 08:25:23 -0300" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="1.0156859866875725" STUDY_ID="STD-Halperin-1999" TOTAL_1="126" TOTAL_2="124" VAR="1.0316180235535075" WEIGHT="1.52386129727846"/>
<DICH_DATA CI_END="27.720842530598954" CI_START="0.08555295523150744" EFFECT_SIZE="1.54" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.4428064258253872" LOG_CI_START="-1.0677649841524612" LOG_EFFECT_SIZE="0.18752072083646307" MODIFIED="2009-03-22 08:25:41 -0300" MODIFIED_BY="[Empty name]" ORDER="604" O_E="0.0" SE="1.4747220737498963" STUDY_ID="STD-Pichichero-2000" TOTAL_1="49" TOTAL_2="10" VAR="2.1748051948051947" WEIGHT="0.7756368694060478"/>
<DICH_DATA CI_END="0.6561809128368519" CI_START="0.13575416199735824" EFFECT_SIZE="0.29846153846153844" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.18297640663846867" LOG_CI_START="-0.8672468467867904" LOG_EFFECT_SIZE="-0.5251116267126296" MODIFIED="2009-03-28 16:55:27 -0300" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="0.40194384373643094" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.16155885351761642" WEIGHT="5.732766253727254"/>
<DICH_DATA CI_END="0.7019721093729661" CI_START="0.2897313317642052" EFFECT_SIZE="0.45098039215686275" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="51" LOG_CI_END="-0.15368014283607104" LOG_CI_START="-0.5380045373246158" LOG_EFFECT_SIZE="-0.3458423400803435" MODIFIED="2009-03-22 08:26:03 -0300" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.2257540517590061" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.050964891885608" WEIGHT="8.834321337003786"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="28.698045652804876" CI_END="0.5466699333588186" CI_START="0.2229025988075249" DF="7" EFFECT_SIZE="0.349076136158886" ESTIMABLE="YES" EVENTS_1="1320" EVENTS_2="2058" I2="75.60809511320909" ID="CMP-001.09.05" LOG_CI_END="-0.2622748114851289" LOG_CI_START="-0.6518848680779132" LOG_EFFECT_SIZE="-0.45707983978152106" MODIFIED="2012-02-10 15:54:49 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="1.6422529969783994E-4" P_Z="4.250292654601321E-6" STUDIES="8" TAU2="0.2449641153090271" TOTAL_1="5838" TOTAL_2="4041" WEIGHT="100.00000000000001" Z="4.598752054120932">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="1.1034973243585111" CI_START="0.30045661407632523" EFFECT_SIZE="0.5758064516129032" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.04277128446845505" LOG_CI_START="-0.5222182312405764" LOG_EFFECT_SIZE="-0.23972347338606068" ORDER="266" O_E="0.0" SE="0.3318776382706931" STUDY_ID="STD-Pichichero-1996" TOTAL_1="124" TOTAL_2="34" VAR="0.11014276678413301" WEIGHT="14.74947056604873"/>
<DICH_DATA CI_END="0.8083953405394343" CI_START="0.10957150921548152" EFFECT_SIZE="0.2976190476190476" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="-0.0923761983529782" LOG_CI_START="-0.9603023564267098" LOG_EFFECT_SIZE="-0.5263392773898441" ORDER="264" O_E="0.0" SE="0.5098241215562823" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.25992063492063494" WEIGHT="10.373928907244483"/>
<DICH_DATA CI_END="0.21060694576772515" CI_START="0.054343623032337085" EFFECT_SIZE="0.10698198198198199" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" LOG_CI_END="-0.6765273099840878" LOG_CI_START="-1.2648514109954188" LOG_EFFECT_SIZE="-0.9706893604897532" ORDER="265" O_E="0.0" SE="0.3455844891853239" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.11942863916548127" WEIGHT="14.373607710141252"/>
<DICH_DATA CI_END="0.5472254440517292" CI_START="0.4849608402553778" EFFECT_SIZE="0.5151532889892569" ESTIMABLE="YES" EVENTS_1="1012" EVENTS_2="1958" LOG_CI_END="-0.2618337176578938" LOG_CI_START="-0.3142933285062331" LOG_EFFECT_SIZE="-0.2880635230820634" ORDER="268" O_E="0.0" SE="0.03081503509157623" STUDY_ID="STD-PVSG-1998" TOTAL_1="3647" TOTAL_2="3635" VAR="9.495663876950744E-4" WEIGHT="21.298686877023055"/>
<DICH_DATA CI_END="1.5092868762686158" CI_START="0.3469484281175733" EFFECT_SIZE="0.7236329935125115" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="5" LOG_CI_END="0.17877179573261537" LOG_CI_START="-0.45973507578116596" LOG_EFFECT_SIZE="-0.1404816400242753" ORDER="267" O_E="0.0" SE="0.3750620969871836" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1079" TOTAL_2="16" VAR="0.14067157659642354" WEIGHT="13.581830248530403"/>
<DICH_DATA CI_END="0.9337492367826381" CI_START="0.05523671276898894" EFFECT_SIZE="0.2271062271062271" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="21" LOG_CI_END="-0.029769740155098198" LOG_CI_START="-1.257772174929906" LOG_EFFECT_SIZE="-0.6437709575425021" MODIFIED="2009-03-22 08:26:43 -0300" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.7213347088968104" STUDY_ID="STD-Halperin-1999" TOTAL_1="52" TOTAL_2="124" VAR="0.5203237622592461" WEIGHT="6.844010807902989"/>
<DICH_DATA CI_END="4.023853368810617" CI_START="0.01046679322207679" EFFECT_SIZE="0.20522388059701493" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.60464214643239" LOG_CI_START="-1.9801863555014803" LOG_EFFECT_SIZE="-0.687772104534545" MODIFIED="2009-03-28 17:13:01 -0300" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="1.5183410571433966" STUDY_ID="STD-Pichichero-2000" TOTAL_1="267" TOTAL_2="10" VAR="2.305359565807327" WEIGHT="2.0537151985906856"/>
<DICH_DATA CI_END="0.4900954589174075" CI_START="0.17607055439064903" EFFECT_SIZE="0.2937539432176656" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="-0.30971932151562687" LOG_CI_START="-0.7543132683082496" LOG_EFFECT_SIZE="-0.5320162949119382" MODIFIED="2009-03-28 17:12:29 -0300" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.26115668512151685" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.06820281418365909" WEIGHT="16.724749684518407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="400.5503285588511" CI_END="0.5068132036783047" CI_START="0.45659921673470527" CI_STUDY="95" CI_TOTAL="95" DF="62" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48105146484583183" ESTIMABLE="YES" EVENTS_1="12460" EVENTS_2="13235" I2="84.52129593225621" I2_Q="47.739591050132354" ID="CMP-001.10" LOG_CI_END="-0.2951520792465045" LOG_CI_START="-0.34046483784816445" LOG_EFFECT_SIZE="-0.31780845854733447" METHOD="MH" MODIFIED="2012-02-10 15:55:49 -0200" MODIFIED_BY="Liz Dooley" NO="10" P_CHI2="1.7763568394002505E-15" P_Q="0.10510822817864784" P_Z="0.0" Q="7.653977610158234" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="33" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03316278800136643" TOTALS="SUB" TOTAL_1="44852" TOTAL_2="27247" WEIGHT="500.0" Z="27.493057229676058">
<NAME>Irritability/fretfulness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="128.68006281152222" CI_END="0.5602658110138827" CI_START="0.4190627081287502" DF="14" EFFECT_SIZE="0.48454773555907604" ESTIMABLE="YES" EVENTS_1="3645" EVENTS_2="4488" I2="89.12030372528974" ID="CMP-001.10.01" LOG_CI_END="-0.25160587858729383" LOG_CI_START="-0.3777209847745972" LOG_EFFECT_SIZE="-0.3146634316809455" MODIFIED="2009-03-22 10:23:43 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-1.3322676295501878E-15" P_Z="1.366500414078812E-22" STUDIES="15" TAU2="0.048074653716680626" TOTAL_1="12875" TOTAL_2="7832" WEIGHT="100.00000000000001" Z="9.780414289632853">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="0.4203403062269893" CI_START="0.2137756726127531" EFFECT_SIZE="0.29976412675623015" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="49" LOG_CI_END="-0.3763989637117199" LOG_CI_START="-0.6700417184498477" LOG_EFFECT_SIZE="-0.5232203410807839" ORDER="271" O_E="0.0" SE="0.1724872076882549" STUDY_ID="STD-Blennow-1988" TOTAL_1="199" TOTAL_2="79" VAR="0.029751836816091178" WEIGHT="7.051507574984033"/>
<DICH_DATA CI_END="1.4946841757120204" CI_START="0.13616007507002006" EFFECT_SIZE="0.45112781954887216" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.17454943665013467" LOG_CI_START="-0.8659502178170191" LOG_EFFECT_SIZE="-0.3457003905834422" ORDER="269" O_E="0.0" SE="0.6111946475903628" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.37355889724310776" WEIGHT="1.3015901753477928"/>
<DICH_DATA CI_END="0.5475721646420293" CI_START="0.06274307520025191" EFFECT_SIZE="0.1853546910755149" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.26155863696175774" LOG_CI_START="-1.2024341992217864" LOG_EFFECT_SIZE="-0.7319964180917721" ORDER="273" O_E="0.0" SE="0.5526749626806877" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.3054496143740995" WEIGHT="1.552351951649726"/>
<DICH_DATA CI_END="0.6658872143452857" CI_START="0.36543639772201597" EFFECT_SIZE="0.4932944606413994" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="98" LOG_CI_END="-0.17659932388594837" LOG_CI_START="-0.43718819879358317" LOG_EFFECT_SIZE="-0.30689376133976576" ORDER="272" O_E="0.0" SE="0.15307119505647926" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.02343079075601872" WEIGHT="7.6748573702774765"/>
<DICH_DATA CI_END="0.4863871272005604" CI_START="0.288713618171862" EFFECT_SIZE="0.37473535638673255" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="52" LOG_CI_END="-0.31301792769038583" LOG_CI_START="-0.5395327306415969" LOG_EFFECT_SIZE="-0.4262753291659913" MODIFIED="2009-03-22 10:23:33 -0300" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.1330559165198995" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.01770387692095047" WEIGHT="8.343057867156205"/>
<DICH_DATA CI_END="0.8476160534735562" CI_START="0.48391660494473" EFFECT_SIZE="0.6404494382022472" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="89" LOG_CI_END="-0.07180082653774407" LOG_CI_START="-0.3152294754070987" LOG_EFFECT_SIZE="-0.1935151509724214" ORDER="278" O_E="0.0" SE="0.14299119333710467" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.02044648137196925" WEIGHT="8.009121372788934"/>
<DICH_DATA CI_END="0.8847149435228003" CI_START="0.05358963450925407" EFFECT_SIZE="0.21774193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="-0.05319663709535036" LOG_CI_START="-1.2709192049111453" LOG_EFFECT_SIZE="-0.6620579210032478" MODIFIED="2009-03-22 10:23:43 -0300" MODIFIED_BY="[Empty name]" ORDER="612" O_E="0.0" SE="0.715296264158924" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.5116487455197132" WEIGHT="0.9804737273356078"/>
<DICH_DATA CI_END="0.9624302052588208" CI_START="0.4259864002799974" EFFECT_SIZE="0.6402985074626866" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="-0.016630755398699498" LOG_CI_START="-0.37060426563350485" LOG_EFFECT_SIZE="-0.19361751051610218" ORDER="275" O_E="0.0" SE="0.20792579210905943" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.0432331350241798" WEIGHT="6.01037540273579"/>
<DICH_DATA CI_END="0.849808911949352" CI_START="0.4607820186079134" EFFECT_SIZE="0.6257608695652174" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="46" LOG_CI_END="-0.07067871877470866" LOG_CI_START="-0.336504477006134" LOG_EFFECT_SIZE="-0.2035915978904213" ORDER="281" O_E="0.0" SE="0.15614736624386436" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.024381999984895514" WEIGHT="7.574102025005961"/>
<DICH_DATA CI_END="1.0156410671409233" CI_START="0.3062186885056366" EFFECT_SIZE="0.5576811594202898" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="23" LOG_CI_END="0.006740253123410227" LOG_CI_START="-0.5139683078663702" LOG_EFFECT_SIZE="-0.25361402737148" ORDER="277" O_E="0.0" SE="0.3058667862743441" STUDY_ID="STD-Heininger-1994" TOTAL_1="75" TOTAL_2="74" VAR="0.0935544909457953" WEIGHT="3.874866919758108"/>
<DICH_DATA CI_END="0.4129968722131397" CI_START="0.37808490567540937" EFFECT_SIZE="0.3951555180874285" ESTIMABLE="YES" EVENTS_1="1672" EVENTS_2="1726" LOG_CI_END="-0.3840532374131335" LOG_CI_START="-0.42241066067695565" LOG_EFFECT_SIZE="-0.40323194904504456" ORDER="274" O_E="0.0" SE="0.022531340297476443" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="5.076612956006858E-4" WEIGHT="11.296169962002256"/>
<DICH_DATA CI_END="1.2403019932204824" CI_START="0.45809510282596416" EFFECT_SIZE="0.7537746806039489" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.09352744163078953" LOG_CI_START="-0.3390443509373606" LOG_EFFECT_SIZE="-0.12275845465328551" ORDER="280" O_E="0.0" SE="0.25409481221943847" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="0.06456417359683171" WEIGHT="4.87215732456786"/>
<DICH_DATA CI_END="0.7093386419550881" CI_START="0.4716828225045816" EFFECT_SIZE="0.5784313725490197" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="68" LOG_CI_END="-0.14914638086661308" LOG_CI_START="-0.32634993937293355" LOG_EFFECT_SIZE="-0.23774816011977332" ORDER="276" O_E="0.0" SE="0.10409024743837407" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.01083477961178194" WEIGHT="9.315894866384824"/>
<DICH_DATA CI_END="0.41920579916682826" CI_START="0.3624665860783449" EFFECT_SIZE="0.38980520120727546" ESTIMABLE="YES" EVENTS_1="743" EVENTS_2="1929" LOG_CI_END="-0.37757271808365067" LOG_CI_START="-0.4407320226120006" LOG_EFFECT_SIZE="-0.4091523703478257" ORDER="279" O_E="0.0" SE="0.03710008812355245" STUDY_ID="STD-PVSG-1998" TOTAL_1="4075" TOTAL_2="4124" VAR="0.0013764165387753573" WEIGHT="11.097719112878341"/>
<DICH_DATA CI_END="0.6447287404235388" CI_START="0.5509198235653546" EFFECT_SIZE="0.5959814123960993" ESTIMABLE="YES" EVENTS_1="785" EVENTS_2="330" LOG_CI_END="-0.19062296957617178" LOG_CI_START="-0.2589116002711674" LOG_EFFECT_SIZE="-0.22476728492366957" ORDER="270" O_E="0.0" SE="0.04011307970441405" STUDY_ID="STD-Black-1997" TOTAL_1="1852" TOTAL_2="464" VAR="0.0016090591633726747" WEIGHT="11.0457543471271"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="98.0878677035771" CI_END="0.5582698175085367" CI_START="0.40855507698407245" DF="11" EFFECT_SIZE="0.4775813734538694" ESTIMABLE="YES" EVENTS_1="3763" EVENTS_2="3695" I2="88.78556516974947" ID="CMP-001.10.02" LOG_CI_END="-0.2531558513611528" LOG_CI_START="-0.3887493882921607" LOG_EFFECT_SIZE="-0.32095261982665674" MODIFIED="2009-03-22 10:25:03 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.440892098500626E-16" P_Z="1.718036559749388E-20" STUDIES="12" TAU2="0.043830302184320914" TOTAL_1="12144" TOTAL_2="7285" WEIGHT="100.00000000000001" Z="9.278548075991209">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="0.9558824253892665" CI_START="0.10296630692701392" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.019595523147400627" LOG_CI_START="-0.9873048637366226" LOG_EFFECT_SIZE="-0.5034501934420116" ORDER="282" O_E="0.0" SE="0.5684372569006009" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="0.3231209150326797" WEIGHT="1.728800383150395"/>
<DICH_DATA CI_END="0.4925293645509463" CI_START="0.24706628142827697" EFFECT_SIZE="0.3488372093023256" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" LOG_CI_END="-0.30756787180135464" LOG_CI_START="-0.6071865212464559" LOG_EFFECT_SIZE="-0.4573771965239053" ORDER="284" O_E="0.0" SE="0.17599747782028696" STUDY_ID="STD-Blennow-1988" TOTAL_1="190" TOTAL_2="75" VAR="0.0309751121991024" WEIGHT="8.480474443609696"/>
<DICH_DATA CI_END="0.8464585126109868" CI_START="0.1589886869819627" EFFECT_SIZE="0.36684782608695654" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.07239432306675388" LOG_CI_START="-0.7986337772902692" LOG_EFFECT_SIZE="-0.4355140501785115" ORDER="286" O_E="0.0" SE="0.42659665035416977" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.18198470209339776" WEIGHT="2.8093146730943324"/>
<DICH_DATA CI_END="0.636115771447984" CI_START="0.3354625671448228" EFFECT_SIZE="0.46194483403459563" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="93" LOG_CI_END="-0.19646383667009565" LOG_CI_START="-0.4743559338837525" LOG_EFFECT_SIZE="-0.3354098852769241" ORDER="285" O_E="0.0" SE="0.1632351934913685" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.026645728394164517" WEIGHT="9.001434951926996"/>
<DICH_DATA CI_END="0.41128847072844976" CI_START="0.23667570884282324" EFFECT_SIZE="0.31199677938808373" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="48" LOG_CI_END="-0.3858534644981035" LOG_CI_START="-0.6258463134983611" LOG_EFFECT_SIZE="-0.5058498889982322" MODIFIED="2009-03-22 10:25:03 -0300" MODIFIED_BY="[Empty name]" ORDER="613" O_E="0.0" SE="0.14097298748651346" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.01987338320087268" WEIGHT="9.95837840599568"/>
<DICH_DATA CI_END="0.722438011832454" CI_START="0.3728712912052773" EFFECT_SIZE="0.5190148305084745" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="80" LOG_CI_END="-0.14119941123445554" LOG_CI_START="-0.42844105335389854" LOG_EFFECT_SIZE="-0.284820232294177" ORDER="289" O_E="0.0" SE="0.16872716245002095" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.028468855348435764" WEIGHT="8.774450859055069"/>
<DICH_DATA CI_END="0.7642512692559071" CI_START="0.3688844699718322" EFFECT_SIZE="0.530961791831357" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="23" LOG_CI_END="-0.11676383133215965" LOG_CI_START="-0.43310962817658216" LOG_EFFECT_SIZE="-0.2749367297543709" ORDER="288" O_E="0.0" SE="0.18582308700336322" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.0345302196634595" WEIGHT="8.09572715907358"/>
<DICH_DATA CI_END="0.8847149435228003" CI_START="0.05358963450925407" EFFECT_SIZE="0.21774193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="-0.05319663709535036" LOG_CI_START="-1.2709192049111453" LOG_EFFECT_SIZE="-0.6620579210032478" MODIFIED="2009-03-22 10:24:09 -0300" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="0.715296264158924" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.5116487455197132" WEIGHT="1.1420510054238133"/>
<DICH_DATA CI_END="0.7749844962037565" CI_START="0.36863562941105027" EFFECT_SIZE="0.5344968639214617" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="-0.11070698559756921" LOG_CI_START="-0.4334026916106842" LOG_EFFECT_SIZE="-0.27205483860412666" ORDER="291" O_E="0.0" SE="0.18955305508161055" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.03593036069077209" WEIGHT="7.953612495870505"/>
<DICH_DATA CI_END="0.48042451804711245" CI_START="0.44493981865903587" EFFECT_SIZE="0.4623418626289825" ESTIMABLE="YES" EVENTS_1="2019" EVENTS_2="1743" LOG_CI_END="-0.3183748368626863" LOG_CI_START="-0.35169872652869794" LOG_EFFECT_SIZE="-0.33503678169569207" ORDER="287" O_E="0.0" SE="0.019574617745729463" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="3.8316565989142675E-4" WEIGHT="14.348239028830154"/>
<DICH_DATA CI_END="0.591765401512633" CI_START="0.5061533390875322" EFFECT_SIZE="0.5472878894440233" ESTIMABLE="YES" EVENTS_1="746" EVENTS_2="1345" LOG_CI_END="-0.2278504301375257" LOG_CI_START="-0.29571789377050456" LOG_EFFECT_SIZE="-0.2617841619540151" ORDER="290" O_E="0.0" SE="0.03986568408737485" STUDY_ID="STD-PVSG-1998" TOTAL_1="4070" TOTAL_2="4016" VAR="0.0015892727677543723" WEIGHT="13.967224607267458"/>
<DICH_DATA CI_END="0.7919591507366555" CI_START="0.6551817448953654" EFFECT_SIZE="0.7203312975745908" ESTIMABLE="YES" EVENTS_1="751" EVENTS_2="253" LOG_CI_END="-0.10129721874785867" LOG_CI_START="-0.18363821167751765" LOG_EFFECT_SIZE="-0.14246771521268814" ORDER="283" O_E="0.0" SE="0.04836750684137027" STUDY_ID="STD-Black-1997" TOTAL_1="1739" TOTAL_2="422" VAR="0.0023394157180499997" WEIGHT="13.740291986702337"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="48.59312603613908" CI_END="0.5949085507388262" CI_START="0.47074055153649474" DF="12" EFFECT_SIZE="0.5291952185050162" ESTIMABLE="YES" EVENTS_1="3482" EVENTS_2="3228" I2="75.30514914583699" ID="CMP-001.10.03" LOG_CI_END="-0.22554978882927834" LOG_CI_START="-0.3272183881604603" LOG_EFFECT_SIZE="-0.27638408849486934" MODIFIED="2009-03-22 10:25:53 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="2.463628310023225E-6" P_Z="1.630445218355541E-26" STUDIES="13" TAU2="0.020786157409741775" TOTAL_1="12268" TOTAL_2="7243" WEIGHT="100.00000000000001" Z="10.656247118843387">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="12.011610864032981" CI_START="0.05646209319620034" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0796012540680135" LOG_CI_START="-1.2482430254680852" LOG_EFFECT_SIZE="-0.08432088570003593" ORDER="292" O_E="0.0" SE="1.3673872528145288" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="1.8697478991596639" WEIGHT="0.18865328832476455"/>
<DICH_DATA CI_END="0.7067461754342595" CI_START="0.29309204676762984" EFFECT_SIZE="0.4551282051282051" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="-0.15073653302208762" LOG_CI_START="-0.5329959662486851" LOG_EFFECT_SIZE="-0.3418662496353863" ORDER="294" O_E="0.0" SE="0.224541083292015" STUDY_ID="STD-Blennow-1988" TOTAL_1="192" TOTAL_2="71" VAR="0.05041869808595161" WEIGHT="5.0088644093006565"/>
<DICH_DATA CI_END="0.5721285466529767" CI_START="0.037635549784612574" EFFECT_SIZE="0.14673913043478262" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.24250638234346364" LOG_CI_START="-1.4244017353576346" LOG_EFFECT_SIZE="-0.8334540588505491" ORDER="296" O_E="0.0" SE="0.6942511808368768" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.4819847020933978" WEIGHT="0.7093797496820671"/>
<DICH_DATA CI_END="0.7529609278604805" CI_START="0.42697384235364944" EFFECT_SIZE="0.567004956337031" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="95" LOG_CI_END="-0.12322755933030737" LOG_CI_START="-0.3695987302898225" LOG_EFFECT_SIZE="-0.24641314481006493" ORDER="295" O_E="0.0" SE="0.14471964537858417" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.02094377575850316" WEIGHT="8.546753837918379"/>
<DICH_DATA CI_END="0.5063564874172926" CI_START="0.2777193607556365" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="38" LOG_CI_END="-0.2955436214869235" LOG_CI_START="-0.5563938430576388" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-03-22 10:25:43 -0300" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="0.15322471138005966" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.023477812177502583" WEIGHT="8.057466824316476"/>
<DICH_DATA CI_END="0.7092087796519495" CI_START="0.291326864776449" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="-0.14922589668816244" LOG_CI_START="-0.53561946495625" LOG_EFFECT_SIZE="-0.3424226808222062" ORDER="298" O_E="0.0" SE="0.2269694946796849" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.05151515151515152" WEIGHT="4.932904697925581"/>
<DICH_DATA CI_END="0.7401847457058195" CI_START="0.3042866763189682" EFFECT_SIZE="0.47458229648062566" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="-0.1306598694220101" LOG_CI_START="-0.5167170635072037" LOG_EFFECT_SIZE="-0.3236884664646069" ORDER="302" O_E="0.0" SE="0.22677190681957388" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.05142549772258549" WEIGHT="4.939029105595304"/>
<DICH_DATA CI_END="1.0250359141573995" CI_START="0.537731164465884" EFFECT_SIZE="0.7424242424242424" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="66" LOG_CI_END="0.010739082023125441" LOG_CI_START="-0.2694347930498354" LOG_EFFECT_SIZE="-0.129347855513355" ORDER="300" O_E="0.0" SE="0.1645755211009062" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.027085102145634827" WEIGHT="7.450304624828229"/>
<DICH_DATA CI_END="0.8925020191183114" CI_START="0.09443922705713562" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="-0.04939079270490192" LOG_CI_START="-1.0248475760849936" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2009-03-22 10:25:53 -0300" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.572988143146418" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.32831541218637994" WEIGHT="1.021638106280623"/>
<DICH_DATA CI_END="0.6493428036202946" CI_START="0.43772583867413856" EFFECT_SIZE="0.5331361208000354" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="71" LOG_CI_END="-0.18752596819855888" LOG_CI_START="-0.35879781650685433" LOG_EFFECT_SIZE="-0.2731618923527066" ORDER="299" O_E="0.0" SE="0.10060593150561516" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.010121553454112527" WEIGHT="11.53936854245888"/>
<DICH_DATA CI_END="0.5207015518310563" CI_START="0.4758026895891117" EFFECT_SIZE="0.49774611885422154" ESTIMABLE="YES" EVENTS_1="1848" EVENTS_2="1461" LOG_CI_END="-0.2834111280076948" LOG_CI_START="-0.322573107337827" LOG_EFFECT_SIZE="-0.3029921176727609" ORDER="297" O_E="0.0" SE="0.023003940513443774" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="5.291812791460599E-4" WEIGHT="16.73233870066101"/>
<DICH_DATA CI_END="0.7644025742934144" CI_START="0.6238706517728796" EFFECT_SIZE="0.6905710189700256" ESTIMABLE="YES" EVENTS_1="653" EVENTS_2="241" LOG_CI_END="-0.11667785903258975" LOG_CI_START="-0.20490544404247168" LOG_EFFECT_SIZE="-0.16079165153753072" ORDER="293" O_E="0.0" SE="0.05182532016839403" STUDY_ID="STD-Black-1997" TOTAL_1="1644" TOTAL_2="419" VAR="0.002685863810556549" WEIGHT="15.194919223800952"/>
<DICH_DATA CI_END="0.5787178112470286" CI_START="0.4864724983652753" EFFECT_SIZE="0.530594288968347" ESTIMABLE="YES" EVENTS_1="624" EVENTS_2="1159" LOG_CI_END="-0.2375331511127556" LOG_CI_START="-0.31294170656892045" LOG_EFFECT_SIZE="-0.27523742884083807" ORDER="301" O_E="0.0" SE="0.044295358753320836" STUDY_ID="STD-PVSG-1998" TOTAL_1="4003" TOTAL_2="3945" VAR="0.0019620788070853967" WEIGHT="15.67837888890709"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="53.84864624671927" CI_END="0.4650351723689562" CI_START="0.28398712888980115" DF="16" EFFECT_SIZE="0.363406113643997" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="445" I2="70.28708962024314" ID="CMP-001.10.04" LOG_CI_END="-0.3325141985335315" LOG_CI_START="-0.5467013429769323" LOG_EFFECT_SIZE="-0.4396077707552319" MODIFIED="2012-02-10 15:55:25 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="5.4891553702418605E-6" P_Z="8.593289840738556E-16" STUDIES="17" TAU2="0.16317983272267633" TOTAL_1="1728" TOTAL_2="868" WEIGHT="99.99999999999997" Z="8.045444559646556">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.42566381766765693" CI_START="0.07491300359228004" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.3709332642111952" LOG_CI_START="-1.1254427898012056" LOG_EFFECT_SIZE="-0.7481880270062004" ORDER="311" O_E="0.0" SE="0.44320263021395917" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.19642857142857145" WEIGHT="4.401818921556897"/>
<DICH_DATA CI_END="0.6510623893834799" CI_START="0.04266530862592416" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.186377392281733" LOG_CI_START="-1.3699251084855542" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="307" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="0.48333333333333334" WEIGHT="2.4484127483441034"/>
<DICH_DATA CI_END="0.8835582862764495" CI_START="0.055303952989796394" EFFECT_SIZE="0.22105263157894736" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.053764795819604055" LOG_CI_START="-1.2572438252902531" LOG_EFFECT_SIZE="-0.6555043105549285" ORDER="306" O_E="0.0" SE="0.7069295392283335" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="0.4997493734335839" WEIGHT="2.3877829835283"/>
<DICH_DATA CI_END="1.0677121582833153" CI_START="0.41278054793608737" EFFECT_SIZE="0.6638755980861244" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.028454188162572967" LOG_CI_START="-0.3842807767952533" LOG_EFFECT_SIZE="-0.17791329431634015" ORDER="305" O_E="0.0" SE="0.2424425614872539" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.058778395620500884" WEIGHT="7.13166206794739"/>
<DICH_DATA CI_END="1.316513450990973" CI_START="0.3139089128268106" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.11942530070856092" LOG_CI_START="-0.5031963531863872" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="313" O_E="0.0" SE="0.36573104152478564" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.1337591947348045" WEIGHT="5.33082865966652"/>
<DICH_DATA CI_END="0.5196540135538447" CI_START="0.24104591415175602" EFFECT_SIZE="0.353921568627451" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="-0.28428571408626324" LOG_CI_START="-0.617900225626256" LOG_EFFECT_SIZE="-0.45109296985625963" ORDER="303" O_E="0.0" SE="0.19596681549705755" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.03840299277605779" WEIGHT="7.852509626390679"/>
<DICH_DATA CI_END="0.8695882411978875" CI_START="0.3462249153481575" EFFECT_SIZE="0.5487012987012987" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="-0.06068634152686622" LOG_CI_START="-0.4606416822466753" LOG_EFFECT_SIZE="-0.26066401188677074" MODIFIED="2009-03-28 17:22:37 -0300" MODIFIED_BY="[Empty name]" ORDER="617" O_E="0.0" SE="0.23493574694968236" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.055194805194805185" WEIGHT="7.2486946874389036"/>
<DICH_DATA CI_END="0.2742535691637351" CI_START="0.03835645664286488" EFFECT_SIZE="0.10256410256410256" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="39" LOG_CI_END="-0.5618477117640853" LOG_CI_START="-1.4161615196329882" LOG_EFFECT_SIZE="-0.9890046156985368" ORDER="308" O_E="0.0" SE="0.5018281596637457" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.2518315018315018" WEIGHT="3.814187579826682"/>
<DICH_DATA CI_END="0.8230286036026829" CI_START="0.35769604786167" EFFECT_SIZE="0.5425809421512966" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="19" LOG_CI_END="-0.08458507101987969" LOG_CI_START="-0.44648585828924825" LOG_EFFECT_SIZE="-0.26553546465456396" ORDER="309" O_E="0.0" SE="0.21258231387981605" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.04519124017449663" WEIGHT="7.596693032938347"/>
<DICH_DATA CI_END="0.43249941210283727" CI_START="0.1929639388818704" EFFECT_SIZE="0.28888888888888886" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="45" LOG_CI_END="-0.3640144785359698" LOG_CI_START="-0.7145238444010441" LOG_EFFECT_SIZE="-0.5392691614685069" ORDER="312" O_E="0.0" SE="0.20589093655848822" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.04239107775693142" WEIGHT="7.700170583721117"/>
<DICH_DATA CI_END="0.8736096745334591" CI_START="0.2464602523439462" EFFECT_SIZE="0.4640151515151515" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="-0.05868256514617006" LOG_CI_START="-0.6082531111923896" LOG_EFFECT_SIZE="-0.33346783816927983" ORDER="315" O_E="0.0" SE="0.3228204591656266" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.104213048855906" WEIGHT="5.919869924729635"/>
<DICH_DATA CI_END="0.6535939453548018" CI_START="0.2760175262448993" EFFECT_SIZE="0.4247391952309985" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="-0.1846919795955595" LOG_CI_START="-0.5590633407254043" LOG_EFFECT_SIZE="-0.37187766016048185" ORDER="310" O_E="0.0" SE="0.21990759069579593" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.04835934844562972" WEIGHT="7.482921456921124"/>
<DICH_DATA CI_END="0.6680748610354884" CI_START="0.3547734681854364" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="38" LOG_CI_END="-0.1751748699900154" LOG_CI_START="-0.4500488664375773" LOG_EFFECT_SIZE="-0.31261186821379633" ORDER="304" O_E="0.0" SE="0.1614623461615245" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.026070089227983963" WEIGHT="8.364236357024925"/>
<DICH_DATA CI_END="0.07519070650810199" CI_START="0.007241853347225184" EFFECT_SIZE="0.02333495381623724" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-1.123835834430542" LOG_CI_START="-2.140150274207732" LOG_EFFECT_SIZE="-1.6319930543191368" MODIFIED="2009-03-22 10:01:52 -0300" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.5969881327627347" STUDY_ID="STD-Pichichero-1997" TOTAL_1="187" TOTAL_2="16" VAR="0.3563948306595365" WEIGHT="3.0465902002219005"/>
<DICH_DATA CI_END="1.3049788323641391" CI_START="0.19947312435944783" EFFECT_SIZE="0.5102040816326531" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.11560346718234028" LOG_CI_START="-0.7001156098952923" LOG_EFFECT_SIZE="-0.292256071356476" MODIFIED="2009-03-22 10:26:35 -0300" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="0.4791574237499549" STUDY_ID="STD-Pichichero-2000" TOTAL_1="49" TOTAL_2="10" VAR="0.22959183673469383" WEIGHT="4.030155942588031"/>
<DICH_DATA CI_END="0.5394269612128832" CI_START="0.1973869301355696" EFFECT_SIZE="0.32630634671451" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="49" LOG_CI_END="-0.26806735077641997" LOG_CI_START="-0.7046816072789424" LOG_EFFECT_SIZE="-0.48637447902768116" MODIFIED="2009-03-22 10:27:28 -0300" MODIFIED_BY="[Empty name]" ORDER="619" O_E="0.0" SE="0.2564693755450079" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.06577654059244632" WEIGHT="6.9136799068929395"/>
<DICH_DATA CI_END="0.6631952658623793" CI_START="0.3488764007905829" EFFECT_SIZE="0.4810126582278481" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="79" LOG_CI_END="-0.1783585826043201" LOG_CI_START="-0.4573284067429424" LOG_EFFECT_SIZE="-0.31784349467363127" MODIFIED="2009-03-22 10:26:46 -0300" MODIFIED_BY="[Empty name]" ORDER="618" O_E="0.0" SE="0.16386825562192744" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.026852805200573353" WEIGHT="8.329785320262491"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.343182698337969" CI_END="0.5107948776198533" CI_START="0.4417287935272588" DF="5" EFFECT_SIZE="0.47500821575097163" ESTIMABLE="YES" EVENTS_1="1256" EVENTS_2="1379" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="-0.29175346660162627" LOG_CI_START="-0.3548442908877778" LOG_EFFECT_SIZE="-0.32329887874470203" MODIFIED="2012-02-10 15:55:49 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.6472372740830455" P_Z="0.0" STUDIES="6" TAU2="0.0" TOTAL_1="5837" TOTAL_2="4019" WEIGHT="100.0" Z="20.087046436668135">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.7928727857174857" CI_START="0.42219244245628473" EFFECT_SIZE="0.5785714285714286" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="-0.10079648846160287" LOG_CI_START="-0.3744895451375736" LOG_EFFECT_SIZE="-0.23764301679958824" ORDER="316" O_E="0.0" SE="0.1607686562939457" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.025846560846560854" WEIGHT="5.313795579820337"/>
<DICH_DATA CI_END="0.5350363739052812" CI_START="0.36577783448204626" EFFECT_SIZE="0.44238495252008764" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="74" LOG_CI_END="-0.27161669190519083" LOG_CI_START="-0.43678261557310816" LOG_EFFECT_SIZE="-0.35419965373914947" ORDER="317" O_E="0.0" SE="0.09701928114704264" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.009412740914288903" WEIGHT="14.591216525626448"/>
<DICH_DATA CI_END="0.5139418745127411" CI_START="0.4309298045879022" EFFECT_SIZE="0.4706090432124267" ESTIMABLE="YES" EVENTS_1="580" EVENTS_2="1216" LOG_CI_END="-0.28908599580202415" LOG_CI_START="-0.3655934675722813" LOG_EFFECT_SIZE="-0.3273397316871527" ORDER="319" O_E="0.0" SE="0.04494086763594222" STUDY_ID="STD-PVSG-1998" TOTAL_1="3822" TOTAL_2="3771" VAR="0.0020196815838712787" WEIGHT="68.0024722098797"/>
<DICH_DATA CI_END="0.7720304495656274" CI_START="0.3918299260194247" EFFECT_SIZE="0.550004212654815" ESTIMABLE="YES" EVENTS_1="408" EVENTS_2="11" LOG_CI_END="-0.11236557036693197" LOG_CI_START="-0.4069023978237301" LOG_EFFECT_SIZE="-0.259633984095331" ORDER="318" O_E="0.0" SE="0.17301239042893315" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1079" TOTAL_2="16" VAR="0.0299332872419336" WEIGHT="4.588314663536449"/>
<DICH_DATA CI_END="1.3581452629244033" CI_START="0.2811895278431235" EFFECT_SIZE="0.6179775280898876" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="4" LOG_CI_END="0.13294622319380997" LOG_CI_START="-0.5510008574951479" LOG_EFFECT_SIZE="-0.20902731715066897" MODIFIED="2009-03-22 10:28:48 -0300" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="0.4017539007893454" STUDY_ID="STD-Pichichero-2000" TOTAL_1="267" TOTAL_2="10" VAR="0.1614061967994552" WEIGHT="0.8509173966267201"/>
<DICH_DATA CI_END="0.6041390708452271" CI_START="0.3439866443710146" EFFECT_SIZE="0.4558681516770746" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="49" LOG_CI_END="-0.21886307669597851" LOG_CI_START="-0.4634584190231502" LOG_EFFECT_SIZE="-0.3411607478595644" MODIFIED="2009-03-22 10:28:59 -0300" MODIFIED_BY="[Empty name]" ORDER="621" O_E="0.0" SE="0.14367651484945215" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.02064294091928484" WEIGHT="6.653283624510349"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="54.27126110742887" CI_END="0.2826259257151968" CI_START="0.21443158217995623" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24617864329828537" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="772" I2="50.24991229418082" I2_Q="80.96455744467882" ID="CMP-001.11" LOG_CI_END="-0.5487880021526665" LOG_CI_START="-0.6687112499663673" LOG_EFFECT_SIZE="-0.608749626059517" METHOD="MH" MODIFIED="2014-05-25 20:29:37 -0300" MODIFIED_BY="Liz Dooley" NO="11" P_CHI2="0.0014093416174522089" P_Q="3.147351712151636E-4" P_Z="0.0" Q="21.013433170125246" RANDOM="YES" SCALE="215.43473885233445" SORT_BY="YEAR" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.144993907490137" TOTALS="SUB" TOTAL_1="35098" TOTAL_2="23917" WEIGHT="500.0" Z="19.898182619810097">
<NAME>Prolonged crying</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.634779536669844" CI_END="0.1922924934115129" CI_START="0.11342843704135655" DF="7" EFFECT_SIZE="0.14768695603354165" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="395" I2="8.314313905476874" ID="CMP-001.11.01" LOG_CI_END="-0.7160376691343193" LOG_CI_START="-0.9452780521282476" LOG_EFFECT_SIZE="-0.8306578606312833" MODIFIED="2009-03-22 10:36:55 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3658969541449141" P_Z="8.659056514696881E-46" STUDIES="8" TAU2="0.015596189076657066" TOTAL_1="10364" TOTAL_2="6820" WEIGHT="100.0" Z="14.203950185823318">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="3.0864026250576906" CI_START="0.03988941804148011" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4894525796775908" LOG_CI_START="-1.399142299694611" LOG_EFFECT_SIZE="-0.4548448600085102" ORDER="321" O_E="0.0" SE="1.1093699808386581" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="1.2307017543859649" WEIGHT="1.4549081489696098"/>
<DICH_DATA CI_END="0.7574564013684633" CI_START="0.06413538567529288" EFFECT_SIZE="0.22040816326530613" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="14" LOG_CI_END="-0.12064235977617432" LOG_CI_START="-1.1929022893069536" LOG_EFFECT_SIZE="-0.656772324541564" ORDER="322" O_E="0.0" SE="0.6298507903786337" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.3967120181405896" WEIGHT="4.397800000698089"/>
<DICH_DATA CI_END="0.3654960460644595" CI_START="0.039464257380295256" EFFECT_SIZE="0.12010008340283569" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.4371173168775987" LOG_CI_START="-1.4037960651295995" LOG_EFFECT_SIZE="-0.9204566910035991" MODIFIED="2009-03-22 10:36:55 -0300" MODIFIED_BY="[Empty name]" ORDER="623" O_E="0.0" SE="0.5678318818602028" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.3224330460568993" WEIGHT="5.364178140601995"/>
<DICH_DATA CI_END="4.731902942858078" CI_START="0.20573353318255275" EFFECT_SIZE="0.9866666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6750358281339461" LOG_CI_START="-0.6866949154553937" LOG_EFFECT_SIZE="-0.005829543660723844" ORDER="325" O_E="0.0" SE="0.7998873794602712" STUDY_ID="STD-Heininger-1994" TOTAL_1="75" TOTAL_2="74" VAR="0.6398198198198198" WEIGHT="2.7665620146215226"/>
<DICH_DATA CI_END="0.6773248026500118" CI_START="0.026247049728908175" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.16920302086962702" LOG_CI_START="-1.580919505913773" LOG_EFFECT_SIZE="-0.8750612633917001" ORDER="324" O_E="0.0" SE="0.8292492514242351" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.6876543209876542" WEIGHT="2.578382820969466"/>
<DICH_DATA CI_END="0.17981931055590983" CI_START="0.11127621657472307" EFFECT_SIZE="0.14145533763607795" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="248" LOG_CI_END="-0.7451636717932673" LOG_CI_START="-0.9535976489097326" LOG_EFFECT_SIZE="-0.8493806603514998" ORDER="323" O_E="0.0" SE="0.12243514992303857" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.014990365936676932" WEIGHT="59.28255186624846"/>
<DICH_DATA CI_END="0.30231766550614153" CI_START="0.06677260411367074" EFFECT_SIZE="0.14207933627171376" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="29" LOG_CI_END="-0.5195364746955512" LOG_CI_START="-1.1754016860677943" LOG_EFFECT_SIZE="-0.8474690803816727" ORDER="320" O_E="0.0" SE="0.3852584717452121" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="0.14842409005145638" WEIGHT="11.055029558701927"/>
<DICH_DATA CI_END="0.21765437619062383" CI_START="0.05510160245172129" EFFECT_SIZE="0.10951303533704629" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="82" LOG_CI_END="-0.6622325964306208" LOG_CI_START="-1.2588357709155389" LOG_EFFECT_SIZE="-0.9605341836730799" ORDER="326" O_E="0.0" SE="0.3504476579257836" STUDY_ID="STD-PVSG-1998" TOTAL_1="4064" TOTAL_2="4055" VAR="0.12281356094566702" WEIGHT="13.100587449188922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2094589883204794" CI_END="0.3544066285519807" CI_START="0.23979801800967002" DF="5" EFFECT_SIZE="0.2915235961226026" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="248" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-0.4504981639954069" LOG_CI_START="-0.6201544107743708" LOG_EFFECT_SIZE="-0.5353262873848887" MODIFIED="2009-03-22 10:37:06 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8194685953283208" P_Z="3.856428237676786E-35" STUDIES="6" TAU2="0.0" TOTAL_1="9867" TOTAL_2="6480" WEIGHT="100.0" Z="12.368778199118054">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="7.209822556158871" CI_START="0.01374629775627757" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" ORDER="328" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="0.38912157116046053"/>
<DICH_DATA CI_END="1.4629175551966493" CI_START="0.1055409738131062" EFFECT_SIZE="0.39293478260869563" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16521985153059598" LOG_CI_START="-0.9765789029606072" LOG_EFFECT_SIZE="-0.40567952571500565" ORDER="329" O_E="0.0" SE="0.6706982403831218" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.44983612965301584" WEIGHT="2.207804327789889"/>
<DICH_DATA CI_END="2.082836003701086" CI_START="0.04307126348200283" EFFECT_SIZE="0.2995169082125604" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.3186550762408191" LOG_CI_START="-1.365812388158147" LOG_EFFECT_SIZE="-0.5235786559586639" MODIFIED="2009-03-22 10:37:06 -0300" MODIFIED_BY="[Empty name]" ORDER="624" O_E="0.0" SE="0.989464526836379" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.9790400498675393" WEIGHT="1.0144121826053507"/>
<DICH_DATA CI_END="0.38522580367162745" CI_START="0.054856134584459953" EFFECT_SIZE="0.145368492224476" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="17" LOG_CI_END="-0.41428463012260164" LOG_CI_START="-1.2607747980399726" LOG_EFFECT_SIZE="-0.8375297140812871" ORDER="327" O_E="0.0" SE="0.4972325148285735" STUDY_ID="STD-Afari-1996" TOTAL_1="261" TOTAL_2="129" VAR="0.24724017380274754" WEIGHT="4.016944894386518"/>
<DICH_DATA CI_END="0.36847964168112285" CI_START="0.24149300825249567" EFFECT_SIZE="0.2983039677063918" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="190" LOG_CI_END="-0.4335865016985229" LOG_CI_START="-0.6170954384996984" LOG_EFFECT_SIZE="-0.5253409700991106" ORDER="330" O_E="0.0" SE="0.10779405786089785" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="0.011619558910118594" WEIGHT="85.47227666097746"/>
<DICH_DATA CI_END="0.6234062908595633" CI_START="0.14088822359426073" EFFECT_SIZE="0.296362286562732" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.20522881952499566" LOG_CI_START="-0.8511253066903084" LOG_EFFECT_SIZE="-0.5281770631076521" ORDER="331" O_E="0.0" SE="0.3794027938000807" STUDY_ID="STD-PVSG-1998" TOTAL_1="4041" TOTAL_2="3992" VAR="0.14394647994330656" WEIGHT="6.899440363080328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.681003499522219" CI_END="0.45659849964207133" CI_START="0.24394361746235277" DF="6" EFFECT_SIZE="0.33374284970703066" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="94" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-0.34046551991157387" LOG_CI_START="-0.6127105402782671" LOG_EFFECT_SIZE="-0.4765880300949205" MODIFIED="2009-03-22 10:37:19 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7197528141298282" P_Z="6.782378650314815E-12" STUDIES="7" TAU2="0.0" TOTAL_1="10096" TOTAL_2="6449" WEIGHT="100.0" Z="6.862166831854483">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8014758782288322" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="333" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="1.0050834475592914"/>
<DICH_DATA CI_END="7.290367272206463" CI_START="0.14718543171635193" EFFECT_SIZE="1.0358744394618835" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8627494076423674" LOG_CI_START="-0.8321351739544001" LOG_EFFECT_SIZE="0.015307116843983679" ORDER="334" O_E="0.0" SE="0.9955835930439293" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.9911866907382603" WEIGHT="2.5801183755206694"/>
<DICH_DATA CI_END="29.055549322364616" CI_START="0.06887461482116557" EFFECT_SIZE="1.4146341463414633" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.4632290905962186" LOG_CI_START="-1.161940816909815" LOG_EFFECT_SIZE="0.15064413684320177" MODIFIED="2009-03-22 10:37:19 -0300" MODIFIED_BY="[Empty name]" ORDER="625" O_E="0.0" SE="1.5420377984696638" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="2.3778805719091674" WEIGHT="1.075486727364118"/>
<DICH_DATA CI_END="1.0239993852914637" CI_START="0.0030140835994817722" EFFECT_SIZE="0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.01029969593218948" LOG_CI_START="-2.520844706138802" LOG_EFFECT_SIZE="-1.255272505103306" ORDER="332" O_E="0.0" SE="1.4868067511433616" STUDY_ID="STD-Afari-1996" TOTAL_1="257" TOTAL_2="128" VAR="2.210594315245478" WEIGHT="1.1568739576991631"/>
<DICH_DATA CI_END="1.606097161324528" CI_START="0.06745675062738168" EFFECT_SIZE="0.329153605015674" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.20577181451098248" LOG_CI_START="-1.1709745824854687" LOG_EFFECT_SIZE="-0.48260138398724306" ORDER="336" O_E="0.0" SE="0.8087076486002915" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.6540080609046126" WEIGHT="3.910317237998543"/>
<DICH_DATA CI_END="0.4597119496893157" CI_START="0.22698765774518948" EFFECT_SIZE="0.32303086338220405" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="67" LOG_CI_END="-0.33751420711181845" LOG_CI_START="-0.6439977565464508" LOG_EFFECT_SIZE="-0.49075598182913455" ORDER="335" O_E="0.0" SE="0.18002995405594044" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="0.03241078435738403" WEIGHT="78.90518680899092"/>
<DICH_DATA CI_END="0.8767514704352773" CI_START="0.13657914677870647" EFFECT_SIZE="0.34604330331481126" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.05712349707304503" LOG_CI_START="-0.8646156046829018" LOG_EFFECT_SIZE="-0.46086955087797343" ORDER="337" O_E="0.0" SE="0.4743248611604277" STUDY_ID="STD-PVSG-1998" TOTAL_1="3991" TOTAL_2="3913" VAR="0.224984073914859" WEIGHT="11.3669334448673"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9004257847450716" CI_END="0.48049067309757126" CI_START="0.09612018106968791" DF="4" EFFECT_SIZE="0.21490660878724685" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="20" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="-0.3183150380923589" LOG_CI_START="-1.0171854197502408" LOG_EFFECT_SIZE="-0.6677502289212999" MODIFIED="2012-02-10 15:56:18 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.7540668477305681" P_Z="1.8012334281575787E-4" STUDIES="6" TAU2="0.0" TOTAL_1="666" TOTAL_2="330" WEIGHT="100.0" Z="3.7453766355055085">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="1.5167593390499818" CI_START="0.09271411513976904" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.18091667767930442" LOG_CI_START="-1.0328541422238666" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="341" O_E="0.0" SE="0.7129749878735812" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.5083333333333332" WEIGHT="33.15277496489327"/>
<DICH_DATA CI_END="0.7168363859275102" CI_START="0.012028475603167525" EFFECT_SIZE="0.09285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.1445799584150197" LOG_CI_START="-1.9197894083277829" LOG_EFFECT_SIZE="-1.0321846833714012" MODIFIED="2009-03-28 17:34:38 -0300" MODIFIED_BY="[Empty name]" ORDER="626" O_E="0.0" SE="1.0427668183072558" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="1.0873626373626373" WEIGHT="15.498657051551497"/>
<DICH_DATA CI_END="8.067501905562539" CI_START="0.013772678632340947" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.906739076657312" LOG_CI_START="-1.8609815860966372" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="340" O_E="0.0" SE="1.6257728177399082" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.6431372549019607" WEIGHT="6.3760066095315855"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="338" O_E="0.0" SE="0.0" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.374940681461145" CI_START="0.0037558501306465594" EFFECT_SIZE="0.07186147186147186" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1382839619700595" LOG_CI_START="-2.425291745674238" LOG_EFFECT_SIZE="-1.1435038918520892" ORDER="342" O_E="0.0" SE="1.5058570605746733" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="2.2676054868825952" WEIGHT="7.43191913436511"/>
<DICH_DATA CI_END="0.7967269860088914" CI_START="0.057633754288857905" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="-0.09869047255921573" LOG_CI_START="-1.2393230893579354" LOG_EFFECT_SIZE="-0.6690067809585756" ORDER="339" O_E="0.0" SE="0.6700132453300822" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.4489177489177489" WEIGHT="37.54064223965854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.504478112077572" CI_END="3.1207818974862507" CI_START="0.023624695952174375" DF="1" EFFECT_SIZE="0.2715281264642072" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="77.799869926801" ID="CMP-001.11.05" LOG_CI_END="0.4942634181276802" LOG_CI_START="-1.6266337721157413" LOG_EFFECT_SIZE="-0.5661851769940305" MODIFIED="2012-02-10 15:56:44 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.0338062585797273" P_Z="0.2953550205089128" STUDIES="2" TAU2="2.4716481430611585" TOTAL_1="4105" TOTAL_2="3838" WEIGHT="99.99999999999999" Z="1.0464463441166352">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.542610870210633" CI_START="0.007593382725941531" EFFECT_SIZE="0.06418918918918919" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.2655115101962293" LOG_CI_START="-2.11956471001599" LOG_EFFECT_SIZE="-1.1925381101061097" ORDER="343" O_E="0.0" SE="1.0890800272854828" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="1.186095305832148" WEIGHT="42.43275173523227"/>
<DICH_DATA CI_END="1.9896818254504496" CI_START="0.31060901040248046" EFFECT_SIZE="0.7861380939879233" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29878363294286336" LOG_CI_START="-0.5077859500520249" LOG_EFFECT_SIZE="-0.10450115855458075" ORDER="344" O_E="0.0" SE="0.47378296563502476" STUDY_ID="STD-PVSG-1998" TOTAL_1="3809" TOTAL_2="3743" VAR="0.22447029852591907" WEIGHT="57.56724826476771"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.71717261061178" CI_END="0.8253752398277328" CI_START="0.6452281598002141" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7297638982155177" ESTIMABLE="YES" EVENTS_1="1174" EVENTS_2="620" I2="9.143442568427583" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.08334856352678317" LOG_CI_START="-0.19028668688293604" LOG_EFFECT_SIZE="-0.13681762520485957" METHOD="MH" MODIFIED="2012-02-10 15:57:39 -0200" MODIFIED_BY="Liz Dooley" NO="12" P_CHI2="0.327010571128591" P_Q="0.6641129851045118" P_Z="5.298049374786595E-7" Q="2.3917818640705173" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008437369532576016" TOTALS="SUB" TOTAL_1="24406" TOTAL_2="9672" WEIGHT="500.0" Z="5.015192139827197">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4848092013758944" CI_END="0.8835501409377453" CI_START="0.6634532945185904" DF="7" EFFECT_SIZE="0.765633235875711" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="269" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="-0.05376879950788714" LOG_CI_START="-0.17818964498764456" LOG_EFFECT_SIZE="-0.1159792222477658" MODIFIED="2009-05-03 12:47:57 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9282366249997301" P_Z="2.582151549080773E-4" STUDIES="8" TAU2="0.0" TOTAL_1="8126" TOTAL_2="3324" WEIGHT="99.99999999999999" Z="3.6539712888797347">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.6355058247525753" CI_START="0.31003814652780776" EFFECT_SIZE="0.7120879120879121" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.21365209517662093" LOG_CI_START="-0.5085848680776215" LOG_EFFECT_SIZE="-0.14746638645050025" ORDER="346" O_E="0.0" SE="0.42424556734616903" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.17998430141287286" WEIGHT="2.9677469933841607"/>
<DICH_DATA CI_END="1.0849177523572635" CI_START="0.19009057590038075" EFFECT_SIZE="0.4541284403669725" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.035396815556611554" LOG_CI_START="-0.7210394135707213" LOG_EFFECT_SIZE="-0.34282129900705494" MODIFIED="2009-03-22 10:42:58 -0300" MODIFIED_BY="[Empty name]" ORDER="632" O_E="0.0" SE="0.44433438540911874" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.19743304605689926" WEIGHT="2.7054633458902475"/>
<DICH_DATA CI_END="2.435699103087868" CI_START="0.32270050746585355" EFFECT_SIZE="0.8865671641791045" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.3866236362022379" LOG_CI_START="-0.49120035164150355" LOG_EFFECT_SIZE="-0.05228835771963286" ORDER="349" O_E="0.0" SE="0.5156381557582337" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.26588270767375244" WEIGHT="2.0089605452259063"/>
<DICH_DATA CI_END="2.704116384288955" CI_START="0.09245164204192984" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.432025379564989" LOG_CI_START="-1.0340853708929514" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="350" O_E="0.0" SE="0.8612007121842542" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.7416666666666667" WEIGHT="0.7201993744373959"/>
<DICH_DATA CI_END="1.348974944325258" CI_START="0.5929089501333661" EFFECT_SIZE="0.8943261809854974" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="26" LOG_CI_END="0.13000388322095074" LOG_CI_START="-0.22701199380380435" LOG_EFFECT_SIZE="-0.04850405529142682" ORDER="347" O_E="0.0" SE="0.20971289342143437" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.043979497667189886" WEIGHT="12.145383592520963"/>
<DICH_DATA CI_END="1.4952298559939174" CI_START="0.29501503232189663" EFFECT_SIZE="0.6641651031894934" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.17470796023002994" LOG_CI_START="-0.5301558542315988" LOG_EFFECT_SIZE="-0.17772394700078445" ORDER="351" O_E="0.0" SE="0.4140404937469143" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="0.1714295304621886" WEIGHT="3.1158451401826386"/>
<DICH_DATA CI_END="8.17122239663613" CI_START="0.03246316283436624" EFFECT_SIZE="0.5150375939849624" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9122870308778926" LOG_CI_START="-1.488609169827213" LOG_EFFECT_SIZE="-0.2881610694746602" ORDER="345" O_E="0.0" SE="1.4102983129220452" STUDY_ID="STD-Afari-1996" TOTAL_1="266" TOTAL_2="137" VAR="1.9889413314307667" WEIGHT="0.26855888654601834"/>
<DICH_DATA CI_END="0.9058977491648079" CI_START="0.6522623945794372" EFFECT_SIZE="0.7686891667731243" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="199" LOG_CI_END="-0.04292081940879403" LOG_CI_START="-0.18557765949288432" LOG_EFFECT_SIZE="-0.11424923945083916" MODIFIED="2009-05-03 12:47:57 -0300" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.08379733402814189" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.007021993190223987" WEIGHT="76.06784212181266"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.72168589153374" CI_END="0.8620399634279184" CI_START="0.4486497184715946" DF="6" EFFECT_SIZE="0.6218954790824576" ESTIMABLE="YES" EVENTS_1="302" EVENTS_2="189" I2="22.296761558527546" ID="CMP-001.12.02" LOG_CI_END="-0.06447260019162766" LOG_CI_START="-0.3480926004333869" LOG_EFFECT_SIZE="-0.20628260031250722" MODIFIED="2009-05-03 12:48:43 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2592107345040505" P_Z="0.004357601898919364" STUDIES="7" TAU2="0.04257601044912096" TOTAL_1="7885" TOTAL_2="3100" WEIGHT="100.0" Z="2.8510434165795933">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.6904262142822568" CI_START="0.26302250153685897" EFFECT_SIZE="0.666798418972332" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2279962189175748" LOG_CI_START="-0.5800070960909602" LOG_EFFECT_SIZE="-0.17600543858669268" ORDER="353" O_E="0.0" SE="0.47462514691692875" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.22526903008591623" WEIGHT="10.362518068982384"/>
<DICH_DATA CI_END="0.865083683401468" CI_START="0.06636888802431642" EFFECT_SIZE="0.2396135265700483" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="-0.06294187926165286" LOG_CI_START="-1.1780354586717878" LOG_EFFECT_SIZE="-0.6204886689667203" MODIFIED="2009-03-22 10:43:18 -0300" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.6550114883477536" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.42904004986753935" WEIGHT="5.885187774072064"/>
<DICH_DATA CI_END="2.7854650007848676" CI_START="0.007513322061307584" EFFECT_SIZE="0.14466546112115733" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4448977059433719" LOG_CI_START="-2.124167994568881" LOG_EFFECT_SIZE="-0.8396351443127547" ORDER="357" O_E="0.0" SE="1.5090819095612134" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="2.277328209764918" WEIGHT="1.1964067516440675"/>
<DICH_DATA CI_END="3.0691919472086093" CI_START="0.19966822894645933" EFFECT_SIZE="0.7828282828282829" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.48702405005018184" LOG_CI_START="-0.6996910342326611" LOG_EFFECT_SIZE="-0.1063334920912396" ORDER="356" O_E="0.0" SE="0.6970823148421492" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.4859237536656892" WEIGHT="5.251750825055596"/>
<DICH_DATA CI_END="1.684699226669316" CI_START="0.5893192982862423" EFFECT_SIZE="0.9964064261555806" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="16" LOG_CI_END="0.22652237650857457" LOG_CI_START="-0.2296493369432078" LOG_EFFECT_SIZE="-0.0015634802173165724" ORDER="354" O_E="0.0" SE="0.2679575225679765" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.07180123390076765" WEIGHT="24.26661953614679"/>
<DICH_DATA CI_END="0.6674785104630557" CI_START="0.4442135798013074" EFFECT_SIZE="0.5445209073793571" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="151" LOG_CI_END="-0.17556271189229644" LOG_CI_START="-0.35240816901441196" LOG_EFFECT_SIZE="-0.2639854404533542" MODIFIED="2009-05-03 12:48:43 -0300" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.10387989691266168" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="0.010791032982585217" WEIGHT="52.0086722769927"/>
<DICH_DATA CI_END="36.28831463967205" CI_START="0.06106042642663937" EFFECT_SIZE="1.4885496183206106" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5597667984654444" LOG_CI_START="-1.214240167051937" LOG_EFFECT_SIZE="0.17276331570675374" ORDER="352" O_E="0.0" SE="1.629465423100849" STUDY_ID="STD-Afari-1996" TOTAL_1="261" TOTAL_2="129" VAR="2.655157565081229" WEIGHT="1.0288447671064014"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.589035948729013" CI_END="1.0398659040652967" CI_START="0.4629554678259031" DF="5" EFFECT_SIZE="0.693838314085317" ESTIMABLE="YES" EVENTS_1="322" EVENTS_2="148" I2="34.115478780445315" ID="CMP-001.12.03" LOG_CI_END="0.016977338453289133" LOG_CI_START="-0.33446078221664477" LOG_EFFECT_SIZE="-0.15874172188167782" MODIFIED="2009-05-03 12:49:14 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.18038650405628365" P_Z="0.07662734660778012" STUDIES="7" TAU2="0.07478205563197958" TOTAL_1="7788" TOTAL_2="3025" WEIGHT="100.0" Z="1.7705993711716312">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="0.8401761757310786" CI_START="0.042220025599300215" EFFECT_SIZE="0.18834080717488788" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.07562963759834126" LOG_CI_START="-1.3744815077021793" LOG_EFFECT_SIZE="-0.7250555726502602" ORDER="359" O_E="0.0" SE="0.7629520179194438" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.5820957816473512" WEIGHT="6.487663717440257"/>
<DICH_DATA CI_END="6.0527125704137275" CI_START="0.05159401398815732" EFFECT_SIZE="0.5588235294117647" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.7819500507426971" LOG_CI_START="-1.2874006829215494" LOG_EFFECT_SIZE="-0.25272531608942617" MODIFIED="2009-03-22 10:43:30 -0300" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="1.2155468644057141" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="1.4775541795665634" WEIGHT="2.7452831513416824"/>
<DICH_DATA CI_END="0.8844989184819296" CI_START="0.03737466552972929" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.05330269378604688" LOG_CI_START="-1.427422685202441" LOG_EFFECT_SIZE="-0.7403626894942439" ORDER="362" O_E="0.0" SE="0.8071648849616486" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.6515151515151515" WEIGHT="5.86757386614105"/>
<DICH_DATA CI_END="4.9042390214142415" CI_START="0.20390523292880386" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6905716285477964" LOG_CI_START="-0.6905716285477964" LOG_EFFECT_SIZE="0.0" ORDER="363" O_E="0.0" SE="0.8112903859873357" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.6581920903954802" WEIGHT="5.814123915290301"/>
<DICH_DATA CI_END="1.3179253015139263" CI_START="0.4816602522743795" EFFECT_SIZE="0.7967384973791497" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="18" LOG_CI_END="0.11989079564520336" LOG_CI_START="-0.3172591911988415" LOG_EFFECT_SIZE="-0.09868419777681907" ORDER="360" O_E="0.0" SE="0.25678406619952615" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.06593805665396262" WEIGHT="30.284246100146618"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="358" O_E="0.0" SE="0.0" STUDY_ID="STD-Afari-1996" TOTAL_1="257" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0737782543489862" CI_START="0.6922235543724125" EFFECT_SIZE="0.8621453472780907" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="110" LOG_CI_END="0.030914604589159834" LOG_CI_START="-0.1597536270009771" LOG_EFFECT_SIZE="-0.06441951120590864" MODIFIED="2009-05-03 12:49:14 -0300" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.1119994630590146" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="0.012543879725507578" WEIGHT="48.801109249640085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8057591663489956" CI_END="1.1069248728855665" CI_START="0.22438017139144528" DF="5" EFFECT_SIZE="0.49836933362268304" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="0.04411814626406727" LOG_CI_START="-0.6490155245806161" LOG_EFFECT_SIZE="-0.30244868915827444" MODIFIED="2012-02-10 15:57:13 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.5777070686328789" P_Z="0.08718093547326439" STUDIES="6" TAU2="0.0" TOTAL_1="551" TOTAL_2="193" WEIGHT="100.0" Z="1.7104595054491278">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="2.038017209809876" CI_START="0.005149001523399271" EFFECT_SIZE="0.1024390243902439" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.3092078470373882" LOG_CI_START="-2.2882769796810583" LOG_EFFECT_SIZE="-0.989534566321835" ORDER="367" O_E="0.0" SE="1.5257754449716752" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="2.3279907084785134" WEIGHT="7.1207863282493715"/>
<DICH_DATA CI_END="14.998130825457398" CI_START="0.063211939731786" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1760371375375547" LOG_CI_START="-1.199200882637185" LOG_EFFECT_SIZE="-0.011581872549815147" ORDER="364" O_E="0.0" SE="1.3952265706684663" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="1.9466571834992887" WEIGHT="8.51568758471716"/>
<DICH_DATA CI_END="2.681155551998083" CI_START="0.00761170430790459" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.42832201107900275" LOG_CI_START="-2.1185180911075165" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="368" O_E="0.0" SE="1.4960264830861913" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="2.238095238095238" WEIGHT="7.406800267951759"/>
<DICH_DATA CI_END="15.018548750620724" CI_START="0.22964799389782506" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1766279686170227" LOG_CI_START="-0.6389373440318625" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2009-04-19 08:50:39 -0300" MODIFIED_BY="[Empty name]" ORDER="635" O_E="0.0" SE="1.0664720518431963" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="1.1373626373626373" WEIGHT="14.575056243859985"/>
<DICH_DATA CI_END="1.9263559639365266" CI_START="0.16040753545178382" EFFECT_SIZE="0.5558794946550049" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.2847365418171607" LOG_CI_START="-0.7947752337559781" LOG_EFFECT_SIZE="-0.25501934596940873" ORDER="365" O_E="0.0" SE="0.6341105606411324" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.40209620311661126" WEIGHT="41.22676185633581"/>
<DICH_DATA CI_END="1.8586473500409653" CI_START="0.05783667590865098" EFFECT_SIZE="0.32786885245901637" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.26919699684040665" LOG_CI_START="-1.2377966755339782" LOG_EFFECT_SIZE="-0.4842998393467859" ORDER="366" O_E="0.0" SE="0.8852155428917011" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.7836065573770491" WEIGHT="21.15490771888593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.337694780626311" CI_START="0.10125155120907692" DF="0" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.12.05" LOG_CI_END="1.0545247612742854" LOG_CI_START="-0.9945983145193992" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2012-02-10 15:57:39 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="1.0" P_Z="0.9542910886168375" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="30" WEIGHT="100.0" Z="0.057318995988340705">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="11.337694780626311" CI_START="0.10125155120907692" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0545247612742854" LOG_CI_START="-0.9945983145193992" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="369" O_E="0.0" SE="1.2036650380440248" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="1.4488095238095238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1141.421974045942" CI_END="0.2684064022837333" CI_START="0.2246253880205405" CI_STUDY="95" CI_TOTAL="95" DF="61" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24554203766398305" ESTIMABLE="YES" EVENTS_1="3466" EVENTS_2="5668" I2="94.65578888552703" I2_Q="93.91828576735978" ID="CMP-001.13" LOG_CI_END="-0.5712071291761625" LOG_CI_START="-0.6485411596769194" LOG_EFFECT_SIZE="-0.609874144426541" METHOD="MH" MODIFIED="2014-05-25 20:29:47 -0300" MODIFIED_BY="Liz Dooley" NO="13" P_CHI2="0.0" P_Q="1.7741363933510002E-13" P_Z="0.0" Q="65.7709298232433" RANDOM="YES" SCALE="50.04488406559045" SORT_BY="YEAR" STUDIES="35" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.38679276155719367" TOTALS="SUB" TOTAL_1="33723" TOTAL_2="12290" WEIGHT="500.0" Z="30.913463334010494">
<NAME>Pain/tenderness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="41.453092718657885" CI_END="0.24838840289400665" CI_START="0.15946430291826402" DF="12" EFFECT_SIZE="0.19902030931659634" ESTIMABLE="YES" EVENTS_1="733" EVENTS_2="1840" I2="71.05161710986441" ID="CMP-001.13.01" LOG_CI_END="-0.6048686849717622" LOG_CI_START="-0.7973365212633229" LOG_EFFECT_SIZE="-0.7011026031175426" MODIFIED="2009-03-22 10:57:52 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.1150120124844314E-5" P_Z="2.952986504218131E-46" STUDIES="13" TAU2="0.08149471719245995" TOTAL_1="10279" TOTAL_2="3901" WEIGHT="100.0" Z="14.279121935948275">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.6167969525578796" CI_START="0.005635568667740732" EFFECT_SIZE="0.09545454545454546" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.20865548192205205" LOG_CI_START="-2.249062254098626" LOG_EFFECT_SIZE="-1.0202033860882869" ORDER="370" O_E="0.0" SE="1.4436755640375487" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="2.0841991341991344" WEIGHT="0.5901935630720464"/>
<DICH_DATA CI_END="0.5035799806591793" CI_START="0.03378456882242936" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="18" LOG_CI_END="-0.29793154318304726" LOG_CI_START="-1.4712816194128138" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="373" O_E="0.0" SE="0.6892316429539153" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.47504025764895336" WEIGHT="2.2966724976094266"/>
<DICH_DATA CI_END="0.2740525286171304" CI_START="0.11627944443465657" EFFECT_SIZE="0.17851239669421487" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="121" LOG_CI_END="-0.5621661864419896" LOG_CI_START="-0.9344970518890486" LOG_EFFECT_SIZE="-0.7483316191655192" ORDER="372" O_E="0.0" SE="0.21870899343111105" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.04783362380764978" WEIGHT="9.883205496890612"/>
<DICH_DATA CI_END="0.2839895622872037" CI_START="0.11619167334978156" EFFECT_SIZE="0.181651376146789" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.5466976216585028" LOG_CI_START="-0.9348249936996823" LOG_EFFECT_SIZE="-0.7407613076790925" MODIFIED="2009-03-22 10:57:27 -0300" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.22798793959846608" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.05197850060235382" WEIGHT="9.576292471205356"/>
<DICH_DATA CI_END="0.39399807943940357" CI_START="0.1455080566476411" EFFECT_SIZE="0.23943661971830985" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="71" LOG_CI_END="-0.4045058951564109" LOG_CI_START="-0.8371129595251918" LOG_EFFECT_SIZE="-0.6208094273408014" ORDER="377" O_E="0.0" SE="0.25411553104972723" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.06457470312068489" WEIGHT="8.750487048800892"/>
<DICH_DATA CI_END="1.9186955345154304" CI_START="0.043929429821575654" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.28300606479774104" LOG_CI_START="-1.3572444335876366" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2009-03-22 10:57:38 -0300" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="0.9634912621224854" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.9283154121863799" WEIGHT="1.2657612886714342"/>
<DICH_DATA CI_END="0.5982272127545667" CI_START="0.1633671401945002" EFFECT_SIZE="0.31261904761904763" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="-0.22313383523592897" LOG_CI_START="-0.7868352933809132" LOG_EFFECT_SIZE="-0.5049845643084211" ORDER="379" O_E="0.0" SE="0.33112102688158396" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.10964113444311464" WEIGHT="6.687277973956671"/>
<DICH_DATA CI_END="0.4721008292442021" CI_START="0.09835572087700611" EFFECT_SIZE="0.21548507462686567" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.3259652367306497" LOG_CI_START="-1.007200374198564" LOG_EFFECT_SIZE="-0.6665828054646069" ORDER="375" O_E="0.0" SE="0.4001608919169691" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.1601287394197842" WEIGHT="5.289960621361531"/>
<DICH_DATA CI_END="0.18778471031265692" CI_START="0.10456114527280022" EFFECT_SIZE="0.14012488849241747" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="95" LOG_CI_END="-0.7263397714797266" LOG_CI_START="-0.9806296685134587" LOG_EFFECT_SIZE="-0.8534847199965926" MODIFIED="2009-03-22 10:57:52 -0300" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="0.14937114427290543" STUDY_ID="STD-Decker-1995" TOTAL_1="1770" TOTAL_2="357" VAR="0.022311738741397132" WEIGHT="12.313093238540501"/>
<DICH_DATA CI_END="0.14833815198066558" CI_START="0.12166680035395872" EFFECT_SIZE="0.13434220603334915" ESTIMABLE="YES" EVENTS_1="412" EVENTS_2="1251" LOG_CI_END="-0.828747135797453" LOG_CI_START="-0.9148279130608206" LOG_EFFECT_SIZE="-0.8717875244291367" ORDER="374" O_E="0.0" SE="0.05056427467122179" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.0025567458730267616" WEIGHT="15.207094844740126"/>
<DICH_DATA CI_END="1.1264770165208073" CI_START="0.17403926985552876" EFFECT_SIZE="0.4427767354596623" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.05172233525202473" LOG_CI_START="-0.7593527473649562" LOG_EFFECT_SIZE="-0.3538152060564657" ORDER="378" O_E="0.0" SE="0.47642951841562475" STUDY_ID="STD-Simondon-1996" TOTAL_1="123" TOTAL_2="118" VAR="0.22698508601774414" WEIGHT="4.143475706917035"/>
<DICH_DATA CI_END="0.41281364841294177" CI_START="0.18319403995177883" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="-0.3842459525328796" LOG_CI_START="-0.7370886598065949" LOG_EFFECT_SIZE="-0.5606673061697374" ORDER="376" O_E="0.0" SE="0.20726155285215014" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.04295735129068463" WEIGHT="10.27044858518475"/>
<DICH_DATA CI_END="0.27384113192503906" CI_START="0.17944806450477357" EFFECT_SIZE="0.22167602735917255" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="147" LOG_CI_END="-0.5625013187059141" LOG_CI_START="-0.7460612215292909" LOG_EFFECT_SIZE="-0.6542812701176025" ORDER="371" O_E="0.0" SE="0.10782399555462485" STUDY_ID="STD-Black-1997" TOTAL_1="1835" TOTAL_2="453" VAR="0.01162601401736376" WEIGHT="13.726036663049609"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.590611530956167" CI_END="0.21510863317967405" CI_START="0.14551215500016407" DF="10" EFFECT_SIZE="0.17692066236908047" ESTIMABLE="YES" EVENTS_1="710" EVENTS_2="1606" I2="43.15149315643813" ID="CMP-001.13.02" LOG_CI_END="-0.6673421592682577" LOG_CI_START="-0.8371007274408588" LOG_EFFECT_SIZE="-0.7522214433545583" MODIFIED="2009-03-22 10:58:32 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06227485528141363" P_Z="1.3997768215419661E-67" STUDIES="11" TAU2="0.03298641081727534" TOTAL_1="9642" TOTAL_2="3544" WEIGHT="100.0" Z="17.369691005813106">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.806106913820122" CI_START="0.006097114607761552" EFFECT_SIZE="0.10493827160493827" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2567434551180188" LOG_CI_START="-2.2148756414467328" LOG_EFFECT_SIZE="-0.979066093164357" ORDER="380" O_E="0.0" SE="1.451841292033982" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="2.1078431372549025" WEIGHT="0.4644687727426949"/>
<DICH_DATA CI_END="0.8657397696950855" CI_START="0.05262100144755042" EFFECT_SIZE="0.2134387351778656" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.06261263173486697" LOG_CI_START="-1.2788408909708318" LOG_EFFECT_SIZE="-0.6707267613528495" ORDER="383" O_E="0.0" SE="0.7144184999021852" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.5103937930024887" WEIGHT="1.829931355346545"/>
<DICH_DATA CI_END="0.3170828673086822" CI_START="0.0933343272106747" EFFECT_SIZE="0.17203114860480206" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="67" LOG_CI_END="-0.49882722323406814" LOG_CI_START="-1.0299585987365838" LOG_EFFECT_SIZE="-0.7643929109853259" ORDER="382" O_E="0.0" SE="0.31198919911288875" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.09733726036310175" WEIGHT="7.629837801822931"/>
<DICH_DATA CI_END="0.23715481826741566" CI_START="0.06947957685947682" EFFECT_SIZE="0.12836438923395446" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.6249680473743543" LOG_CI_START="-1.158142835132162" LOG_EFFECT_SIZE="-0.8915554412532583" MODIFIED="2009-03-22 10:58:09 -0300" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.31318950958670116" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.0980876689151584" WEIGHT="7.586156430578663"/>
<DICH_DATA CI_END="0.43464334116562264" CI_START="0.13675334260092423" EFFECT_SIZE="0.24380100439422472" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="54" LOG_CI_END="-0.36186696947761227" LOG_CI_START="-0.864062049598589" LOG_EFFECT_SIZE="-0.6129645095381007" ORDER="386" O_E="0.0" SE="0.2949918759688005" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.08702020688759218" WEIGHT="8.285780333296165"/>
<DICH_DATA CI_END="0.44780154499708774" CI_START="0.09429877340263103" EFFECT_SIZE="0.20549242424242425" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.34891441235914966" LOG_CI_START="-1.0254939563393783" LOG_EFFECT_SIZE="-0.6872041843492639" ORDER="385" O_E="0.0" SE="0.39742617325674295" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.15794756318949868" WEIGHT="5.207813214054324"/>
<DICH_DATA CI_END="0.6737060883542605" CI_START="0.1791622731305541" EFFECT_SIZE="0.3474229615489501" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="-0.17152952786372141" LOG_CI_START="-0.7467534360588208" LOG_EFFECT_SIZE="-0.45914148196127114" ORDER="387" O_E="0.0" SE="0.3378893710780693" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.11416922708753321" WEIGHT="6.757121147390919"/>
<DICH_DATA CI_END="0.3932469038957591" CI_START="0.0013685922814829828" EFFECT_SIZE="0.0231990231990232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.40533468797048716" LOG_CI_START="-2.863725913644692" LOG_EFFECT_SIZE="-1.6345303008075895" MODIFIED="2009-03-22 10:58:19 -0300" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="1.4440711751938577" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="2.0853415590257693" WEIGHT="0.4694025132085934"/>
<DICH_DATA CI_END="0.15602939463503687" CI_START="0.07114918984814997" EFFECT_SIZE="0.10536301543131799" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="67" LOG_CI_END="-0.8067935764838624" LOG_CI_START="-1.147830040716466" LOG_EFFECT_SIZE="-0.9773118086001642" MODIFIED="2009-03-22 10:58:32 -0300" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.20032650724795564" STUDY_ID="STD-Decker-1995" TOTAL_1="1770" TOTAL_2="357" VAR="0.04013070950616523" WEIGHT="13.599393253533336"/>
<DICH_DATA CI_END="0.1859146760285389" CI_START="0.1557735462754453" EFFECT_SIZE="0.1701781078447402" ESTIMABLE="YES" EVENTS_1="524" EVENTS_2="1229" LOG_CI_END="-0.7306863258459889" LOG_CI_START="-0.8075062930181423" LOG_EFFECT_SIZE="-0.7690963094320656" ORDER="384" O_E="0.0" SE="0.045124428981893235" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="0.002036214090941926" WEIGHT="28.39160329787506"/>
<DICH_DATA CI_END="0.2754026241219545" CI_START="0.1644866831564784" EFFECT_SIZE="0.21283811729671603" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="105" LOG_CI_END="-0.560031925966331" LOG_CI_START="-0.7838692567764071" LOG_EFFECT_SIZE="-0.671950591371369" ORDER="381" O_E="0.0" SE="0.1314831561304959" STUDY_ID="STD-Black-1997" TOTAL_1="1727" TOTAL_2="415" VAR="0.01728782034603636" WEIGHT="19.77849188015076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.665113229715692" CI_END="0.2363142062328436" CI_START="0.17382004409884397" DF="11" EFFECT_SIZE="0.20267250861568814" ESTIMABLE="YES" EVENTS_1="712" EVENTS_2="1358" I2="24.99205544686235" ID="CMP-001.13.03" LOG_CI_END="-0.6265101695945425" LOG_CI_START="-0.7599001442303246" LOG_EFFECT_SIZE="-0.6932051569124336" MODIFIED="2009-03-22 10:59:12 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1983473258472328" P_Z="0.0" STUDIES="12" TAU2="0.015050195584948628" TOTAL_1="9769" TOTAL_2="3564" WEIGHT="100.0" Z="20.371203235559268">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="6.331051965327361" CI_START="0.012187626045361447" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8014758782288322" LOG_CI_START="-1.9140808797634066" LOG_EFFECT_SIZE="-0.5563025007672873" ORDER="388" O_E="0.0" SE="1.5951314818673865" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="2.5444444444444443" WEIGHT="0.2398652635789296"/>
<DICH_DATA CI_END="0.8493568021062881" CI_START="0.016224887235034364" EFFECT_SIZE="0.11739130434782609" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.07090983079994112" LOG_CI_START="-1.7898183129172704" LOG_EFFECT_SIZE="-0.9303640718586056" ORDER="391" O_E="0.0" SE="1.0096953511299327" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="1.019484702093398" WEIGHT="0.5934394845812052"/>
<DICH_DATA CI_END="0.3880677681745677" CI_START="0.11836223731194301" EFFECT_SIZE="0.21431884954383795" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="58" LOG_CI_END="-0.41109242704929855" LOG_CI_START="-0.926786834293359" LOG_EFFECT_SIZE="-0.6689396306713288" ORDER="390" O_E="0.0" SE="0.30292144754364686" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.09176140338193839" WEIGHT="5.747820109404366"/>
<DICH_DATA CI_END="0.2807669196354341" CI_START="0.08720060402589211" EFFECT_SIZE="0.1564705882352941" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.5516540627320651" LOG_CI_START="-1.0594805067623487" LOG_EFFECT_SIZE="-0.805567284747207" MODIFIED="2009-03-22 10:58:45 -0300" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.2982997670048284" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.0889827509951349" WEIGHT="5.901340648723312"/>
<DICH_DATA CI_END="0.713360572929822" CI_START="0.2359400400630689" EFFECT_SIZE="0.41025641025641024" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="39" LOG_CI_END="-0.14669089756592346" LOG_CI_START="-0.6271983511752254" LOG_EFFECT_SIZE="-0.3869446243705744" ORDER="395" O_E="0.0" SE="0.28225245680036015" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.07966644936983919" WEIGHT="6.481794797023944"/>
<DICH_DATA CI_END="0.5235119137547226" CI_START="0.04025085132635429" EFFECT_SIZE="0.14516129032258066" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.28107343047213" LOG_CI_START="-1.395224929645728" LOG_EFFECT_SIZE="-0.838149180058929" MODIFIED="2009-03-22 10:58:56 -0300" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="0.6544581057534393" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.4283154121863799" WEIGHT="1.3847124037102851"/>
<DICH_DATA CI_END="0.7621450191776482" CI_START="0.17047795875580346" EFFECT_SIZE="0.3604565537555228" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="-0.11796238425580498" LOG_CI_START="-0.7683317633548474" LOG_EFFECT_SIZE="-0.44314707380532625" ORDER="396" O_E="0.0" SE="0.38203019266312555" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.14594706810622482" WEIGHT="3.813318576874461"/>
<DICH_DATA CI_END="0.4896303063771347" CI_START="0.07325948539534743" EFFECT_SIZE="0.1893939393939394" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.31013170874441826" LOG_CI_START="-1.1351361363232062" LOG_EFFECT_SIZE="-0.7226339225338123" ORDER="393" O_E="0.0" SE="0.4846116845975599" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.23484848484848486" WEIGHT="2.456731085553066"/>
<DICH_DATA CI_END="0.1997582707804758" CI_START="0.08878863992314567" EFFECT_SIZE="0.13317757009345793" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="54" LOG_CI_END="-0.699495230136824" LOG_CI_START="-1.0516425965445373" LOG_EFFECT_SIZE="-0.8755689133406807" MODIFIED="2009-03-22 10:59:12 -0300" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.20685310618546787" STUDY_ID="STD-Decker-1995" TOTAL_1="1712" TOTAL_2="342" VAR="0.04278820753857645" WEIGHT="10.614640503617181"/>
<DICH_DATA CI_END="0.22049792445789476" CI_START="0.18301277332398394" EFFECT_SIZE="0.20088289291829114" ESTIMABLE="YES" EVENTS_1="511" EVENTS_2="1001" LOG_CI_END="-0.656595494181293" LOG_CI_START="-0.7375185977530228" LOG_EFFECT_SIZE="-0.6970570459671579" ORDER="392" O_E="0.0" SE="0.04753463161385714" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="0.0022595412026651064" WEIGHT="35.467544307133444"/>
<DICH_DATA CI_END="0.2708965216972352" CI_START="0.12055063816675692" EFFECT_SIZE="0.18071178314586023" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="51" LOG_CI_END="-0.5671965712584345" LOG_CI_START="-0.9188304862274859" LOG_EFFECT_SIZE="-0.7430135287429602" ORDER="394" O_E="0.0" SE="0.2065515022687721" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.04266352308948657" WEIGHT="10.637572323535883"/>
<DICH_DATA CI_END="0.29279269175492106" CI_START="0.16414046913405916" EFFECT_SIZE="0.21922392612047784" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="87" LOG_CI_END="-0.5334397676755352" LOG_CI_START="-0.7847843296428687" LOG_EFFECT_SIZE="-0.6591120486592019" ORDER="389" O_E="0.0" SE="0.14764103987525917" STUDY_ID="STD-Black-1997" TOTAL_1="1628" TOTAL_2="414" VAR="0.02179787665544787" WEIGHT="16.661220496263923"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="110.7904251351939" CI_END="0.5264399662561197" CI_START="0.35611871565659603" DF="20" EFFECT_SIZE="0.4329839773634021" ESTIMABLE="YES" EVENTS_1="620" EVENTS_2="661" I2="81.947898497912" ID="CMP-001.13.04" LOG_CI_END="-0.27865114738494523" LOG_CI_START="-0.4484052015776513" LOG_EFFECT_SIZE="-0.36352817448129826" MODIFIED="2012-02-10 15:58:12 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="1.432187701766452E-14" P_Z="4.6779069973410476E-17" STUDIES="21" TAU2="0.13793431548954035" TOTAL_1="2018" TOTAL_2="1033" WEIGHT="100.00000000000001" Z="8.39452268444911">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.4161053157193792" CI_START="0.13539639481186155" EFFECT_SIZE="0.23735871505056513" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.3807967360867748" LOG_CI_START="-0.8683928994186708" LOG_EFFECT_SIZE="-0.6245948177527227" ORDER="409" O_E="0.0" SE="0.28641639998109086" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.08203435417812824" WEIGHT="4.520169142412132"/>
<DICH_DATA CI_END="0.47401233947198856" CI_START="0.03296327689993259" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" LOG_CI_END="-0.32421035264059545" LOG_CI_START="-1.4819696213432916" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="401" O_E="0.0" SE="0.6800735254367721" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="0.46249999999999997" WEIGHT="1.6559606392892179"/>
<DICH_DATA CI_END="1.004722720101262" CI_START="0.018997882197978547" EFFECT_SIZE="0.13815789473684212" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.002046223204130061" LOG_CI_START="-1.7212948096258365" LOG_EFFECT_SIZE="-0.8596242932108532" ORDER="400" O_E="0.0" SE="1.0122990533600158" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="1.024749373433584" WEIGHT="0.855172909366397"/>
<DICH_DATA CI_END="0.7504621802793345" CI_START="0.2691059128634866" EFFECT_SIZE="0.4493927125506073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.12467118924330035" LOG_CI_START="-0.5700767597027162" LOG_EFFECT_SIZE="-0.3473739744730083" ORDER="399" O_E="0.0" SE="0.261633436880993" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.06845205529416055" WEIGHT="4.817641732608858"/>
<DICH_DATA CI_END="0.9539614419105106" CI_START="0.6003185912316227" EFFECT_SIZE="0.7567567567567568" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="37" LOG_CI_END="-0.02046917865430347" LOG_CI_START="-0.22161820679524805" LOG_EFFECT_SIZE="-0.12104369272477575" ORDER="411" O_E="0.0" SE="0.11815593483373864" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.01396082493643469" WEIGHT="6.545934189473333"/>
<DICH_DATA CI_END="0.5745380973464239" CI_START="0.4265943797307668" EFFECT_SIZE="0.4950704225352113" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="71" LOG_CI_END="-0.24068116816150292" LOG_CI_START="-0.3699848705649621" LOG_EFFECT_SIZE="-0.30533301936323254" ORDER="397" O_E="0.0" SE="0.07595363485544164" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.00576895464775376" WEIGHT="6.919088145866779"/>
<DICH_DATA CI_END="0.5968906587175835" CI_START="0.33131912044786793" EFFECT_SIZE="0.44470359572400386" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="30" LOG_CI_END="-0.22410521772275357" LOG_CI_START="-0.4797535002321767" LOG_EFFECT_SIZE="-0.3519293589774652" ORDER="405" O_E="0.0" SE="0.15016906662544297" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.02255074857115673" WEIGHT="6.195564669826163"/>
<DICH_DATA CI_END="0.3886368643939267" CI_START="0.06162886066633047" EFFECT_SIZE="0.15476190476190477" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.41045600650639164" LOG_CI_START="-1.2102158610036982" LOG_EFFECT_SIZE="-0.8103359337550449" MODIFIED="2009-03-22 11:01:52 -0300" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="0.4697828974068455" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.2206959706959707" WEIGHT="2.772480828389706"/>
<DICH_DATA CI_END="0.8850027555667223" CI_START="0.10697656658977488" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.05305537706990461" LOG_CI_START="-0.9707113448878443" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="407" O_E="0.0" SE="0.5390356579665584" STUDY_ID="STD-Kanra-1993a" TOTAL_1="55" TOTAL_2="55" VAR="0.29055944055944055" WEIGHT="2.3204435978189277"/>
<DICH_DATA CI_END="0.23953713230487134" CI_START="0.049682595478074756" EFFECT_SIZE="0.10909090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="55" LOG_CI_END="-0.6206271540443551" LOG_CI_START="-1.3037957241768452" LOG_EFFECT_SIZE="-0.9622114391106003" ORDER="404" O_E="0.0" SE="0.4012965998347868" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.16103896103896104" WEIGHT="3.3257005591750812"/>
<DICH_DATA CI_END="0.2656547577968902" CI_START="0.07261350640495073" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="36" LOG_CI_END="-0.5756824016009143" LOG_CI_START="-1.1389825912616227" LOG_EFFECT_SIZE="-0.8573324964312684" ORDER="410" O_E="0.0" SE="0.3308853197876093" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.1094850948509485" WEIGHT="4.01866446759748"/>
<DICH_DATA CI_END="0.723414534883297" CI_START="0.2130962263386993" EFFECT_SIZE="0.3926282051282051" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.14061276961891686" LOG_CI_START="-0.6714242410168662" LOG_EFFECT_SIZE="-0.4060185053178915" ORDER="413" O_E="0.0" SE="0.31180128585831557" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.09722004186289902" WEIGHT="4.228267781740633"/>
<DICH_DATA CI_END="1.831511393932659" CI_START="0.3363762287984266" EFFECT_SIZE="0.7849056603773585" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.2628096247787177" LOG_CI_START="-0.4731747027268102" LOG_EFFECT_SIZE="-0.10518253897404628" ORDER="408" O_E="0.0" SE="0.43232083715792474" STUDY_ID="STD-Kanra-1993b" TOTAL_1="53" TOTAL_2="52" VAR="0.18690130624092888" WEIGHT="3.060919204711653"/>
<DICH_DATA CI_END="1.2138923770876833" CI_START="0.6345185149062142" EFFECT_SIZE="0.8776315789473684" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="19" LOG_CI_END="0.0841801841784027" LOG_CI_START="-0.19755570090688745" LOG_EFFECT_SIZE="-0.056687758364242384" ORDER="403" O_E="0.0" SE="0.1654930535142227" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.027387950761461374" WEIGHT="6.014287218998357"/>
<DICH_DATA CI_END="0.7044245193173696" CI_START="0.3433589523021854" EFFECT_SIZE="0.4918032786885246" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="-0.15216553569893249" LOG_CI_START="-0.46425162488327676" LOG_EFFECT_SIZE="-0.3082085802911046" ORDER="406" O_E="0.0" SE="0.1833209136379403" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.03360655737704917" WEIGHT="5.79626054312155"/>
<DICH_DATA CI_END="0.6734554782189046" CI_START="0.35142501499859785" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="-0.1716911099676801" LOG_CI_START="-0.45416732795969766" LOG_EFFECT_SIZE="-0.3129292189636889" ORDER="398" O_E="0.0" SE="0.16592792872834136" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.02753207753207753" WEIGHT="6.00904857338215"/>
<DICH_DATA CI_END="0.7843404343755805" CI_START="0.3156219111791761" EFFECT_SIZE="0.49754901960784315" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="-0.1054953956318221" LOG_CI_START="-0.500832854721512" LOG_EFFECT_SIZE="-0.303164125176667" ORDER="402" O_E="0.0" SE="0.2322231804212676" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.0539276055249686" WEIGHT="5.1823498257064395"/>
<DICH_DATA CI_END="0.40568052647868263" CI_START="0.22105924366401752" EFFECT_SIZE="0.2994652406417112" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="14" LOG_CI_END="-0.391815838846896" LOG_CI_START="-0.655491320213701" LOG_EFFECT_SIZE="-0.5236535795302986" ORDER="412" O_E="0.0" SE="0.15488428296954423" STUDY_ID="STD-Pichichero-1997" TOTAL_1="187" TOTAL_2="16" VAR="0.023989141110989848" WEIGHT="6.140528455875289"/>
<DICH_DATA CI_END="0.8864172751782702" CI_START="0.555799518556876" EFFECT_SIZE="0.7019047619047619" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="10" LOG_CI_END="-0.05236178866992256" LOG_CI_START="-0.2550818337518507" LOG_EFFECT_SIZE="-0.1537218112108866" MODIFIED="2009-03-22 11:02:28 -0300" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="0.11907875796153165" STUDY_ID="STD-Pichichero-2000" TOTAL_1="49" TOTAL_2="10" VAR="0.014179750597661037" WEIGHT="6.5365131477009495"/>
<DICH_DATA CI_END="0.7661821075115924" CI_START="0.5043362885652456" EFFECT_SIZE="0.6216216216216216" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="111" LOG_CI_END="-0.11566799422153272" LOG_CI_START="-0.29727978187727155" LOG_EFFECT_SIZE="-0.20647388804940214" MODIFIED="2009-03-22 11:02:39 -0300" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.10667966306182868" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.011380550510985292" WEIGHT="6.659052909880672"/>
<DICH_DATA CI_END="0.8245175470112434" CI_START="0.49609320909354143" EFFECT_SIZE="0.6395604395604395" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="70" LOG_CI_END="-0.08380009746146662" LOG_CI_START="-0.3044367178809437" LOG_EFFECT_SIZE="-0.19411840767120514" MODIFIED="2009-03-22 11:02:50 -0300" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.12960304300328615" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.016796948755711638" WEIGHT="6.425951457058256"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="41.52877969940463" CI_END="0.5795008409937648" CI_START="0.31726145725799004" DF="4" EFFECT_SIZE="0.42878115781353143" ESTIMABLE="YES" EVENTS_1="691" EVENTS_2="203" I2="90.36812536040556" ID="CMP-001.13.05" LOG_CI_END="-0.23694592943518014" LOG_CI_START="-0.4985826852803" LOG_EFFECT_SIZE="-0.36776430735774013" MODIFIED="2012-02-10 15:58:39 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="2.0887719331952326E-8" P_Z="3.589032867410453E-8" STUDIES="5" TAU2="0.10564576943063811" TOTAL_1="2015" TOTAL_2="248" WEIGHT="99.99999999999999" Z="5.509965867694688">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.6695739131300824" CI_START="0.369571577453145" EFFECT_SIZE="0.49744897959183676" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="-0.17420147497350483" LOG_CI_START="-0.43230143634237356" LOG_EFFECT_SIZE="-0.3032514556579392" ORDER="414" O_E="0.0" SE="0.15160919492348737" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.022985347985347987" WEIGHT="18.36228283740209"/>
<DICH_DATA CI_END="0.3416647854749698" CI_START="0.21877198770396927" EFFECT_SIZE="0.2733983983983984" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="81" LOG_CI_END="-0.4663997805281503" LOG_CI_START="-0.6600082872948201" LOG_EFFECT_SIZE="-0.5632040339114852" ORDER="415" O_E="0.0" SE="0.11372659525230686" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.012933738467682023" WEIGHT="19.918795427189288"/>
<DICH_DATA CI_END="0.42563343088296507" CI_START="0.28183879809843726" EFFECT_SIZE="0.34635244273798493" ESTIMABLE="YES" EVENTS_1="327" EVENTS_2="14" LOG_CI_END="-0.3709642682181799" LOG_CI_START="-0.5499992218716957" LOG_EFFECT_SIZE="-0.46048174504493783" ORDER="416" O_E="0.0" SE="0.1051660180133888" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1079" TOTAL_2="16" VAR="0.011059891344792419" WEIGHT="20.238615196467546"/>
<DICH_DATA CI_END="0.6993581648220909" CI_START="0.5014906038233097" EFFECT_SIZE="0.5922174840085288" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="10" LOG_CI_END="-0.15530035048020183" LOG_CI_START="-0.2997371997241542" LOG_EFFECT_SIZE="-0.22751877510217802" MODIFIED="2009-03-22 11:03:04 -0300" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.08484292021983232" STUDY_ID="STD-Pichichero-2000" TOTAL_1="267" TOTAL_2="10" VAR="0.007198321111428832" WEIGHT="20.931188760858536"/>
<DICH_DATA CI_END="0.6231141623760593" CI_START="0.4269974254672169" EFFECT_SIZE="0.5158179360072105" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="70" LOG_CI_END="-0.20543237782263277" LOG_CI_START="-0.3695747434966434" LOG_EFFECT_SIZE="-0.28750356065963806" MODIFIED="2009-03-22 11:03:16 -0300" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.09641803811472803" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.009296438073893147" WEIGHT="20.549117778082532"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="268.16672710232643" CI_END="0.51680420590646" CI_START="0.4386445172528073" CI_STUDY="95" CI_TOTAL="95" DF="63" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4761232313320361" ESTIMABLE="YES" EVENTS_1="3113" EVENTS_2="2412" I2="76.50715259094743" I2_Q="81.7202383621469" ID="CMP-001.14" LOG_CI_END="-0.286673960580824" LOG_CI_START="-0.357887294646311" LOG_EFFECT_SIZE="-0.3222806276135675" METHOD="MH" MODIFIED="2014-05-25 20:29:52 -0300" MODIFIED_BY="Liz Dooley" NO="14" P_CHI2="-6.661338147750939E-16" P_Q="2.11544261506047E-4" P_Z="2.0633167218380308E-70" Q="21.88212340645044" RANDOM="YES" SCALE="101.75219512442855" SORT_BY="YEAR" STUDIES="35" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11585312715158054" TOTALS="SUB" TOTAL_1="19136" TOTAL_2="6394" WEIGHT="500.0" Z="17.73989187071878">
<NAME>Redness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="47.30559145227004" CI_END="0.39384885447349965" CI_START="0.2278260464304563" DF="12" EFFECT_SIZE="0.299548038561199" ESTIMABLE="YES" EVENTS_1="512" EVENTS_2="620" I2="74.63301983633869" ID="CMP-001.14.01" LOG_CI_END="-0.40467041335719234" LOG_CI_START="-0.6423966262868639" LOG_EFFECT_SIZE="-0.5235335198220281" MODIFIED="2009-03-22 11:13:24 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.126522784697606E-6" P_Z="5.9932330583640935E-18" STUDIES="13" TAU2="0.13191019111827357" TOTAL_1="5348" TOTAL_2="1805" WEIGHT="99.99999999999999" Z="8.632677321572636">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="2.6732974545566934" CI_START="0.2652683759637299" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4270472848640239" LOG_CI_START="-0.5763145214578324" LOG_EFFECT_SIZE="-0.07463361829690421" ORDER="417" O_E="0.0" SE="0.5893796917545019" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.3473684210526316" WEIGHT="4.0685653761709135"/>
<DICH_DATA CI_END="0.15934519347991274" CI_START="0.015299429946767262" EFFECT_SIZE="0.049375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="24" LOG_CI_END="-0.7976610321377464" LOG_CI_START="-1.8153247505932202" LOG_EFFECT_SIZE="-1.3064928913654834" ORDER="419" O_E="0.0" SE="0.5977807057373956" STUDY_ID="STD-Blennow-1988" TOTAL_1="200" TOTAL_2="79" VAR="0.3573417721518987" WEIGHT="3.9856280882024504"/>
<DICH_DATA CI_END="2.443927983430842" CI_START="0.03524223716368027" EFFECT_SIZE="0.29347826086956524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3880884041648678" LOG_CI_START="-1.4529365305380035" LOG_EFFECT_SIZE="-0.5324240631865679" ORDER="422" O_E="0.0" SE="1.0814271598648695" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="1.1694847020933978" WEIGHT="1.4983740732265418"/>
<DICH_DATA CI_END="0.6789860579971272" CI_START="0.39658670636963045" EFFECT_SIZE="0.518918918918919" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="111" LOG_CI_END="-0.168139143240969" LOG_CI_START="-0.40166184748592176" LOG_EFFECT_SIZE="-0.28490049536344536" ORDER="420" O_E="0.0" SE="0.1371723924295143" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.01881626524483667" WEIGHT="12.937187100850876"/>
<DICH_DATA CI_END="0.5779822124515094" CI_START="0.1887285192820666" EFFECT_SIZE="0.3302752293577982" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="-0.2380855268961228" LOG_CI_START="-0.7241624674505498" LOG_EFFECT_SIZE="-0.48112399717333637" MODIFIED="2009-03-22 11:13:14 -0300" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="0.2855240010013315" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.08152395514780836" WEIGHT="9.136196813544611"/>
<DICH_DATA CI_END="1.215191456163961" CI_START="0.11572250552510968" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.08464470740353658" LOG_CI_START="-0.9365821719480987" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="425" O_E="0.0" SE="0.5998737240857319" STUDY_ID="STD-Pichichero-1993" TOTAL_1="88" TOTAL_2="22" VAR="0.3598484848484848" WEIGHT="3.965311569103065"/>
<DICH_DATA CI_END="0.6033958459995785" CI_START="0.28313825091292355" EFFECT_SIZE="0.41333333333333333" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="75" LOG_CI_END="-0.2193976839947572" LOG_CI_START="-0.5480014551200976" LOG_EFFECT_SIZE="-0.38369956955742734" ORDER="426" O_E="0.0" SE="0.19302348177392573" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.037258064516129036" WEIGHT="11.526845623046306"/>
<DICH_DATA CI_END="1.3166059674246755" CI_START="0.06401854686815277" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.11945581916995532" LOG_CI_START="-1.1936941879598508" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2009-03-22 11:13:24 -0300" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.7713508143854173" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.5949820788530465" WEIGHT="2.682620860852915"/>
<DICH_DATA CI_END="0.34569427753335685" CI_START="0.019493219948130098" EFFECT_SIZE="0.08208955223880597" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.4613078095124257" LOG_CI_START="-1.7101164169007395" LOG_EFFECT_SIZE="-1.0857121132065826" ORDER="423" O_E="0.0" SE="0.7335563576821993" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="0.5381049298959747" WEIGHT="2.9103468054063892"/>
<DICH_DATA CI_END="0.707770036937915" CI_START="0.20268103340546392" EFFECT_SIZE="0.37875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="-0.15010782693157165" LOG_CI_START="-0.6931868900477056" LOG_EFFECT_SIZE="-0.4216473584896386" ORDER="427" O_E="0.0" SE="0.31900732995913555" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.10176567656765677" WEIGHT="8.34479138273122"/>
<DICH_DATA CI_END="0.31900634452192284" CI_START="0.23375426919240497" EFFECT_SIZE="0.27307342406661006" ESTIMABLE="YES" EVENTS_1="245" EVENTS_2="183" LOG_CI_END="-0.49620067943980606" LOG_CI_START="-0.6312404486061508" LOG_EFFECT_SIZE="-0.5637205640229784" ORDER="421" O_E="0.0" SE="0.07932302886594904" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.006292142908468185" WEIGHT="14.109576229302158"/>
<DICH_DATA CI_END="0.4062220298598699" CI_START="0.19956264768586096" EFFECT_SIZE="0.2847222222222222" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="48" LOG_CI_END="-0.39123652803326175" LOG_CI_START="-0.6999207427177665" LOG_EFFECT_SIZE="-0.5455786353755142" ORDER="424" O_E="0.0" SE="0.1813226357171842" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.03287789822342668" WEIGHT="11.833236096174236"/>
<DICH_DATA CI_END="0.24969291994363002" CI_START="0.14741569152109946" EFFECT_SIZE="0.19185581685581685" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="111" LOG_CI_END="-0.6025937719177996" LOG_CI_START="-0.8314562859591992" LOG_EFFECT_SIZE="-0.7170250289384995" ORDER="418" O_E="0.0" SE="0.13443497363563364" STUDY_ID="STD-Black-1997" TOTAL_1="1848" TOTAL_2="463" VAR="0.018072762136413515" WEIGHT="13.001319981388312"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="43.919148598050775" CI_END="0.508772733129147" CI_START="0.2943570194212871" DF="11" EFFECT_SIZE="0.3869894382108091" ESTIMABLE="YES" EVENTS_1="599" EVENTS_2="551" I2="74.95397713495701" ID="CMP-001.14.02" LOG_CI_END="-0.2934761720626049" LOG_CI_START="-0.53112560327093" LOG_EFFECT_SIZE="-0.4123008876667674" MODIFIED="2009-03-22 11:13:45 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.507558117625379E-6" P_Z="1.040898426224438E-11" STUDIES="12" TAU2="0.11951981074378959" TOTAL_1="4821" TOTAL_2="1606" WEIGHT="100.0" Z="6.800730694048055">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.986970739729328" CI_START="0.1604919122298975" EFFECT_SIZE="0.5647058823529412" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2981914717058606" LOG_CI_START="-0.7945468483832716" LOG_EFFECT_SIZE="-0.24817768833870552" ORDER="428" O_E="0.0" SE="0.6418798983622782" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="0.4120098039215686" WEIGHT="3.666243413389932"/>
<DICH_DATA CI_END="0.5140572410641787" CI_START="0.1242785323548325" EFFECT_SIZE="0.25275735294117646" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="-0.28898851895377264" LOG_CI_START="-0.9056038841100242" LOG_EFFECT_SIZE="-0.5972962015318984" ORDER="430" O_E="0.0" SE="0.36220291778806657" STUDY_ID="STD-Blennow-1988" TOTAL_1="192" TOTAL_2="75" VAR="0.13119095365418892" WEIGHT="7.772769364203138"/>
<DICH_DATA CI_END="2.443927983430842" CI_START="0.03524223716368027" EFFECT_SIZE="0.29347826086956524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3880884041648678" LOG_CI_START="-1.4529365305380035" LOG_EFFECT_SIZE="-0.5324240631865679" ORDER="433" O_E="0.0" SE="1.0814271598648695" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="1.1694847020933978" WEIGHT="1.5117999428095859"/>
<DICH_DATA CI_END="0.8170902596523257" CI_START="0.4958696611626122" EFFECT_SIZE="0.6365298659081674" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="107" LOG_CI_END="-0.0877299665963537" LOG_CI_START="-0.3046324623738034" LOG_EFFECT_SIZE="-0.19618121448507858" ORDER="431" O_E="0.0" SE="0.12740959970434423" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.016233206096821235" WEIGHT="14.354870294164947"/>
<DICH_DATA CI_END="0.2718534458650587" CI_START="0.06818086145715552" EFFECT_SIZE="0.13614404918752745" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="22" LOG_CI_END="-0.5656651577489145" LOG_CI_START="-1.1663375158128257" LOG_EFFECT_SIZE="-0.8660013367808701" MODIFIED="2009-03-22 11:13:36 -0300" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="0.35283791650286794" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.1244945953220848" WEIGHT="7.986073364301617"/>
<DICH_DATA CI_END="10.768222840232665" CI_START="0.16311171393417012" EFFECT_SIZE="1.3253012048192772" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.032144034368944" LOG_CI_START="-0.7875148488046418" LOG_EFFECT_SIZE="0.12231459278215115" ORDER="435" O_E="0.0" SE="1.0688766354329065" STUDY_ID="STD-Pichichero-1993" TOTAL_1="83" TOTAL_2="22" VAR="1.1424972617743703" WEIGHT="1.5441288325047733"/>
<DICH_DATA CI_END="0.6794822463387342" CI_START="0.3274204461337483" EFFECT_SIZE="0.4716740190387741" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="73" LOG_CI_END="-0.1678218861247891" LOG_CI_START="-0.48489420407555023" LOG_EFFECT_SIZE="-0.3263580451001697" ORDER="436" O_E="0.0" SE="0.1862498490975641" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.03468900628886539" WEIGHT="12.636871135428665"/>
<DICH_DATA CI_END="1.2243211537913545" CI_START="0.3854783659743356" EFFECT_SIZE="0.6869856750990552" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.0878953532873383" LOG_CI_START="-0.41399999063925824" LOG_EFFECT_SIZE="-0.16305231867595996" ORDER="437" O_E="0.0" SE="0.2948158094445035" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.08691636149841779" WEIGHT="9.439803730240493"/>
<DICH_DATA CI_END="6.042269344972036" CI_START="0.055798373770016896" EFFECT_SIZE="0.5806451612903226" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.7812000808227068" LOG_CI_START="-1.25337845828464" LOG_EFFECT_SIZE="-0.23608918873096657" MODIFIED="2009-03-22 11:13:45 -0300" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.1951215051978523" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="1.42831541218638" WEIGHT="1.258995091932001"/>
<DICH_DATA CI_END="0.679974940518903" CI_START="0.22003959527629663" EFFECT_SIZE="0.3868092691622103" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="-0.16750709228626287" LOG_CI_START="-0.657499162529001" LOG_EFFECT_SIZE="-0.41250312740763195" ORDER="434" O_E="0.0" SE="0.28782376756045" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.08284252117269193" WEIGHT="9.629840347920222"/>
<DICH_DATA CI_END="0.41641179396963657" CI_START="0.30909412273627335" EFFECT_SIZE="0.3587623700363272" ESTIMABLE="YES" EVENTS_1="304" EVENTS_2="171" LOG_CI_END="-0.3804769785289448" LOG_CI_START="-0.5099092527415217" LOG_EFFECT_SIZE="-0.4451931156352333" ORDER="432" O_E="0.0" SE="0.07602915857255807" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.00578043295325118" WEIGHT="15.552379558816302"/>
<DICH_DATA CI_END="0.3315357449806639" CI_START="0.2101307476959578" EFFECT_SIZE="0.2639428990913059" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="116" LOG_CI_END="-0.47946964068012654" LOG_CI_START="-0.6775103941545014" LOG_EFFECT_SIZE="-0.578490017417314" ORDER="429" O_E="0.0" SE="0.11633011890838788" STUDY_ID="STD-Black-1997" TOTAL_1="1738" TOTAL_2="419" VAR="0.013532696565239661" WEIGHT="14.646224924288319"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.421354219683412" CI_END="0.5375366276374548" CI_START="0.4125384302222018" DF="12" EFFECT_SIZE="0.470908182719829" ESTIMABLE="YES" EVENTS_1="807" EVENTS_2="583" I2="31.119017220590855" ID="CMP-001.14.03" LOG_CI_END="-0.26959193766563444" LOG_CI_START="-0.38453558831155366" LOG_EFFECT_SIZE="-0.327063762988594" MODIFIED="2009-03-22 11:44:53 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13442295594321196" P_Z="6.855926114979161E-29" STUDIES="13" TAU2="0.01496402377295695" TOTAL_1="4972" TOTAL_2="1660" WEIGHT="100.0" Z="11.153868743571993">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="2.2791340746358673" CI_START="0.2975694583259114" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.35776987417633915" LOG_CI_START="-0.526411645576411" LOG_EFFECT_SIZE="-0.08432088570003593" ORDER="438" O_E="0.0" SE="0.5193726014718758" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="0.2697478991596639" WEIGHT="1.6011776602346874"/>
<DICH_DATA CI_END="1.0267342804166415" CI_START="0.3309271236067919" EFFECT_SIZE="0.582901554404145" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.011458062408990532" LOG_CI_START="-0.4802676355297756" LOG_EFFECT_SIZE="-0.23440478656039251" ORDER="440" O_E="0.0" SE="0.28884210905069235" STUDY_ID="STD-Blennow-1988" TOTAL_1="193" TOTAL_2="72" VAR="0.08342976396085205" WEIGHT="4.633162124375968"/>
<DICH_DATA CI_END="1.7546844484439499" CI_START="0.08726303624756288" EFFECT_SIZE="0.391304347826087" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.24419902700057333" LOG_CI_START="-1.0591696801571093" LOG_EFFECT_SIZE="-0.40748532657826797" ORDER="443" O_E="0.0" SE="0.7656052303635761" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.5861513687600644" WEIGHT="0.7583807972063032"/>
<DICH_DATA CI_END="0.7602570280915781" CI_START="0.4426187874418461" EFFECT_SIZE="0.5800896860986547" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="100" LOG_CI_END="-0.11903955638964075" LOG_CI_START="-0.35397015590999104" LOG_EFFECT_SIZE="-0.23650485614981592" MODIFIED="2009-03-22 11:44:06 -0300" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="0.1379993970834768" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.019043833595403105" WEIGHT="13.40497184707394"/>
<DICH_DATA CI_END="0.7439735738960879" CI_START="0.2793495992536574" EFFECT_SIZE="0.45588235294117646" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="19" LOG_CI_END="-0.12844249041505204" LOG_CI_START="-0.5538519473288752" LOG_EFFECT_SIZE="-0.34114721887196364" MODIFIED="2009-03-22 11:44:53 -0300" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="0.24988762080195354" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.06244382303006092" WEIGHT="5.889252697627025"/>
<DICH_DATA CI_END="4.052028519218188" CI_START="0.20320395059230723" EFFECT_SIZE="0.9074074074074074" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.6076724933751876" LOG_CI_START="-0.6920678529640973" LOG_EFFECT_SIZE="-0.04219767979445483" ORDER="446" O_E="0.0" SE="0.7634739132581737" STUDY_ID="STD-Pichichero-1993" TOTAL_1="81" TOTAL_2="21" VAR="0.5828924162257494" WEIGHT="0.7625147779676991"/>
<DICH_DATA CI_END="1.0470238275094452" CI_START="0.08050170265270859" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.019956565191851173" LOG_CI_START="-1.0941949339817467" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2009-03-22 11:14:09 -0300" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="0.6544581057534393" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.4283154121863799" WEIGHT="1.0284130812781287"/>
<DICH_DATA CI_END="1.1437288896798117" CI_START="0.39963390159838086" EFFECT_SIZE="0.6760716223548562" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" LOG_CI_END="0.05832309117926682" LOG_CI_START="-0.3983376769711129" LOG_EFFECT_SIZE="-0.17000729289592303" ORDER="448" O_E="0.0" SE="0.26824479571879234" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.07195527043021663" WEIGHT="5.2448006484793535"/>
<DICH_DATA CI_END="0.8307712450136286" CI_START="0.3106579995719943" EFFECT_SIZE="0.5080213903743316" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="-0.08051854385098267" LOG_CI_START="-0.5077174586443196" LOG_EFFECT_SIZE="-0.2941180012476512" ORDER="444" O_E="0.0" SE="0.2509387572183393" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.06297025987428465" WEIGHT="5.8494714940298005"/>
<DICH_DATA CI_END="0.8165786984438516" CI_START="0.37277426530453867" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="58" LOG_CI_END="-0.08800195342227285" LOG_CI_START="-0.42855407706378973" LOG_EFFECT_SIZE="-0.2582780152430313" ORDER="447" O_E="0.0" SE="0.20004200318722662" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.04001680303915838" WEIGHT="8.291515370622221"/>
<DICH_DATA CI_END="0.5203412786631791" CI_START="0.39075169040282" EFFECT_SIZE="0.450914885786666" ESTIMABLE="YES" EVENTS_1="369" EVENTS_2="163" LOG_CI_END="-0.2837117201648087" LOG_CI_START="-0.40809913453454905" LOG_EFFECT_SIZE="-0.3459054273496789" ORDER="442" O_E="0.0" SE="0.07306578292841694" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.005338608634942543" WEIGHT="22.453953824470453"/>
<DICH_DATA CI_END="0.5562739443155937" CI_START="0.31799418303210064" EFFECT_SIZE="0.4205851619644723" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="54" LOG_CI_END="-0.25471128179019986" LOG_CI_START="-0.4975808243557125" LOG_EFFECT_SIZE="-0.37614605307295623" ORDER="445" O_E="0.0" SE="0.14266277152660706" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.020352666379652887" WEIGHT="12.908185014854352"/>
<DICH_DATA CI_END="0.4204021618414401" CI_START="0.27571966191896063" EFFECT_SIZE="0.3404601914070454" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="120" LOG_CI_END="-0.3763350593578911" LOG_CI_START="-0.5595322626993213" LOG_EFFECT_SIZE="-0.4679336610286063" ORDER="439" O_E="0.0" SE="0.10761094408353807" STUDY_ID="STD-Black-1997" TOTAL_1="1637" TOTAL_2="418" VAR="0.011580115286550357" WEIGHT="17.17420066178007"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.64419939427792" CI_END="0.5928747313716812" CI_START="0.43740791415321634" DF="20" EFFECT_SIZE="0.5092426726065241" ESTIMABLE="YES" EVENTS_1="503" EVENTS_2="523" I2="49.55125767305388" ID="CMP-001.14.04" LOG_CI_END="-0.22703705911649708" LOG_CI_START="-0.3591133634063456" LOG_EFFECT_SIZE="-0.2930752112614214" MODIFIED="2012-02-10 15:59:04 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.005538873501703456" P_Z="3.3701879881289515E-18" STUDIES="21" TAU2="0.05290531920386129" TOTAL_1="1980" TOTAL_2="1075" WEIGHT="100.00000000000001" Z="8.698257600746683">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.42566381766765693" CI_START="0.07491300359228004" EFFECT_SIZE="0.17857142857142858" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.3709332642111952" LOG_CI_START="-1.1254427898012056" LOG_EFFECT_SIZE="-0.7481880270062004" ORDER="461" O_E="0.0" SE="0.44320263021395917" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.19642857142857145" WEIGHT="2.414035800650003"/>
<DICH_DATA CI_END="6.0558931308155035" CI_START="0.4586900260249003" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7821782025047912" LOG_CI_START="-0.3384807032720784" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="453" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="0.43333333333333335" WEIGHT="1.2378714344516306"/>
<DICH_DATA CI_END="1.8233459656252724" CI_START="0.21876921565031265" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26086908045234897" LOG_CI_START="-0.6600137902627572" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="452" O_E="0.0" SE="0.540931156701781" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="0.2926065162907268" WEIGHT="1.7420559195619014"/>
<DICH_DATA CI_END="1.116594372319971" CI_START="0.41633384923118394" EFFECT_SIZE="0.6818181818181818" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.047895434658471514" LOG_CI_START="-0.3805582781915215" LOG_EFFECT_SIZE="-0.16633142176652502" ORDER="462" O_E="0.0" SE="0.2516758318081696" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.06334072431633408" WEIGHT="5.177818703115492"/>
<DICH_DATA CI_END="1.4861482244425976" CI_START="0.48841639524853053" EFFECT_SIZE="0.8519736842105263" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.17206212695295384" LOG_CI_START="-0.31120976600795763" LOG_EFFECT_SIZE="-0.06957381952750191" ORDER="451" O_E="0.0" SE="0.283876302159691" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.08058575492786019" WEIGHT="4.508922729231492"/>
<DICH_DATA CI_END="0.9988649474820755" CI_START="0.2217049339407375" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-4.932270174729487E-4" LOG_CI_START="-0.6542246417551878" LOG_EFFECT_SIZE="-0.32735893438633035" ORDER="459" O_E="0.0" SE="0.38400506903962656" STUDY_ID="STD-Kanra-1993a" TOTAL_1="55" TOTAL_2="55" VAR="0.14745989304812834" WEIGHT="3.0040191684825177"/>
<DICH_DATA CI_END="0.7861946596202483" CI_START="0.06854575449352374" EFFECT_SIZE="0.23214285714285715" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.1044699105354343" LOG_CI_START="-1.164019438863293" LOG_EFFECT_SIZE="-0.6342446746993636" MODIFIED="2009-03-22 11:14:22 -0300" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.6223846377945373" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.3873626373626374" WEIGHT="1.3671241100444091"/>
<DICH_DATA CI_END="0.8568984325623609" CI_START="0.4464876235634467" EFFECT_SIZE="0.6185422740524781" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="25" LOG_CI_END="-0.06707065157945674" LOG_CI_START="-0.3501905750567261" LOG_EFFECT_SIZE="-0.2086306133180914" ORDER="457" O_E="0.0" SE="0.1663060445167718" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.027657700442814487" WEIGHT="7.471181454491085"/>
<DICH_DATA CI_END="0.6703535579711213" CI_START="0.39765609716597455" EFFECT_SIZE="0.5163043478260869" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="46" LOG_CI_END="-0.17369608121478075" LOG_CI_START="-0.4004923542265967" LOG_EFFECT_SIZE="-0.2870942177206887" ORDER="449" O_E="0.0" SE="0.13322125342679814" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.017747902364607174" WEIGHT="8.519086956548136"/>
<DICH_DATA CI_END="0.6017851789977978" CI_START="0.0942019584098723" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="21" LOG_CI_END="-0.22055851243963145" LOG_CI_START="-1.0259400683561695" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="456" O_E="0.0" SE="0.473085112648373" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.2238095238095238" WEIGHT="2.175166795345815"/>
<DICH_DATA CI_END="0.6259644934317967" CI_START="0.12382750573578957" EFFECT_SIZE="0.2784090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" LOG_CI_END="-0.20345030056589072" LOG_CI_START="-0.9071828750053818" LOG_EFFECT_SIZE="-0.5553165877856362" ORDER="464" O_E="0.0" SE="0.4133759977581822" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.17087971552257264" WEIGHT="2.6896389163727545"/>
<DICH_DATA CI_END="1.0717774810598084" CI_START="0.4709696417475407" EFFECT_SIZE="0.7104749512036435" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" LOG_CI_END="0.030104627913597692" LOG_CI_START="-0.3270070861756511" LOG_EFFECT_SIZE="-0.1484512291310267" ORDER="460" O_E="0.0" SE="0.2097691885875191" STUDY_ID="STD-Kanra-1993b" TOTAL_1="53" TOTAL_2="52" VAR="0.04400311248066616" WEIGHT="6.211027542592514"/>
<DICH_DATA CI_END="0.7841993478719954" CI_START="0.3187964905586831" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="-0.10557352318821152" LOG_CI_START="-0.49648646813975084" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="450" O_E="0.0" SE="0.2296241989148198" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.05272727272727273" WEIGHT="5.69806086642698"/>
<DICH_DATA CI_END="0.8968421259467745" CI_START="0.14899393548153259" EFFECT_SIZE="0.36554621848739494" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="-0.04728400050613659" LOG_CI_START="-0.8268314083696504" LOG_EFFECT_SIZE="-0.43705770443789344" ORDER="454" O_E="0.0" SE="0.4579100062009312" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.20968157377893687" WEIGHT="2.2921971902895972"/>
<DICH_DATA CI_END="0.8438430403756474" CI_START="0.3052181954186" EFFECT_SIZE="0.5075" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="-0.0737383271161015" LOG_CI_START="-0.5153895797133976" LOG_EFFECT_SIZE="-0.2945639534147495" ORDER="455" O_E="0.0" SE="0.2594281319846108" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.06730295566502463" WEIGHT="5.007150622189304"/>
<DICH_DATA CI_END="0.9563013769628306" CI_START="0.5206672555643255" EFFECT_SIZE="0.7056307911617962" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="23" LOG_CI_END="-0.019405218889754352" LOG_CI_START="-0.28343973397186556" LOG_EFFECT_SIZE="-0.15142247643081" ORDER="458" O_E="0.0" SE="0.15509518115116072" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.024054515216311363" WEIGHT="7.820974964887337"/>
<DICH_DATA CI_END="0.4761837321969779" CI_START="0.15962215677146827" EFFECT_SIZE="0.2756981580510992" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="9" LOG_CI_END="-0.3222254454237144" LOG_CI_START="-0.7969068254181717" LOG_EFFECT_SIZE="-0.559566135420943" ORDER="463" O_E="0.0" SE="0.2788301923194708" STUDY_ID="STD-Pichichero-1997" TOTAL_1="187" TOTAL_2="16" VAR="0.07774627614891308" WEIGHT="4.606916101382789"/>
<DICH_DATA CI_END="0.5506299796143648" CI_START="0.33573220663888814" EFFECT_SIZE="0.42995839112343964" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="103" LOG_CI_END="-0.25914014669016644" LOG_CI_START="-0.4740069950801463" LOG_EFFECT_SIZE="-0.3665735708851564" MODIFIED="2009-03-22 11:15:04 -0300" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.1262138503523274" STUDY_ID="STD-Halperin-1999" TOTAL_1="126" TOTAL_2="124" VAR="0.015929936020759698" WEIGHT="8.744079415961215"/>
<DICH_DATA CI_END="0.698895039795255" CI_START="0.32445125047810075" EFFECT_SIZE="0.47619047619047616" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="-0.15558804179430288" LOG_CI_START="-0.48885054767353564" LOG_EFFECT_SIZE="-0.3222192947339193" MODIFIED="2009-03-22 11:15:12 -0300" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="0.19576004562947108" STUDY_ID="STD-Pichichero-2000" TOTAL_1="49" TOTAL_2="10" VAR="0.0383219954648526" WEIGHT="6.59781492514396"/>
<DICH_DATA CI_END="0.9854952181887472" CI_START="0.49215130236090965" EFFECT_SIZE="0.6964285714285714" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="56" LOG_CI_END="-0.006345478659300943" LOG_CI_START="-0.30790136130010154" LOG_EFFECT_SIZE="-0.15712341997970122" MODIFIED="2009-03-22 11:15:33 -0300" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.17713541818889972" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.03137695637695638" WEIGHT="7.1414889329238225"/>
<DICH_DATA CI_END="0.6332138651574997" CI_START="0.25233227515391515" EFFECT_SIZE="0.39972527472527475" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="48" LOG_CI_END="-0.19844958418323377" LOG_CI_START="-0.5980271964710261" LOG_EFFECT_SIZE="-0.3982383903271299" MODIFIED="2009-03-22 11:15:22 -0300" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.23471386739892985" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.05509059954936243" WEIGHT="5.573367449907251"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.312204737094934" CI_END="0.8026044485987516" CI_START="0.5224795880992466" DF="4" EFFECT_SIZE="0.6475680981259798" ESTIMABLE="YES" EVENTS_1="692" EVENTS_2="135" I2="61.21101062306055" ID="CMP-001.14.05" LOG_CI_END="-0.09549843742982056" LOG_CI_START="-0.2819306716265196" LOG_EFFECT_SIZE="-0.18871455452817007" MODIFIED="2012-02-10 15:59:32 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.03548455835414965" P_Z="7.25038535274017E-5" STUDIES="5" TAU2="0.035100847206851686" TOTAL_1="2015" TOTAL_2="248" WEIGHT="100.00000000000001" Z="3.967916083047">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="1.434016370886396" CI_START="0.6128983377342683" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="16" LOG_CI_END="0.15655410931298247" LOG_CI_START="-0.21261155651346952" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="465" O_E="0.0" SE="0.2168497395059757" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.047023809523809516" WEIGHT="14.603052450720877"/>
<DICH_DATA CI_END="0.8120749569110415" CI_START="0.5073733617445949" EFFECT_SIZE="0.6418918918918919" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="53" LOG_CI_END="-0.09040388224846325" LOG_CI_START="-0.294672337963756" LOG_EFFECT_SIZE="-0.19253811010610963" ORDER="466" O_E="0.0" SE="0.11998830203232634" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.014397192624600768" WEIGHT="24.2286497368173"/>
<DICH_DATA CI_END="0.815058817750612" CI_START="0.3368040823072672" EFFECT_SIZE="0.523941921532283" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="9" LOG_CI_END="-0.08881104978416784" LOG_CI_START="-0.47262265317958824" LOG_EFFECT_SIZE="-0.280716851481878" ORDER="467" O_E="0.0" SE="0.22545283573254793" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1079" TOTAL_2="16" VAR="0.05082898113984724" WEIGHT="13.95639550095021"/>
<DICH_DATA CI_END="0.6483257739524839" CI_START="0.39757478483282277" EFFECT_SIZE="0.5076987099459009" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="9" LOG_CI_END="-0.18820671283664395" LOG_CI_START="-0.4005811674216598" LOG_EFFECT_SIZE="-0.2943939401291519" MODIFIED="2009-03-22 11:15:47 -0300" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="0.12474980589374311" STUDY_ID="STD-Pichichero-2000" TOTAL_1="267" TOTAL_2="10" VAR="0.015562514070526584" WEIGHT="23.671360120963392"/>
<DICH_DATA CI_END="0.9627126666124323" CI_START="0.5877732241256381" EFFECT_SIZE="0.7522344900105152" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="48" LOG_CI_END="-0.016503314043673833" LOG_CI_START="-0.23079020199826317" LOG_EFFECT_SIZE="-0.12364675802096849" MODIFIED="2009-03-22 11:15:56 -0300" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.12587317872172848" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.015844057121512198" WEIGHT="23.540542190548223"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="747.2978863595959" CI_END="0.5161385342287104" CI_START="0.44262563054518045" CI_STUDY="95" CI_TOTAL="95" DF="70" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4779708612056264" ESTIMABLE="YES" EVENTS_1="6892" EVENTS_2="5509" I2="90.63291877607207" I2_Q="93.0011018321583" ID="CMP-001.15" LOG_CI_END="-0.2872337158609461" LOG_CI_START="-0.35396344155640264" LOG_EFFECT_SIZE="-0.32059857870867436" METHOD="MH" MODIFIED="2014-09-08 05:40:02 -0300" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="-1.3322676295501878E-15" P_Q="1.1496803509203346E-11" P_Z="0.0" Q="57.15185310709427" RANDOM="YES" SCALE="126.94" SORT_BY="YEAR" STUDIES="39" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.17291840216085283" TOTALS="SUB" TOTAL_1="35080" TOTAL_2="12949" WEIGHT="500.0" Z="18.833036138391165">
<NAME>Swelling/induration</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Whole-cell vaccine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours whole-cell</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="47.27523973579659" CI_END="0.30742847054909206" CI_START="0.19022201994612992" DF="14" EFFECT_SIZE="0.2418256906467913" ESTIMABLE="YES" EVENTS_1="1238" EVENTS_2="1670" I2="70.38618930704382" ID="CMP-001.15.01" LOG_CI_END="-0.5122559155291334" LOG_CI_START="-0.72073921091299" LOG_EFFECT_SIZE="-0.6164975632210616" MODIFIED="2009-03-22 11:37:35 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.7317067220412596E-5" P_Z="4.552979462541361E-31" STUDIES="15" TAU2="0.08906394396431008" TOTAL_1="10606" TOTAL_2="4006" WEIGHT="100.0" Z="11.591461255879107">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="0.14227705096336246" CI_START="0.008292083290393843" EFFECT_SIZE="0.03434782608695652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="23" LOG_CI_END="-0.8468651451984575" LOG_CI_START="-2.0813363442558455" LOG_EFFECT_SIZE="-1.4641007447271515" ORDER="470" O_E="0.0" SE="0.7251344930572976" STUDY_ID="STD-Blennow-1988" TOTAL_1="200" TOTAL_2="79" VAR="0.525820033021464" WEIGHT="2.4390716264367485"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="468" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Anderson-1988" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="3.083154349247206"/>
<DICH_DATA CI_END="1.867607932746826" CI_START="0.029515227676754685" EFFECT_SIZE="0.23478260869565218" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2712857099475967" LOG_CI_START="-1.5299538623368456" LOG_EFFECT_SIZE="-0.6293340761946243" ORDER="473" O_E="0.0" SE="1.058057041039564" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="1.1194847020933978" WEIGHT="1.240948030274799"/>
<DICH_DATA CI_END="0.4085856499142224" CI_START="0.12326021371323558" EFFECT_SIZE="0.22441558441558443" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="55" LOG_CI_END="-0.3887168904507758" LOG_CI_START="-0.9091770836084389" LOG_EFFECT_SIZE="-0.6489469870296074" ORDER="471" O_E="0.0" SE="0.30572089378031775" STUDY_ID="STD-Blumberg-1991" TOTAL_1="245" TOTAL_2="252" VAR="0.09346526489383632" WEIGHT="8.216471605824601"/>
<DICH_DATA CI_END="0.4102277200184316" CI_START="0.12361300348933346" EFFECT_SIZE="0.22518765638031693" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="-0.38697499671193714" LOG_CI_START="-0.9079358411677856" LOG_EFFECT_SIZE="-0.6474554189398614" MODIFIED="2009-03-22 11:37:25 -0300" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.30601497883113576" STUDY_ID="STD-Pichichero-1992" TOTAL_1="218" TOTAL_2="72" VAR="0.09364516726902047" WEIGHT="8.208381353797524"/>
<DICH_DATA CI_END="2.109166642980437" CI_START="0.06667325242792793" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.324110894233443" LOG_CI_START="-1.1760483587780053" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="477" O_E="0.0" SE="0.8812009711269907" STUDY_ID="STD-Pichichero-1993" TOTAL_1="88" TOTAL_2="22" VAR="0.7765151515151515" WEIGHT="1.7326505106801924"/>
<DICH_DATA CI_END="0.7784734465621517" CI_START="0.0027456372456694375" EFFECT_SIZE="0.04623208506703652" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.10875619646542693" LOG_CI_START="-2.5613568424127564" LOG_EFFECT_SIZE="-1.3350565194390915" ORDER="479" O_E="0.0" SE="1.4406697599984593" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="99" VAR="2.075529357374018" WEIGHT="0.6928535078110621"/>
<DICH_DATA CI_END="0.30236067452134524" CI_START="0.0055717353103503" EFFECT_SIZE="0.041044776119402986" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5194746944835935" LOG_CI_START="-2.254009523257534" LOG_EFFECT_SIZE="-1.3867421088705638" ORDER="475" O_E="0.0" SE="1.0188743445076898" STUDY_ID="STD-Halperin-1994a" TOTAL_1="67" TOTAL_2="33" VAR="1.0381049298959746" WEIGHT="1.3305424738001461"/>
<DICH_DATA CI_END="4.414602437813451" CI_START="0.019092817987527228" EFFECT_SIZE="0.2903225806451613" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6448915987769837" LOG_CI_START="-1.7191299675668792" LOG_EFFECT_SIZE="-0.5371191843949478" MODIFIED="2009-03-22 11:37:35 -0300" MODIFIED_BY="[Empty name]" ORDER="669" O_E="0.0" SE="1.3886379701658673" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="1.92831541218638" WEIGHT="0.743413011164254"/>
<DICH_DATA CI_END="0.5303406584575762" CI_START="0.21600496056802942" EFFECT_SIZE="0.3384615384615385" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="65" LOG_CI_END="-0.27544507650789957" LOG_CI_START="-0.6655362751333991" LOG_EFFECT_SIZE="-0.4704906758206493" ORDER="478" O_E="0.0" SE="0.22914150105519407" STUDY_ID="STD-Podda-1994" TOTAL_1="240" TOTAL_2="240" VAR="0.05250582750582751" WEIGHT="10.593688513037835"/>
<DICH_DATA CI_END="0.8573049806642956" CI_START="0.26846929353152366" EFFECT_SIZE="0.47975" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="-0.06686465315564481" LOG_CI_START="-0.5711053800293369" LOG_EFFECT_SIZE="-0.31898501659249084" ORDER="480" O_E="0.0" SE="0.2961934989974603" STUDY_ID="STD-Vanura-1994" TOTAL_1="200" TOTAL_2="101" VAR="0.08773058884835852" WEIGHT="8.482988913496088"/>
<DICH_DATA CI_END="0.26321898679512756" CI_START="0.178002538905351" EFFECT_SIZE="0.21645703485363274" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="147" LOG_CI_END="-0.5796827869313871" LOG_CI_START="-0.7495738031702049" LOG_EFFECT_SIZE="-0.664628295050796" ORDER="472" O_E="0.0" SE="0.09979482391277518" STUDY_ID="STD-Decker-1995" TOTAL_1="1814" TOTAL_2="370" VAR="0.009959006879781804" WEIGHT="15.145439002094424"/>
<DICH_DATA CI_END="0.3406357035209627" CI_START="0.29629340185452546" EFFECT_SIZE="0.3176918497370299" ESTIMABLE="YES" EVENTS_1="919" EVENTS_2="1180" LOG_CI_END="-0.4677098336796639" LOG_CI_START="-0.5282780196980671" LOG_EFFECT_SIZE="-0.4979939266888655" ORDER="474" O_E="0.0" SE="0.03557805228456632" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2102" VAR="0.001265797804363335" WEIGHT="16.603015047439268"/>
<DICH_DATA CI_END="0.34594191575540506" CI_START="0.10072339562656782" EFFECT_SIZE="0.18666666666666668" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.46099681387922076" LOG_CI_START="-0.9968696415477031" LOG_EFFECT_SIZE="-0.728933227713462" ORDER="476" O_E="0.0" SE="0.3147743515857443" STUDY_ID="STD-Halperin-1996" TOTAL_1="324" TOTAL_2="108" VAR="0.09908289241622575" WEIGHT="7.971146848216363"/>
<DICH_DATA CI_END="0.24124181298356018" CI_START="0.13506697469350157" EFFECT_SIZE="0.1805098386494901" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="97" LOG_CI_END="-0.6175474163733724" LOG_CI_START="-0.8694508276005055" LOG_EFFECT_SIZE="-0.743499121986939" ORDER="469" O_E="0.0" SE="0.147969310696814" STUDY_ID="STD-Black-1997" TOTAL_1="1851" TOTAL_2="463" VAR="0.02189491690809027" WEIGHT="13.516235206679484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="50.11664797727562" CI_END="0.451428119506727" CI_START="0.2757783042380713" DF="13" EFFECT_SIZE="0.3528371880668853" ESTIMABLE="YES" EVENTS_1="1842" EVENTS_2="1576" I2="74.06051576734625" ID="CMP-001.15.02" LOG_CI_END="-0.34541139216510325" LOG_CI_START="-0.5594399032084271" LOG_EFFECT_SIZE="-0.45242564768676513" MODIFIED="2009-03-22 11:38:00 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.8471780842975747E-6" P_Z="1.1695669411991168E-16" STUDIES="14" TAU2="0.09196073516297243" TOTAL_1="10034" TOTAL_2="3745" WEIGHT="100.0" Z="8.286166836611528">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="0.47541842294556536" CI_START="0.10155214846100813" EFFECT_SIZE="0.2197265625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="-0.32292399293056817" LOG_CI_START="-0.9933108841263307" LOG_EFFECT_SIZE="-0.6581174385284495" ORDER="483" O_E="0.0" SE="0.39378857835702197" STUDY_ID="STD-Blennow-1988" TOTAL_1="192" TOTAL_2="75" VAR="0.15506944444444443" WEIGHT="6.398356736906061"/>
<DICH_DATA CI_END="18.799956202692492" CI_START="0.18847132179213538" EFFECT_SIZE="1.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2741568375109602" LOG_CI_START="-0.7247547236276962" LOG_EFFECT_SIZE="0.27470105694163205" ORDER="481" O_E="0.0" SE="1.1741705457846552" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="16" VAR="1.3786764705882353" WEIGHT="1.074763515929722"/>
<DICH_DATA CI_END="4.286377634244062" CI_START="0.14288903656488317" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6320904301784372" LOG_CI_START="-0.8450010920070108" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="486" O_E="0.0" SE="0.8676508718526889" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="0.7528180354267311" WEIGHT="1.8710072612346669"/>
<DICH_DATA CI_END="0.9354105632898262" CI_START="0.32694774290176853" EFFECT_SIZE="0.5530193236714975" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="36" LOG_CI_END="-0.028997730052296448" LOG_CI_START="-0.4855216564620692" LOG_EFFECT_SIZE="-0.25725969325718284" ORDER="484" O_E="0.0" SE="0.2681644142029823" STUDY_ID="STD-Blumberg-1991" TOTAL_1="230" TOTAL_2="241" VAR="0.07191215304482867" WEIGHT="9.645202639657795"/>
<DICH_DATA CI_END="0.1698867014105212" CI_START="0.009387734040562482" EFFECT_SIZE="0.03993558776167472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.7698406160107228" LOG_CI_START="-2.027439222690005" LOG_EFFECT_SIZE="-1.398639919350364" MODIFIED="2009-03-22 11:37:49 -0300" MODIFIED_BY="[Empty name]" ORDER="670" O_E="0.0" SE="0.7387196467769123" STUDY_ID="STD-Pichichero-1992" TOTAL_1="207" TOTAL_2="62" VAR="0.545706716534206" WEIGHT="2.4787014135713394"/>
<DICH_DATA CI_END="0.8750201881177908" CI_START="0.003043988611288363" EFFECT_SIZE="0.0516096065406234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.057981926992527175" LOG_CI_START="-2.5165569767581903" LOG_EFFECT_SIZE="-1.2872694518753587" ORDER="491" O_E="0.0" SE="1.4441791543751243" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="100" VAR="2.085653429931649" WEIGHT="0.7258343738049436"/>
<DICH_DATA CI_END="1.2237663095568818" CI_START="0.05741041471002477" EFFECT_SIZE="0.26506024096385544" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.08769849284253728" LOG_CI_START="-1.2410093159502724" LOG_EFFECT_SIZE="-0.5766554115538677" ORDER="489" O_E="0.0" SE="0.7804895440946258" STUDY_ID="STD-Pichichero-1993" TOTAL_1="83" TOTAL_2="22" VAR="0.6091639284410368" WEIGHT="2.2543597393728763"/>
<DICH_DATA CI_END="0.6705422043602169" CI_START="0.30664690251235754" EFFECT_SIZE="0.45345307361497594" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="67" LOG_CI_END="-0.1735738821764106" LOG_CI_START="-0.5133614178298552" LOG_EFFECT_SIZE="-0.3434676500031329" ORDER="490" O_E="0.0" SE="0.19959288041826148" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="239" VAR="0.03983731791365843" WEIGHT="11.992492886000637"/>
<DICH_DATA CI_END="0.48908129137681405" CI_START="0.11277023228667238" EFFECT_SIZE="0.23484848484848486" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.3106189497471368" LOG_CI_START="-0.9478055249960176" LOG_EFFECT_SIZE="-0.6292122373715772" ORDER="488" O_E="0.0" SE="0.3742865484256091" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="31" VAR="0.14009042033235583" WEIGHT="6.811374028870333"/>
<DICH_DATA CI_END="1.510567336243009" CI_START="0.01394959344250422" EFFECT_SIZE="0.14516129032258066" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.1791400894947443" LOG_CI_START="-1.8554384496126024" LOG_EFFECT_SIZE="-0.838149180058929" MODIFIED="2009-03-22 11:38:00 -0300" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="1.1951215051978523" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="1.42831541218638" WEIGHT="1.0396711259767062"/>
<DICH_DATA CI_END="0.7705235497639633" CI_START="0.2495821128226865" EFFECT_SIZE="0.4385303815355629" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="-0.11321408325802901" LOG_CI_START="-0.6027865431112833" LOG_EFFECT_SIZE="-0.35800031318465614" ORDER="492" O_E="0.0" SE="0.2875772863405623" STUDY_ID="STD-Vanura-1994" TOTAL_1="193" TOTAL_2="98" VAR="0.08270069561900174" WEIGHT="9.049434708245581"/>
<DICH_DATA CI_END="0.42664320462540534" CI_START="0.2909601654765177" EFFECT_SIZE="0.35232964311456927" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="122" LOG_CI_END="-0.3699351672168374" LOG_CI_START="-0.5361664649588501" LOG_EFFECT_SIZE="-0.45305081608784376" ORDER="485" O_E="0.0" SE="0.09764508715185301" STUDY_ID="STD-Decker-1995" TOTAL_1="1774" TOTAL_2="358" VAR="0.009534563044892969" WEIGHT="15.573009211452733"/>
<DICH_DATA CI_END="0.5158841109751171" CI_START="0.4601096248257721" EFFECT_SIZE="0.48719938911531707" ESTIMABLE="YES" EVENTS_1="1444" EVENTS_2="1183" LOG_CI_END="-0.2874478480175522" LOG_CI_START="-0.33713868182974427" LOG_EFFECT_SIZE="-0.31229326492364823" ORDER="487" O_E="0.0" SE="0.029188641754875972" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2040" VAR="8.51976807494489E-4" WEIGHT="17.029857013694137"/>
<DICH_DATA CI_END="0.35377327734213565" CI_START="0.2018566100726829" EFFECT_SIZE="0.2672292545710267" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="81" LOG_CI_END="-0.45127497510396253" LOG_CI_START="-0.6949570244499124" LOG_EFFECT_SIZE="-0.5731159997769374" ORDER="482" O_E="0.0" SE="0.14314004203140931" STUDY_ID="STD-Black-1997" TOTAL_1="1738" TOTAL_2="418" VAR="0.020489071632753625" WEIGHT="14.055935345282464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="114.12016329614569" CI_END="0.5418158216460096" CI_START="0.2891665108661069" DF="14" EFFECT_SIZE="0.3958219178840776" ESTIMABLE="YES" EVENTS_1="2791" EVENTS_2="1658" I2="87.73222926112581" ID="CMP-001.15.03" LOG_CI_END="-0.2661483172186288" LOG_CI_START="-0.5388520052510161" LOG_EFFECT_SIZE="-0.4025001612348224" MODIFIED="2009-03-22 11:38:22 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="-2.220446049250313E-16" P_Z="7.222688216838024E-9" STUDIES="15" TAU2="0.2237224425427412" TOTAL_1="10157" TOTAL_2="3759" WEIGHT="100.0" Z="5.785663006494623">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="0.8132577418006864" CI_START="0.24131782657965703" EFFECT_SIZE="0.4430051813471503" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="-0.08977179376352075" LOG_CI_START="-0.6174105947956814" LOG_EFFECT_SIZE="-0.3535911942796011" ORDER="495" O_E="0.0" SE="0.3099376435804797" STUDY_ID="STD-Blennow-1988" TOTAL_1="193" TOTAL_2="72" VAR="0.09606134290822047" WEIGHT="8.024182314415999"/>
<DICH_DATA CI_END="2.8400097614401862" CI_START="0.10613432879307398" EFFECT_SIZE="0.5490196078431373" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4533198327696865" LOG_CI_START="-0.9741441222811207" LOG_EFFECT_SIZE="-0.2604121447557171" ORDER="493" O_E="0.0" SE="0.8384993932573817" STUDY_ID="STD-Anderson-1988" TOTAL_1="17" TOTAL_2="14" VAR="0.7030812324929971" WEIGHT="2.7686590642334896"/>
<DICH_DATA CI_END="3.0674223345991773" CI_START="0.009055739558409236" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4867735754472843" LOG_CI_START="-2.0430760762145717" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="498" O_E="0.0" SE="1.4860462083439174" STUDY_ID="STD-Edwards-1989a" TOTAL_1="23" TOTAL_2="27" VAR="2.2083333333333335" WEIGHT="1.0550758831705993"/>
<DICH_DATA CI_END="0.8307864687203599" CI_START="0.269916041374096" EFFECT_SIZE="0.473542600896861" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.08051058556969876" LOG_CI_START="-0.5687713041310356" LOG_EFFECT_SIZE="-0.3246409448503672" ORDER="496" O_E="0.0" SE="0.28680676301246594" STUDY_ID="STD-Blumberg-1991" TOTAL_1="223" TOTAL_2="231" VAR="0.0822581193096888" WEIGHT="8.386164729281571"/>
<DICH_DATA CI_END="0.42527106979183343" CI_START="0.09366287091621689" EFFECT_SIZE="0.19957983193277312" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="-0.37133416033115685" LOG_CI_START="-1.028432534532134" LOG_EFFECT_SIZE="-0.6998833474316454" MODIFIED="2009-03-22 11:38:13 -0300" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="0.385982837695065" STUDY_ID="STD-Pichichero-1992" TOTAL_1="204" TOTAL_2="57" VAR="0.1489827509951349" WEIGHT="6.884807188477873"/>
<DICH_DATA CI_END="3.109240272703812" CI_START="0.13511211263919334" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.4926542843067562" LOG_CI_START="-0.8693057152521421" LOG_EFFECT_SIZE="-0.1883257154726929" ORDER="502" O_E="0.0" SE="0.8000220455516251" STUDY_ID="STD-Pichichero-1993" TOTAL_1="81" TOTAL_2="21" VAR="0.6400352733686065" WEIGHT="2.9707443978607184"/>
<DICH_DATA CI_END="1.5786898764782598" CI_START="0.06756686143645041" EFFECT_SIZE="0.3265993265993266" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.19829682401568458" LOG_CI_START="-1.1702662541176196" LOG_EFFECT_SIZE="-0.48598471505096746" ORDER="504" O_E="0.0" SE="0.8039007265919973" STUDY_ID="STD-Tian-1993" TOTAL_1="99" TOTAL_2="97" VAR="0.6462563782151411" WEIGHT="2.949500992929037"/>
<DICH_DATA CI_END="0.8961807025097441" CI_START="0.12968256060300423" EFFECT_SIZE="0.3409090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="-0.04760441200048506" LOG_CI_START="-0.8871184228605273" LOG_EFFECT_SIZE="-0.46736141743050624" ORDER="500" O_E="0.0" SE="0.4931346856405643" STUDY_ID="STD-Halperin-1994a" TOTAL_1="66" TOTAL_2="30" VAR="0.24318181818181817" WEIGHT="5.495780637492121"/>
<DICH_DATA CI_END="0.7749660334996225" CI_START="0.24509874983197844" EFFECT_SIZE="0.43582474226804124" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="-0.11071733205750217" LOG_CI_START="-0.6106589039354288" LOG_EFFECT_SIZE="-0.3606881179964655" ORDER="505" O_E="0.0" SE="0.29366815407178715" STUDY_ID="STD-Vanura-1994" TOTAL_1="194" TOTAL_2="89" VAR="0.08624098471593092" WEIGHT="8.27840696673938"/>
<DICH_DATA CI_END="3.4319204473901896" CI_START="0.15349860618229536" EFFECT_SIZE="0.7258064516129032" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.5355372122594511" LOG_CI_START="-0.8138955637052715" LOG_EFFECT_SIZE="-0.1391791757229102" MODIFIED="2009-03-22 11:38:22 -0300" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="0.7926634924016495" STUDY_ID="STD-Pichichero-1994" TOTAL_1="62" TOTAL_2="18" VAR="0.6283154121863799" WEIGHT="3.011607267693978"/>
<DICH_DATA CI_END="0.6621719980873896" CI_START="0.2560515598667831" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="51" LOG_CI_END="-0.17902918862964576" LOG_CI_START="-0.5916725740983885" LOG_EFFECT_SIZE="-0.38535088136401713" ORDER="503" O_E="0.0" SE="0.24238876724204048" STUDY_ID="STD-Podda-1994" TOTAL_1="236" TOTAL_2="236" VAR="0.05875231448511607" WEIGHT="9.0840095683295"/>
<DICH_DATA CI_END="0.44866734893014526" CI_START="0.3088425921402664" EFFECT_SIZE="0.3722466750050126" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="122" LOG_CI_END="-0.348075534423743" LOG_CI_START="-0.5102628111344089" LOG_EFFECT_SIZE="-0.4291691727790759" ORDER="497" O_E="0.0" SE="0.09526960917981284" STUDY_ID="STD-Decker-1995" TOTAL_1="1717" TOTAL_2="342" VAR="0.009076298433274278" WEIGHT="11.022410967063493"/>
<DICH_DATA CI_END="0.36019236871200366" CI_START="0.1082842331990621" EFFECT_SIZE="0.1974921630094044" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="-0.44346549268632207" LOG_CI_START="-0.9654347745208767" LOG_EFFECT_SIZE="-0.7044501336035994" ORDER="501" O_E="0.0" SE="0.3066073399392334" STUDY_ID="STD-Halperin-1996" TOTAL_1="319" TOTAL_2="105" VAR="0.09400806090461261" WEIGHT="8.07603729516571"/>
<DICH_DATA CI_END="0.7550422573989213" CI_START="0.6907027131604013" EFFECT_SIZE="0.7221563097669292" ESTIMABLE="YES" EVENTS_1="2338" EVENTS_2="1274" LOG_CI_END="-0.12202874156073944" LOG_CI_START="-0.16070883803138522" LOG_EFFECT_SIZE="-0.14136878979606232" ORDER="499" O_E="0.0" SE="0.022720880136422823" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2001" VAR="5.162383941736933E-4" WEIGHT="11.443179138101069"/>
<DICH_DATA CI_END="0.45867411761473104" CI_START="0.2652730707515376" EFFECT_SIZE="0.34881784881784883" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="77" LOG_CI_END="-0.338495765850665" LOG_CI_START="-0.5763068352706313" LOG_EFFECT_SIZE="-0.45740130056064815" ORDER="494" O_E="0.0" SE="0.1396913993610672" STUDY_ID="STD-Black-1997" TOTAL_1="1638" TOTAL_2="419" VAR="0.019513687055453165" WEIGHT="10.54943358904546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.772441733918484" CI_END="0.5668724857382338" CI_START="0.4579695965638976" DF="20" EFFECT_SIZE="0.5095197381816653" ESTIMABLE="YES" EVENTS_1="446" EVENTS_2="493" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="-0.24651462182724324" LOG_CI_START="-0.3391633527446285" LOG_EFFECT_SIZE="-0.2928389872859358" MODIFIED="2012-02-10 16:00:02 -0200" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.6023957428281126" P_Z="2.9644368778104593E-35" STUDIES="22" TAU2="0.0" TOTAL_1="2144" TOTAL_2="1157" WEIGHT="100.00000000000001" Z="12.389891640532275">
<NAME>aP booster (previous wP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="0.8626395146952034" CI_START="0.09463124708594846" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.06417065212441682" LOG_CI_START="-1.0239654365761346" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="518" O_E="0.0" SE="0.5637882074477462" STUDY_ID="STD-Lewis-1986" TOTAL_1="40" TOTAL_2="20" VAR="0.31785714285714284" WEIGHT="0.9317988677091744"/>
<DICH_DATA CI_END="32.72441962136761" CI_START="0.48893151307571864" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.514871952931805" LOG_CI_START="-0.31075197027588036" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="510" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-Edwards-1989c" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="0.25754689200657305"/>
<DICH_DATA CI_END="8.495189495944357" CI_START="0.01582595002838123" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9291730708007208" LOG_CI_START="-1.8006302099235953" LOG_EFFECT_SIZE="-0.4357285695614374" ORDER="509" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Edwards-1989b" TOTAL_1="19" TOTAL_2="21" VAR="2.5712121212121213" WEIGHT="0.11519038953034115"/>
<DICH_DATA CI_END="0.9898150624110164" CI_START="0.2798586531655355" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="-0.004445941642041966" LOG_CI_START="-0.5530612602636159" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="520" O_E="0.0" SE="0.3222593538479378" STUDY_ID="STD-Morgan-1990" TOTAL_1="41" TOTAL_2="41" VAR="0.10385109114249039" WEIGHT="2.8519577651926875"/>
<DICH_DATA CI_END="1.2878132101391595" CI_START="0.2190284398460349" EFFECT_SIZE="0.5311004784688995" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.10985287568786274" LOG_CI_START="-0.6594994903366559" LOG_EFFECT_SIZE="-0.2748233073243966" ORDER="508" O_E="0.0" SE="0.4519213881584344" STUDY_ID="STD-Blumberg-1990" TOTAL_1="38" TOTAL_2="37" VAR="0.20423294107504633" WEIGHT="1.4502015406942932"/>
<DICH_DATA CI_END="1.0058061230527082" CI_START="0.14707505819696445" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.00251427515039779" LOG_CI_START="-0.8324609710920337" LOG_EFFECT_SIZE="-0.4149733479708179" ORDER="516" O_E="0.0" SE="0.4904685928369324" STUDY_ID="STD-Kanra-1993a" TOTAL_1="55" TOTAL_2="55" VAR="0.24055944055944056" WEIGHT="1.2312089067000271"/>
<DICH_DATA CI_END="1.0034312247331663" CI_START="0.44769496089950656" EFFECT_SIZE="0.6702470461868958" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="19" LOG_CI_END="0.0014876112605185258" LOG_CI_START="-0.3490177938583558" LOG_EFFECT_SIZE="-0.17376509129891865" ORDER="514" O_E="0.0" SE="0.2058886099965643" STUDY_ID="STD-Glode-1992" TOTAL_1="343" TOTAL_2="52" VAR="0.04239011972631736" WEIGHT="6.986980167071341"/>
<DICH_DATA CI_END="0.6213108846673645" CI_START="0.3577835072034576" EFFECT_SIZE="0.4714814814814815" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="45" LOG_CI_END="-0.20669103796974939" LOG_CI_START="-0.44637968304091435" LOG_EFFECT_SIZE="-0.3265353605053319" ORDER="506" O_E="0.0" SE="0.14079429659273066" STUDY_ID="STD-Bernstein-1992" TOTAL_1="240" TOTAL_2="76" VAR="0.01982303395304181" WEIGHT="14.94115010392296"/>
<DICH_DATA CI_END="0.5200660740285404" CI_START="0.08345627593349976" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="24" LOG_CI_END="-0.2839414760516662" LOG_CI_START="-1.0785409986995083" LOG_EFFECT_SIZE="-0.6812412373755872" ORDER="513" O_E="0.0" SE="0.4667516929344155" STUDY_ID="STD-Feldman-1992" TOTAL_1="84" TOTAL_2="84" VAR="0.21785714285714286" WEIGHT="1.3595098233789593"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-22 11:38:39 -0300" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="0.0" STUDY_ID="STD-Englund-1992" TOTAL_1="28" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7551260643548643" CI_START="0.1862271832983832" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="-0.12198053912128387" LOG_CI_START="-0.7299569254232784" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="519" O_E="0.0" SE="0.3571283388454409" STUDY_ID="STD-Marcinak-1993" TOTAL_1="164" TOTAL_2="82" VAR="0.12754065040650403" WEIGHT="2.322231577646519"/>
<DICH_DATA CI_END="1.0304664826097283" CI_START="0.45773820034392054" EFFECT_SIZE="0.6867924528301886" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" LOG_CI_END="0.01303387029827452" LOG_CI_START="-0.33938284220174064" LOG_EFFECT_SIZE="-0.1631744859517331" ORDER="517" O_E="0.0" SE="0.20701132141337059" STUDY_ID="STD-Kanra-1993b" TOTAL_1="53" TOTAL_2="52" VAR="0.04285368719330983" WEIGHT="6.911398883170022"/>
<DICH_DATA CI_END="0.714402261029413" CI_START="0.1764782411868225" EFFECT_SIZE="0.35507246376811596" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.14605717960797085" LOG_CI_START="-0.7533088331374747" LOG_EFFECT_SIZE="-0.44968300637272285" ORDER="522" O_E="0.0" SE="0.35670262722739476" STUDY_ID="STD-Rothstein-1993" TOTAL_1="48" TOTAL_2="49" VAR="0.12723676427092576" WEIGHT="2.327777883261036"/>
<DICH_DATA CI_END="1.1256997915414908" CI_START="0.295674067977406" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.05142258566584126" LOG_CI_START="-0.5291867634961147" LOG_EFFECT_SIZE="-0.23888208891513676" ORDER="507" O_E="0.0" SE="0.3410528057603636" STUDY_ID="STD-Bernstein-1994" TOTAL_1="110" TOTAL_2="55" VAR="0.1163170163170163" WEIGHT="2.5463077990269105"/>
<DICH_DATA CI_END="1.048610282954074" CI_START="0.19035786724644999" EFFECT_SIZE="0.44677871148459386" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.02061411220691999" LOG_CI_START="-0.7204291696449064" LOG_EFFECT_SIZE="-0.3499075287189932" ORDER="511" O_E="0.0" SE="0.43529249198316833" STUDY_ID="STD-Englund-1994a" TOTAL_1="102" TOTAL_2="29" VAR="0.18947955357691665" WEIGHT="1.5631181318322516"/>
<DICH_DATA CI_END="0.9317471855098006" CI_START="0.3592914631739332" EFFECT_SIZE="0.5785920925747348" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="-0.030701910427526607" LOG_CI_START="-0.44455310158326816" LOG_EFFECT_SIZE="-0.23762750600539737" ORDER="515" O_E="0.0" SE="0.24309823828131819" STUDY_ID="STD-Halperin-1994b" TOTAL_1="61" TOTAL_2="30" VAR="0.05909675345548055" WEIGHT="5.011763057858668"/>
<DICH_DATA CI_END="1.0298944921957447" CI_START="0.31986593859768486" EFFECT_SIZE="0.5739583333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.01279273557487987" LOG_CI_START="-0.49503200395044644" LOG_EFFECT_SIZE="-0.24111963418778334" ORDER="512" O_E="0.0" SE="0.29829876577017894" STUDY_ID="STD-Englund-1994b" TOTAL_1="80" TOTAL_2="29" VAR="0.08898215366001208" WEIGHT="3.328520536142739"/>
<DICH_DATA CI_END="0.6570180614761574" CI_START="0.17827868678687864" EFFECT_SIZE="0.3422459893048128" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="-0.18242269148799226" LOG_CI_START="-0.7489005736172314" LOG_EFFECT_SIZE="-0.46566163255261184" ORDER="521" O_E="0.0" SE="0.3327519120734558" STUDY_ID="STD-Pichichero-1997" TOTAL_1="187" TOTAL_2="16" VAR="0.11072383498854085" WEIGHT="2.674933774089485"/>
<DICH_DATA CI_END="0.6733837077830664" CI_START="0.4293860651038195" EFFECT_SIZE="0.5377188676157748" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="97" LOG_CI_END="-0.1717373953811159" LOG_CI_START="-0.36715205386045147" LOG_EFFECT_SIZE="-0.26944472462078367" MODIFIED="2009-03-22 11:39:12 -0300" MODIFIED_BY="[Empty name]" ORDER="680" O_E="0.0" SE="0.11478753770892186" STUDY_ID="STD-Halperin-1999" TOTAL_1="126" TOTAL_2="124" VAR="0.013176178813277158" WEIGHT="22.4783626577009"/>
<DICH_DATA CI_END="0.7441103293646543" CI_START="0.22388783567566156" EFFECT_SIZE="0.40816326530612246" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="-0.12836266676343464" LOG_CI_START="-0.6499695019656303" LOG_EFFECT_SIZE="-0.3891660843645325" MODIFIED="2009-03-22 11:39:26 -0300" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.3063944369932459" STUDY_ID="STD-Pichichero-2000" TOTAL_1="49" TOTAL_2="10" VAR="0.09387755102040815" WEIGHT="3.1549494270805205"/>
<DICH_DATA CI_END="0.6738184690576726" CI_START="0.3411516356447819" EFFECT_SIZE="0.4794520547945205" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="73" LOG_CI_END="-0.17145708937759663" LOG_CI_START="-0.467052542162764" LOG_EFFECT_SIZE="-0.3192548157701803" MODIFIED="2009-03-22 11:39:45 -0300" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.17363423218709712" STUDY_ID="STD-Kosuwon-2003" TOTAL_1="165" TOTAL_2="165" VAR="0.030148846587202748" WEIGHT="9.823889114659456"/>
<DICH_DATA CI_END="0.7668393244194966" CI_START="0.3560376887651822" EFFECT_SIZE="0.5225166989872873" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="51" LOG_CI_END="-0.11529562409276958" LOG_CI_START="-0.4485040268687254" LOG_EFFECT_SIZE="-0.2818998254807475" MODIFIED="2009-03-22 11:39:34 -0300" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.1957282651987915" STUDY_ID="STD-Halperin-2003" TOTAL_1="91" TOTAL_2="97" VAR="0.03830955379772845" WEIGHT="7.731202701325141"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.691197923714085" CI_END="0.7978959411529177" CI_START="0.5757454280784429" DF="5" EFFECT_SIZE="0.6777794185434806" ESTIMABLE="YES" EVENTS_1="575" EVENTS_2="112" I2="0.0" ID="CMP-001.15.05" LOG_CI_END="-0.09805374415034522" LOG_CI_START="-0.2397695020275393" LOG_EFFECT_SIZE="-0.1689116230889423" MODIFIED="2012-02-10 16:00:30 -0200" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.4547162256790178" P_Z="2.9802097729723546E-6" STUDIES="6" TAU2="0.0" TOTAL_1="2139" TOTAL_2="282" WEIGHT="100.0" Z="4.672179054518647">
<NAME>aP booster (previous aP) versus wP booster (previous wP)</NAME>
<DICH_DATA CI_END="2.8281903942940585" CI_START="0.46892609548205644" EFFECT_SIZE="1.1516129032258065" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.4515086428928868" LOG_CI_START="-0.3288955983370458" LOG_EFFECT_SIZE="0.061306522277920515" ORDER="525" O_E="0.0" SE="0.45841331436175914" STUDY_ID="STD-Pichichero-1996" TOTAL_1="124" TOTAL_2="34" VAR="0.21014276678413302" WEIGHT="3.2975929458970854"/>
<DICH_DATA CI_END="0.8910476525239802" CI_START="0.2805686085271089" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.050099069616524446" LOG_CI_START="-0.551960921711438" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="523" O_E="0.0" SE="0.29479613617678563" STUDY_ID="STD-Halperin-1995" TOTAL_1="56" TOTAL_2="30" VAR="0.08690476190476193" WEIGHT="7.9738473495625835"/>
<DICH_DATA CI_END="0.9575902599733142" CI_START="0.43027296548320615" EFFECT_SIZE="0.6418918918918919" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="27" LOG_CI_END="-0.018820279958951386" LOG_CI_START="-0.3662559402532679" LOG_EFFECT_SIZE="-0.19253811010610963" ORDER="524" O_E="0.0" SE="0.20408542669113708" STUDY_ID="STD-Halperin-1996" TOTAL_1="296" TOTAL_2="95" VAR="0.04165086138770349" WEIGHT="16.637478368772374"/>
<DICH_DATA CI_END="0.9328337104047326" CI_START="0.30066078095240706" EFFECT_SIZE="0.5295908910366741" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="7" LOG_CI_END="-0.03019576792573112" LOG_CI_START="-0.5219232188126792" LOG_EFFECT_SIZE="-0.27605949336920516" ORDER="526" O_E="0.0" SE="0.2888431387411317" STUDY_ID="STD-Pichichero-1997" TOTAL_1="1079" TOTAL_2="16" VAR="0.08343035879782867" WEIGHT="8.305913043690376"/>
<DICH_DATA CI_END="0.8971418820974006" CI_START="0.3791170020324831" EFFECT_SIZE="0.5831995719636169" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="7" LOG_CI_END="-0.04713886828337286" LOG_CI_START="-0.421226738593044" LOG_EFFECT_SIZE="-0.2341828034382084" MODIFIED="2009-03-22 11:39:56 -0300" MODIFIED_BY="[Empty name]" ORDER="682" O_E="0.0" SE="0.21974106678472374" STUDY_ID="STD-Pichichero-2000" TOTAL_1="267" TOTAL_2="10" VAR="0.048286136431688415" WEIGHT="14.351227010241509"/>
<DICH_DATA CI_END="0.9610064214594097" CI_START="0.6041791643559459" EFFECT_SIZE="0.7619842889837323" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="51" LOG_CI_END="-0.01727371035947756" LOG_CI_START="-0.2188342558274947" LOG_EFFECT_SIZE="-0.11805398309348615" MODIFIED="2009-03-22 11:40:06 -0300" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.0" SE="0.11839766214870469" STUDY_ID="STD-Halperin-2003" TOTAL_1="317" TOTAL_2="97" VAR="0.01401800640227882" WEIGHT="49.43394128183608"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-05-25 20:31:54 -0300" MODIFIED_BY="Liz Dooley" NO="2">
<NAME>Safety: acellular vaccines versus placebo/DT</NAME>
<DICH_OUTCOME CHI2="3.1324752914029728" CI_END="1.288499737670313" CI_START="0.3785844057601189" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6984310327498231" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="28" I2="36.15272862681575" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.11008433446756216" LOG_CI_START="-0.4218372789929577" LOG_EFFECT_SIZE="-0.1558764722626978" METHOD="MH" MODIFIED="2014-05-25 20:30:10 -0300" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.20882950424340996" P_Q="1.0" P_Z="0.2506749283261769" Q="0.0" RANDOM="YES" SCALE="74.43323643172262" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10872878269409347" TOTALS="YES" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="100.0" Z="1.1487116294616218">
<NAME>Primary series non-completion due to adverse events</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9129000456713374" CI_START="0.08541538331928948" EFFECT_SIZE="0.2792413066385669" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="-0.03957677119491739" LOG_CI_START="-1.068463905786052" LOG_EFFECT_SIZE="-0.5540203384904848" ORDER="527" O_E="0.0" SE="0.6043733959322889" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="954" VAR="0.3652672017107272" WEIGHT="20.596613343869674"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="530" O_E="0.0" SE="0.0" STUDY_ID="STD-Trollfors-1995" TOTAL_1="1724" TOTAL_2="1726" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.052210842200687" CI_START="0.35839829238092274" EFFECT_SIZE="0.8576181326501565" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="6" LOG_CI_END="0.3122219777362529" LOG_CI_START="-0.4456340682378956" LOG_EFFECT_SIZE="-0.06670604525082138" ORDER="528" O_E="0.0" SE="0.44516839285314497" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="0.19817489799545202" WEIGHT="31.810345172134433"/>
<DICH_DATA CI_END="1.663836755201884" CI_START="0.49265411739930787" EFFECT_SIZE="0.9053706578692025" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.2211107139061179" LOG_CI_START="-0.30745788320546896" LOG_EFFECT_SIZE="-0.04317358464967554" ORDER="529" O_E="0.0" SE="0.31048381040009954" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.09640019652056497" WEIGHT="47.59304148399589"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5534831119219805" CI_END="4.420027464663336" CI_START="0.2646388838315257" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0815318463888124" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.645424967927073" LOG_CI_START="-0.5773463438492505" LOG_EFFECT_SIZE="0.03403931203891125" METHOD="MH" MODIFIED="2014-05-25 20:30:16 -0300" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="0.4657030142852949" P_Q="1.0" P_Z="0.9131054660155414" Q="0.0" RANDOM="YES" SCALE="133.31750129007042" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="100.0" Z="0.10912232731052307">
<NAME>Death (all causes)</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5534831119219805" CI_END="4.420027464663336" CI_START="0.2646388838315257" DF="3" EFFECT_SIZE="1.0815318463888124" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.645424967927073" LOG_CI_START="-0.5773463438492505" LOG_EFFECT_SIZE="0.03403931203891125" NO="1" P_CHI2="0.4657030142852949" P_Z="0.9131054660155414" STUDIES="4" TAU2="0.0" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="100.0" Z="0.10912232731052307">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="66.64401167386033" CI_START="0.20415076504881247" EFFECT_SIZE="3.688553370786517" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.8237611317868148" LOG_CI_START="-0.6900489882325095" LOG_EFFECT_SIZE="0.5668560717771526" ORDER="531" O_E="0.0" SE="1.4766245080601323" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="954" VAR="2.180419937803828" WEIGHT="23.660588436251654"/>
<DICH_DATA CI_END="73.67646143106056" CI_START="0.122439127616857" EFFECT_SIZE="3.0034782608695654" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86732875918298" LOG_CI_START="-0.9120797734273234" LOG_EFFECT_SIZE="0.4776244928778283" ORDER="534" O_E="0.0" SE="1.6326383303494194" STUDY_ID="STD-Trollfors-1995" TOTAL_1="1724" TOTAL_2="1726" VAR="2.66550791772614" WEIGHT="19.354667237523575"/>
<DICH_DATA CI_END="22.495682945081434" CI_START="0.0600799558723095" EFFECT_SIZE="1.1625573700501655" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.3520991824217032" LOG_CI_START="-1.2212703949855712" LOG_EFFECT_SIZE="0.06541439371806594" ORDER="532" O_E="0.0" SE="1.5116100281538831" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="2.284964877215383" WEIGHT="22.578035785585023"/>
<DICH_DATA CI_END="2.7530916428912886" CI_START="0.022657716620138886" EFFECT_SIZE="0.24975742286046962" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.43982066810948295" LOG_CI_START="-1.6447838592228592" LOG_EFFECT_SIZE="-0.6024815955566881" ORDER="533" O_E="0.0" SE="1.22450701831385" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="1.4994174378998752" WEIGHT="34.40670854063975"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.162347043423747" CI_END="7.797155342217367" CI_START="0.18866664302895092" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.212873910837974" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="7.507908775211913" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.8919361867275061" LOG_CI_START="-0.7243048779433883" LOG_EFFECT_SIZE="0.0838156543920589" METHOD="MH" MODIFIED="2014-05-25 20:30:23 -0300" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="0.3391974626953921" P_Q="1.0" P_Z="0.8389152951466483" Q="0.0" RANDOM="YES" SCALE="330.41656947098926" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20364270598452655" TOTALS="YES" TOTAL_1="19093" TOTAL_2="6809" WEIGHT="100.0" Z="0.20328114108713402">
<NAME>Death (infection)</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.162347043423747" CI_END="7.797155342217367" CI_START="0.18866664302895092" DF="2" EFFECT_SIZE="1.212873910837974" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="7.507908775211913" ID="CMP-002.03.01" LOG_CI_END="0.8919361867275061" LOG_CI_START="-0.7243048779433883" LOG_EFFECT_SIZE="0.0838156543920589" NO="1" P_CHI2="0.3391974626953921" P_Z="0.8389152951466483" STUDIES="4" TAU2="0.20364270598452655" TOTAL_1="19093" TOTAL_2="6809" WEIGHT="100.0" Z="0.20328114108713402">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="55.982275256224426" CI_START="0.16257595667742838" EFFECT_SIZE="3.0168480168480167" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7480505452759614" LOG_CI_START="-0.7889436817087726" LOG_EFFECT_SIZE="0.47955343178359433" ORDER="535" O_E="0.0" SE="1.4902429672547943" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2848" TOTAL_2="954" VAR="2.220824101452374" WEIGHT="37.17673409286675"/>
<DICH_DATA CI_END="73.67646143106056" CI_START="0.122439127616857" EFFECT_SIZE="3.0034782608695654" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86732875918298" LOG_CI_START="-0.9120797734273234" LOG_EFFECT_SIZE="0.4776244928778283" ORDER="538" O_E="0.0" SE="1.6326383303494194" STUDY_ID="STD-Trollfors-1995" TOTAL_1="1724" TOTAL_2="1726" VAR="2.66550791772614" WEIGHT="31.41478773271702"/>
<DICH_DATA CI_END="4.086637103907759" CI_START="0.00678667504510382" EFFECT_SIZE="0.1665373172940111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6113660737850417" LOG_CI_START="-2.168342944899719" LOG_EFFECT_SIZE="-0.7784884355573386" ORDER="537" O_E="0.0" SE="1.6328148373569857" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="2.66608429309312" WEIGHT="31.40847817441622"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="536" O_E="0.0" SE="0.0" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-05-25 20:30:44 -0300" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="555.9400487686668" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="14521" TOTAL_2="4129" WEIGHT="0.0" Z="0.0">
<NAME>Encephalopathy</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="14521" TOTAL_2="4129" WEIGHT="0.0" Z="0.0">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="540" O_E="0.0" SE="0.0" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="539" O_E="0.0" SE="0.0" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.711235414230988" CI_END="1.691085317583819" CI_START="0.115894012755956" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4427038099762289" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="71.99202627911447" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.22816551890534661" LOG_CI_START="-0.9359389997069356" LOG_EFFECT_SIZE="-0.35388674040079454" METHOD="MH" MODIFIED="2014-05-25 20:30:53 -0300" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.01339437365129481" P_Q="1.0" P_Z="0.2333967188234055" Q="0.0" RANDOM="YES" SCALE="597.2602279566576" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.0929016425137403" TOTALS="YES" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="99.99999999999999" Z="1.1916546232784546">
<NAME>Convulsions</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.711235414230988" CI_END="1.691085317583819" CI_START="0.115894012755956" DF="3" EFFECT_SIZE="0.4427038099762289" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="71.99202627911447" ID="CMP-002.05.01" LOG_CI_END="0.22816551890534661" LOG_CI_START="-0.9359389997069356" LOG_EFFECT_SIZE="-0.35388674040079454" NO="1" P_CHI2="0.01339437365129481" P_Z="0.2333967188234055" STUDIES="4" TAU2="1.0929016425137403" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="99.99999999999999" Z="1.1916546232784546">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="24.673256520153842" CI_START="0.041015008764197995" EFFECT_SIZE="1.0059691011235956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.392226473988961" LOG_CI_START="-1.3870571913117808" LOG_EFFECT_SIZE="0.0025846413385900643" ORDER="541" O_E="0.0" SE="1.6325649826736799" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="954" VAR="2.665268422652313" WEIGHT="12.441785940442628"/>
<DICH_DATA CI_END="104.1911012253386" CI_START="0.24050042975055944" EFFECT_SIZE="5.005797101449275" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.017830628236399" LOG_CI_START="-0.6188841432480297" LOG_EFFECT_SIZE="0.6994732424941846" ORDER="544" O_E="0.0" SE="1.5488193087185713" STUDY_ID="STD-Trollfors-1995" TOTAL_1="1724" TOTAL_2="1726" VAR="2.398841251059473" WEIGHT="13.391119822893383"/>
<DICH_DATA CI_END="1.2568468260398815" CI_START="0.19852465386080093" EFFECT_SIZE="0.49951484572093924" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.09928235273838817" LOG_CI_START="-0.7021855525238019" LOG_EFFECT_SIZE="-0.30145159989270687" ORDER="543" O_E="0.0" SE="0.47078621488112576" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.22163966012209754" WEIGHT="35.57008622309423"/>
<DICH_DATA CI_END="0.25733400641070836" CI_START="0.06673369271702241" EFFECT_SIZE="0.13104521551530407" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="-0.5895028184509953" LOG_CI_START="-1.175654842746201" LOG_EFFECT_SIZE="-0.8825788305985981" ORDER="542" O_E="0.0" SE="0.3443086005703189" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="0.11854841242669142" WEIGHT="38.59700801356975"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0961982994209283" CI_END="5.125727861905894" CI_START="0.016485809991738275" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2906918911850474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="52.29458967330292" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.7097555446476819" LOG_CI_START="-1.7828897099524108" LOG_EFFECT_SIZE="-0.5365670826523645" METHOD="MH" MODIFIED="2014-05-25 20:30:57 -0300" MODIFIED_BY="Liz Dooley" NO="6" P_CHI2="0.14766594891674034" P_Q="1.0" P_Z="0.3987788859460951" Q="0.0" RANDOM="YES" SCALE="355.19553667955057" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.283016275734051" TOTALS="YES" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="100.0" Z="0.8438041115939562">
<NAME>Hypotonic hyporesponsive episodes</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0961982994209283" CI_END="5.125727861905894" CI_START="0.016485809991738275" DF="1" EFFECT_SIZE="0.2906918911850474" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="52.29458967330292" ID="CMP-002.06.01" LOG_CI_END="0.7097555446476819" LOG_CI_START="-1.7828897099524108" LOG_EFFECT_SIZE="-0.5365670826523645" NO="1" P_CHI2="0.14766594891674034" P_Z="0.3987788859460951" STUDIES="4" TAU2="2.283016275734051" TOTAL_1="19092" TOTAL_2="6809" WEIGHT="100.0" Z="0.8438041115939562">
<NAME>Primary series</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="545" O_E="0.0" SE="0.0" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="954" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="548" O_E="0.0" SE="0.0" STUDY_ID="STD-Trollfors-1995" TOTAL_1="1724" TOTAL_2="1726" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.77973393516983" CI_START="0.06108007540593436" EFFECT_SIZE="1.4988358556461001" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5656085832243665" LOG_CI_START="-1.2141004354603941" LOG_EFFECT_SIZE="0.17575407388198633" ORDER="547" O_E="0.0" SE="1.6328148373569857" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="2.66608429309312" WEIGHT="43.31814752054007"/>
<DICH_DATA CI_END="0.9147399346518795" CI_START="0.007530249949337472" EFFECT_SIZE="0.08299530315969257" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="-0.03870236057783702" LOG_CI_START="-2.123190608153026" LOG_EFFECT_SIZE="-1.0809464843654315" ORDER="546" O_E="0.0" SE="1.2244387150089042" STUDY_ID="STD-Greco-1996" TOTAL_1="9368" TOTAL_2="1555" VAR="1.4992501668126563" WEIGHT="56.681852479459934"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.488533009094487" CI_END="1.1637527061909965" CI_START="0.9608881834994327" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0574668902118949" ESTIMABLE="YES" EVENTS_1="1824" EVENTS_2="796" I2="38.35278337347592" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.06586070389913071" LOG_CI_START="-0.017327147310184227" LOG_EFFECT_SIZE="0.024266778294473268" METHOD="MH" MODIFIED="2011-09-18 17:05:43 -0300" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.1655143971213312" P_Q="0.9306942127496297" P_Z="0.252837483285003" Q="0.1436490442015105" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005481562910093303" TOTALS="SUB" TOTAL_1="20988" TOTAL_2="9547" WEIGHT="300.0" Z="1.14348455421241">
<NAME>Anorexia</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3227496415332565E-4" CI_END="1.1974025691802426" CI_START="0.9343678108277444" DF="1" EFFECT_SIZE="1.0577402409119454" ESTIMABLE="YES" EVENTS_1="750" EVENTS_2="325" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.07824018564498034" LOG_CI_START="-0.029482131512374173" LOG_EFFECT_SIZE="0.024379027066303127" NO="1" P_CHI2="0.9878402555345416" P_Z="0.3750072704191313" STUDIES="2" TAU2="0.0" TOTAL_1="8000" TOTAL_2="3526" WEIGHT="100.00000000000001" Z="0.8871330711960832">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.4069587600086233" CI_START="0.798356350901033" EFFECT_SIZE="1.0598369976127116" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="59" LOG_CI_END="0.14828136782339216" LOG_CI_START="-0.09780321555964415" LOG_EFFECT_SIZE="0.02523907613187401" ORDER="549" O_E="0.0" SE="0.14455130241752914" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="952" VAR="0.020895079030603964" WEIGHT="19.162076046327254"/>
<DICH_DATA CI_END="1.213614771744566" CI_START="0.9210208519346412" EFFECT_SIZE="1.0572438275973264" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="266" LOG_CI_END="0.08408085390928588" LOG_CI_START="-0.03573053725414104" LOG_EFFECT_SIZE="0.024175158327572395" ORDER="550" O_E="0.0" SE="0.07037780424534823" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.004953035330396555" WEIGHT="80.83792395367276"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.466653851845623" CI_END="1.4610293898253137" CI_START="0.6643581221371464" DF="1" EFFECT_SIZE="0.9852140588783365" ESTIMABLE="YES" EVENTS_1="656" EVENTS_2="276" I2="84.53605182973271" ID="CMP-002.07.02" LOG_CI_END="0.16465895221806087" LOG_CI_START="-0.1775977511423151" LOG_EFFECT_SIZE="-0.006469399462127115" NO="2" P_CHI2="0.010991756264456587" P_Z="0.940934632266538" STUDIES="2" TAU2="0.06874398860189852" TOTAL_1="7903" TOTAL_2="3483" WEIGHT="100.00000000000001" Z="0.07409520294491265">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.0377188792722445" CI_START="0.6059297399550576" EFFECT_SIZE="0.7929594760540319" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="70" LOG_CI_END="0.016079717947451454" LOG_CI_START="-0.21757773114532133" LOG_EFFECT_SIZE="-0.10074900659893496" ORDER="551" O_E="0.0" SE="0.1372515422201215" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2792" TOTAL_2="928" VAR="0.018837985841801796" WEIGHT="46.1492235066609"/>
<DICH_DATA CI_END="1.3866111250548707" CI_START="1.0155437652513637" EFFECT_SIZE="1.1866609805996204" ESTIMABLE="YES" EVENTS_1="489" EVENTS_2="206" LOG_CI_END="0.1419546803071197" LOG_CI_START="0.0066986442328032195" LOG_EFFECT_SIZE="0.07432666226996143" ORDER="552" O_E="0.0" SE="0.07945006511823008" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.006312312847290999" WEIGHT="53.85077649333911"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2595093015500178" CI_START="0.9088313147195717" DF="0" EFFECT_SIZE="1.0698978897208986" ESTIMABLE="YES" EVENTS_1="418" EVENTS_2="195" I2="0.0" ID="CMP-002.07.03" LOG_CI_END="0.10020137913617985" LOG_CI_START="-0.04151671731130029" LOG_EFFECT_SIZE="0.029342330912439773" NO="3" P_CHI2="1.0" P_Z="0.4170154614818553" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="0.811609995511774">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.2595093015500178" CI_START="0.9088313147195717" EFFECT_SIZE="1.0698978897208986" ESTIMABLE="YES" EVENTS_1="418" EVENTS_2="195" LOG_CI_END="0.10020137913617985" LOG_CI_START="-0.04151671731130029" LOG_EFFECT_SIZE="0.029342330912439773" ORDER="553" O_E="0.0" SE="0.08324591136914115" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="0.006929881759678904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9291550147222749" CI_END="1.0745423246506007" CI_START="0.9702008719372943" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.021039617404506" ESTIMABLE="YES" EVENTS_1="3559" EVENTS_2="1691" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.03122352638883219" LOG_CI_START="-0.013138339401374188" LOG_EFFECT_SIZE="0.009042593493728995" METHOD="MH" MODIFIED="2014-05-25 20:31:06 -0300" MODIFIED_BY="Liz Dooley" NO="8" P_CHI2="0.9203413375921653" P_Q="0.8046031600797465" P_Z="0.4242749384775575" Q="0.4348124865905615" RANDOM="YES" SCALE="2.4168215141052496" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19976" TOTAL_2="9221" WEIGHT="300.0" Z="0.7990266982169087">
<NAME>Drowsiness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.492448149844691" CI_END="1.1126286744786973" CI_START="0.9638962629531747" DF="1" EFFECT_SIZE="1.0355957808839125" ESTIMABLE="YES" EVENTS_1="1696" EVENTS_2="792" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.04635024831323793" LOG_CI_START="-0.015969703494729877" LOG_EFFECT_SIZE="0.015190272409254002" NO="1" P_CHI2="0.4828373163995242" P_Z="0.3393406545517911" STUDIES="2" TAU2="0.0" TOTAL_1="7557" TOTAL_2="3397" WEIGHT="99.99999999999999" Z="0.955468865869177">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.5700103516650306" CI_START="0.8464551589312759" EFFECT_SIZE="1.1527980576590038" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="49" LOG_CI_END="0.19590251588450788" LOG_CI_START="-0.07239604375058675" LOG_EFFECT_SIZE="0.06175323606696058" ORDER="554" O_E="0.0" SE="0.1575999020289441" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2404" TOTAL_2="823" VAR="0.02483772911953278" WEIGHT="5.395324065487705"/>
<DICH_DATA CI_END="1.1080796101046988" CI_START="0.956089592341464" EFFECT_SIZE="1.0292829458933486" ESTIMABLE="YES" EVENTS_1="1531" EVENTS_2="743" LOG_CI_END="0.04457096344940552" LOG_CI_START="-0.019501409359447854" LOG_EFFECT_SIZE="0.012534777044978854" ORDER="555" O_E="0.0" SE="0.037636428951281026" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.0014165007842048246" WEIGHT="94.60467593451229"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0050618558601749405" CI_END="1.0918740868703602" CI_START="0.9082406498278909" DF="1" EFFECT_SIZE="0.9958335353809746" ESTIMABLE="YES" EVENTS_1="1145" EVENTS_2="549" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.038172559128535975" LOG_CI_START="-0.041799064424844726" LOG_EFFECT_SIZE="-0.0018132526481544004" NO="2" P_CHI2="0.9432809847179686" P_Z="0.9291778560206039" STUDIES="2" TAU2="0.0" TOTAL_1="7334" TOTAL_2="3286" WEIGHT="100.0" Z="0.08887927310572222">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.3745162458638018" CI_START="0.7372186430682536" EFFECT_SIZE="1.0066374728028864" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="49" LOG_CI_END="0.13814987728047465" LOG_CI_START="-0.13240369070839966" LOG_EFFECT_SIZE="0.002873093286037458" ORDER="556" O_E="0.0" SE="0.15892450509842565" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2223" TOTAL_2="731" VAR="0.025256998320779524" WEIGHT="8.737059527011816"/>
<DICH_DATA CI_END="1.0954541199206935" CI_START="0.9034039951050835" EFFECT_SIZE="0.994805321854823" ESTIMABLE="YES" EVENTS_1="995" EVENTS_2="500" LOG_CI_END="0.039594193049140476" LOG_CI_START="-0.04411799319873801" LOG_EFFECT_SIZE="-0.0022619000747987447" ORDER="557" O_E="0.0" SE="0.049172952584008826" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.0024179792658291805" WEIGHT="91.26294047298818"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.152783087978733" CI_START="0.9094242368285659" DF="0" EFFECT_SIZE="1.0238988621997471" ESTIMABLE="YES" EVENTS_1="718" EVENTS_2="350" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="0.06174759649140297" LOG_CI_START="-0.041233475707508405" LOG_EFFECT_SIZE="0.010257060391947265" NO="3" P_CHI2="1.0" P_Z="0.6962183366534584" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="0.39043036795418906">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.152783087978733" CI_START="0.9094242368285659" EFFECT_SIZE="1.0238988621997471" ESTIMABLE="YES" EVENTS_1="718" EVENTS_2="350" LOG_CI_END="0.06174759649140297" LOG_CI_START="-0.041233475707508405" LOG_EFFECT_SIZE="0.010257060391947265" ORDER="558" O_E="0.0" SE="0.060491591574169286" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="0.0036592326511761084" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.003643602860407" CI_END="1.089731074234288" CI_START="0.9565831463021265" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0209889223758657" ESTIMABLE="YES" EVENTS_1="2745" EVENTS_2="1284" I2="25.034143226271706" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.03731933520108805" LOG_CI_START="-0.01927727507650009" LOG_EFFECT_SIZE="0.009021030062293994" METHOD="MH" MODIFIED="2011-09-18 17:07:12 -0300" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.237836539402992" P_Q="0.7740972738327772" P_Z="0.5320997136982415" Q="0.5121155025879851" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0029157901082790707" TOTALS="SUB" TOTAL_1="20308" TOTAL_2="9454" WEIGHT="300.0" Z="0.624803992282584">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.056188555625287" CI_END="1.9003284068857638" CI_START="0.7323565464147588" DF="2" EFFECT_SIZE="1.179710959990081" ESTIMABLE="YES" EVENTS_1="557" EVENTS_2="230" I2="71.65608622511124" ID="CMP-002.09.01" LOG_CI_END="0.27882866041263926" LOG_CI_START="-0.13527743200024647" LOG_EFFECT_SIZE="0.07177561420619641" NO="1" P_CHI2="0.02936085644163211" P_Z="0.4968667740274081" STUDIES="3" TAU2="0.10229110129129727" TOTAL_1="7762" TOTAL_2="3493" WEIGHT="100.0" Z="0.679427911783164">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="2.309018530321033" CI_START="1.1213362940508118" EFFECT_SIZE="1.6090948641036795" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="34" LOG_CI_END="0.3634274182285148" LOG_CI_START="0.04973587909607467" LOG_EFFECT_SIZE="0.20658164866229473" ORDER="559" O_E="0.0" SE="0.1842639628845572" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2569" TOTAL_2="857" VAR="0.033953208017921475" WEIGHT="43.42902430170377"/>
<DICH_DATA CI_END="2.6767663217830737" CI_START="0.007328129188338533" EFFECT_SIZE="0.1400560224089636" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.427610459498556" LOG_CI_START="-2.1350068830509046" LOG_EFFECT_SIZE="-0.8536982117761743" ORDER="561" O_E="0.0" SE="1.5052941121739825" STUDY_ID="STD-Tian-1993" TOTAL_1="101" TOTAL_2="99" VAR="2.2659103641456584" WEIGHT="2.498502558297831"/>
<DICH_DATA CI_END="1.1972063919009495" CI_START="0.8597369657888065" EFFECT_SIZE="1.0145356527968286" ESTIMABLE="YES" EVENTS_1="393" EVENTS_2="193" LOG_CI_END="0.07816902687839497" LOG_CI_START="-0.06563439966286318" LOG_EFFECT_SIZE="0.006267313607765888" ORDER="560" O_E="0.0" SE="0.08447084458877678" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5092" TOTAL_2="2537" VAR="0.007135323585541279" WEIGHT="54.0724731399984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0688891434594815" CI_END="1.1059256293790896" CI_START="0.911237338846233" DF="1" EFFECT_SIZE="1.0038728642000674" ESTIMABLE="YES" EVENTS_1="1053" EVENTS_2="502" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.04372592277676604" LOG_CI_START="-0.04036849292079022" LOG_EFFECT_SIZE="0.001678714927987901" NO="2" P_CHI2="0.7929611095929596" P_Z="0.9376286829491195" STUDIES="3" TAU2="0.0" TOTAL_1="7476" TOTAL_2="3377" WEIGHT="100.0" Z="0.07825063702206524">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.4826510110108386" CI_START="0.7427873799778674" EFFECT_SIZE="1.0494257762654189" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="40" LOG_CI_END="0.17103893806240952" LOG_CI_START="-0.12913548357056243" LOG_EFFECT_SIZE="0.020951727245923552" ORDER="562" O_E="0.0" SE="0.17632394115455888" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2351" TOTAL_2="771" VAR="0.031090132224276344" WEIGHT="7.8485051880248164"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="564" O_E="0.0" SE="0.0" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1062121810011938" CI_START="0.9041407516373092" EFFECT_SIZE="1.0000857527236184" ESTIMABLE="YES" EVENTS_1="925" EVENTS_2="462" LOG_CI_END="0.04383843637187064" LOG_CI_START="-0.043763955695934074" LOG_EFFECT_SIZE="3.724033796827709E-5" ORDER="563" O_E="0.0" SE="0.051458078739462884" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5023" TOTAL_2="2509" VAR="0.0026479338675567624" WEIGHT="92.15149481197518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002609818651935368" CI_END="1.127267864608522" CI_START="0.9422501810162621" DF="1" EFFECT_SIZE="1.0306155197168319" ESTIMABLE="YES" EVENTS_1="1135" EVENTS_2="552" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.0520271266039574" LOG_CI_START="-0.025833770445769243" LOG_EFFECT_SIZE="0.013096678079094159" NO="3" P_CHI2="0.9592567041414053" P_Z="0.5096673170001766" STUDIES="2" TAU2="0.0" TOTAL_1="5070" TOTAL_2="2584" WEIGHT="100.00000000000001" Z="0.659355808236987">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="15.114497166819081" CI_START="0.06087091811892903" EFFECT_SIZE="0.9591836734693877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1793937035278435" LOG_CI_START="-1.2155901477134359" LOG_EFFECT_SIZE="-0.01809822209279622" ORDER="566" O_E="0.0" SE="1.406825369580392" STUDY_ID="STD-Tian-1993" TOTAL_1="98" TOTAL_2="94" VAR="1.9791576204950065" WEIGHT="0.10568993410900678"/>
<DICH_DATA CI_END="1.1274069830242996" CI_START="0.9422771185295302" EFFECT_SIZE="1.0306938456080001" ESTIMABLE="YES" EVENTS_1="1134" EVENTS_2="551" LOG_CI_END="0.052080720460688894" LOG_CI_START="-0.025821354798225005" LOG_EFFECT_SIZE="0.013129682831231941" ORDER="565" O_E="0.0" SE="0.04576006462857779" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="4972" TOTAL_2="2490" VAR="0.0020939835148116163" WEIGHT="99.894310065891"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1931462726457316" CI_END="1.0102118971399248" CI_START="0.9449868599911632" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9770552536085015" ESTIMABLE="YES" EVENTS_1="6937" EVENTS_2="3309" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.004412478838570784" LOG_CI_START="-0.024574230298149837" LOG_EFFECT_SIZE="-0.01008087572978956" METHOD="MH" MODIFIED="2014-05-25 20:31:17 -0300" MODIFIED_BY="Liz Dooley" NO="10" P_CHI2="0.8792257606451356" P_Q="0.8462288883947009" P_Z="0.17280182669605496" Q="0.3339308662684506" RANDOM="YES" SCALE="2.2276175392203816" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20988" TOTAL_2="9547" WEIGHT="300.0" Z="1.3632560543398609">
<NAME>Irritability/fretfulness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03522121704357282" CI_END="1.0475933911027981" CI_START="0.9293673429041054" DF="1" EFFECT_SIZE="0.9867112476976782" ESTIMABLE="YES" EVENTS_1="2373" EVENTS_2="1084" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.02019274995113291" LOG_CI_START="-0.031812592289390706" LOG_EFFECT_SIZE="-0.005809921169128903" NO="1" P_CHI2="0.8511329287677355" P_Z="0.6614401936932794" STUDIES="2" TAU2="0.0" TOTAL_1="8000" TOTAL_2="3526" WEIGHT="100.0" Z="0.43792563432594234">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.13393432997016" CI_START="0.8774277591886837" EFFECT_SIZE="0.9974695274607837" ESTIMABLE="YES" EVENTS_1="701" EVENTS_2="235" LOG_CI_END="0.05458790380078608" LOG_CI_START="-0.05678862993590286" LOG_EFFECT_SIZE="-0.001100363067558374" ORDER="567" O_E="0.0" SE="0.06542312723966467" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="952" VAR="0.0042801855778173544" WEIGHT="21.80261180408778"/>
<DICH_DATA CI_END="1.0526452312674823" CI_START="0.9193310714191767" EFFECT_SIZE="0.9837324170146177" ESTIMABLE="YES" EVENTS_1="1672" EVENTS_2="849" LOG_CI_END="0.022282027345551625" LOG_CI_START="-0.03652806141287561" LOG_EFFECT_SIZE="-0.007123017033661977" ORDER="568" O_E="0.0" SE="0.03454533725133454" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.0011933803258084418" WEIGHT="78.19738819591223"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8284276649411689" CI_END="1.0333380237490488" CI_START="0.9295674531561138" DF="1" EFFECT_SIZE="0.9800803002743066" ESTIMABLE="YES" EVENTS_1="2716" EVENTS_2="1267" I2="0.0" ID="CMP-002.10.02" LOG_CI_END="0.014242410421423093" LOG_CI_START="-0.031719090592892914" LOG_EFFECT_SIZE="-0.008738340085734942" NO="2" P_CHI2="0.362727647068509" P_Z="0.4561093627462913" STUDIES="2" TAU2="0.0" TOTAL_1="7903" TOTAL_2="3483" WEIGHT="100.0" Z="0.7452686041462617">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.0534205031034294" CI_START="0.8217320377437306" EFFECT_SIZE="0.9303920553273265" ESTIMABLE="YES" EVENTS_1="697" EVENTS_2="249" LOG_CI_END="0.022601766933960724" LOG_CI_START="-0.08526978039393743" LOG_EFFECT_SIZE="-0.03133400672998834" ORDER="569" O_E="0.0" SE="0.06336428087317846" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2792" TOTAL_2="928" VAR="0.004015032090575049" WEIGHT="18.154094432754682"/>
<DICH_DATA CI_END="1.0511760001727461" CI_START="0.93512935893794" EFFECT_SIZE="0.9914562719416767" ESTIMABLE="YES" EVENTS_1="2019" EVENTS_2="1018" LOG_CI_END="0.02167543677475439" LOG_CI_START="-0.029128307857966492" LOG_EFFECT_SIZE="-0.003726435541606048" ORDER="570" O_E="0.0" SE="0.02984237107985203" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="8.905671116675889E-4" WEIGHT="81.84590556724531"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.024183175046553" CI_START="0.9051000721298071" DF="0" EFFECT_SIZE="0.9628022982984462" ESTIMABLE="YES" EVENTS_1="1848" EVENTS_2="958" I2="0.0" ID="CMP-002.10.03" LOG_CI_END="0.010377637106209363" LOG_CI_START="-0.043303400495277346" LOG_EFFECT_SIZE="-0.016462881694533967" NO="3" P_CHI2="1.0" P_Z="0.2293007411357023" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="1.2021621281827337">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.024183175046553" CI_START="0.9051000721298071" EFFECT_SIZE="0.9628022982984462" ESTIMABLE="YES" EVENTS_1="1848" EVENTS_2="958" LOG_CI_END="0.010377637106209363" LOG_CI_START="-0.043303400495277346" LOG_EFFECT_SIZE="-0.016462881694533967" ORDER="571" O_E="0.0" SE="0.03153250721253499" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="9.942990111085712E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6859385171930255" CI_END="1.3591746915980578" CI_START="0.885993396025005" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0973694914659338" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="154" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.13327527919115403" LOG_CI_START="-0.052569515224222214" LOG_EFFECT_SIZE="0.040352881983465906" METHOD="MH" MODIFIED="2014-05-25 20:31:26 -0300" MODIFIED_BY="Liz Dooley" NO="11" P_CHI2="0.6116776129542991" P_Q="0.8537723480857411" P_Z="0.3946902443269644" Q="0.31618142848007685" RANDOM="YES" SCALE="4.862458005850836" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20987" TOTAL_2="9547" WEIGHT="300.0" Z="0.8511424342961817">
<NAME>Prolonged crying</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.230831479520682" CI_END="2.3371614745787914" CI_START="0.7076131237266896" DF="1" EFFECT_SIZE="1.2860039392165075" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="50" I2="55.1736646546309" ID="CMP-002.11.01" LOG_CI_END="0.36868871885175813" LOG_CI_START="-0.15020412105735464" LOG_EFFECT_SIZE="0.10924229889720173" NO="1" P_CHI2="0.13528112541960535" P_Z="0.40922352489919844" STUDIES="2" TAU2="0.11089312135985938" TOTAL_1="7999" TOTAL_2="3526" WEIGHT="100.0" Z="0.8252608437008994">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="4.0604541250331145" CI_START="0.9110981954306935" EFFECT_SIZE="1.9234012649332397" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="8" LOG_CI_END="0.6085746081995353" LOG_CI_START="-0.04043481354785675" LOG_EFFECT_SIZE="0.2840698973258393" ORDER="572" O_E="0.0" SE="0.3812313469828687" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2846" TOTAL_2="952" VAR="0.14533733992237244" WEIGHT="36.25766246036719"/>
<DICH_DATA CI_END="1.4747292059483337" CI_START="0.7093863714849629" EFFECT_SIZE="1.022816112666685" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="42" LOG_CI_END="0.16871228122324142" LOG_CI_START="-0.14911715931732075" LOG_EFFECT_SIZE="0.009797560952960343" ORDER="573" O_E="0.0" SE="0.18669458665463043" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.034854868686143306" WEIGHT="63.7423375396328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.32277463427021597" CI_END="1.4021972382879904" CI_START="0.8277451175532815" DF="1" EFFECT_SIZE="1.07734020524604" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="78" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.14680910740754394" LOG_CI_START="-0.08210337225021795" LOG_EFFECT_SIZE="0.03235286757866302" NO="2" P_CHI2="0.569945076569085" P_Z="0.5795686930311634" STUDIES="2" TAU2="0.0" TOTAL_1="7903" TOTAL_2="3483" WEIGHT="99.99999999999999" Z="0.554014838732913">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="2.5863313180695844" CI_START="0.6496959804020542" EFFECT_SIZE="1.2962750716332379" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="10" LOG_CI_END="0.41268415874723724" LOG_CI_START="-0.1872898201587617" LOG_EFFECT_SIZE="0.1126971692942378" ORDER="574" O_E="0.0" SE="0.3524276851284776" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2792" TOTAL_2="928" VAR="0.12420527324501734" WEIGHT="14.557074649053764"/>
<DICH_DATA CI_END="1.3883132962590712" CI_START="0.7849489761943679" EFFECT_SIZE="1.0439133587303049" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="68" LOG_CI_END="0.1424874830373708" LOG_CI_START="-0.10515857265274134" LOG_EFFECT_SIZE="0.01866445519231476" ORDER="575" O_E="0.0" SE="0.1454685189801181" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.021161090014268975" WEIGHT="85.44292535094623"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6792516732356373" CI_START="0.6638412180281184" DF="0" EFFECT_SIZE="1.0558202859087815" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="26" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.2251157897095376" LOG_CI_START="-0.17793578566284066" LOG_EFFECT_SIZE="0.023590002023348464" NO="3" P_CHI2="1.0" P_Z="0.8185366770926956" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="0.22942748365775814">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.6792516732356373" CI_START="0.6638412180281184" EFFECT_SIZE="1.0558202859087815" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="26" LOG_CI_END="0.2251157897095376" LOG_CI_START="-0.17793578566284066" LOG_EFFECT_SIZE="0.023590002023348464" ORDER="576" O_E="0.0" SE="0.23675449051121028" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="0.05605268877722276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.975382200617901" CI_END="1.0909994773663445" CI_START="0.8887745095631713" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9847093608928216" ESTIMABLE="YES" EVENTS_1="1124" EVENTS_2="525" I2="19.604166298958226" I2_Q="43.67848293272286" ID="CMP-002.12" LOG_CI_END="0.0378245425434592" LOG_CI_START="-0.05120840964190279" LOG_EFFECT_SIZE="-0.006691933549221775" METHOD="MH" MODIFIED="2014-05-25 20:31:31 -0300" MODIFIED_BY="Liz Dooley" NO="12" P_CHI2="0.2898328403549215" P_Q="0.16939533503328208" P_Z="0.7682755233322889" Q="3.5510407108014532" RANDOM="YES" SCALE="1.922403368496246" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.003433700729726073" TOTALS="SUB" TOTAL_1="20988" TOTAL_2="9547" WEIGHT="300.0" Z="0.2946313341627326">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.041077434372024" CI_END="1.3041857248309738" CI_START="0.944364258075869" DF="1" EFFECT_SIZE="1.1097866391442737" ESTIMABLE="YES" EVENTS_1="513" EVENTS_2="209" I2="3.9456656167753525" ID="CMP-002.12.01" LOG_CI_END="0.11533944225921436" LOG_CI_START="-0.024860458287681745" LOG_EFFECT_SIZE="0.04523949198576636" NO="1" P_CHI2="0.30757135834842253" P_Z="0.205915652137997" STUDIES="2" TAU2="7.183072875268557E-4" TOTAL_1="8000" TOTAL_2="3526" WEIGHT="100.00000000000001" Z="1.26487643179649">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="1.3240903086947053" CI_START="0.6980026213944867" EFFECT_SIZE="0.9613628380751669" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="48" LOG_CI_END="0.12191760687878815" LOG_CI_START="-0.15614294635245113" LOG_EFFECT_SIZE="-0.017112669736831457" ORDER="577" O_E="0.0" SE="0.16333414538996713" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2847" TOTAL_2="952" VAR="0.026678043050270918" WEIGHT="24.755853497491458"/>
<DICH_DATA CI_END="1.3908487738149513" CI_START="0.9732573039674588" EFFECT_SIZE="1.1634662555611939" ESTIMABLE="YES" EVENTS_1="375" EVENTS_2="161" LOG_CI_END="0.14327991197044235" LOG_CI_START="-0.011772328364117797" LOG_EFFECT_SIZE="0.06575379180316225" ORDER="578" O_E="0.0" SE="0.0910784534934887" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.008295284690765584" WEIGHT="75.24414650250856"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16219950903661823" CI_END="1.0713297424870967" CI_START="0.7584582134045735" DF="1" EFFECT_SIZE="0.9014204581958106" ESTIMABLE="YES" EVENTS_1="370" EVENTS_2="185" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.029923162056773943" LOG_CI_START="-0.1200683412948085" LOG_EFFECT_SIZE="-0.045072589619017285" NO="2" P_CHI2="0.6871397234130399" P_Z="0.2388197151804371" STUDIES="2" TAU2="0.0" TOTAL_1="7903" TOTAL_2="3483" WEIGHT="100.0" Z="1.177942088308242">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="1.3807923919080827" CI_START="0.6704322794230795" EFFECT_SIZE="0.9621474890665058" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="38" LOG_CI_END="0.1401283854384574" LOG_CI_START="-0.17364508382015045" LOG_EFFECT_SIZE="-0.01675834919084653" ORDER="579" O_E="0.0" SE="0.18431208904622887" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2792" TOTAL_2="928" VAR="0.033970946168585" WEIGHT="22.850771996943493"/>
<DICH_DATA CI_END="1.0762766804675243" CI_START="0.7263704079685487" EFFECT_SIZE="0.8841807120030559" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="147" LOG_CI_END="0.03192393058129163" LOG_CI_START="-0.13884185710501873" LOG_EFFECT_SIZE="-0.053458963261863564" ORDER="580" O_E="0.0" SE="0.10030866899122061" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.010061829074790262" WEIGHT="77.1492280030565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.129791050281648" CI_START="0.7462677684738837" DF="0" EFFECT_SIZE="0.9182192798757008" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="131" I2="0.0" ID="CMP-002.12.03" LOG_CI_END="0.052998130120002485" LOG_CI_START="-0.1271053152819491" LOG_EFFECT_SIZE="-0.03705359258097332" NO="3" P_CHI2="1.0" P_Z="0.41997386419832505" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="0.806466603617138">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.129791050281648" CI_START="0.7462677684738837" EFFECT_SIZE="0.9182192798757008" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="131" LOG_CI_END="0.052998130120002485" LOG_CI_START="-0.1271053152819491" LOG_EFFECT_SIZE="-0.03705359258097332" ORDER="581" O_E="0.0" SE="0.10579365535553943" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="0.011192297513486656" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6543335106067945" CI_END="1.1486564815202807" CI_START="0.909499957833434" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0221071477627948" ESTIMABLE="YES" EVENTS_1="1599" EVENTS_2="768" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.0601901675167085" LOG_CI_START="-0.041197316735415025" LOG_EFFECT_SIZE="0.009496425390646672" METHOD="MH" MODIFIED="2014-05-25 20:31:39 -0300" MODIFIED_BY="Liz Dooley" NO="13" P_CHI2="0.4548027244791072" P_Q="0.8688435815949334" P_Z="0.7135005961622396" Q="0.28118435805636444" RANDOM="YES" SCALE="2.978473660990833" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20797" TOTAL_2="9479" WEIGHT="300.0" Z="0.3671587649074038">
<NAME>Pain/tenderness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2580066430747907" CI_END="1.3220588251804979" CI_START="0.7756267936071257" DF="1" EFFECT_SIZE="1.0126323358133262" ESTIMABLE="YES" EVENTS_1="458" EVENTS_2="226" I2="20.5091638025199" ID="CMP-002.13.01" LOG_CI_END="0.12125077956937194" LOG_CI_START="-0.1103471968667495" LOG_EFFECT_SIZE="0.005451791351311213" NO="1" P_CHI2="0.2620288363266522" P_Z="0.9264798041579767" STUDIES="2" TAU2="0.015186008087959092" TOTAL_1="7940" TOTAL_2="3511" WEIGHT="100.0" Z="0.09227468101599867">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="2.702983470379036" CI_START="0.7312942312439443" EFFECT_SIZE="1.4059431777408096" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" LOG_CI_END="0.4318433898551728" LOG_CI_START="-0.13590785245952658" LOG_EFFECT_SIZE="0.14796776869782308" ORDER="582" O_E="0.0" SE="0.3334998901496296" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2787" TOTAL_2="937" VAR="0.11122217672981503" WEIGHT="14.640959184575223"/>
<DICH_DATA CI_END="1.121013816047235" CI_START="0.8173411175936293" EFFECT_SIZE="0.9572098438931487" ESTIMABLE="YES" EVENTS_1="412" EVENTS_2="215" LOG_CI_END="0.0496109651338674" LOG_CI_START="-0.08759665268422262" LOG_EFFECT_SIZE="-0.018992843775177626" ORDER="583" O_E="0.0" SE="0.08059643389500808" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.006495785156592406" WEIGHT="85.35904081542478"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.188591239746403" CI_END="1.5065670926983328" CI_START="0.8099643156028655" DF="1" EFFECT_SIZE="1.1046563194709946" ESTIMABLE="YES" EVENTS_1="630" EVENTS_2="289" I2="54.30850759889396" ID="CMP-002.13.02" LOG_CI_END="0.1779884770912505" LOG_CI_START="-0.09153411430424667" LOG_EFFECT_SIZE="0.04322718139350196" NO="2" P_CHI2="0.13903651014573237" P_Z="0.5295489215197815" STUDIES="2" TAU2="0.03151224974257425" TOTAL_1="7772" TOTAL_2="3430" WEIGHT="100.0" Z="0.6286947468542274">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="2.1411808572412503" CI_START="0.9078303926645246" EFFECT_SIZE="1.3942127019917325" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="25" LOG_CI_END="0.3306533520140018" LOG_CI_START="-0.04199528188668762" LOG_EFFECT_SIZE="0.14432903506365707" ORDER="584" O_E="0.0" SE="0.21889565219375276" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2661" TOTAL_2="875" VAR="0.04791530654932838" WEIGHT="31.556901210189608"/>
<DICH_DATA CI_END="1.1414458518019552" CI_START="0.8625205538838937" EFFECT_SIZE="0.9922300682425903" ESTIMABLE="YES" EVENTS_1="524" EVENTS_2="264" LOG_CI_END="0.05745531414303701" LOG_CI_START="-0.06423054688425667" LOG_EFFECT_SIZE="-0.0033876163706097967" ORDER="585" O_E="0.0" SE="0.07147887712215906" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.005109229874644713" WEIGHT="68.44309878981039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1629995293105482" CI_START="0.8738211254050738" DF="0" EFFECT_SIZE="1.0080940221763615" ESTIMABLE="YES" EVENTS_1="511" EVENTS_2="253" I2="0.0" ID="CMP-002.13.03" LOG_CI_END="0.06557953896071583" LOG_CI_START="-0.058577460043081134" LOG_EFFECT_SIZE="0.003501039458817348" NO="3" P_CHI2="1.0" P_Z="0.9119842724786602" STUDIES="1" TAU2="0.0" TOTAL_1="5085" TOTAL_2="2538" WEIGHT="100.0" Z="0.11053603587061178">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="1.1629995293105482" CI_START="0.8738211254050738" EFFECT_SIZE="1.0080940221763615" ESTIMABLE="YES" EVENTS_1="511" EVENTS_2="253" LOG_CI_END="0.06557953896071583" LOG_CI_START="-0.058577460043081134" LOG_EFFECT_SIZE="0.003501039458817348" ORDER="586" O_E="0.0" SE="0.07293043580188732" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="0.005318848466253209" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.958498881075247" CI_END="1.2003203566816978" CI_START="1.074230971728818" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1355268834968468" ESTIMABLE="YES" EVENTS_1="4822" EVENTS_2="2084" I2="66.58963513747338" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.07929717152360638" LOG_CI_START="0.031097669596932536" LOG_EFFECT_SIZE="0.055197420560269425" METHOD="MH" MODIFIED="2014-05-25 20:31:45 -0300" MODIFIED_BY="Liz Dooley" NO="14" P_CHI2="0.006336757214650435" P_Q="0.6376917096857464" P_Z="7.1541933538454346E-6" Q="0.8998007397808544" RANDOM="YES" SCALE="7.1274934678580655" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.009466110414991777" TOTALS="SUB" TOTAL_1="21100" TOTAL_2="9769" WEIGHT="300.0" Z="4.489048725118411">
<NAME>Swelling/induration</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.424186853225064" CI_END="2.6823480808341174" CI_START="0.6236988046898112" DF="2" EFFECT_SIZE="1.2934362341369008" ESTIMABLE="YES" EVENTS_1="933" EVENTS_2="391" I2="17.498108805463527" ID="CMP-002.14.01" LOG_CI_END="0.42851513435698996" LOG_CI_START="-0.20502508826747765" LOG_EFFECT_SIZE="0.11174502304475611" MODIFIED="2011-09-18 18:16:55 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2975737470027666" P_Z="0.4893115003290408" STUDIES="3" TAU2="0.16212934522277272" TOTAL_1="8042" TOTAL_2="3610" WEIGHT="100.0" Z="0.6914043111960164">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="35.74550362061295" CI_START="0.619783336276249" EFFECT_SIZE="4.706853247219232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.5532214202470778" LOG_CI_START="-0.20776010454165345" LOG_EFFECT_SIZE="0.6727306578527121" ORDER="589" O_E="0.0" SE="1.0344092646600345" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2787" TOTAL_2="937" VAR="1.070002526814513" WEIGHT="11.2400022454172"/>
<DICH_DATA CI_END="7.850578865436474" CI_START="0.013340784238694024" EFFECT_SIZE="0.32362459546925565" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8949016807957151" LOG_CI_START="-1.8748186396453845" LOG_EFFECT_SIZE="-0.48995847942483467" ORDER="591" O_E="0.0" SE="1.6269474265638055" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="99" VAR="2.646957928802589" WEIGHT="4.930129845522255"/>
<DICH_DATA CI_END="1.3156048781170533" CI_START="1.0585299372470036" EFFECT_SIZE="1.1800877717674632" ESTIMABLE="YES" EVENTS_1="919" EVENTS_2="389" LOG_CI_END="0.11912547512939989" LOG_CI_START="0.024703145205993426" LOG_EFFECT_SIZE="0.07191431016769664" MODIFIED="2011-09-18 18:16:55 -0300" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.05546414399508017" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5153" TOTAL_2="2574" VAR="0.0030762712691069878" WEIGHT="83.82986790906054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.126223312446173" CI_END="8.007032554046388" CI_START="0.5399939547696286" DF="1" EFFECT_SIZE="2.079362684773551" ESTIMABLE="YES" EVENTS_1="1549" EVENTS_2="663" I2="92.92096707037803" ID="CMP-002.14.02" LOG_CI_END="0.9034715942139229" LOG_CI_START="-0.26761110207497185" LOG_EFFECT_SIZE="0.3179302460694755" MODIFIED="2011-09-18 18:18:01 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.7094510787740713E-4" P_Z="0.28723910584903567" STUDIES="3" TAU2="0.8836313547112457" TOTAL_1="7874" TOTAL_2="3527" WEIGHT="100.0" Z="1.0641978296952117">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="8.810416802399365" CI_START="2.10928510511145" EFFECT_SIZE="4.310879368658399" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="8" LOG_CI_END="0.9449964544620253" LOG_CI_START="0.32413528585999196" LOG_EFFECT_SIZE="0.6345658701610086" ORDER="592" O_E="0.0" SE="0.3646969237491848" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2661" TOTAL_2="874" VAR="0.1330038461921187" WEIGHT="46.54630263963491"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="594" O_E="0.0" SE="0.0" STUDY_ID="STD-Tian-1993" TOTAL_1="102" TOTAL_2="98" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1928883609929657" CI_START="1.0181740693529393" EFFECT_SIZE="1.1020744061976786" ESTIMABLE="YES" EVENTS_1="1444" EVENTS_2="655" LOG_CI_END="0.07659980119473554" LOG_CI_START="0.00782203231992808" LOG_EFFECT_SIZE="0.0422109167573318" MODIFIED="2011-09-18 18:18:01 -0300" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.04040040189250865" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5111" TOTAL_2="2555" VAR="0.0016321924730762168" WEIGHT="53.4536973603651"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8637145726774265" CI_END="1.1984216519759385" CI_START="1.0720839889265341" DF="1" EFFECT_SIZE="1.1334940075122986" ESTIMABLE="YES" EVENTS_1="2340" EVENTS_2="1030" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.07860964685800016" LOG_CI_START="0.030228810075504573" LOG_EFFECT_SIZE="0.05441922846675236" MODIFIED="2011-09-18 18:18:16 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3527013680736112" P_Z="1.0376634307729241E-5" STUDIES="2" TAU2="0.0" TOTAL_1="5184" TOTAL_2="2632" WEIGHT="100.00000000000001" Z="4.409172513522196">
<NAME>Primary series: Dose 3</NAME>
<DICH_DATA CI_END="97.66032990523694" CI_START="0.23103034796107227" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9897181870357756" LOG_CI_START="-0.6363309677860426" LOG_EFFECT_SIZE="0.6766936096248666" ORDER="596" O_E="0.0" SE="1.5425542726953" STUDY_ID="STD-Tian-1993" TOTAL_1="99" TOTAL_2="94" VAR="2.3794736842105264" WEIGHT="0.03394228291192045"/>
<DICH_DATA CI_END="1.1978500834007006" CI_START="1.0715524109937207" EFFECT_SIZE="1.1329426926711916" ESTIMABLE="YES" EVENTS_1="2338" EVENTS_2="1030" LOG_CI_END="0.07840246744733649" LOG_CI_START="0.03001341779380681" LOG_EFFECT_SIZE="0.05420794262057165" MODIFIED="2011-09-18 18:18:16 -0300" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="0.028423967296142157" STUDY_ID="STD-Gustafsson-1996" TOTAL_1="5085" TOTAL_2="2538" VAR="8.079219168521588E-4" WEIGHT="99.96605771708809"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8951593837208451" CI_END="16.168031296664022" CI_START="3.5702661106403872" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="7.597642674820442" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="1.208657141177419" LOG_CI_START="0.5527005875619287" LOG_EFFECT_SIZE="0.8806788643696739" METHOD="MH" MODIFIED="2014-05-25 20:31:54 -0300" MODIFIED_BY="Liz Dooley" NO="15" P_CHI2="0.3440830985776434" P_Q="0.34771063148763004" P_Z="1.4184310490937043E-7" Q="0.8817949517673862" RANDOM="YES" SCALE="96.86143302641057" SORT_BY="YEAR" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5448" TOTAL_2="1811" WEIGHT="200.0" Z="5.262845066784723">
<NAME>Redness</NAME>
<GROUP_LABEL_1>Acellular vaccine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/DT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acellular</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/DT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.851427395047722" CI_START="0.38386267781568356" DF="0" EFFECT_SIZE="3.025834230355221" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="1.3775143746232195" LOG_CI_START="-0.4158241113956215" LOG_EFFECT_SIZE="0.48084513161379894" NO="1" P_CHI2="1.0" P_Z="0.2932382373206852" STUDIES="1" TAU2="0.0" TOTAL_1="2787" TOTAL_2="937" WEIGHT="100.0" Z="1.051044348238637">
<NAME>Primary series: Dose 1</NAME>
<DICH_DATA CI_END="23.851427395047722" CI_START="0.38386267781568356" EFFECT_SIZE="3.025834230355221" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.3775143746232195" LOG_CI_START="-0.4158241113956215" LOG_EFFECT_SIZE="0.48084513161379894" ORDER="587" O_E="0.0" SE="1.0534159038561421" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2787" TOTAL_2="937" VAR="1.1096850664970528" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.716664761915148" CI_START="3.8907840641094418" DF="0" EFFECT_SIZE="8.75861205060754" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="6" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="1.294833452288761" LOG_CI_START="0.5900371284218296" LOG_EFFECT_SIZE="0.9424352903552954" NO="2" P_CHI2="1.0" P_Z="1.5916807727137276E-7" STUDIES="1" TAU2="0.0" TOTAL_1="2661" TOTAL_2="874" WEIGHT="100.00000000000001" Z="5.241625599638274">
<NAME>Primary series: Dose 2</NAME>
<DICH_DATA CI_END="19.716664761915148" CI_START="3.8907840641094418" EFFECT_SIZE="8.75861205060754" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="6" LOG_CI_END="1.294833452288761" LOG_CI_START="0.5900371284218296" LOG_EFFECT_SIZE="0.9424352903552954" ORDER="588" O_E="0.0" SE="0.4140008494375052" STUDY_ID="STD-AHGSPV-1988" TOTAL_1="2661" TOTAL_2="874" VAR="0.17139670333497584" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Primary series: Dose 3</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-09-08 06:34:50 -0300" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-09-08 06:34:50 -0300" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEZCAMAAABxStv9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-09-08 06:34:50 -0300" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWgAAAdtCAIAAADGmlILAABee0lEQVR42u3dvW4cR9628QEMGA4m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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-09-08 05:44:15 -0300" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-09-08 05:44:15 -0300" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-04-17 20:41:08 -0300" MODIFIED_BY="[Empty name]">Response to Zhang et al: Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews 2011, Issue 1</TITLE>
<DATE_SUBMITTED>
<DATE DAY="25" MONTH="1" YEAR="2011"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2014-09-08 05:44:15 -0300" MODIFIED_BY="[Empty name]">
<P>A meta-analysis initially done by Jefferson et al (1) of acellular (acP) vaccine efficacy and safety in children was revisited by Zhang et al in the Cochrane Library (2).  Zhang correctly did not perform a formal meta-analysis, stating that it was not appropriate due to the small number of efficacy trials and the significant heterogeneity across these trials with respect to immunization schedules, case definitions, follow-up duration, products used, and background pertussis rates.  The inappropriateness of applying a meta-analysis methodology to these studies was previously highlighted by Desauziers et al (3) and Simondon (4) following Jefferson et al&#8217;s previous publication (1).</P>
<P>The review by Zhang et al concludes that &#8220;of the currently available acellular vaccines, multi-component vaccines confer better protection, against both classical whooping cough and mild pertussis infection, than vaccines containing only one or two components.&#8221;  Although it is intuitively attractive to adopt a &#8220;more components is better&#8221; position on acP vaccines, this strong conclusion on differential efficacy of acellular vaccines is not objectively supported by the reviewed trials nor by the data these trials generated. Nor is this conclusion supported by previously published commentaries or by the positions expressed by professional pediatric and national immunization policy bodies. </P>
<P>Zhang et al included in their review six controlled trials that were designed well enough to ensure high internal validity and one trial without active surveillance of cases.  All of these trials were performed between 1988 and 1997.  Only three of these trials were efficacy trials that directly compared different acellular vaccines in a double-blind, randomized design, with an active follow-up, and laboratory confirmation of cases. The majority of currently licensed pertussis vaccines have not been compared in head-to-head efficacy trials.  Most critically there are no clinical trials that directly compare the efficacy of licensed 2-acP vaccines with that of licensed 3-acP or 5-acP vaccines. In fact, the only study in which a 2-acP vaccine was less efficacious than multi-component acellular vaccines involved an experimental 2-acP vaccine that was never licensed/registered, precisely because of its limited efficacy.  Since other 2-acP vaccines did demonstrate sufficient efficacy to be licensed, the more appropriate interpretation of the experimental 2-acP vaccine data is that it is not the number of acP components but rather some other feature or combination of features (e.g. the source of the antigens, their relative concentrations, the processes for their purification and detoxification, or the nature and concentration of the adjuvants) of each individual vaccine that determine efficacy. The biasing potential of including data from the unlicensed, experimental 2-acP vaccine is not clearly discussed in Zhang et al&#8217;s review. </P>
<P>The Zhang et al publication highlights the continuing debate over the relative merits of data from randomized controlled trials (RCTs) versus data from observational studies in evidence-based reviews.  Our belief is that, in the real world of vaccination policy decision making, these two different data sets are entirely complementary.  Well-designed RCTs offer higher internal validity, while equally well-designed observational studies provide higher external validity and a better reflection of the real world.  For example, a well-designed case-control study performed in Germany by Liese et al (5) reported that a licensed 2-acP vaccine was 93% effective in prevention of 21 or more days of paroxysmal cough that was laboratory-confirmed as pertussis. This study was excluded from the review because it was not a RCT.  The exclusion of this study and the associated potential for bias should also have been discussed by Zhang et al. </P>
<P>Other published effectiveness data clearly support the effectiveness of both 1- and 2-acP vaccines as well as other multi-component acP vaccines. These data, with their high external validity, have been reported not only from Japan, the United States and Canada (6-10) but also from France, Austria, Finland, Denmark, Sweden and Germany (11-16), and underscore the effectiveness of national vaccination programs in preventing whooping cough in children, regardless of the number of acP components in the licensed vaccines used. </P>
<P>Observational studies might overestimate vaccine effectiveness, if persons included as cases in the studies had more severe pertussis than persons not included, or if the vaccination status would influence the likelihood of the diagnosis of pertussis in a coughing person. Nonetheless, none of these studies identified a lower effectiveness of 2-acP licensed vaccines in pre-school children compared to &#8220;multi-component vaccines or whole cell vaccines&#8221; (9, 15). These results contradict the conclusions of Zhang et al and as a result they should have been discussed. </P>
<P>The studies included in the review did not use the same follow-up duration but these differences are not addressed even though they contribute to the heterogeneity of the data. The impact of duration of follow-up on efficacy estimates has been well illustrated.  In one study (17), a highly effective whole cell vaccine and a 2-acP vaccine demonstrated equivalent efficacies until 18 months of age with a relative risk: 1.16 (95%CI 0.77-1.72). Only after 18 months of age was the whole cell vaccine shown to retain higher efficacy (relative risk: 1.76 [95%CI 1.33-2.33]) than the acellular vaccine in the absence of a booster dose in the two groups.</P>
<P>The inappropriateness of relating acP vaccine efficacy to the number of pertussis components has been addressed by both American and European regulatory authorities (18, 19) and by international expert panels charged with comparing results between studies (20-22).  These groups have concluded that the available data support the practical policy guidance that all licensed acellular vaccines are highly effective. </P>
<P>In summary, the overall body of available data supports a conclusion that all licensed acP vaccines, regardless of the number of pertussis components, have proven highly effective.  Despite the intrinsic attractiveness of such a conclusion, these data do not support the Zhang et al conclusion that 1- and 2-acP vaccines are less effective than those with more acellular components. The dangers of this conclusion coming from such respected authors include confusion in the vaccination community and the inappropriate preference for one group of vaccines over another.  This in turn might lead to negative impacts on vaccine supply and immunization rates. </P>
<P>
<SUP>
<I>1</I>
</SUP>
<I>Sanofi Pasteur, Lyon France<BR/>
</I>
</P>
<P>
<B>References:</B>
</P>
<P>1. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003 May 16;21(17-18):2003-14.</P>
<P>2. Zhang L, Prietsch SOM, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD001478. DOI:10.1002/14651858.CD001478.pub4.</P>
<P>3. Desauziers E, Hessel L, Decker MD, Caro JJ, Liese JG. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2004 Jul 29;22(21-22):2681-4; author reply 2685.</P>
<P>4. Simondon F. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2004 Aug 13;22(23-24):2965.</P>
<P>5. Liese JG, Stojanov S, Belohradsky BH. [Pertussis vaccination with acellular vaccines. Tolerance--effectiveness--current vaccination recommendations]. Fortschr Med. 1997 Aug 30;115(24):22-7.</P>
<P>6. Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int. 2004 Dec;46(6):650-5.</P>
<P>7. Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev Vaccines. 2005 Apr;4(2):173-84.</P>
<P>8. Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol Infect. 2009 Jan;137(1):124-30.</P>
<P>9. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005 Aug;116(2):e285-94.</P>
<P>10. Bettinger JA, Halperin SA, De Serres G, Scheifele DW, Tam T. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada. Pediatr Infect Dis J. 2007 Jan;26(1):31-5.</P>
<P>11. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V; Renacoq. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill. 2007 Jan 20;12(1).</P>
<P>12. Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine. 2006 Aug 14;24(33-34):5960-5.</P>
<P>13. Elomaa A, He Q, Minh NN, Mertsola J. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine. 2009 Sep 4;27(40):5443-9.</P>
<P>14. Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine. 2004 Sep 9;22(27-28):3530-4.</P>
<P>15. Carlsson RM, Trollfors B. Control of pertussis--lessons learnt from a 10-year</P>
<P>surveillance programme in Sweden. Vaccine. 2009 Sep 25;27(42):5709-18.</P>
<P>16. Juretzko P, von Kries R, Hermann M, Wirsing von König CH, Weil J, Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis. 2002 Jul 15;35(2):162-7.</P>
<P>17. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, Sanden G, Mboup S, Hoffenbach A, Knudsen K, Guiso N, Wassilak S, Cadoz M. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis  vaccine in Senegal. Vaccine. 1997 Oct;15(15):1606-12.</P>
<P>18. Purvis WV. Letter to all manufacturer of acellular pertussis vaccines. Center for Biologics Evaluation and Research, Food and Drug Administration, Washington; 25 June 1998.</P>
<P>19. European regulatory authorities&#8217; view on proving safety and immunogenicity of combine vaccines&#8212;general aspects&#8212;recent experiences. In: Viral hepatitis, vol. 10.2 June 2002.</P>
<P>20. Informal consultation on control of pertussis with whole cell and acellular vaccines. CVI/WHO, Geneva; 18-19 May 1998.</P>
<P>21. Halperin SA. Acellular pertussis vaccines: the next step. Dev Biol Stand 1997;89:363-5.</P>
<P>22. Orenstein WA. Rapporteur&#8217;s summary of the symposium. Dev Biol Stand 1997;89:397-403.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-01-30 02:11:39 -0200" MODIFIED_BY="Liz Dooley">
<P>We thank Philippe P. J. André and David R. Johnson from Sanofi Pasteur (Lyon, France) for their interests and comments on our review. Their main concern is one of the review&#8217;s conclusions &#8220;Of the currently available acellular vaccines, multi-component vaccines confer better protection against both classical whooping cough and mild pertussis infection than vaccines containing only one or two components&#8221;. We recognise that this conclusion is based on indirect evidence since the majority of currently licensed pertussis vaccines have not been compared in head to head efficacy trials as André and Johnson pointed out.</P>
<P>André and Johnson&#8217;s comments are likely to provoke an old and ongoing debate on the comparative efficacy of acellular pertussis vaccines with different antigen components which is ironic since Sanofi Pasteur markets both two and five component acellular pertussis vaccines. This question has been well addressed by Patrick Olin in 1997 (1). In this commentary, Olin stated that &#8220;Contrary to the position taken in most commentaries, analysis of the results of the four placebo-controlled trials of two one-component, two two-component, two three-component and one five-component vaccine unequivocally demonstrate the multi-component vaccines to have better protective efficacy against both mild and typical pertussis than one- and two-component vaccines&#8221;. The results from another recent systematic review with 49 randomised controlled trials (RCTs) and 3 cohort studies are also consistent with the findings of our review (2). The current evidence on comparative efficacy of acellular pertussis vaccines with different antigen components has been cited by the most recent WHO position paper on pertussis vaccines (3).</P>
<P>We are conscious that the clinical implication of any possible superiority of multi-component vaccines over mono- and bivalent vaccines in the efficacy demonstrated by RCTs needs to consider the transferability of this conclusion to whole countries and vaccine delivery systems. The effectiveness of vaccination programmes on a national scale for controlling infectious disease depends not only on the efficacy of the vaccine but also other factors such as the vaccination schedule and adherence, and transportation and storage of the vaccine. Moreover, indirect effects in producing herd immunity in the population may also contribute to the effectiveness of large-scale vaccination in controlling infectious diseases (4,5). Therefore, successful control of pertussis infections by two-component vaccines in Japan and in other countries (5-7) does not necessarily exclude the potential additional benefits of large-scale vaccination with multi-component vaccines.</P>
<P>This is a systematic review of RCTs, so we did not included observational studies in the review. In the next update, we will devote a special paragraph in the discussion to compare the results from RCTs and observational studies, and to address the potential contribution of follow-up duration for the heterogeneity across the studies, as suggested by André and Johnson. We will also modify the conclusion to be &#8220;Currently available evidence suggests that multi-component vaccines confer better protection against both classical whooping cough and mild pertussis infection than vaccines containing only one or two components&#8221;.</P>
<P>
<B>References:</B>
</P>
<P>1. Olin P. Commentary: The best acellular pertussis vaccines are multicomponent. Pediatr Infect Dis J  1997;16(5):517-519.</P>
<P>2. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21(17-18):2003-2014.</P>
<P>3. WHO. Pertussis vaccines: WHO position paper.  Weekly Epidemiol Record 2010;85:385-400.</P>
<P>4. Stephens DS. Vaccines for the unvaccinated: Protecting the herd. JID 2008;197:643-645.</P>
<P>5. Carlsson RM, Trollfors B. Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden. Vaccine. 2009;27(42):5709-5718.</P>
<P>6. Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int. 2004;46(6):650-655.</P>
<P>7. Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine. 2004;22(27-28):3530-3534.  </P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-04-17 20:44:46 -0300" MODIFIED_BY="[Empty name]">
<P>
<B>Philippe P. J. André, MD, PhD<SUP>1</SUP>
</B>
<BR/>
<B>David R. Johnson, MD, MPH<SUP>1</SUP>
</B>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-09-08 07:47:14 -0300" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-01-30 02:24:14 -0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-05-18 02:49:37 -0300" MODIFIED_BY="[Empty name]">Initial search 1997 and 1998</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-30 02:24:14 -0200" MODIFIED_BY="[Empty name]">
<P>The initial search was carried out in March 1997 and updated in March 1998, covering the period up to and including January 1998. The databases used were MEDLINE (Medline SilverPlatter CD-ROM) and the Cochrane Central Register of Controlled Trials (CENTRAL). We searched CENTRAL using the term 'pertus* OR whoop*'. We searched MEDLINE using the following strategy:</P>
<P>1. explode PERTUSSIS-VACCINE / all subheadings<BR/>2. explode BORDETELLA-PERTUSSIS / all subheadings<BR/>3. explode WHOOPING-COUGH / all subheadings<BR/>4. PERTUS*<BR/>5. WHOOP*<BR/>6. #1 or #2 or #3 or #4 or #5</P>
<P>The files downloaded from MEDLINE SilverPlatter were screened for randomised controlled trials using the RCT FILTER.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-09-08 05:45:15 -0300" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-05-18 02:50:00 -0300" MODIFIED_BY="[Empty name]">April 2009 updated search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 05:45:15 -0300" MODIFIED_BY="[Empty name]">
<P>In the 2009 updated review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2009, Issue 2), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1950 to April week 2 2009) and EMBASE.com (1974 to April 2009).</P>
<P>We used the following search strategy to search MEDLINE and CENTRAL. The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision- maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We modified the search strategy to search Embase.com (see below).</P>
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>1     exp Pertussis Vaccine/<BR/>2     pertussis vaccin*.tw.<BR/>3     Whooping Cough/<BR/>4     whoop*.tw.<BR/>5     Bordetella pertussis/<BR/>6     pertuss*.tw.<BR/>7     1 or 2 or 3 or 4 or 5 or 6<BR/>8     exp Vaccines, Acellular/<BR/>9     (acellular adj5 vaccin*).tw.<BR/>10     8 or 9<BR/>11     7 and 10</P>
<SUBSECTION>
<HEADING LEVEL="5">EMBASE.com</HEADING>
<P>1. 'pertussis vaccine'/de<BR/>2. 'diphtheria pertussis tetanus vaccine'/de<BR/>3. 'diphtheria pertussis poliomyelitis tetanus vaccine'/de<BR/>4. 'diphtheria pertussis tetanus haemophilus influenzae type b hepatitis b vaccine'/de<BR/>5. 'diphtheria pertussis tetanus haemophilus influenzae type b vaccine'/de<BR/>6. 'bordetella pertussis'/de<BR/>7. 'pertussis'/de<BR/>8. 'dpt vaccine':ti,ab<BR/>9. pertuss*:ti,ab<BR/>10. whoop*:ti,ab<BR/>11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10<BR/>12. 'acellular vaccine'/de<BR/>13. (acellular:ti,ab AND vaccin*:ti,ab)<BR/>14. #12 OR #13<BR/>15. #11 AND #14<BR/>16. 'randomized controlled trial'/de<BR/>17. 'controlled clinical trial'/de<BR/>18. 'single blind procedure'/de<BR/>19. 'double blind procedure'/de<BR/>20. 'phase 3 clinical trial'/de<BR/>21. random*:ti,ab<BR/>22. placebo*:ti,ab<BR/>23. 'clinical trial':it<BR/>24. 'randomized controlled trial':it<BR/>25. (singl*:ti,ab OR doubl*:ti,ab OR trebl*:ti,ab OR tripl*:ti,ab) AND (mask*:ti,ab OR blind*:ti,ab)<BR/>26. 'controlled clinical trial':ti,ab<BR/>27. 'controlled clinical trials':ti,ab<BR/>28. #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27<BR/>29. ('nonhuman'/exp OR 'animal'/exp) NOT 'human'/exp<BR/>30. #28 NOT #29<BR/>31. #15 AND #30<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-01-27 05:36:40 -0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-01-27 05:34:58 -0200" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-27 05:36:40 -0200" MODIFIED_BY="[Empty name]">
<P>1     exp Pertussis Vaccine/<BR/>2     pertussis vaccin*.tw.<BR/>3     Whooping Cough/<BR/>4     whoop*.tw.<BR/>5     Bordetella pertussis/<BR/>6     pertuss*.tw.<BR/>7     1 or 2 or 3 or 4 or 5 or 6<BR/>8     exp Vaccines, Acellular/<BR/>9     (acellular adj5 vaccin*).tw.<BR/>10     8 or 9<BR/>11     7 and 10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-01-27 05:38:36 -0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-01-27 05:38:06 -0200" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-27 05:38:36 -0200" MODIFIED_BY="[Empty name]">
<P>#14. #10 AND #13 269 17 May 2011<BR/>#13. #11 OR #12 861,917 17 May 2011<BR/>#12. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1<BR/>blind*):ab,ti AND [embase]/lim 822,212 17 May 2011<BR/>#11. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp AND [embase]/lim 241,991 17 May 2011<BR/>#10. #6 AND #9 1,393 17 May 2011<BR/>#9. #7 OR #8 1,451 17 May 2011<BR/>#8. (acellular NEAR/5 vaccin*):ab,ti AND [embase]/lim 1,321 17 May 2011<BR/>#7. 'acellular vaccine'/de AND [embase]/lim 271 17 May 2011<BR/>#6. #1 OR #2 OR #3 OR #4 OR #5 25,318 17 May 2011<BR/>#5. pertuss*:ab,ti OR whoop*:ab,ti AND [embase]/lim 19,626 17 May 2011<BR/>#4. 'bordetella pertussis'/de AND [embase]/lim 4,046 17 May 2011<BR/>#3. 'pertussis'/de AND [embase]/lim 5,903 17 May 2011<BR/>#2. 'diphtheria pertussis tetanus vaccine'/de OR 'diphtheria pertussis tetanus hepatitis b vaccine'/de OR 'diphtheria pertussis tetanus haemophilus influenzae type b vaccine'/de OR<BR/>'diphtheria pertussis tetanus haemophilus influenzae type b hepatitis b vaccine'/de OR 'diphtheria pertussis poliomyelitis tetanus vaccine'/de OR 'diphtheria pertussis poliomyelitis tetanus hepatitis b vaccine'/de OR 'diphtheria pertussis poliomyelitis tetanus haemophilus influenzae type b hepatitis b vaccine'/de AND [embase]/lim 5,402 17 May 2011<BR/>#1. 'pertussis vaccine'/de AND [embase]/lim 4,338 17 May 2011</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-01-27 05:51:16 -0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-01-27 05:51:16 -0200" MODIFIED_BY="[Empty name]">Biosis Previews (Thomson ISI)</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-27 05:45:42 -0200" MODIFIED_BY="[Empty name]">
<P>Topic=(pertuss* or whoop* or bordetella*) AND Topic=(acellular vaccin*)</P>
<P>Refined by: Topic=(random* or placebo* or clinical trial* or singl* blind* or doubl* blind*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-01-27 05:45:36 -0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2012-01-27 05:43:43 -0200" MODIFIED_BY="[Empty name]">CINAHL (Ebsco)</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-27 05:45:36 -0200" MODIFIED_BY="[Empty name]">
<P>S18 S7 and S16<BR/>S17 S7 and S16<BR/>S16 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15<BR/>S15 (MH "Quantitative Studies")<BR/>S14 (MH "Placebos")<BR/>S13 TI placebo* or AB placebo*<BR/>S12 TI random* or AB random*<BR/>S11 TI ( singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask* ) or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl*<BR/>mask* or doubl* mask* or tripl* mask* or trebl* mask* )<BR/>S10 TI clinic* trial* or AB clinic* trial*<BR/>S9 PT clinical trial<BR/>S8 (MH "Clinical Trials+")<BR/>S7 S5 and S6 Search modes<BR/>S6 TI acellular N5 vaccin* or AB acellular N5 vaccin*<BR/>S5 S1 or S2 or S3 or S4<BR/>S4 TI ( whoop* or pertuss* ) or AB ( whoop* or pertuss* )<BR/>S3 (MH "Bordetella Pertussis")<BR/>S2 (MH "Whooping Cough")<BR/>S1 (MH "Pertussis Vaccine+")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2014-05-25 20:34:30 -0300" MODIFIED_BY="Liz Dooley">Comparison of results between the first published (primary) review and the updated reviews</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P>
<B> Minor adverse events: acellular vaccines versus whole-cell vaccines</B>
</P>
<TABLE COLS="4" ROWS="10">
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Number of  trials</P>
<P> </P>
<P>Primary    Update</P>
</TH>
<TH VALIGN="TOP">
<P>Sample size (n)</P>
<P> </P>
<P>Primary    Update</P>
</TH>
<TH VALIGN="TOP">
<P>Effect size - RR (95% CI)</P>
<P> </P>
<P>Primary                   Update</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anorexia</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>10               11</P>
<P>7                  8</P>
<P>8                  9</P>
<P>11               14</P>
<P>3                  4</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>13,942      19,632</P>
<P>18,232      18,501</P>
<P>18,385      18,646</P>
<P>1380         1939</P>
<P>8033         8447</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.47 (0.35 to 0.64)     0.43 (0.32 to 0.57)</P>
<P>0.50 (0.37 to 0.67)     0.45 (0.33 to 0.60)</P>
<P>0.52 (0.45 to 0.61)     0.50 (0.43 to 0.60)</P>
<P>0.35 (0.24 to 0.51)     0.40 (0.30 to 0.54)</P>
<P>0.41 (0.26 to 0.64)     0.42 (0.31 to 0.58)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Drowsiness</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>11               12</P>
<P>7                  8</P>
<P>8                  9</P>
<P>10               14</P>
<P>2                  3</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>20,200      20,490</P>
<P>19,039      19,308</P>
<P>19,169      19,430</P>
<P>1695         2254</P>
<P>7953         8367</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.74 (0.50 to 1.09)     0.72 (0.50 to 1.03)</P>
<P>0.67 (0.43 to 1.03)     0.61 (0.41 to 0.93)</P>
<P>0.56 (0.40 to 0.79)     0.56 (0.40 to 0.77)</P>
<P>0.43 (0.34 to 0.53)     0.48 (0.41 to 0.56)</P>
<P>0.50 (0.45 to 0.55)     0.49 (0.44 to 0.54)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Fever </B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>18               19</P>
<P>15               17</P>
<P>15               17</P>
<P>19               25</P>
<P>5                  8</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>22,977      23,267</P>
<P>21,652      22,001</P>
<P>21,390      21,731</P>
<P>2513         3381</P>
<P>9012         9879</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.17 (0.13 to 0.21)     0.17 (0.13 to 0.20)</P>
<P>0.31(0.25 to 0.37)     0.31 (0.26 to 0.37)</P>
<P>0.34 (0.29 to 0.38)     0.34 (0.30 to 0.38)</P>
<P>0.33 (0.24 to 0.45)     0.33 (0.26 to 0.43)</P>
<P>0.38 (0.21 to 0.68)     0.35 (0.22 to 0.55)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Irritability/fretfulness     </B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>13               15</P>
<P>10               12</P>
<P>11               13</P>
<P>13               16</P>
<P>4                  6</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>20,337      20,707</P>
<P>19,080      19,429</P>
<P>19,170      19,511</P>
<P>1978         2596</P>
<P>9165         9856</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.50 (0.43 to 0.58)     0.48 (0.42 to 0.56)</P>
<P>0.51 (0.43 to 0.60)     0.48 (0.41 to 0.56)</P>
<P>0.55 (0.49 to 0.62)     0.53 (0.47 to 0.59)</P>
<P>0.32 (0.23 to 0.45)     0.36 (0.28 to 0.47)</P>
<P>0.48 (0.44 to 0.51)     0.48 (0.44 to 0.51)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prolonged crying</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>7                 8</P>
<P>5                 6</P>
<P>6                 7</P>
<P>4                 7</P>
<P>2                 2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>16,849      17,184</P>
<P>16,078      16,347</P>
<P>16,248      16,545</P>
<P>955           996</P>
<P>7943         7943</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.14 (0.12 to 0.18)     0.15 (0.11 to 0.19)</P>
<P>0.29 (0.24 to 0.35)     0.29 (0.24 to 0.35)</P>
<P>0.32 (0.24 to 0.44)     0.33 (0.24 to 0.46)</P>
<P>0.23 (0.10 to 0.55)     0.21 (0.10 to 0.48)</P>
<P>0.48 (0.22 to 1.02)     0.27 (0.02 to 3.12)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vomiting</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>7                 8</P>
<P>6                 7</P>
<P>5                 6</P>
<P>5                 6</P>
<P>1                 1</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>11,160      11,450</P>
<P>10,716      10,985</P>
<P>10,552      10,813</P>
<P>703           744</P>
<P>86             86</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.78 (0.67 to 0.90)     0.77 (0.66 to 0.88)</P>
<P>0.71 (0.60 to 0.85)     0.62 (0.45 to 0.86)</P>
<P>0.80 (0.66 to 0.97)     0.69 (0.46 to 1.04)</P>
<P>0.35 (0.15 to 0.82)     0.50 (0.22 to 1.11)</P>
<P>1.07 (0.10 to 11.34)   1.07 (0.10 to 11.34)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Pain/tenderness   </B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>10               13</P>
<P>8                 11</P>
<P>9                 12</P>
<P>16               21</P>
<P>3                 5</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>11,683      14,180</P>
<P>10,710      13,186</P>
<P>10,938      13,333</P>
<P>2433         3051</P>
<P>1572         2263</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.21 (0.16 to 0.28)     0.20 (0.16 to 0.25)</P>
<P>0.19 (0.16 to 0.22)     0.18 (0.15 to 0.22)</P>
<P>0.21 (0.19 to 0.25)     0.20 (0.17 to 0.24)</P>
<P>0.40 (0.31 to 0.51)     0.43 (0.36 to 0.53)</P>
<P>0.36 (0.26 to 0.49)     0.43 (0.32 to 0.58) </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Redness</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
<P>11               13</P>
<P>10               12</P>
<P>11               13</P>
<P>16               22</P>
<P>3                  5</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
<P>6783          7253</P>
<P>6078          6427</P>
<P>6291          6632</P>
<P>2187          3055</P>
<P>1572          2263</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
<P>0.30 (0.22 to 0.40)     0.30 (0.23 to 0.39)</P>
<P>0.42 (0.32 to 0.55)     0.39 (0.29 to 0.51)</P>
<P>0.48 (0.41 to 0.56)     0.47 (0.41 to 0.54)</P>
<P>0.52 (0.43 to 0.63)     0.51 (0.44 to 0.59)</P>
<P>0.67 (0.51 to 0.89)     0.65 (0.52 to 0.80)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Swelling/induration</B>
</P>
<P>Primary dose 1</P>
<P>Primary dose 2</P>
<P>Primary dose 3</P>
<P>aP booster (pre wP)</P>
<P>aP booster (pre aP)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>13               15</P>
<P>12               14</P>
<P>13               15</P>
<P>17               22</P>
<P>4                  6</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>14,242      14,612</P>
<P>13,430      13,779</P>
<P>13,575      13,916</P>
<P>2433         3301</P>
<P>1730         2421</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.24 (0.19 to 0.31)     0.24 (0.19 to 0.31)</P>
<P>0.38 (0.30 to 0.47)     0.35 (0.28 to 0.45)</P>
<P>0.41 (0.30 to 0.57)     0.40 (0.29 to 0.54)</P>
<P>0.51 (0.44 to 0.59)     0.51 (0.46 to 0.57)</P>
<P>0.61 (0.47 to 0.80)     0.68 (0.58 to 0.80)</P>
</TD>
</TR>
</TABLE>
<P>CI: confidence interval<BR/>RR: risk ratio</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2009-06-15 02:46:59 -0300" MODIFIED_BY="Liz Dooley">Incidence of severe adverse events: acellular vaccines versus whole-cell vaccines</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Number of trials</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Acellular vaccines</P>
<P>n/N*                 Incidence #</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Whole-cell vaccines</P>
<P>n/N                  Incidence</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>RR 95% CI</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Primary series non-completion due to adverse events</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>248/80,060         3.09</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>338/28,849      11.72</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.23 (0.12 to 0.43)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Death (infection)</B>
</P>
<P>Primary series</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>5/22,154             0.23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>3/12,344           0.24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0.97 (0.23 to 4.16)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Death (all causes)</B>
</P>
<P>Primary series</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>81/86,863           0.93</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>61/35,588         1.71</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0.87 (0.62 to 1.22)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Encephalopathy</B>
</P>
<P>Primary series</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0/81,601            0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0/32,161           0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Convulsions</B>
</P>
<P>Primary series</P>
<P>Booster</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>15</P>
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>43/88,513          0.49</P>
<P>1/2250              0.44</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>41/35,874         1.14</P>
<P>0/397                0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0.47 (0.31 to 0.73)</P>
<P>0.46 (0.02 to 11.2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hypotonic hyporesponsive episodes</B>
</P>
<P>Primary series</P>
<P>Booster</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>11</P>
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>70/86,347         0.81</P>
<P>0/2171              0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>51/35,226         1.45</P>
<P>0/316                0.0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> </P>
<P>0.26 (0.08 to 0.81)</P>
<P>-</P>
</TD>
</TR>
</TABLE>
<P>*n/N: number of events/number of recipients<BR/># Incidence: number of events per 1000 recipients<BR/>CI: confidence interval<BR/>RR: risk ratio</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2014-09-08 07:47:00 -0300" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2009-06-15 02:46:59 -0300" MODIFIED_BY="Liz Dooley">Incidence of minor adverse events over the primary series: acellular vaccines versus whole-cell vaccines</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 07:47:00 -0300" MODIFIED_BY="[Empty name]">
<P> </P>
<TABLE COLS="4" ROWS="10">
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Dose 1 </B>
</P>
<P>
<B>Acellular            Whole-cell</B>
</P>
<P>n/N*                     n/N   </P>
<P>Incidence#        Incidence</P>
<P>Number of trials</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Dose 2 </B>
</P>
<P>
<B>Acellular            Whole-cell</B>
</P>
<P>n/N                      n/N   </P>
<P>Incidence           Incidence</P>
<P>Number of trials</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Dose 3 </B>
</P>
<P>
<B>Acellular            Whole-cell</B>
</P>
<P>n/N                      n/N   </P>
<P>Incidence           Incidence</P>
<P>Number of trials</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anorexia</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1275/12,310        1896/7322</P>
<P>103.57                 258.95</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>1047/11,653        1208/6848</P>
<P>89.85                   176.40</P>
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>941/11,840         966/6806</P>
<P>79.48                  141.93</P>
<P>9</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Drowsiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3427/12,813        2435/7677</P>
<P>267.46                 317.18</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>2087/12,134        1500/7174</P>
<P>171.99                 209.09</P>
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>1548/12,301          1231/7129</P>
<P>125.84                   172.67</P>
<P>10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>898/14,910          3900/8357</P>
<P>60.23                   466.67</P>
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>1809/14,167         3427/7834</P>
<P>127.69                  437.45</P>
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>2270/14,024           3439/7707</P>
<P>161.87                   446.22</P>
<P>17</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Irritability/fretfulness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>3645/12,875         4488/7832</P>
<P>283.11                  573.03</P>
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>3763/12,144         3695/7285</P>
<P>309.86                  507.21</P>
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>3482/12,268           3228/7243</P>
<P>283.83                    445.67</P>
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Prolonged crying</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>116/10,364           395/6820</P>
<P>11.19                    57.92</P>
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>161/9867              248/6480</P>
<P>16.32                    38.27</P>
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>68/10,096               94/6449</P>
<P>6.74                        14.58</P>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Vomiting</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>530/8126              269/3324</P>
<P>65.22                    80.93</P>
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>356/7885              189/3100</P>
<P>45.15                    60.97</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>322/7788                148/3025</P>
<P>41.35                      48.93</P>
<P>7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pain/tenderness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>733/10,279           1840/3901</P>
<P>71.31                    471.67</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>710/9642              1606/3544</P>
<P>73.64                    453.16</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>712/9769               1358/3564</P>
<P>72.88                      381.03</P>
<P>12</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Redness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>512/5348               620/1805</P>
<P>95.74                     343.49</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>599/4821              551/1606</P>
<P>124.25                  343.09</P>
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>807/4972                583/1660</P>
<P>162.31                    351.20</P>
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Swelling/induration</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1238/10,606          1670/4006</P>
<P>116.73                   416.87</P>
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>1842/10,034         1576/3745</P>
<P>183.58                   420.83</P>
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>2791/10,157           1658/3759</P>
<P>274.79                    441.07</P>
<P>15</P>
</TD>
</TR>
</TABLE>
<P>*n/N: number of events/number of recipients<BR/># Incidence: number of events per 1000 recipients</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2014-09-08 07:47:14 -0300" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2009-06-15 02:46:59 -0300" MODIFIED_BY="Liz Dooley">Incidence of minor adverse events in boosters: acellular vaccines versus whole-cell vaccines</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 07:47:14 -0300" MODIFIED_BY="[Empty name]">
<P> </P>
<TABLE COLS="3" ROWS="10">
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>aP booster (previous wP) versus wP booster (previous wP)</P>
<P>
<B>Acellular                    Whole-cell</B>
</P>
<P>n/N*                             n/N   </P>
<P>Incidence#                 Incidence</P>
<P>Number of trials</P>
</TH>
<TH VALIGN="BOTTOM">
<P>aP booster (previous aP) versus wP booster (previous wP)</P>
<P>
<B>Acellular                   Whole-cell</B>
</P>
<P>n/N                            n/N  </P>
<P>Incidence                 Incidence</P>
<P>Number of trials</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Anorexia</P>
</TD>
<TD VALIGN="TOP">
<P>129/1149                   244/790</P>
<P>112.27                        308.86</P>
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>457/4474                   735/3973</P>
<P>102.15                       184.99                  </P>
<P>4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Drowsiness</P>
</TD>
<TD VALIGN="TOP">
<P>203/1453                    292/801</P>
<P>139.71                         364.54</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>532/4419                  913/3948</P>
<P>120.39                       231.26</P>
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Fever</P>
</TD>
<TD VALIGN="TOP">
<P>191/2184                    305/1197</P>
<P>87.45                           254.80</P>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>1320/5838                 2058/4041</P>
<P>226.10                       509.28</P>
<P>8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Irritability/fretfulness</P>
</TD>
<TD VALIGN="TOP">
<P>314/1728                    445/868</P>
<P>181.71                         512.67</P>
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>1256/5837                 1379/4019</P>
<P>215.18                       343.12</P>
<P>6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Prolonged crying</P>
</TD>
<TD VALIGN="TOP">
<P>7/666                          20/330</P>
<P>10.51                           60.61</P>
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>9/4105                       15/3838</P>
<P>2.19                           3.91</P>
<P>2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vomiting</P>
</TD>
<TD VALIGN="TOP">
<P>18/551                        13/193</P>
<P>32.67                           67.36</P>
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>2/56                           1/30</P>
<P>35.71                         33.33</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pain/tenderness</P>
</TD>
<TD VALIGN="TOP">
<P>620/2018                     661/1033</P>
<P>307.23                         639.88</P>
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>691/2015                   203/248</P>
<P>342.93                       818.55</P>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Redness</P>
</TD>
<TD VALIGN="TOP">
<P>503/1980                     523/1075</P>
<P>254.04                         486.51</P>
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>692/2015                   135/248</P>
<P>343.42                       544.35</P>
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Swelling/induration</P>
</TD>
<TD VALIGN="TOP">
<P>446/2144                     493/1157</P>
<P>208.02                         426.10</P>
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>575/2139                   112/282</P>
<P>268.82                       397.16</P>
<P>6</P>
</TD>
</TR>
</TABLE>
<P> *n/N: number of events/number of recipients<BR/># Incidence: number of events per 1000 recipients </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2014-09-08 06:11:14 -0300" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2009-05-03 13:29:03 -0300" MODIFIED_BY="[Empty name]">Incidence of severe adverse events: acellular vaccines versus placebo/DT</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 06:11:14 -0300" MODIFIED_BY="[Empty name]">
<P> </P>
<TABLE COLS="5" ROWS="7">
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Number of trials</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Acellular vaccine</P>
<P>n/N*                 Incidence#</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Placebo/DT</P>
<P>n/N                  Incidence</P>
</TH>
<TH VALIGN="BOTTOM">
<P>RR 95% CI</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Primary series non-completion due to adverse events</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>65/19,092         3.40</P>
</TD>
<TD VALIGN="TOP">
<P>28/6809           4.11</P>
</TD>
<TD VALIGN="TOP">
<P>0.70 (0.38 to 1.29)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Death (infection)</B>
</P>
<P>Primary series</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>5/19,093           0.26</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1/6809             0.15</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1.21 (0.19 to 7.80)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Death (all causes)</B>
</P>
<P>Primary series</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>10/19,092         0.52</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2/6809             0.29</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1.08 (0.26 to 4.42)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Encephalopathy</B>
</P>
<P>Primary series</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0/14,521           0.0</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0/4129             0.0</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Convulsions</B>
</P>
<P>Primary series</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>27/19,092         1.41</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>28/6809           4.11</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>0.44 (0.12 to 1.69)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Hypotonic hyporesponsive episodes</B>
</P>
<P>Primary series  </P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P> 2/19,092          0.10</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P> 2/6809            0.29</P>
</TD>
<TD VALIGN="TOP">
<P>  </P>
<P>0.29 (0.02 to 5.13)</P>
</TD>
</TR>
</TABLE>
<P>*n/N: number of events/number of recipients<BR/># Incidence: number of events per 1000 recipients<BR/>CI: confidence interval<BR/>RR: risk ratio<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2009-05-03 13:46:55 -0300" MODIFIED_BY="[Empty name]">Incidence of minor adverse events over the primary series: acellular vaccines versus placebo/DT</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-08 06:34:42 -0300" MODIFIED_BY="[Empty name]">
<P> </P>
<TABLE COLS="4" ROWS="10">
<TR>
<TH VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Dose 1 </B>
</P>
<P>
<B>Acellular           Placebo/DT</B>
</P>
<P>n/N*                    n/N   </P>
<P>Incidence#        Incidence</P>
<P>Number of trials</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Dose 2 </B>
</P>
<P>
<B>Acellular            Placebo/DT</B>
</P>
<P>n/N                     n/N   </P>
<P>Incidence          Incidence</P>
<P>Number of trials</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Dose 3 </B>
</P>
<P>
<B>Acellular           Placebo/DT</B>
</P>
<P>n/N                     n/N  </P>
<P>Incidence          Incidence</P>
<P>Number of trials</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anorexia</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>750/8000            325/3526</P>
<P>93.75                  92.17 </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>656/7903            276/3483</P>
<P>83.00                  79.24 </P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>418/5085             195/2538</P>
<P>82.20                   76.83</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Drowsiness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1696/7557          792/3397</P>
<P>224.43                 233.15</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>1145/7334           549/3286</P>
<P>156.12                 167.07</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>718/5085             350/2538</P>
<P>141.20                  137.90</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>557/7762             230/3493</P>
<P>71.76                   65.85</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1053/7476            502/3377</P>
<P>140.85                  148.65</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1135/5070            552/2584</P>
<P>223.87                  213.63</P>
<P>2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Irritability/fretfulness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2373/8000           1084/3526</P>
<P>296.63                 307.43</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>2716/7903            1267/3483</P>
<P>343.67                  368.53</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>1848/5085            958/2538</P>
<P>363.42                  377.46</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Prolonged crying</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>132/7999              50/3526</P>
<P>16.50                     14.18</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>181/7903               78/3483</P>
<P>22.90                     22.39</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>55/5085                26/2538</P>
<P>10.82                    10.24</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Vomiting</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>513/8000              209/3526</P>
<P>64.13                    59.27</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>370/7903               185/3483</P>
<P>46.82                     53.12</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>241/5085              131/2538</P>
<P>47.39                    51.62</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pain/tenderness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>458/7940               226/3511</P>
<P>57.68                     64.37</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>630/7772               289/3430</P>
<P>81.06                     84.26</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>511/5085              253/2538</P>
<P>100.49                  99.68</P>
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Redness</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>9/2787                   1/937</P>
<P>3.23                       1.07</P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>160/2661               6/874</P>
<P>60.13                     6.86</P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>-                              -</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Swelling/induration</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>933/8042               391/3610</P>
<P>116.02                   108.31</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1549/7874             663/3527</P>
<P>196.72                   187.98</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2340/5184            1030/2632</P>
<P>451.39                  391.34</P>
<P>2</P>
</TD>
</TR>
</TABLE>
<P>*n/N: number of events/number of recipients<BR/># Incidence: number of events per 1000 recipients</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_18794_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="18794"><ADDRESS><DEPARTMENT>Department of Health Sciences</DEPARTMENT><ORGANISATION>Mid Sweden University</ORGANISATION><CITY>Östersund</CITY><ZIP>SE-831 25</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>